CINXE.COM

<!DOCTYPE html>      <html class="no-js" lang="en">  <head> <meta charset="UTF-8" /> <meta name="viewport" content="width=device-width, user-scalable=no, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0"> <title>guidetopharmacology blog | The official blog of the IUPHAR/BPS Guide to PHARMACOLOGY</title> <link rel="profile" href="http://gmpg.org/xfn/11" /> <link rel="pingback" href="https://blog.guidetopharmacology.org/xmlrpc.php" /> <meta name='robots' content='max-image-preview:large' />  <script id="wpcom_remote_login_js"> var wpcom_remote_login_extra_auth = ''; function wpcom_remote_login_remove_dom_node_id( element_id ) { var dom_node = document.getElementById( element_id ); if ( dom_node ) { dom_node.parentNode.removeChild( dom_node ); } } function wpcom_remote_login_remove_dom_node_classes( class_name ) { var dom_nodes = document.querySelectorAll( '.' + class_name ); for ( var i = 0; i < dom_nodes.length; i++ ) { dom_nodes[ i ].parentNode.removeChild( dom_nodes[ i ] ); } } function wpcom_remote_login_final_cleanup() { wpcom_remote_login_remove_dom_node_classes( "wpcom_remote_login_msg" ); wpcom_remote_login_remove_dom_node_id( "wpcom_remote_login_key" ); wpcom_remote_login_remove_dom_node_id( "wpcom_remote_login_validate" ); wpcom_remote_login_remove_dom_node_id( "wpcom_remote_login_js" ); wpcom_remote_login_remove_dom_node_id( "wpcom_request_access_iframe" ); wpcom_remote_login_remove_dom_node_id( "wpcom_request_access_styles" ); } // Watch for messages back from the remote login window.addEventListener( "message", function( e ) { if ( e.origin === "https://r-login.wordpress.com" ) { var data = {}; try { data = JSON.parse( e.data ); } catch( e ) { wpcom_remote_login_final_cleanup(); return; } if ( data.msg === 'LOGIN' ) { // Clean up the login check iframe wpcom_remote_login_remove_dom_node_id( "wpcom_remote_login_key" ); var id_regex = new RegExp( /^[0-9]+$/ ); var token_regex = new RegExp( /^.*|.*|.*$/ ); if ( token_regex.test( data.token ) && id_regex.test( data.wpcomid ) ) { // We have everything we need to ask for a login var script = document.createElement( "script" ); script.setAttribute( "id", "wpcom_remote_login_validate" ); script.src = '/remote-login.php?wpcom_remote_login=validate' + '&wpcomid=' + data.wpcomid + '&token=' + encodeURIComponent( data.token ) + '&host=' + window.location.protocol + '//' + window.location.hostname + '&postid=4725' + '&is_singular='; document.body.appendChild( script ); } return; } // Safari ITP, not logged in, so redirect if ( data.msg === 'LOGIN-REDIRECT' ) { window.location = 'https://wordpress.com/log-in?redirect_to=' + window.location.href; return; } // Safari ITP, storage access failed, remove the request if ( data.msg === 'LOGIN-REMOVE' ) { var css_zap = 'html { -webkit-transition: margin-top 1s; transition: margin-top 1s; } /* 9001 */ html { margin-top: 0 !important; } * html body { margin-top: 0 !important; } @media screen and ( max-width: 782px ) { html { margin-top: 0 !important; } * html body { margin-top: 0 !important; } }'; var style_zap = document.createElement( 'style' ); style_zap.type = 'text/css'; style_zap.appendChild( document.createTextNode( css_zap ) ); document.body.appendChild( style_zap ); var e = document.getElementById( 'wpcom_request_access_iframe' ); e.parentNode.removeChild( e ); document.cookie = 'wordpress_com_login_access=denied; path=/; max-age=31536000'; return; } // Safari ITP if ( data.msg === 'REQUEST_ACCESS' ) { console.log( 'request access: safari' ); // Check ITP iframe enable/disable knob if ( wpcom_remote_login_extra_auth !== 'safari_itp_iframe' ) { return; } // If we are in a "private window" there is no ITP. var private_window = false; try { var opendb = window.openDatabase( null, null, null, null ); } catch( e ) { private_window = true; } if ( private_window ) { console.log( 'private window' ); return; } var iframe = document.createElement( 'iframe' ); iframe.id = 'wpcom_request_access_iframe'; iframe.setAttribute( 'scrolling', 'no' ); iframe.setAttribute( 'sandbox', 'allow-storage-access-by-user-activation allow-scripts allow-same-origin allow-top-navigation-by-user-activation' ); iframe.src = 'https://r-login.wordpress.com/remote-login.php?wpcom_remote_login=request_access&origin=' + encodeURIComponent( data.origin ) + '&wpcomid=' + encodeURIComponent( data.wpcomid ); var css = 'html { -webkit-transition: margin-top 1s; transition: margin-top 1s; } /* 9001 */ html { margin-top: 46px !important; } * html body { margin-top: 46px !important; } @media screen and ( max-width: 660px ) { html { margin-top: 71px !important; } * html body { margin-top: 71px !important; } #wpcom_request_access_iframe { display: block; height: 71px !important; } } #wpcom_request_access_iframe { border: 0px; height: 46px; position: fixed; top: 0; left: 0; width: 100%; min-width: 100%; z-index: 99999; background: #23282d; } '; var style = document.createElement( 'style' ); style.type = 'text/css'; style.id = 'wpcom_request_access_styles'; style.appendChild( document.createTextNode( css ) ); document.body.appendChild( style ); document.body.appendChild( iframe ); } if ( data.msg === 'DONE' ) { wpcom_remote_login_final_cleanup(); } } }, false ); // Inject the remote login iframe after the page has had a chance to load // more critical resources window.addEventListener( "DOMContentLoaded", function( e ) { var iframe = document.createElement( "iframe" ); iframe.style.display = "none"; iframe.setAttribute( "scrolling", "no" ); iframe.setAttribute( "id", "wpcom_remote_login_key" ); iframe.src = "https://r-login.wordpress.com/remote-login.php" + "?wpcom_remote_login=key" + "&origin=aHR0cHM6Ly9ibG9nLmd1aWRldG9waGFybWFjb2xvZ3kub3Jn" + "&wpcomid=28218243" + "&time=1744378902"; document.body.appendChild( iframe ); }, false ); </script> <link rel='dns-prefetch' href='//s1.wp.com' /> <link rel='dns-prefetch' href='//s2.wp.com' /> <link rel='dns-prefetch' href='//s0.wp.com' /> <link rel='dns-prefetch' href='//af.pubmine.com' /> <link rel='dns-prefetch' href='//s.pubmine.com' /> <link rel='dns-prefetch' href='//x.bidswitch.net' /> <link rel='dns-prefetch' href='//static.criteo.net' /> <link rel='dns-prefetch' href='//ib.adnxs.com' /> <link rel='dns-prefetch' href='//aax.amazon-adsystem.com' /> <link rel='dns-prefetch' href='//bidder.criteo.com' /> <link rel='dns-prefetch' href='//cas.criteo.com' /> <link rel='dns-prefetch' href='//gum.criteo.com' /> <link rel='dns-prefetch' href='//ads.pubmatic.com' /> <link rel='dns-prefetch' href='//gads.pubmatic.com' /> <link rel='dns-prefetch' href='//tpc.googlesyndication.com' /> <link rel='dns-prefetch' href='//ad.doubleclick.net' /> <link rel='dns-prefetch' href='//googleads.g.doubleclick.net' /> <link rel='dns-prefetch' href='//www.googletagservices.com' /> <link rel='dns-prefetch' href='//cdn.switchadhub.com' /> <link rel='dns-prefetch' href='//delivery.g.switchadhub.com' /> <link rel='dns-prefetch' href='//delivery.swid.switchadhub.com' /> <link rel='dns-prefetch' href='//a.teads.tv' /> <link rel='dns-prefetch' href='//prebid.media.net' /> <link rel='dns-prefetch' href='//adserver-us.adtech.advertising.com' /> <link rel='dns-prefetch' href='//fastlane.rubiconproject.com' /> <link rel='dns-prefetch' href='//prebid-server.rubiconproject.com' /> <link rel='dns-prefetch' href='//hb-api.omnitagjs.com' /> <link rel='dns-prefetch' href='//mtrx.go.sonobi.com' /> <link rel='dns-prefetch' href='//apex.go.sonobi.com' /> <link rel='dns-prefetch' href='//u.openx.net' /> <link rel="alternate" type="application/rss+xml" title="guidetopharmacology blog » Feed" href="https://blog.guidetopharmacology.org/feed/" /> <link rel="alternate" type="application/rss+xml" title="guidetopharmacology blog » Comments Feed" href="https://blog.guidetopharmacology.org/comments/feed/" /> <script type="text/javascript"> /* <![CDATA[ */ function addLoadEvent(func) { var oldonload = window.onload; if (typeof window.onload != 'function') { window.onload = func; } else { window.onload = function () { oldonload(); func(); } } } /* ]]> */ </script> <script type="text/javascript"> /* <![CDATA[ */ window._wpemojiSettings = {"baseUrl":"https:\/\/s0.wp.com\/wp-content\/mu-plugins\/wpcom-smileys\/twemoji\/2\/72x72\/","ext":".png","svgUrl":"https:\/\/s0.wp.com\/wp-content\/mu-plugins\/wpcom-smileys\/twemoji\/2\/svg\/","svgExt":".svg","source":{"concatemoji":"https:\/\/s1.wp.com\/wp-includes\/js\/wp-emoji-release.min.js?m=1743601627i&ver=6.8-RC2-60138"}}; /*! This file is auto-generated */ !function(i,n){var o,s,e;function c(e){try{var t={supportTests:e,timestamp:(new Date).valueOf()};sessionStorage.setItem(o,JSON.stringify(t))}catch(e){}}function p(e,t,n){e.clearRect(0,0,e.canvas.width,e.canvas.height),e.fillText(t,0,0);var t=new Uint32Array(e.getImageData(0,0,e.canvas.width,e.canvas.height).data),r=(e.clearRect(0,0,e.canvas.width,e.canvas.height),e.fillText(n,0,0),new Uint32Array(e.getImageData(0,0,e.canvas.width,e.canvas.height).data));return t.every(function(e,t){return e===r[t]})}function u(e,t,n){switch(t){case"flag":return n(e,"\ud83c\udff3\ufe0f\u200d\u26a7\ufe0f","\ud83c\udff3\ufe0f\u200b\u26a7\ufe0f")?!1:!n(e,"\ud83c\uddfa\ud83c\uddf3","\ud83c\uddfa\u200b\ud83c\uddf3")&&!n(e,"\ud83c\udff4\udb40\udc67\udb40\udc62\udb40\udc65\udb40\udc6e\udb40\udc67\udb40\udc7f","\ud83c\udff4\u200b\udb40\udc67\u200b\udb40\udc62\u200b\udb40\udc65\u200b\udb40\udc6e\u200b\udb40\udc67\u200b\udb40\udc7f");case"emoji":return!n(e,"\ud83d\udc26\u200d\ud83d\udd25","\ud83d\udc26\u200b\ud83d\udd25")}return!1}function f(e,t,n){var r="undefined"!=typeof WorkerGlobalScope&&self instanceof WorkerGlobalScope?new OffscreenCanvas(300,150):i.createElement("canvas"),a=r.getContext("2d",{willReadFrequently:!0}),o=(a.textBaseline="top",a.font="600 32px Arial",{});return e.forEach(function(e){o[e]=t(a,e,n)}),o}function t(e){var t=i.createElement("script");t.src=e,t.defer=!0,i.head.appendChild(t)}"undefined"!=typeof Promise&&(o="wpEmojiSettingsSupports",s=["flag","emoji"],n.supports={everything:!0,everythingExceptFlag:!0},e=new Promise(function(e){i.addEventListener("DOMContentLoaded",e,{once:!0})}),new Promise(function(t){var n=function(){try{var e=JSON.parse(sessionStorage.getItem(o));if("object"==typeof e&&"number"==typeof e.timestamp&&(new Date).valueOf()<e.timestamp+604800&&"object"==typeof e.supportTests)return e.supportTests}catch(e){}return null}();if(!n){if("undefined"!=typeof Worker&&"undefined"!=typeof OffscreenCanvas&&"undefined"!=typeof URL&&URL.createObjectURL&&"undefined"!=typeof Blob)try{var e="postMessage("+f.toString()+"("+[JSON.stringify(s),u.toString(),p.toString()].join(",")+"));",r=new Blob([e],{type:"text/javascript"}),a=new Worker(URL.createObjectURL(r),{name:"wpTestEmojiSupports"});return void(a.onmessage=function(e){c(n=e.data),a.terminate(),t(n)})}catch(e){}c(n=f(s,u,p))}t(n)}).then(function(e){for(var t in e)n.supports[t]=e[t],n.supports.everything=n.supports.everything&&n.supports[t],"flag"!==t&&(n.supports.everythingExceptFlag=n.supports.everythingExceptFlag&&n.supports[t]);n.supports.everythingExceptFlag=n.supports.everythingExceptFlag&&!n.supports.flag,n.DOMReady=!1,n.readyCallback=function(){n.DOMReady=!0}}).then(function(){return e}).then(function(){var e;n.supports.everything||(n.readyCallback(),(e=n.source||{}).concatemoji?t(e.concatemoji):e.wpemoji&&e.twemoji&&(t(e.twemoji),t(e.wpemoji)))}))}((window,document),window._wpemojiSettings); /* ]]> */ </script> <link crossorigin='anonymous' rel='stylesheet' id='all-css-0-1' href='https://s0.wp.com/_static/??-eJx9jEEOwjAMBD9EMEWt4IJ4S5qYKK1jR7Wjqr+nSCA4cRzt7MBaXRA2ZIORJLlKLWVWWGWJPiokktHTMage4Mct7WvmmNAUsO2rzBkd+RUMSyVvqKC2Ef4LTGjVh/nNoI2hSGy0fzM/MmdDp2ERog9vr9y93LpL33fD+TRcpycptUsO&cssminify=yes' type='text/css' media='all' /> <style id='wp-emoji-styles-inline-css'> img.wp-smiley, img.emoji { display: inline !important; border: none !important; box-shadow: none !important; height: 1em !important; width: 1em !important; margin: 0 0.07em !important; vertical-align: -0.1em !important; background: none !important; padding: 0 !important; } </style> <link crossorigin='anonymous' rel='stylesheet' id='all-css-2-1' href='https://s2.wp.com/_static/??-eJydzEEOwiAQheELCdMSEtOF8SxAyYSKQGYGDbe37cadC5cvL98P76ZCLRKLQMsdU2HAvk8fCfeHIrzMpCdtwfeUV/C5hofKyZOjASwjRx2YL/AzdCqGLUpzB3ejdlFIaf03QU5SQf7y+/M2X+1slsUYu30AMZRP0A==&cssminify=yes' type='text/css' media='all' /> <style id='wp-block-library-inline-css'> .has-text-align-justify { text-align:justify; } .has-text-align-justify{text-align:justify;} </style> <link crossorigin='anonymous' rel='stylesheet' id='all-css-4-1' href='https://s2.wp.com/_static/??-eJzTLy/QzcxLzilNSS3WzyrWz01NyUxMzUnNTc0rQeEU5CRWphbp5qSmJyZX6uVm5uklFxfr6OPTDpRD5sM02efaGpoZmFkYGRuZGmQBAHPvL0Y=&cssminify=yes' type='text/css' media='all' /> <style id='jetpack-sharing-buttons-style-inline-css'> .jetpack-sharing-buttons__services-list{display:flex;flex-direction:row;flex-wrap:wrap;gap:0;list-style-type:none;margin:5px;padding:0}.jetpack-sharing-buttons__services-list.has-small-icon-size{font-size:12px}.jetpack-sharing-buttons__services-list.has-normal-icon-size{font-size:16px}.jetpack-sharing-buttons__services-list.has-large-icon-size{font-size:24px}.jetpack-sharing-buttons__services-list.has-huge-icon-size{font-size:36px}@media print{.jetpack-sharing-buttons__services-list{display:none!important}}.editor-styles-wrapper .wp-block-jetpack-sharing-buttons{gap:0;padding-inline-start:0}ul.jetpack-sharing-buttons__services-list.has-background{padding:1.25em 2.375em} </style> <link crossorigin='anonymous' rel='stylesheet' id='all-css-6-1' href='https://s2.wp.com/wp-content/plugins/coblocks/2.18.1-simple-rev.4/dist/coblocks-style.css?m=1681832297i&cssminify=yes' type='text/css' media='all' /> <style id='classic-theme-styles-inline-css'> /*! This file is auto-generated */ .wp-block-button__link{color:#fff;background-color:#32373c;border-radius:9999px;box-shadow:none;text-decoration:none;padding:calc(.667em + 2px) calc(1.333em + 2px);font-size:1.125em}.wp-block-file__button{background:#32373c;color:#fff;text-decoration:none} </style> <link crossorigin='anonymous' rel='stylesheet' id='all-css-8-1' href='https://s1.wp.com/_static/??/wp-content/mu-plugins/core-compat/wp-mediaelement.css,/wp-content/mu-plugins/wpcom-bbpress-premium-themes.css?m=1432920480j&cssminify=yes' type='text/css' media='all' /> <style id='global-styles-inline-css'> :root{--wp--preset--aspect-ratio--square: 1;--wp--preset--aspect-ratio--4-3: 4/3;--wp--preset--aspect-ratio--3-4: 3/4;--wp--preset--aspect-ratio--3-2: 3/2;--wp--preset--aspect-ratio--2-3: 2/3;--wp--preset--aspect-ratio--16-9: 16/9;--wp--preset--aspect-ratio--9-16: 9/16;--wp--preset--color--black: #000000;--wp--preset--color--cyan-bluish-gray: #abb8c3;--wp--preset--color--white: #ffffff;--wp--preset--color--pale-pink: #f78da7;--wp--preset--color--vivid-red: #cf2e2e;--wp--preset--color--luminous-vivid-orange: #ff6900;--wp--preset--color--luminous-vivid-amber: #fcb900;--wp--preset--color--light-green-cyan: #7bdcb5;--wp--preset--color--vivid-green-cyan: #00d084;--wp--preset--color--pale-cyan-blue: #8ed1fc;--wp--preset--color--vivid-cyan-blue: #0693e3;--wp--preset--color--vivid-purple: #9b51e0;--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;--wp--preset--font-family--albert-sans: 'Albert Sans', sans-serif;--wp--preset--font-family--alegreya: Alegreya, serif;--wp--preset--font-family--arvo: Arvo, serif;--wp--preset--font-family--bodoni-moda: 'Bodoni Moda', serif;--wp--preset--font-family--bricolage-grotesque: 'Bricolage Grotesque', sans-serif;--wp--preset--font-family--cabin: Cabin, sans-serif;--wp--preset--font-family--chivo: Chivo, sans-serif;--wp--preset--font-family--commissioner: Commissioner, sans-serif;--wp--preset--font-family--cormorant: Cormorant, serif;--wp--preset--font-family--courier-prime: 'Courier Prime', monospace;--wp--preset--font-family--crimson-pro: 'Crimson Pro', serif;--wp--preset--font-family--dm-mono: 'DM Mono', monospace;--wp--preset--font-family--dm-sans: 'DM Sans', sans-serif;--wp--preset--font-family--dm-serif-display: 'DM Serif Display', serif;--wp--preset--font-family--domine: Domine, serif;--wp--preset--font-family--eb-garamond: 'EB Garamond', serif;--wp--preset--font-family--epilogue: Epilogue, sans-serif;--wp--preset--font-family--fahkwang: Fahkwang, sans-serif;--wp--preset--font-family--figtree: Figtree, sans-serif;--wp--preset--font-family--fira-sans: 'Fira Sans', sans-serif;--wp--preset--font-family--fjalla-one: 'Fjalla One', sans-serif;--wp--preset--font-family--fraunces: Fraunces, serif;--wp--preset--font-family--gabarito: Gabarito, system-ui;--wp--preset--font-family--ibm-plex-mono: 'IBM Plex Mono', monospace;--wp--preset--font-family--ibm-plex-sans: 'IBM Plex Sans', sans-serif;--wp--preset--font-family--ibarra-real-nova: 'Ibarra Real Nova', serif;--wp--preset--font-family--instrument-serif: 'Instrument Serif', serif;--wp--preset--font-family--inter: Inter, sans-serif;--wp--preset--font-family--josefin-sans: 'Josefin Sans', sans-serif;--wp--preset--font-family--jost: Jost, sans-serif;--wp--preset--font-family--libre-baskerville: 'Libre Baskerville', serif;--wp--preset--font-family--libre-franklin: 'Libre Franklin', sans-serif;--wp--preset--font-family--literata: Literata, serif;--wp--preset--font-family--lora: Lora, serif;--wp--preset--font-family--merriweather: Merriweather, serif;--wp--preset--font-family--montserrat: Montserrat, sans-serif;--wp--preset--font-family--newsreader: Newsreader, serif;--wp--preset--font-family--noto-sans-mono: 'Noto Sans Mono', sans-serif;--wp--preset--font-family--nunito: Nunito, sans-serif;--wp--preset--font-family--open-sans: 'Open Sans', sans-serif;--wp--preset--font-family--overpass: Overpass, sans-serif;--wp--preset--font-family--pt-serif: 'PT Serif', serif;--wp--preset--font-family--petrona: Petrona, serif;--wp--preset--font-family--piazzolla: Piazzolla, serif;--wp--preset--font-family--playfair-display: 'Playfair Display', serif;--wp--preset--font-family--plus-jakarta-sans: 'Plus Jakarta Sans', sans-serif;--wp--preset--font-family--poppins: Poppins, sans-serif;--wp--preset--font-family--raleway: Raleway, sans-serif;--wp--preset--font-family--roboto: Roboto, sans-serif;--wp--preset--font-family--roboto-slab: 'Roboto Slab', serif;--wp--preset--font-family--rubik: Rubik, sans-serif;--wp--preset--font-family--rufina: Rufina, serif;--wp--preset--font-family--sora: Sora, sans-serif;--wp--preset--font-family--source-sans-3: 'Source Sans 3', sans-serif;--wp--preset--font-family--source-serif-4: 'Source Serif 4', serif;--wp--preset--font-family--space-mono: 'Space Mono', monospace;--wp--preset--font-family--syne: Syne, sans-serif;--wp--preset--font-family--texturina: Texturina, serif;--wp--preset--font-family--urbanist: Urbanist, sans-serif;--wp--preset--font-family--work-sans: 'Work Sans', sans-serif;--wp--preset--spacing--20: 0.44rem;--wp--preset--spacing--30: 0.67rem;--wp--preset--spacing--40: 1rem;--wp--preset--spacing--50: 1.5rem;--wp--preset--spacing--60: 2.25rem;--wp--preset--spacing--70: 3.38rem;--wp--preset--spacing--80: 5.06rem;--wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);--wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);--wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);--wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1), 6px 6px rgba(0, 0, 0, 1);--wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);}:where(.is-layout-flex){gap: 0.5em;}:where(.is-layout-grid){gap: 0.5em;}body .is-layout-flex{display: flex;}.is-layout-flex{flex-wrap: wrap;align-items: center;}.is-layout-flex > :is(*, div){margin: 0;}body .is-layout-grid{display: grid;}.is-layout-grid > :is(*, div){margin: 0;}:where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;}:where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;}.has-black-color{color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-color{color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-color{color: var(--wp--preset--color--white) !important;}.has-pale-pink-color{color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-color{color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-color{color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-color{color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-color{color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-color{color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-color{color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-color{color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-color{color: var(--wp--preset--color--vivid-purple) !important;}.has-black-background-color{background-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-background-color{background-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-background-color{background-color: var(--wp--preset--color--white) !important;}.has-pale-pink-background-color{background-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-background-color{background-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-background-color{background-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-background-color{background-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-background-color{background-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-background-color{background-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-background-color{background-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-background-color{background-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-background-color{background-color: var(--wp--preset--color--vivid-purple) !important;}.has-black-border-color{border-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-border-color{border-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-border-color{border-color: var(--wp--preset--color--white) !important;}.has-pale-pink-border-color{border-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-border-color{border-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-border-color{border-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-border-color{border-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-border-color{border-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-border-color{border-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-border-color{border-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-border-color{border-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-border-color{border-color: var(--wp--preset--color--vivid-purple) !important;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;}.has-albert-sans-font-family{font-family: var(--wp--preset--font-family--albert-sans) !important;}.has-alegreya-font-family{font-family: var(--wp--preset--font-family--alegreya) !important;}.has-arvo-font-family{font-family: var(--wp--preset--font-family--arvo) !important;}.has-bodoni-moda-font-family{font-family: var(--wp--preset--font-family--bodoni-moda) !important;}.has-bricolage-grotesque-font-family{font-family: var(--wp--preset--font-family--bricolage-grotesque) !important;}.has-cabin-font-family{font-family: var(--wp--preset--font-family--cabin) !important;}.has-chivo-font-family{font-family: var(--wp--preset--font-family--chivo) !important;}.has-commissioner-font-family{font-family: var(--wp--preset--font-family--commissioner) !important;}.has-cormorant-font-family{font-family: var(--wp--preset--font-family--cormorant) !important;}.has-courier-prime-font-family{font-family: var(--wp--preset--font-family--courier-prime) !important;}.has-crimson-pro-font-family{font-family: var(--wp--preset--font-family--crimson-pro) !important;}.has-dm-mono-font-family{font-family: var(--wp--preset--font-family--dm-mono) !important;}.has-dm-sans-font-family{font-family: var(--wp--preset--font-family--dm-sans) !important;}.has-dm-serif-display-font-family{font-family: var(--wp--preset--font-family--dm-serif-display) !important;}.has-domine-font-family{font-family: var(--wp--preset--font-family--domine) !important;}.has-eb-garamond-font-family{font-family: var(--wp--preset--font-family--eb-garamond) !important;}.has-epilogue-font-family{font-family: var(--wp--preset--font-family--epilogue) !important;}.has-fahkwang-font-family{font-family: var(--wp--preset--font-family--fahkwang) !important;}.has-figtree-font-family{font-family: var(--wp--preset--font-family--figtree) !important;}.has-fira-sans-font-family{font-family: var(--wp--preset--font-family--fira-sans) !important;}.has-fjalla-one-font-family{font-family: var(--wp--preset--font-family--fjalla-one) !important;}.has-fraunces-font-family{font-family: var(--wp--preset--font-family--fraunces) !important;}.has-gabarito-font-family{font-family: var(--wp--preset--font-family--gabarito) !important;}.has-ibm-plex-mono-font-family{font-family: var(--wp--preset--font-family--ibm-plex-mono) !important;}.has-ibm-plex-sans-font-family{font-family: var(--wp--preset--font-family--ibm-plex-sans) !important;}.has-ibarra-real-nova-font-family{font-family: var(--wp--preset--font-family--ibarra-real-nova) !important;}.has-instrument-serif-font-family{font-family: var(--wp--preset--font-family--instrument-serif) !important;}.has-inter-font-family{font-family: var(--wp--preset--font-family--inter) !important;}.has-josefin-sans-font-family{font-family: var(--wp--preset--font-family--josefin-sans) !important;}.has-jost-font-family{font-family: var(--wp--preset--font-family--jost) !important;}.has-libre-baskerville-font-family{font-family: var(--wp--preset--font-family--libre-baskerville) !important;}.has-libre-franklin-font-family{font-family: var(--wp--preset--font-family--libre-franklin) !important;}.has-literata-font-family{font-family: var(--wp--preset--font-family--literata) !important;}.has-lora-font-family{font-family: var(--wp--preset--font-family--lora) !important;}.has-merriweather-font-family{font-family: var(--wp--preset--font-family--merriweather) !important;}.has-montserrat-font-family{font-family: var(--wp--preset--font-family--montserrat) !important;}.has-newsreader-font-family{font-family: var(--wp--preset--font-family--newsreader) !important;}.has-noto-sans-mono-font-family{font-family: var(--wp--preset--font-family--noto-sans-mono) !important;}.has-nunito-font-family{font-family: var(--wp--preset--font-family--nunito) !important;}.has-open-sans-font-family{font-family: var(--wp--preset--font-family--open-sans) !important;}.has-overpass-font-family{font-family: var(--wp--preset--font-family--overpass) !important;}.has-pt-serif-font-family{font-family: var(--wp--preset--font-family--pt-serif) !important;}.has-petrona-font-family{font-family: var(--wp--preset--font-family--petrona) !important;}.has-piazzolla-font-family{font-family: var(--wp--preset--font-family--piazzolla) !important;}.has-playfair-display-font-family{font-family: var(--wp--preset--font-family--playfair-display) !important;}.has-plus-jakarta-sans-font-family{font-family: var(--wp--preset--font-family--plus-jakarta-sans) !important;}.has-poppins-font-family{font-family: var(--wp--preset--font-family--poppins) !important;}.has-raleway-font-family{font-family: var(--wp--preset--font-family--raleway) !important;}.has-roboto-font-family{font-family: var(--wp--preset--font-family--roboto) !important;}.has-roboto-slab-font-family{font-family: var(--wp--preset--font-family--roboto-slab) !important;}.has-rubik-font-family{font-family: var(--wp--preset--font-family--rubik) !important;}.has-rufina-font-family{font-family: var(--wp--preset--font-family--rufina) !important;}.has-sora-font-family{font-family: var(--wp--preset--font-family--sora) !important;}.has-source-sans-3-font-family{font-family: var(--wp--preset--font-family--source-sans-3) !important;}.has-source-serif-4-font-family{font-family: var(--wp--preset--font-family--source-serif-4) !important;}.has-space-mono-font-family{font-family: var(--wp--preset--font-family--space-mono) !important;}.has-syne-font-family{font-family: var(--wp--preset--font-family--syne) !important;}.has-texturina-font-family{font-family: var(--wp--preset--font-family--texturina) !important;}.has-urbanist-font-family{font-family: var(--wp--preset--font-family--urbanist) !important;}.has-work-sans-font-family{font-family: var(--wp--preset--font-family--work-sans) !important;} :where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;} :root :where(.wp-block-pullquote){font-size: 1.5em;line-height: 1.6;} :where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;} </style> <link crossorigin='anonymous' rel='stylesheet' id='all-css-10-1' href='https://s1.wp.com/wp-content/themes/pub/responsive/style.css?m=1499906764i&cssminify=yes' type='text/css' media='all' /> <style id='jetpack_facebook_likebox-inline-css'> .widget_facebook_likebox { overflow: hidden; } </style> <style id='akismet-widget-style-inline-css'> .a-stats { --akismet-color-mid-green: #357b49; --akismet-color-white: #fff; --akismet-color-light-grey: #f6f7f7; max-width: 350px; width: auto; } .a-stats * { all: unset; box-sizing: border-box; } .a-stats strong { font-weight: 600; } .a-stats a.a-stats__link, .a-stats a.a-stats__link:visited, .a-stats a.a-stats__link:active { background: var(--akismet-color-mid-green); border: none; box-shadow: none; border-radius: 8px; color: var(--akismet-color-white); cursor: pointer; display: block; font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Roboto', 'Oxygen-Sans', 'Ubuntu', 'Cantarell', 'Helvetica Neue', sans-serif; font-weight: 500; padding: 12px; text-align: center; text-decoration: none; transition: all 0.2s ease; } /* Extra specificity to deal with TwentyTwentyOne focus style */ .widget .a-stats a.a-stats__link:focus { background: var(--akismet-color-mid-green); color: var(--akismet-color-white); text-decoration: none; } .a-stats a.a-stats__link:hover { filter: brightness(110%); box-shadow: 0 4px 12px rgba(0, 0, 0, 0.06), 0 0 2px rgba(0, 0, 0, 0.16); } .a-stats .count { color: var(--akismet-color-white); display: block; font-size: 1.5em; line-height: 1.4; padding: 0 13px; white-space: nowrap; } </style> <link crossorigin='anonymous' rel='stylesheet' id='all-css-14-1' href='https://s1.wp.com/_static/??-eJzTLy/QTc7PK0nNK9HPLdUtyClNz8wr1i9KTcrJTwcy0/WTi5G5ekCujj52Temp+bo5+cmJJZn5eSgc3bScxMwikFb7XFtDE1NLExMLc0OTLACohS2q&cssminify=yes' type='text/css' media='all' /> <style id='jetpack-global-styles-frontend-style-inline-css'> :root { --font-headings: unset; --font-base: unset; --font-headings-default: -apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif; --font-base-default: -apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif;} </style> <link crossorigin='anonymous' rel='stylesheet' id='all-css-16-1' href='https://s2.wp.com/wp-content/themes/h4/global.css?m=1420737423i&cssminify=yes' type='text/css' media='all' /> <script type="text/javascript" id="wpcom-actionbar-placeholder-js-extra"> /* <![CDATA[ */ var actionbardata = {"siteID":"28218243","postID":"0","siteURL":"https:\/\/blog.guidetopharmacology.org","xhrURL":"https:\/\/blog.guidetopharmacology.org\/wp-admin\/admin-ajax.php","nonce":"42e3bcad00","isLoggedIn":"","statusMessage":"","subsEmailDefault":"instantly","proxyScriptUrl":"https:\/\/s0.wp.com\/wp-content\/js\/wpcom-proxy-request.js?ver=20211021","i18n":{"followedText":"New posts from this site will now appear in your <a href=\"https:\/\/wordpress.com\/reader\">Reader<\/a>","foldBar":"Collapse this bar","unfoldBar":"Expand this bar","shortLinkCopied":"Shortlink copied to clipboard."}}; /* ]]> */ </script> <script type="text/javascript" id="jetpack-mu-wpcom-settings-js-before"> /* <![CDATA[ */ var JETPACK_MU_WPCOM_SETTINGS = {"assetsUrl":"https:\/\/s1.wp.com\/wp-content\/mu-plugins\/jetpack-mu-wpcom-plugin\/sun\/jetpack_vendor\/automattic\/jetpack-mu-wpcom\/src\/build\/"}; /* ]]> */ </script> <script crossorigin='anonymous' type='text/javascript' src='https://s1.wp.com/_static/??-eJyFTkkOwjAM/BAmpYjtgHhLm1ghVeIEO2kpr6dlE+LCaTSaVQ0JdKSMlFUnin2GxPE6LjtZqElzpH0xKLPYXQry+IJlcPTXBMFZbjJ+m99r+YxhiqTSKkZJkcT1+PjwYRCiQSZ3499w66OF5It1JGqIbBojoH0j8nyhQ1J9PQNQJLAmzRWncFzt6mqzrrb7Q3cHtxtdBw=='></script> <script type="text/javascript" id="rlt-proxy-js-after"> /* <![CDATA[ */ rltInitialize( {"token":null,"iframeOrigins":["https:\/\/widgets.wp.com"]} ); /* ]]> */ </script> <link rel="EditURI" type="application/rsd+xml" title="RSD" href="https://guidetopharmacology.wordpress.com/xmlrpc.php?rsd" /> <meta name="generator" content="WordPress.com" /> <link rel='shortlink' href='https://wp.me/1UoQX' />  <meta property="og:type" content="website" /> <meta property="og:title" content="guidetopharmacology blog" /> <meta property="og:description" content="The official blog of the IUPHAR/BPS Guide to PHARMACOLOGY" /> <meta property="og:url" content="https://blog.guidetopharmacology.org/" /> <meta property="og:site_name" content="guidetopharmacology blog" /> <meta property="og:image" content="https://secure.gravatar.com/blavatar/b0ee620758eba563c7003e3aeb0236b12bff8ba81d569b54bdd4ab6b9471a595?s=200&ts=1744378902" /> <meta property="og:image:width" content="200" /> <meta property="og:image:height" content="200" /> <meta property="og:image:alt" content="" /> <meta property="og:locale" content="en_US" />  <link rel="shortcut icon" type="image/x-icon" href="https://secure.gravatar.com/blavatar/b0ee620758eba563c7003e3aeb0236b12bff8ba81d569b54bdd4ab6b9471a595?s=32" sizes="16x16" /> <link rel="icon" type="image/x-icon" href="https://secure.gravatar.com/blavatar/b0ee620758eba563c7003e3aeb0236b12bff8ba81d569b54bdd4ab6b9471a595?s=32" sizes="16x16" /> <link rel="apple-touch-icon" href="https://secure.gravatar.com/blavatar/b0ee620758eba563c7003e3aeb0236b12bff8ba81d569b54bdd4ab6b9471a595?s=114" /> <link rel='openid.server' href='https://blog.guidetopharmacology.org/?openidserver=1' /> <link rel='openid.delegate' href='https://blog.guidetopharmacology.org/' /> <link rel="search" type="application/opensearchdescription+xml" href="https://blog.guidetopharmacology.org/osd.xml" title="guidetopharmacology blog" /> <link rel="search" type="application/opensearchdescription+xml" href="https://s1.wp.com/opensearch.xml" title="WordPress.com" /> <meta name="theme-color" content="#efefef" /> <style type="text/css"> .recentcomments a { display: inline !important; padding: 0 !important; margin: 0 !important; } table.recentcommentsavatartop img.avatar, table.recentcommentsavatarend img.avatar { border: 0px; margin: 0; } table.recentcommentsavatartop a, table.recentcommentsavatarend a { border: 0px !important; background-color: transparent !important; } td.recentcommentsavatarend, td.recentcommentsavatartop { padding: 0px 0px 1px 0px; margin: 0px; } td.recentcommentstextend { border: none !important; padding: 0px 0px 2px 10px; } .rtl td.recentcommentstextend { padding: 0px 10px 2px 0px; } td.recentcommentstexttop { border: none; padding: 0px 0px 0px 10px; } .rtl td.recentcommentstexttop { padding: 0px 10px 0px 0px; } </style> <meta name="description" content="The official blog of the IUPHAR/BPS Guide to PHARMACOLOGY" /> <style type="text/css"> .site-title, .site-description { color: #1e73be; } </style> <script type="text/javascript"> /* <![CDATA[ */ var wa_client = {}; wa_client.cmd = []; wa_client.config = { 'blog_id': 28218243, 'blog_language': 'en', 'is_wordads': false, 'hosting_type': 0, 'theme': 'pub/responsive', '_': { 'title': 'Advertisement', 'privacy_settings': 'Privacy Settings' }, 'formats': [ 'belowpost', 'bottom_sticky', 'sidebar_sticky_right', 'sidebar' ] }; /* ]]> */ </script> <script type="text/javascript"> function __ATA_CC() {var v = document.cookie.match('(^|;) ?personalized-ads-consent=([^;]*)(;|$)');return v ? 1 : 0;} var __ATA_PP = { 'pt': 0, 'ht': 0, 'tn': 'responsive', 'uloggedin': 0, 'amp': false, 'consent': __ATA_CC(), 'gdpr_applies': false, 'ad': { 'label': { 'text': 'Advertisements' }, 'reportAd': { 'text': 'Report this ad' } }, 'disabled_slot_formats': [ 'MTS', 'DPR' ], 'siteid': 8982, 'blogid': 28218243 }; var __ATA = __ATA || {}; __ATA.cmd = __ATA.cmd || []; __ATA.criteo = __ATA.criteo || {}; __ATA.criteo.cmd = __ATA.criteo.cmd || []; </script> <script type="text/javascript"> (function(){var g=Date.now||function(){return+new Date};function h(a,b){a:{for(var c=a.length,d="string"==typeof a?a.split(""):a,e=0;e<c;e++)if(e in d&&b.call(void 0,d[e],e,a)){b=e;break a}b=-1}return 0>b?null:"string"==typeof a?a.charAt(b):a[b]};function k(a,b,c){c=null!=c?"="+encodeURIComponent(String(c)):"";if(b+=c){c=a.indexOf("#");0>c&&(c=a.length);var d=a.indexOf("?");if(0>d||d>c){d=c;var e=""}else e=a.substring(d+1,c);a=[a.substr(0,d),e,a.substr(c)];c=a[1];a[1]=b?c?c+"&"+b:b:c;a=a[0]+(a[1]?"?"+a[1]:"")+a[2]}return a};var l=0;function m(a,b){var c=document.createElement("script");c.src=a;c.onload=function(){b&&b(void 0)};c.onerror=function(){b&&b("error")};a=document.getElementsByTagName("head");var d;a&&0!==a.length?d=a[0]:d=document.documentElement;d.appendChild(c)}function n(a){var b=void 0===b?document.cookie:b;return(b=h(b.split("; "),function(c){return-1!=c.indexOf(a+"=")}))?b.split("=")[1]:""}function p(a){return"string"==typeof a&&0<a.length} function r(a,b,c){b=void 0===b?"":b;c=void 0===c?".":c;var d=[];Object.keys(a).forEach(function(e){var f=a[e],q=typeof f;"object"==q&&null!=f||"function"==q?d.push(r(f,b+e+c)):null!==f&&void 0!==f&&(e=encodeURIComponent(b+e),d.push(e+"="+encodeURIComponent(f)))});return d.filter(p).join("&")}function t(a,b){a||((window.__ATA||{}).config=b.c,m(b.url))}var u=Math.floor(1E13*Math.random()),v=window.__ATA||{};window.__ATA=v;window.__ATA.cmd=v.cmd||[];v.rid=u;v.createdAt=g();var w=window.__ATA||{},x="s.pubmine.com"; w&&w.serverDomain&&(x=w.serverDomain);var y="//"+x+"/conf",z=window.top===window,A=window.__ATA_PP&&window.__ATA_PP.gdpr_applies,B="boolean"===typeof A?Number(A):null,C=window.__ATA_PP||null,D=z?document.referrer?document.referrer:null:null,E=z?window.location.href:document.referrer?document.referrer:null,F,G=n("__ATA_tuuid");F=G?G:null;var H=window.innerWidth+"x"+window.innerHeight,I=n("usprivacy"),J=r({gdpr:B,pp:C,rid:u,src:D,ref:E,tuuid:F,vp:H,us_privacy:I?I:null},"","."); (function(a){var b=void 0===b?"cb":b;l++;var c="callback__"+g().toString(36)+"_"+l.toString(36);a=k(a,b,c);window[c]=function(d){t(void 0,d)};m(a,function(d){d&&t(d)})})(y+"?"+J);}).call(this); </script> <script> var sas_fallback = sas_fallback || []; sas_fallback.push( { tag: "<div id="atatags-26942-{{unique_id}}"></div><script>__ATA.cmd.push(function() {__ATA.initDynamicSlot({id: \'atatags-26942-{{unique_id}}\',location: 120,formFactor: \'001\',label: {text: \'Advertisements\',},creative: {reportAd: {text: \'Report this ad\',},privacySettings: {text: \'Privacy\',}}});});</script>", type: 'belowpost' }, { tag: "<div id="atatags-26942-{{unique_id}}"></div><script>__ATA.cmd.push(function() {__ATA.initDynamicSlot({id: \'atatags-26942-{{unique_id}}\',location: 310,formFactor: \'001\',label: {text: \'Advertisements\',},creative: {reportAd: {text: \'Report this ad\',},privacySettings: {text: \'Privacy\',}}});});</script>", type: 'inline' }, { tag: "<div id="atatags-26942-{{unique_id}}"></div><script>__ATA.cmd.push(function() {__ATA.initDynamicSlot({id: \'atatags-26942-{{unique_id}}\',location: 140,formFactor: \'003\',label: {text: \'Advertisements\',},creative: {reportAd: {text: \'Report this ad\',},privacySettings: {text: \'Privacy\',}}});});</script>", type: 'sidebar' }, { tag: "<div id="atatags-26942-{{unique_id}}"></div><script>__ATA.cmd.push(function() {__ATA.initDynamicSlot({id: \'atatags-26942-{{unique_id}}\',location: 110,formFactor: \'002\',label: {text: \'Advertisements\',},creative: {reportAd: {text: \'Report this ad\',},privacySettings: {text: \'Privacy\',}}});});</script>", type: 'top' } ); </script> <script type="text/javascript"> window.doNotSellCallback = function() { var linkElements = [ 'a[href="https://wordpress.com/?ref=footer_blog"]', 'a[href="https://wordpress.com/?ref=footer_website"]', 'a[href="https://wordpress.com/?ref=vertical_footer"]', 'a[href^="https://wordpress.com/?ref=footer_segment_"]', ].join(','); var dnsLink = document.createElement( 'a' ); dnsLink.href = 'https://wordpress.com/advertising-program-optout/'; dnsLink.classList.add( 'do-not-sell-link' ); dnsLink.rel = 'nofollow'; dnsLink.style.marginLeft = '0.5em'; dnsLink.textContent = 'Do Not Sell or Share My Personal Information'; var creditLinks = document.querySelectorAll( linkElements ); if ( 0 === creditLinks.length ) { return false; } Array.prototype.forEach.call( creditLinks, function( el ) { el.insertAdjacentElement( 'afterend', dnsLink ); }); return true; }; </script> <script type="text/javascript"> window.google_analytics_uacct = "UA-52447-2"; </script> <script type="text/javascript"> var _gaq = _gaq || []; _gaq.push(['_setAccount', 'UA-52447-2']); _gaq.push(['_gat._anonymizeIp']); _gaq.push(['_setDomainName', 'none']); _gaq.push(['_setAllowLinker', true]); _gaq.push(['_initData']); _gaq.push(['_trackPageview']); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; (document.getElementsByTagName('head')[0] || document.getElementsByTagName('body')[0]).appendChild(ga); })(); </script> </head> <body class="home blog wp-theme-pubresponsive customizer-styles-applied jetpack-reblog-enabled"> <div id="container" class="hfeed"> <div id="header"> <div id="logo"> <a href="https://blog.guidetopharmacology.org/" title="guidetopharmacology blog" rel="home"> <img src="https://blog.guidetopharmacology.org/wp-content/uploads/2014/01/cropped-gtp_header.jpg" class="header-image" width="947" height="117" alt="" /> </a> <a href="https://blog.guidetopharmacology.org/" class="site-logo-link" rel="home" itemprop="url"></a> <span class="site-name site-title"><a href="https://blog.guidetopharmacology.org/" title="guidetopharmacology blog" rel="home">guidetopharmacology blog</a></span> <span class="site-description">The official blog of the IUPHAR/BPS Guide to PHARMACOLOGY</span> </div> <nav role="navigation" class="site-navigation main-navigation"> <h1 class="assistive-text">Menu</h1> <div class="assistive-text skip-link"><a href="#content" title="Skip to content">Skip to content</a></div> <div class="menu-bar-container"><ul id="menu-bar" class="menu"><li id="menu-item-362" class="menu-item menu-item-type-custom menu-item-object-custom current-menu-item current_page_item menu-item-home menu-item-362"><a href="https://blog.guidetopharmacology.org/" aria-current="page">Home</a></li> <li id="menu-item-340" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-340"><a href="https://blog.guidetopharmacology.org/about/">About</a></li> <li id="menu-item-349" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-349"><a>Categories</a> <ul class="sub-menu"> <li id="menu-item-352" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-352"><a href="https://blog.guidetopharmacology.org/category/drug-targets/">Drug targets</a></li> <li id="menu-item-1049" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-1049"><a href="https://blog.guidetopharmacology.org/category/hot-topics/">Hot Topics</a></li> <li id="menu-item-353" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-353"><a href="https://blog.guidetopharmacology.org/category/chemical-curation/">Chemical curation</a></li> <li id="menu-item-354" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-354"><a href="https://blog.guidetopharmacology.org/category/database-updates/">Database updates</a></li> <li id="menu-item-351" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-351"><a href="https://blog.guidetopharmacology.org/category/events/">Events</a></li> <li id="menu-item-355" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-355"><a href="https://blog.guidetopharmacology.org/category/technical/">Technical</a></li> <li id="menu-item-472" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-472"><a href="https://blog.guidetopharmacology.org/category/publications/">Publications</a></li> <li id="menu-item-1050" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-1050"><a href="https://blog.guidetopharmacology.org/category/guide-to-immunopharmacology/">Guide to Immunopharmacology</a></li> <li id="menu-item-3568" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-3568"><a href="https://blog.guidetopharmacology.org/category/guide-to-malaria-pharmacology/">Guide to Malaria Pharmacology</a></li> <li id="menu-item-1077" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-1077"><a href="https://blog.guidetopharmacology.org/category/concise-guide-to-pharmacology/">Concise Guide to Pharmacology</a></li> </ul> </li> <li id="menu-item-3207" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-3207"><a href="https://blog.guidetopharmacology.org/category/hot-topics/">Hot Topics</a></li> <li id="menu-item-341" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-341"><a href="http://guidetopharmacology.org">GtoPdb homepage</a></li> <li id="menu-item-356" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-356"><a>Useful links</a> <ul class="sub-menu"> <li id="menu-item-3206" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-3206"><a href="https://blog.guidetopharmacology.org/category/hot-topics/">Hot Topics</a></li> <li id="menu-item-357" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-357"><a href="http://www.iuphar.org/">IUPHAR</a></li> <li id="menu-item-358" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-358"><a href="http://www.bps.ac.uk/view/index.html">British Pharmacological Society</a></li> <li id="menu-item-359" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-359"><a href="http://cdsouthan.blogspot.co.uk/">Bio Chem blog</a></li> <li id="menu-item-360" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-360"><a href="http://www.slideshare.net/GuidetoPHARM">SlideShare</a></li> <li id="menu-item-361" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-361"><a href="https://uk.linkedin.com/company/guide-to-pharmacology">Linkedin</a></li> </ul> </li> </ul></div> </nav> </div> <div id="wrapper" class="clearfix"> <div id="content-blog" class="grid col-620"> <div id="post-4725" class="post-4725 post type-post status-publish format-standard hentry category-chemical-curation category-database-updates category-technical"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2025/04/01/database-release-2025-1/" rel="bookmark">Database Release 2025.1</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2025/04/01/database-release-2025-1/" title="1:46 pm" rel="bookmark"><span class="timestamp">April 1, 2025</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2025/04/01/database-release-2025-1/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>The latest release (version 2025.1) of the IUPHAR/BPS Guide to Pharmacology database has been made. Released on 2nd April 2025 this is the first release of the year. The following blog post gives details of the key content updates and website changes. GtoPdb now contains:</p> <ul> <li><strong>3,097 </strong>human targets, <strong>1,758 </strong>of which have curated quantitative ligand interactions.</li> <li><strong>13,131</strong> ligands, <strong>9,485 </strong>of which have curated quantitative target interactions.</li> <li><strong>2,098 </strong>approved drugs, <strong>1,175 </strong>with curated quantitative interactions.</li> <li>Clinical use summaries for <strong>3,996</strong> ligands.</li> <li><strong>23,652</strong> curated interaction, <strong>21,491</strong> which are quantitative.</li> <li>Data curated from over <strong>47,009</strong> references</li> </ul> <p>In this release, <strong>181 new ligands</strong>, <strong>178 new curated interactions</strong> have been added.</p> <h3>Curation Update</h3> <h4>New targets curation</h4> <p>We have added 8 protein targets since release 2024.3, summarised in the table below:</p> <table border="1" cellspacing="0" cellpadding="0"> <tbody> <tr style="color: blue" bgcolor="lightgrey"> <td valign="top" width="73"><strong>TID</strong></td> <td valign="top" width="124"><strong>Family</strong></td> <td valign="top" width="74"><strong>Gene</strong></td> <td valign="top" width="113"><strong>Name</strong></td> <td valign="top" width="314"><strong>Comment</strong></td> </tr> <tr> <td valign="top"><a title="Original URL: https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=991&objId=3299#3299. Click or tap if you trust this link." href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3299" target="_blank" rel="noopener noreferrer">3299</a></td> <td valign="top"><span>Neuropilins and Plexins</span></td> <td valign="top"><a href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9107"><i>PLXND1</i></a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3299">plexin D1</a></td> <td valign="top">Involved in axon guidance. Expression upregulated in prostate cancer, drives aggressiveness, invasiveness, and drug resistance. A preclinical synthetic PlexinD1:Fc decoy fusion protein (D1SP) is curated (oncology)</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3300">3300</a></td> <td valign="top">Sortilin family proteins</td> <td valign="top"><a href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11186"><em>SORT1</em></a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3300">sortilin 1</a></td> <td valign="top">Blocking sortilin 1 activity increases progranulin (PGRN) in a preclinical model of frontotemporal dementia and in patients- ? Translation to reduced disease progression. Two anti-SORT1 mAbs curated (neurodegeneration)</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3301">3301</a></td> <td valign="top">CD33-related SIGLECs</td> <td valign="top"><a href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10875"><i>SIGLEC6</i></a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3301">sialic acid binding Ig like lectin 6</a></td> <td valign="top">Considered as a therapeutic target for the treatment of eosinophil- and mast cell-mediated inflammation- development of anti-SIGLEC6 mAb discontinued at phase 1 (lack of efficacy)</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3302">3302</a></td> <td valign="top">Thioredoxin (Trx) system proteins</td> <td valign="top"><a href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12437"><i>TXNRD1</i></a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3302">thioredoxin reductase 1</a></td> <td valign="top">thioredoxin antioxidant system- overexpression is associated with drug resistance and poor prognosis in several types of cancer. Inhibitors hyperactivate ROS production -> ER stress and apoptosis. Synthetic and NP inhibitors curated (oncology)</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3303">3303</a></td> <td valign="top">Tumour-associated antigens</td> <td valign="top"><a href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11378"><i>STEAP1</i></a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3303">STEAP family member 1</a></td> <td valign="top">Antigen highly expressed on prostate cancer and metastases, functions in cell-cell junctions. Anti-STEAP1 mAb curated (oncology)</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3304">3304</a></td> <td valign="top">T-box transcription factors</td> <td valign="top"><a href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10875"><i>TBXT</i></a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3304">T-box transcription factor T</a></td> <td valign="top">Aka brachyury- oncogenic in chordoma (a bone cancer) – inhibitor compound curated (oncology)</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3305">3305</a></td> <td valign="top">WD repeat-containing proteins</td> <td valign="top"><a href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10875"><i>SIGLEC6</i></a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3305">NACHT and WD repeat domain containing 1</a></td> <td valign="top">Novel target for metabolic dysfunction-associated steatohepatitis (MASH) (metabolic disease)</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3306">3306</a></td> <td valign="top">Lymphocyte antigens</td> <td valign="top"><a href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10875"><i>LY75</i></a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3306">lymphocyte antigen 75</a></td> <td valign="top">Differentially expressed in malignancies from various histotypes- rapidly internalises so good target for delivery of cytotoxic agents to tumour cells- ADC OBT076 (maytansinoid microtubule disruptor payload) curated (oncology)</td> </tr> </tbody> </table> <p> </p> <p><b>Ligands</b></p> <p class="x_MsoNormal"><span>In total, 180 new ligands have been added to the GtoPdb since the last update in December 2024 (<a href="https://blog.guidetopharmacology.org/2024/12/05/database-release-2024-4/">release 2024.4</a>). These include synthetic small molecules, antibacterials, antibodies, peptides and natural products.</span></p> <p class="x_MsoNormal">Our list of approved drugs for 2024 was expanded to a total of 61. This set includes first approvals from regulatory agencies other than the FDA and EMA, such as China’s NPMA and Japan’s PMDA. 7 of the new approvals are not included as fully-curated ligand entries as they fall out with our inclusion criteria. Presentation of this set of drugs on the website is discussed in more detail below, in the database development section.</p> <p class="x_MsoNormal">The new WHO INN proposed list 132 (PL132) was published in mid-February 2025.</p> <p class="x_MsoNormal">Of the 249 INNs, 54 are curated in the GtoPdb; 24 existed under alternate names and were matched on chemical structures to the INNS. A further 30 (the majority of which are kinase inhibitors) are brand new entities for the GtoPdb, and where possible the structures are matched to internal company IDs (even speculatively when no name-structure has been formally disclosed), patent claims, target-specific quantitative data and clinical trials. The INN secutrelvir was matched to the Shionogi SARS-CoV-2 Mpro inhibitor S892216.</p> <p class="x_MsoNormal">GtoPdb ligands that have INNS from PL132 are listed in tables 1 and 2 below.</p> <p><strong>Table 1: INNs from PL132 for kinase inhibitors that are in the GtoPdb</strong></p> <table border="1" cellspacing="0" cellpadding="0"> <tbody> <tr style="color: blue" bgcolor="lightgrey"> <td style="text-align: center" valign="top" width="64"><strong>LID</strong></td> <td style="text-align: center" valign="top" width="163"><strong>INN</strong></td> </tr> <tr> <td>8204</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8204">rizavasertib</a></td> </tr> <tr> <td>12625</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12625">veludacigib</a></td> </tr> <tr> <td>12703</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12703">ubavitinib</a></td> </tr> <tr> <td>12711</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12711">gozanertinib</a></td> </tr> <tr> <td>12903</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12903">tersolisib</a></td> </tr> <tr> <td>13267</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13267">famlasertib</a></td> </tr> <tr> <td>13297</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13297">cirtociclib</a></td> </tr> <tr> <td>13371</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13371">silevertinib</a></td> </tr> <tr> <td>13731</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13731">alnodesertib</a></td> </tr> <tr> <td>13732</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13732">andamertinib</a></td> </tr> <tr> <td>13733</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13733">atebimetinib</a></td> </tr> <tr> <td>13734</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13734">balomenib</a></td> </tr> <tr> <td>13735</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13735">birelentinib</a></td> </tr> <tr> <td>13736</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12903">catadegbrutinib</a></td> </tr> <tr> <td>13740</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13740">pruvonertinib</a></td> </tr> <tr> <td>13741</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13741">perzebertinib</a></td> </tr> <tr> <td>13742</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13742">emupertinib</a></td> </tr> <tr> <td>13743</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12903">engasertib</a></td> </tr> <tr> <td>13744</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12903">enozertinib</a></td> </tr> <tr> <td>13746</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13746">lasmotinib</a></td> </tr> <tr> <td>13747</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13747">lirucitinib</a></td> </tr> <tr> <td>13750</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=113750">lomonitinib</a></td> </tr> <tr> <td>13751</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13751">pasodacigib</a></td> </tr> <tr> <td>13752</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13752">tosposertib</a></td> </tr> <tr> <td>13753</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13753">romaciclib</a></td> </tr> <tr> <td>13754</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13754">zeltociclib</a></td> </tr> <tr> <td>13806</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13806">fosizensertib</a></td> </tr> <tr> <td>13808</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13808">claturafenib</a></td> </tr> <tr> <td>13809</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13809">dabogratinib</a></td> </tr> <tr> <td>13811</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13811">dirozalkib</a></td> </tr> </tbody> </table> <p><strong>Table 2: INNs from PL132 in the GtoPdb for miscellaneous protein targets</strong></p> <table border="1" cellspacing="0" cellpadding="0"> <tbody> <tr style="color: blue" bgcolor="lightgrey"> <td style="text-align: center" valign="top" width="64"><strong>LID</strong></td> <td style="text-align: center" valign="top" width="163"><strong>INN</strong></td> </tr> <tr> <td>11116</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11116">olisutrigine bromide</a></td> </tr> <tr> <td>11514</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11514">solangepras</a></td> </tr> <tr> <td>11859</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11859">tetrandrine</a></td> </tr> <tr> <td>11946</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11946">palacaparib</a></td> </tr> <tr> <td>11953</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11953">ceperognastat</a></td> </tr> <tr> <td>12116</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12116">navlimetostat</a></td> </tr> <tr> <td>12622</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12622">elironrasib</a></td> </tr> <tr> <td>12802</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12802">vilagletistat</a></td> </tr> <tr> <td>12895</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12895">nedizantrep</a></td> </tr> <tr> <td>12902</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12902">vopimetostat</a></td> </tr> <tr> <td>12973</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12973">elunetirom</a></td> </tr> <tr> <td>13002</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13002">fudapirine</a></td> </tr> <tr> <td>13241</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13241">xeruborbactam isoboxil</a></td> </tr> <tr> <td>13320</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13320">ralometostat</a></td> </tr> <tr> <td>13368</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13368">daraxonrasib</a></td> </tr> <tr> <td>13552</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13552">zalsupindole</a></td> </tr> <tr> <td>13737</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13737">ratutrelvir</a></td> </tr> <tr> <td>13738</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13738">secutrelvir</a></td> </tr> <tr> <td>13739</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13739">rugocrixan</a></td> </tr> <tr> <td>13745</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13745">larubrilstat</a></td> </tr> <tr> <td>13798</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13798">adimanebart</a></td> </tr> <tr> <td>13800</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13800">balertatug</a></td> </tr> <tr> <td>13802</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13802">becondogrel</a></td> </tr> <tr> <td>13803</td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13803">darlifarnib</a></td> </tr> </tbody> </table> <h3>Antibacterial Curation</h3> <p>Our collaboration with Antibiotic DB (ADB; <a class="ms-outlook-linkify" href="http://www.antibioticdb.com/" target="_blank" rel="noopener">www.antibioticdb.com</a>) continues to allow us to extend the coverage of ligands with annotated antibacterial activity in GtoPdb and provide comprehensive chemistry and pharmacology for select antibacterials curated within ADB, via reciprocal links. This project is supported by the Global Antibiotic Research and Development Partnership (GARDP; <a class="ms-outlook-linkify" href="https://gardp.org/" target="_blank" rel="noopener">https://gardp.org/</a>).</p> <p>Currently we have <a href="https://www.guidetopharmacology.org/GRAC/LigandListForward?type=AntiBac&database=all"><b>648 ligands</b></a> tagged in GtoPdb as ‘antibacterial’ and <b>628 </b>of these have links to compounds at ADB. <strong>267</strong> are approved drugs. Since our last release we have added <b>34 </b>new antibacterial ligands including:</p> <ul> <li style="list-style-type: none"> <ul type="disc"> <li><b>3</b> drugs that are approved, or have been approved in the past, for clinical use in human</li> </ul> </li> </ul> <p><span>We are developing a new landing page for antibacterials </span>in the Guide to Pharmacology and this will be publicly available as part of a future database release.</p> <h3>Website Updates</h3> <h4>Drug Approvals summary page</h4> <p>We have developed a new page that records details of drug approvals. <a href="https://www.guidetopharmacology.org/GRAC/DrugApprovalsForward">https://www.guidetopharmacology.org/GRAC/DrugApprovalsForward</a></p> <p>Each year, the Guide to Pharmacology Curation Team puts together a list of the latest approved drugs from FDA, EMA and MHRA as well as first-time approvals from other agencies. The new drug approval page, shows these approved drugs in table, organised by year of approval. The majority of these drugs will be curated in the database, and if so they are hyperlinked to their respective summary pages from the INN in the table. There are some cases were we have listed an approved drug but it doesn’t have a link because it will not have been curated.</p> <p> </p> <div class="wordads-tag" data-slot-type="belowpost" style="display: none;"></div> </div> <div class="post-data"> Posted in <a href="https://blog.guidetopharmacology.org/category/chemical-curation/" rel="category tag">Chemical curation</a>, <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/technical/" rel="category tag">Technical</a> </div> </div> <div id="post-4678" class="post-4678 post type-post status-publish format-standard hentry category-chemical-curation category-database-updates category-technical"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2024/12/05/database-release-2024-4/" rel="bookmark">Database Release 2024.4</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2024/12/05/database-release-2024-4/" title="10:51 am" rel="bookmark"><span class="timestamp">December 5, 2024</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2024/12/05/database-release-2024-4/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>The latest release (version 2024.4) of the IUPHAR/BPS Guide to Pharmacology database has been made. Released on 4th December 2024 this is the fourth release of the year. The following blog post gives details of the key content updates and website changes. GtoPdb now contains:</p> <ul> <li><strong>3,089 </strong>human targets, <strong>1,750 </strong>of which have curated quantitative ligand interactions.</li> <li><strong>12,950</strong> ligands, <strong>9,392 </strong>of which have curated quantitative target interactions.</li> <li><strong>2,038 </strong>approved drugs, <strong>1,140</strong> with curated quantitative interactions.</li> <li>Clinical use summaries for <strong>3,876</strong> ligands.</li> <li><strong>23,474</strong> curated interaction, <strong>21,330</strong> which are quantitative.</li> <li>Data curated from over <strong>46,431</strong> references</li> </ul> <p>In this release, <strong>60 new curated interactions</strong> have been added.</p> <p>So far in 2024 <strong>826 new curated interactions</strong> have been added to the database, along with updates to <strong>341 existing interactions</strong>.</p> <h3>Curation Update</h3> <h4>New targets curation</h4> <p>We have added 3 protein targets since release 2024.3. These are supported with evidence of pharmacological tool modulators, and were added in conjunction with our natural products curation project.</p> <table border="1" cellspacing="0" cellpadding="0"> <tbody> <tr style="color: blue" bgcolor="lightgrey"> <td valign="top" width="73"><strong>TID</strong></td> <td valign="top" width="124"><strong>Family</strong></td> <td valign="top" width="74"><strong>Gene</strong></td> <td valign="top" width="113"><strong>Name</strong></td> <td valign="top" width="314"><strong>Comment</strong></td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3296">3296</a></td> <td valign="top">Cholesterol biosynthesis pathway</td> <td valign="top"><i>SC5D</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3296">sterol-C5-desaturase</a></td> <td valign="top">SC5D deficiency causes a rare autosomal recessive cholesterol biosynthesis disorder known as lathosterolosis</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3297">3297</a></td> <td valign="top">Cholesterol biosynthesis pathway</td> <td valign="top"><em>NSDHL</em></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3297">NAD(P) dependent steroid dehydrogenase-like</a></td> <td valign="top">Therapeutic potential for cholesterol-related diseases and carcinomas. Variants in <i>NSDHL</i> are associated with the lipid metabolism disorder CHILD syndrome. An inhibitor compound was curated</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3298">3298</a></td> <td valign="top">Hydrolases & Lipases</td> <td valign="top"><i>CES2</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3298">carboxylesterase 2</a></td> <td valign="top">detoxification of xenobiotics and activation of ester and amide prodrugs; natural product (+)-Yanhusanine B is an inhibitor</td> </tr> </tbody> </table> <p><b>Approved drugs</b></p> <p>Since the 2024.3 release the FDA have approved 9 more drugs, bringing the total for the year so far to 49.</p> <table border="1" width="906" cellspacing="0" cellpadding="0"> <tbody> <tr style="color: blue" bgcolor="lightgrey"> <td valign="top" width="74"><b>LID</b></td> <td valign="top" width="119"><b>INN</b></td> <td valign="top" width="82"><b>Trade name</b></td> <td valign="top" width="96"><b>Molecule type</b></td> <td valign="top" width="69"><b>FDA approval</b></td> <td valign="top" width="94"><b>Indication</b></td> <td valign="top" width="69"><b>EMA approval</b></td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9636">9636</a></td> <td valign="top">inavolisib</td> <td valign="top">Itovebi</td> <td valign="top">sm</td> <td valign="top">10/10/2024</td> <td valign="top">To treat locally advanced or metastatic breast cancer</td> <td valign="top">n/a</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13403">13403</a></td> <td valign="top">marstacimab-hncq</td> <td valign="top">Hympavzi</td> <td valign="top">mAb</td> <td valign="top">11/10/2024</td> <td valign="top">To prevent or reduce bleeding episodes related to hemophilia A or B</td> <td valign="top">n/a</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9209">9209</a></td> <td valign="top">zolbetuximab</td> <td valign="top">Vyloy</td> <td valign="top">mAb</td> <td valign="top">18/10/2024</td> <td valign="top">To treat CLDN18.2+ve gastric and gastroesophageal cancers</td> <td valign="top">19/09/2024</td> </tr> <tr> <td valign="top">n/a, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13174">13174</a></td> <td valign="top">foscarbidopa + foslevodopa</td> <td valign="top">Vyalev</td> <td valign="top">sm</td> <td valign="top">16/10/2024</td> <td valign="top">To treat advanced Parkinson’s disease motor fluctuations</td> <td valign="top">2024</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10862">10862</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4357">4357</a></td> <td valign="top">sulopenem etzadroxil + probenecid</td> <td valign="top">Orlynvah</td> <td valign="top">sm</td> <td valign="top">25/10/2024</td> <td valign="top">To treat uncomplicated UTIs</td> <td valign="top">n/a</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11882">11882</a></td> <td valign="top">revumenib</td> <td valign="top">Revuforj</td> <td valign="top">sm</td> <td valign="top">15/11/2024</td> <td valign="top">To treat acute r/r leukemia with KMT2A translocation</td> <td valign="top">n/a</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13627">13627</a></td> <td valign="top">zanidatamab</td> <td valign="top">Ziihera</td> <td valign="top">mAb</td> <td valign="top">20/11/2024</td> <td valign="top">To treat unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer</td> <td valign="top">n/a</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13628">13628</a></td> <td valign="top">acoramidis</td> <td valign="top">Attruby</td> <td valign="top">sm</td> <td valign="top">22/11/2024</td> <td valign="top">To treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis</td> <td valign="top">n/a</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13192">13192</a></td> <td valign="top">landiolol</td> <td valign="top">Rapiblyk</td> <td valign="top">sm</td> <td valign="top">22/11/2024</td> <td valign="top">To treat supraventricular tachycardia</td> <td valign="top">n/a</td> </tr> </tbody> </table> <p>Use the Ligand ID link to view the ligand at the Guide to Pharmacology</p> <h3><b>Coronavirus antiviral development</b></h3> <p>Continuing to follow developments towards pan-coronavirus antivirals we have added new inhibitors <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13635">SS148</a> and <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13634">CoV nsp16 inhibitor 2a</a> [PMID: 34257831].</p> <p>These compounds inhibit both of the CoV methyltransferases (nsp16 and nsp14) that are essential for viral RNA capping and enabling the virus to evade immune detection in humans. SS148 has demonstrated broad-spectrum activity across human coronaviruses in vitro.</p> <h3><b>Curation of nucleic acid class drugs</b></h3> <p>We now have all 18 of the currently approved drugs in this class in the GtoPdb. Unfortunately, for many of these we are unable to provide sull chemical structures, and are restricted to the available nucleic acid sequence information. We have added new fields to present both the sequences and targets for each of these drugs. In line with all of our other approved drugs we curate approval information (dates, indications, trade names etc). We are continuing to add drugs from this class that are clinical candidates in phase 1-3 development.</p> <table border="1" width="906" cellspacing="0" cellpadding="0"> <tbody> <tr style="color: blue" bgcolor="lightgrey"> <td valign="top" width="72"><b>INN</b></td> <td valign="top" width="50"><b>LID</b></td> <td valign="top" width="50"><b>Type</b></td> <td valign="top" width="50"><b>First approval</b></td> <td valign="top" width="120"><b>Target</b></td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7364">mipomersen</a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7364">7364</a></td> <td valign="top">ASO</td> <td valign="top">2013</td> <td valign="top">apolipoprotein B (APOB) 100 mRNA</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9416">nusinersen</a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9416">9416</a></td> <td valign="top">ASO</td> <td valign="top">2017</td> <td valign="top">survival of motor neuron 2, centromeric (SMN2) with exon 7 skipping mutations</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11430">viltolarsen</a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11430">11430</a></td> <td valign="top">ASO</td> <td valign="top">2020</td> <td valign="top">dystrophin (DMD) pre-mRNA</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11444">casimersen</a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11444">11444</a></td> <td valign="top">ASO</td> <td valign="top">2021</td> <td valign="top">dystrophin (DMD) pre-mRNA with exon 45 skipping variants</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13533">fomivirsen</a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13533">13533</a></td> <td valign="top">ASO</td> <td valign="top">1998</td> <td valign="top">Major intermediate early region 2 mRNA (CMV gene UL123 that encodes protein IE2)</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13536">tofersen</a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13536">13536</a></td> <td valign="top">ASO</td> <td valign="top">2023</td> <td valign="top">SOD1 mRNA</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13605">golodirsen</a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13605">13605</a></td> <td valign="top">ASO</td> <td valign="top">2019</td> <td valign="top">dystrophin (DMD) pre-mRNA</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13543">inotersen</a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13543">13543</a></td> <td valign="top">ASO</td> <td valign="top">2018</td> <td valign="top">transthyretin (TTR)</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13606">eplontersen</a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13606">13606</a></td> <td valign="top">ASO</td> <td valign="top">2023</td> <td valign="top">transthyretin (TTR)</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6836">pegaptanib</a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6836">6836</a></td> <td valign="top">aptamer</td> <td valign="top">2004</td> <td valign="top">Vascular endothelial growth factor A</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12857">avacincaptad pegol</a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12857">12857</a></td> <td valign="top">aptamer</td> <td valign="top">2023</td> <td valign="top">complement C5 (C5)</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13611">patisiran</a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13611">13611</a></td> <td valign="top">siRNA</td> <td valign="top">2018</td> <td valign="top">transthyretin (TTR) mRNA</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13613">lumasiran</a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13613">13613</a></td> <td valign="top">siRNA</td> <td valign="top">2020</td> <td valign="top">hydroxyacid oxidase 1 (HAO1) mRNA</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13614">givosiran</a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13614">13614</a></td> <td valign="top">siRNA</td> <td valign="top">2019</td> <td valign="top">5′-aminolevulinic acid synthase (ALAS1) mRNA</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13615">nedosiran</a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13615">13615</a></td> <td valign="top">siRNA</td> <td valign="top">2023</td> <td valign="top">actate dehydrogenase A (LDHA) mRNA</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13616">vutrisiran</a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13616">13616</a></td> <td valign="top">siRNA</td> <td valign="top">2022</td> <td valign="top">transthyretin (TTR) mRNA</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13624">inclisiran</a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13624">13624</a></td> <td valign="top">siRNA</td> <td valign="top">2020</td> <td valign="top">PCSK9 mRNA</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13625">imetelstat</a></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13625">13625</a></td> <td valign="top">telomerase inhibitor</td> <td valign="top">2024</td> <td valign="top">Telomerase reverse transcriptase (TERT)</td> </tr> </tbody> </table> <h3>Antibacterial Curation</h3> <p>Our collaboration with Antibiotic DB (ADB; <a class="ms-outlook-linkify" href="http://www.antibioticdb.com/" target="_blank" rel="noopener">www.antibioticdb.com</a>) continues to allow us to extend the coverage of ligands with annotated antibacterial activity in GtoPdb and provide comprehensive chemistry and pharmacology for select antibacterials curated within ADB, via reciprocal links. This project is supported by the Global Antibiotic Research and Development Partnership (GARDP; <a class="ms-outlook-linkify" href="https://gardp.org/" target="_blank" rel="noopener">https://gardp.org/</a>).</p> <p>Currently we have <a href="https://www.guidetopharmacology.org/GRAC/LigandListForward?type=AntiBac&database=all"><b>613 ligands</b></a> tagged in GtoPdb as ‘antibacterial’ and <b>589 </b>of these have links to compounds at ADB. 260 are approved drugs. Since our last release we have added <strong>18</strong> new antibacterial ligands including:</p> <ul> <li style="list-style-type: none"> <ul type="disc"> <li><b>3</b> drugs that are approved, or have been approved in the past, for clinical use in human</li> </ul> </li> </ul> <h3>Website Updates</h3> <p>A reminder of some new pages and updates made at our last release (2024.3):</p> <ul> <li>Nucleic acid ligands <ul> <li>We have re-classified a small number of ligands as ‘nucleic acids’ and made this a new ligand category (<a href="https://www.guidetopharmacology.org/GRAC/LigandListForward?type=Nucleic-acid" rel="nofollow">https://www.guidetopharmacology.org/GRAC/LigandListForward?type=Nucleic-acid</a>).</li> </ul> </li> <li>Natural products <ul> <li>A new landing page (<a href="https://www.guidetopharmacology.org/GRAC/NaturalProductsForward" rel="nofollow">https://www.guidetopharmacology.org/GRAC/NaturalProductsForward</a>) for <a href="https://www.guidetopharmacology.org/GRAC/NaturalProductsForward">natural products</a> in the Guide to Pharmacology is available. This is part of the collaboration between <b>IUPHAR</b> (<a href="https://iuphar.org/" target="_blank" rel="noopener">https://iuphar.org/</a>) and the <b>Italian Society of Pharmacology</b> (SIF; <a href="https://www.sifweb.org/" target="_blank" rel="noopener">https://www.sifweb.org/</a>) to provide an expert-driven project to curate NPs as a resource within the Guide to Pharmacology.</li> </ul> </li> </ul> <div id="atatags-370373-67f91c1634107"> <script type="text/javascript"> __ATA.cmd.push(function() { __ATA.initVideoSlot('atatags-370373-67f91c1634107', { sectionId: '370373', format: 'inread' }); }); </script> </div> </div> <div class="post-data"> Posted in <a href="https://blog.guidetopharmacology.org/category/chemical-curation/" rel="category tag">Chemical curation</a>, <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/technical/" rel="category tag">Technical</a> </div> </div> <div id="post-4692" class="post-4692 post type-post status-publish format-standard hentry category-database-updates category-publications"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2024/12/04/gtopdb-database-report-nov-2024-now-available/" rel="bookmark">GtoPdb Database Report – Nov 2024 now available</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2024/12/04/gtopdb-database-report-nov-2024-now-available/" title="9:07 pm" rel="bookmark"><span class="timestamp">December 4, 2024</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2024/12/04/gtopdb-database-report-nov-2024-now-available/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>Our latest database report provides an overview of progress and status of the IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb) for the period April 2024 to October 2024.</p> <p><p><a href="https://www.guidetopharmacology.org/pdfs/GtoPdb_Database_Report_Nov_2024.pdf" target="_blank" rel="noopener noreferrer nofollow">Click to access GtoPdb_Database_Report_Nov_2024.pdf</a></p></p> <p>It can also be access at our Zenodo repository <a href="https://doi.org/10.5281/zenodo.14046004">https://doi.org/10.5281/zenodo.14046004</a></p> <p> </p> </div> <div class="post-data"> Posted in <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/publications/" rel="category tag">Publications</a> </div> </div> <div id="post-4656" class="post-4656 post type-post status-publish format-standard hentry category-chemical-curation category-database-updates category-technical"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2024/10/03/database-release-2024-3/" rel="bookmark">Database Release 2024.3</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2024/10/03/database-release-2024-3/" title="10:57 am" rel="bookmark"><span class="timestamp">October 3, 2024</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2024/10/03/database-release-2024-3/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>The latest release (version 2024.3) of the IUPHAR/BPS Guide to Pharmacology database has been made. Released on 3rd October 2024 this is the third release of the year. The following blog post gives details of the key content updates and website changes. GtoPdb now contains:</p> <ul> <li><strong>3,086 </strong>human targets, <strong>1,747 </strong>of which have curated quantitative ligand interactions.</li> <li><strong>12,862</strong> ligands, <strong>9,356 </strong>of which have curated quantitative target interactions.</li> <li><strong>2,019 </strong>approved drugs, <strong>1,138</strong> with curated quantitative interactions.</li> <li>Clinical use summaries for <strong>3,825</strong> ligands, of which <strong>2,008 </strong>are approved drugs.</li> <li>A total of <strong>21,268 </strong>curated binding constants</li> <li>Data curated from over <strong>46,200</strong> references</li> </ul> <p>In this release, <strong>119 new curated interactions</strong> have been added.</p> <p>So far in 2024 <strong>761 new curated interactions</strong> have been added to the database, along with updated to <strong>338 existing interactions</strong>.</p> <h3>Curation Update</h3> <h4>New targets curation</h4> <p>3 new protein targets have been added to the Guide since our last update.</p> <table border="1" cellspacing="0" cellpadding="0"> <tbody> <tr style="color: blue" bgcolor="lightgrey"> <td valign="top" width="73"><strong>TID</strong></td> <td valign="top" width="124"><strong>Family</strong></td> <td valign="top" width="74"><strong>Gene</strong></td> <td valign="top" width="113"><strong>Name</strong></td> <td valign="top" width="314"><strong>Comment</strong></td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3293">3293</a></td> <td valign="top">5.-.-.- Isomerases</td> <td valign="top"><i>PDIA3</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3293">protein disulfide isomerase family A member 3</a></td> <td valign="top">Required for protein folding in ER; aberrant expression has been detected in cancers and downregulation/inhibition has antitumour effects; punicalagin (natural product) curated as an inhibitor</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3294">3294</a></td> <td valign="top">Zinc finger TFs</td> <td valign="top"><i>WIZ</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3294">CoV Non-structural protein 10</a></td> <td valign="top">Sickle cell disease target- its inhibition increases fetal hemoglobin (HbF) expression; molecular glue degrader dWIZ-1 curated</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3295">3295</a></td> <td valign="top">CD Molecules</td> <td valign="top"><i>CD226</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3295">CoV Non-structural protein 16</a></td> <td valign="top">Stimulatory immune checkpoint in the CD155 (PVR)-TIGIT/CD226 axis; molecular target for cancer immunotherapy development; salvianolic acid B (natural product) curated as an inhibitor</td> </tr> </tbody> </table> <h4>New ligand curation</h4> <p>A range of new ligands have been curated from analysis of <a title="Original URL: https://www.who.int/publications/m/item/inn-pl-131. Click or tap if you trust this link." href="https://www.who.int/publications/m/item/inn-pl-131" target="_blank" rel="noopener noreferrer">INN proposed list 131</a> (August 2024)</p> <p>In total 28 synthetic small molecules with INNs in this list are now included in the GtoPdb; 6 matched chemical structures that were already in our data set (the top 6 in the table below), and 22 are brand new entries (LIDs >13480). Where possible the INNs have been linked to (probable) company research codes, corroborating publications, quantitative interaction data, and clinical trials. 18/28 are kinase inhibitors, 2 are EZH2 inhibitors, 1 is a PROTAC, and the others are intended to modulate a range of therapeutic targets including SLC6A19, cannabinoid, orexin and opioid receptors, COX-2 and autotaxin. Analysis is continuing to identify any of the monoclonal antibodies that are directed against proteins that are not already included in the GtoPdb, to expand our coverage of emerging drug targets.</p> <table border="1" width="906" cellspacing="0" cellpadding="0"> <tbody> <tr style="color: blue" bgcolor="lightgrey"> <td valign="top" width="74"><b>Ligand ID</b></td> <td valign="top" width="113"><b>INN</b></td> <td valign="top" width="65"><b>INN #</b></td> <td valign="top" width="379"><b>Drug classification (WHO)</b></td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10516">10516</a></td> <td valign="top" width="115">mevrometostat</td> <td valign="top" width="64">13206</td> <td valign="top" width="401">enhancer of zeste homolog 2 (EZH2) inhibitor, antineoplastic</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11727">11727</a></td> <td valign="top" width="113">beroterkib</td> <td valign="top" width="64">13233</td> <td valign="top" width="411">extracellular signal-regulated kinases (ERK) inhibitor, antineoplastic</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12899">12899</a></td> <td valign="top" width="113">repinatrabit</td> <td valign="top" width="64">13200</td> <td valign="top" width="401">solute carrier family 6 member 19 (SLC6A19) inhibitor (phenylketonuria)</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12940">12940</a></td> <td valign="top" width="113">evetifator</td> <td valign="top" width="64">13162</td> <td valign="top" width="399">eukaryotic translation initiation factor 2B (eIF2B) activator</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13064">13064</a></td> <td valign="top" width="113">pebezertinib</td> <td valign="top" width="64">13193</td> <td valign="top" width="401">epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor,antineoplastic</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13068">13068</a></td> <td valign="top" width="113">istisociclib</td> <td valign="top" width="64">13208</td> <td valign="top" width="380">cyclin-dependent kinase (CDK) inhibitor, antineoplastic</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13485">13485</a></td> <td valign="top" width="113">atirmociclib</td> <td valign="top" width="64">13204</td> <td valign="top" width="380">cyclin-dependent kinase (CDK) inhibitor, antineoplastic</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13486">13486</a></td> <td valign="top" width="113">bosmolisib</td> <td valign="top" width="64">13264</td> <td valign="top" width="401">phosphatidylinositol 3-kinase (PI3K) inhibitor, antineoplastic</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13487">13487</a></td> <td valign="top" width="113">cenacitinib</td> <td valign="top" width="64">13191</td> <td valign="top" width="380">Janus kinase inhibitor, anti-inflammatory</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13488">13488</a></td> <td valign="top" width="113">deulorlatinib</td> <td valign="top" width="64">13094</td> <td valign="top" width="380">tyrosine kinase inhibitor, antineoplastic</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13498">13489</a></td> <td valign="top" width="113">enrupatinib</td> <td valign="top" width="64">13274</td> <td valign="top" width="401">colony-stimulating factor 1 receptor (CSF1R) inhibitor, antineoplastic</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13490">13490</a></td> <td valign="top" width="113">zelebrudomide</td> <td valign="top" width="64">13078</td> <td valign="top" width="380">protein degrader, antineoplastic</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13491">13491</a></td> <td valign="top" width="113">sevabertinib</td> <td valign="top" width="64">13219</td> <td valign="top" width="409">epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, antineoplastic</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13492">13492</a></td> <td valign="top" width="113">soxataltinib</td> <td valign="top" width="64">13087</td> <td valign="top" width="380">RET-kinase inhibitor, antineoplastic</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13493">13493</a></td> <td valign="top" width="113">veonetinib</td> <td valign="top" width="64">13085</td> <td valign="top" width="380">tyrosine kinase inhibitor, antineoplastic</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13494">13494</a></td> <td valign="top" width="113">fanregratinib</td> <td valign="top" width="64">12971</td> <td valign="top" width="401">fibroblast growth factor receptor tyrosine kinase inhibitor, antineoplastic</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13495">13495</a></td> <td valign="top" width="113">luvometinib</td> <td valign="top" width="64">13248</td> <td valign="top" width="401">mitogen-activated protein kinase (MEK) inhibitor, antineoplastic</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13496">13496</a></td> <td valign="top" width="113">mobinitinib</td> <td valign="top" width="64">13061</td> <td valign="top" width="401">dual FMS-like tyrosine kinase-3 (FLT3)-Aurora kinase inhibitor, antineoplastic</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13499">13499</a></td> <td valign="top" width="113">mocaciclib</td> <td valign="top" width="64">13088</td> <td valign="top" width="380">cyclin-dependent kinase (CDK) inhibitor, antineoplastic</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13500">13500</a></td> <td valign="top" width="113">mosperafenib</td> <td valign="top" width="64">13239</td> <td valign="top" width="380">B-Raf (BRAF) inhibitor, antineoplastic</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13502">13502</a></td> <td valign="top" width="113">nacresertib</td> <td valign="top" width="64">13134</td> <td valign="top" width="380">serine/threonine kinase inhibitor</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13504">13504</a></td> <td valign="top" width="113">ocadusertib</td> <td valign="top" width="64">13241</td> <td valign="top" width="380">serine/threonine kinase inhibitor</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13505">13505</a></td> <td valign="top" width="113">tigemocoxib</td> <td valign="top" width="64">13201</td> <td valign="top" width="380">cyclo-oxygenase 2 (COX-2) inhibitor, anti-inflammatory</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13506">13506</a></td> <td valign="top" width="113">cambritaxestat</td> <td valign="top" width="64">13154</td> <td valign="top" width="380">autotaxin inhibitor, antineoplastic</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13507">13507</a></td> <td valign="top" width="113">nispomeben</td> <td valign="top" width="64">13124</td> <td valign="top" width="380">non-opioid analgesic</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13511">13511</a></td> <td valign="top" width="113">selonabant</td> <td valign="top" width="64">13203</td> <td valign="top" width="380">cannabinoid receptor 1 (CB1) antagonist</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13512">13512</a></td> <td valign="top" width="113">zeprumetostat</td> <td valign="top" width="64">13165</td> <td valign="top" width="401">enhancer of zeste homolog 2 (EZH2) inhibitor, antineoplastic</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13513">13513</a></td> <td valign="top" width="113">oveporexton</td> <td valign="top" width="64">13257</td> <td valign="top" width="380">orexin type 2 receptor agonist</td> </tr> </tbody> </table> <p>Use the Ligand ID link to view the ligand at the Guide to Pharmacology</p> <p><b>Approved drugs</b></p> <p>With access to the EMA’s master <a title="Original URL: https://www.ema.europa.eu/en/medicines/download-medicine-data. Click or tap if you trust this link." href="https://www.ema.europa.eu/en/medicines/download-medicine-data" target="_blank" rel="noopener noreferrer">EPAR download</a> file restored (it had been unavailable since Dec 2023), we were able to retrospectively update the EU approval data for >30 drugs. In addition, the FDA has approved 16 new drugs since our last update, 14 of which meet the inclusion criteria for the GToPdb. We have also included 2 new drugs that were approved in jurisdictions outside of the US and EU.</p> <table border="1" width="906" cellspacing="0" cellpadding="0"> <tbody> <tr style="color: blue" bgcolor="lightgrey"> <td valign="top" width="74"><b>LID</b></td> <td valign="top" width="119"><b>INN</b></td> <td valign="top" width="82"><b>Trade name</b></td> <td valign="top" width="96"><b>Molecule type</b></td> <td valign="top" width="69"><b>FDA approval</b></td> <td valign="top" width="69"><b>EMA approval</b></td> <td valign="top" width="93"><b>Other approval</b></td> <td valign="top" width="94"><b>Indication</b></td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13433">13433</a></td> <td valign="top" width="119">zastaprazan</td> <td valign="top" width="82">JAQBO</td> <td valign="top" width="96">synthetic small mol</td> <td valign="top" width="69">n/a</td> <td valign="top" width="69">n/a</td> <td valign="top" width="93">First approved in S Korea, Apr 2024</td> <td valign="top" width="94">To treat GERD</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13434">13434</a></td> <td valign="top" width="119">tegileridine</td> <td valign="top" width="82">Asut</td> <td valign="top" width="96">synthetic small mol</td> <td valign="top" width="69">n/a</td> <td valign="top" width="69">n/a</td> <td valign="top" width="93">First approved in China, Jan 2024</td> <td valign="top" width="94">To treat postoperative pain</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8357">8357</a></td> <td valign="top" width="119">donanemab-azbt</td> <td valign="top" width="82">Kisunla</td> <td valign="top" width="96">monoclonal antibody</td> <td valign="top" width="69">02/07/2024</td> <td valign="top" width="69">n/a</td> <td valign="top" width="93"></td> <td valign="top" width="94">To treat early symptomatic AD</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11410">11410</a></td> <td valign="top" width="119">deuruxolitinib</td> <td valign="top" width="82">Leqselvi</td> <td valign="top" width="96">synthetic small mol</td> <td valign="top" width="69">26/07/2024</td> <td valign="top" width="69">n/a</td> <td valign="top" width="93"></td> <td valign="top" width="84">To treat severe alopecia areata</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13477">13477</a></td> <td valign="top" width="119">benzgalantamine</td> <td valign="top" width="82">Zunveyl</td> <td valign="top" width="96">synthetic small mol</td> <td valign="top" width="69">01/08/2024</td> <td valign="top" width="69">n/a</td> <td valign="top" width="93"></td> <td valign="top" width="94">To treat mild-to-moderate Alzheimer’s disease</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10663">10663</a></td> <td valign="top" width="119">vorasidenib</td> <td valign="top" width="82">Voranigo</td> <td valign="top" width="96">synthetic small mol</td> <td valign="top" width="69">06/08/2024</td> <td valign="top" width="69">n/a</td> <td valign="top" width="93"></td> <td valign="top" width="94">To treat IDH1/2 mutation positive astrocytoma or oligodendroglioma</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13484">13484</a></td> <td valign="top" width="119">palopegteriparatide</td> <td valign="top" width="82">Yorvipath</td> <td valign="top" width="96">peptide</td> <td valign="top" width="69">09/08/2024</td> <td valign="top" width="69">17/11/2023</td> <td valign="top" width="93"></td> <td valign="top" width="94">To treat hypoparathyroidism</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8720">8720</a></td> <td valign="top" width="119">nemolizumab-iito</td> <td valign="top" width="82">Nemluvio</td> <td valign="top" width="96">monoclonal antibody</td> <td valign="top" width="69">12/08/2024</td> <td valign="top" width="69">n/a</td> <td valign="top" width="93">First approved in Japan, Mar 2022 to treat atopic dermatitis</td> <td valign="top" width="84">To treat prurigo nodularis</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11137">11137</a></td> <td valign="top" width="119">seladelpar</td> <td valign="top" width="82">Livdelzi</td> <td valign="top" width="96">synthetic small mol</td> <td valign="top" width="69">14/08/2024</td> <td valign="top" width="69">n/a</td> <td valign="top" width="93"></td> <td valign="top" width="84">To treat primary biliary cholangitis</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13497">13497</a></td> <td valign="top" width="119">axatilimab-csfr</td> <td valign="top" width="82">Niktimvo</td> <td valign="top" width="96">monoclonal antibody</td> <td valign="top" width="69">14/08/2024</td> <td valign="top" width="69">n/a</td> <td valign="top" width="93"></td> <td valign="top" width="94">To treat chronic graft-versus-host disease</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10136">10136</a></td> <td valign="top" width="119">lazertinib</td> <td valign="top" width="82">Lazcluze</td> <td valign="top" width="96">synthetic small mol</td> <td valign="top" width="69">19/08/2024</td> <td valign="top" width="69">n/a</td> <td valign="top" width="93">First approved in S Korea, 2021</td> <td valign="top" width="94">To treat non-small cell lung cancer (EGFR mutation positive advanced NSCLC)</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7684">7684</a></td> <td valign="top" width="119">lebrikizumab-lbkz</td> <td valign="top" width="82">Ebglyss</td> <td valign="top" width="96">monoclonal antibody</td> <td valign="top" width="69">13/09/2024</td> <td valign="top" width="69">16/11/2023</td> <td valign="top" width="93"></td> <td valign="top" width="94">To treat moderate-to-severe atopic dermatitis</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8271">8271</a></td> <td valign="top" width="119">arimoclomol</td> <td valign="top" width="82">Miplyffa</td> <td valign="top" width="96">synthetic small mol</td> <td valign="top" width="69">20/09/2024</td> <td valign="top" width="69">n/a</td> <td valign="top" width="93"></td> <td valign="top" width="94">To treat Niemann-Pick disease type C</td> </tr> <tr> <td valign="top" width="74">n/a</td> <td valign="top" width="119">levacetylleucine</td> <td valign="top" width="82">Aqneursa</td> <td valign="top" width="96">synthetic small mol</td> <td valign="top" width="69">25/09/2024</td> <td valign="top" width="69">n/a</td> <td valign="top" width="93"></td> <td valign="top" width="94">To treat Niemann-Pick disease type C</td> </tr> <tr> <td valign="top" width="74"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=57">57</a></td> <td valign="top" width="119">xanomeline (+ trospium)</td> <td valign="top" width="82">Cobenfy</td> <td valign="top" width="96">synthetic small mol</td> <td valign="top" width="69">26/09/2024</td> <td valign="top" width="69">n/a</td> <td valign="top" width="93"></td> <td valign="top" width="94">To treat schizophrenia</td> </tr> <tr> <td valign="top" width="74">n/a</td> <td valign="top" width="119">flurpiridaz F 18</td> <td valign="top" width="82">Flyrcado</td> <td valign="top" width="96">synthetic small mol</td> <td valign="top" width="69">27/09/2024</td> <td valign="top" width="69">n/a</td> <td valign="top" width="93"></td> <td valign="top" width="94">PET tracer for detection of coronary artery disease</td> </tr> </tbody> </table> <h3>Antibacterial Curation</h3> <p>Our collaboration with Antibiotic DB (ADB; <a class="ms-outlook-linkify" href="http://www.antibioticdb.com/" target="_blank" rel="noopener">www.antibioticdb.com</a>) continues to allow us to extend the coverage of ligands with annotated antibacterial activity in GtoPdb and provide comprehensive chemistry and pharmacology for select antibacterials curated within ADB, via reciprocal links. This project is supported by the Global Antibiotic Research and Development Partnership (GARDP; <a class="ms-outlook-linkify" href="https://gardp.org/" target="_blank" rel="noopener">https://gardp.org/</a>).</p> <p>Currently we have <a href="https://www.guidetopharmacology.org/GRAC/LigandListForward?type=AntiBac&database=all"><b>594 ligands</b></a> tagged in GtoPdb as ‘antibacterial’ and <b>566 </b>of these have links to compounds at ADB. 255 are approved drugs.</p> <p>Since our last release we have added <strong>31</strong> new antibacterial ligands including:</p> <ul type="disc"> <li style="list-style-type: none"> <ul type="disc"> <li><b>3</b> drugs that are approved, or have been approved in the past, for clinical use in human</li> </ul> </li> </ul> <h3>Website Updates</h3> <ul> <li>Nucleic acid ligands <ul> <li>We have re-classified a small number of ligands as ‘nucleic acids’ and made this a new ligand category (<a href="https://www.guidetopharmacology.org/GRAC/LigandListForward?type=Nucleic-acid" rel="nofollow">https://www.guidetopharmacology.org/GRAC/LigandListForward?type=Nucleic-acid</a>).</li> </ul> </li> <li>Natural products <ul> <li>A new landing page (<a href="https://www.guidetopharmacology.org/GRAC/NaturalProductsForward" rel="nofollow">https://www.guidetopharmacology.org/GRAC/NaturalProductsForward</a>) for <a href="https://www.guidetopharmacology.org/GRAC/NaturalProductsForward">natural products</a> in the Guide to Pharmacology is available. This is part of the collaboration between <b>IUPHAR</b> (<a href="https://iuphar.org/" target="_blank" rel="noopener">https://iuphar.org/</a>) and the <b>Italian Society of Pharmacology</b> (SIF; <a href="https://www.sifweb.org/" target="_blank" rel="noopener">https://www.sifweb.org/</a>) to provide an expert-driven project to curate NPs as a resource within the Guide to Pharmacology.</li> </ul> </li> </ul> </div> <div class="post-data"> Posted in <a href="https://blog.guidetopharmacology.org/category/chemical-curation/" rel="category tag">Chemical curation</a>, <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/technical/" rel="category tag">Technical</a> </div> </div> <div id="post-4641" class="post-4641 post type-post status-publish format-standard hentry category-chemical-curation category-database-updates category-technical"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2024/06/26/database-release-2024-2/" rel="bookmark">Database Release 2024.2</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2024/06/26/database-release-2024-2/" title="12:26 pm" rel="bookmark"><span class="timestamp">June 26, 2024</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2024/06/26/database-release-2024-2/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>The latest release (version 2024.2) of the IUPHAR/BPS Guide to Pharmacology database has been made. Released on 26th June 2024 this is the second release of the year. The following blog post gives details of the key content updates and website changes. GtoPdb now contains:</p> <ul> <li><strong>3,083 </strong>human targets, <strong>1,744 </strong>of which have curated quantitative ligand interactions.</li> <li><strong>12,730</strong> ligands, <strong>9,292 </strong>of which have curated quantitative target interactions.</li> <li><strong>1,995 </strong>approved drugs, <strong>1,133</strong> with curated quantitative interactions.</li> <li>Clinical use summaries for <strong>3,770</strong> ligands, of which <strong>1,985 </strong>are approved drugs.</li> <li>A total of <strong>20,949 </strong>curated binding constants</li> <li>Data curated from over <strong>45,800</strong> references</li> </ul> <h3>Curation Update</h3> <h4>General protein family updates</h4> <p>The <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=4"><strong>Adrenoceptors</strong><strong> family</strong></a> has been widely updated. This includes a completely revised detailed introduction, and additions to ligands, interactions and other tables on all nine of the receptor subtypes pages. The updated material was provided by the Adrenoceptors subcommittee, Roger J. Summers, Martin C. Michel and Jillian G. Baker.</p> <h4>New targets curation</h4> <p>19 new protein targets have been added to the Guide since our last update. They represent molecular targets for cancer, inflammation, immunity, viral infection and Parkinson’s disease. Experimental tool compounds or clinical candidates that modulate protein functions have been curated where available.</p> <table border="1" cellspacing="0" cellpadding="0"> <tbody> <tr style="color: blue" bgcolor="lightgrey"> <td valign="top" width="73"><strong>TID</strong></td> <td valign="top" width="124"><strong>Family</strong></td> <td valign="top" width="74"><strong>Gene</strong></td> <td valign="top" width="113"><strong>Name</strong></td> <td valign="top" width="314"><strong>Comment</strong></td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3274">3274</a></td> <td valign="top">Methyllysine reader proteins</td> <td valign="top"><i>SPIN1</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3274">spindlin 1</a></td> <td valign="top">Overexpressed in malignancies, making it a target for anti-cancer drug development- two inhibitors tool compounds curated (MS8535, MS31)</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3275">3275</a></td> <td valign="top">Coronavirus (CoV) proteins</td> <td valign="top"><i>n/a</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3275">CoV Non-structural protein 10</a></td> <td valign="top">subunit of the betacoronavirus 2′-O-methyltransferase (mRNA capping enzyme)</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3276">3276</a></td> <td valign="top">Coronavirus (CoV) proteins</td> <td valign="top"><i>n/a</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3276">CoV Non-structural protein 16</a></td> <td valign="top">subunit of the betacoronavirus 2′-O-methyltransferase (mRNA capping enzyme)</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3277">3277</a></td> <td valign="top">Coronavirus (CoV) proteins</td> <td valign="top"><i>n/a</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3277">CoV 2′-O-methyltransferase (complex)</a></td> <td valign="top">Target for coronavirus antivirals- sinefungin curated as an inhibitor</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3278">3278</a></td> <td valign="top">Gasdermins (GSDM)</td> <td valign="top"><i>GSDMD</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3278">gasdermin D</a></td> <td valign="top">Inflammasome component & pyroptosis effector. Target for the development of drugs with anti-inflammatory effects. disulfiram and LDC7559 curated as inhibitor tools.</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3279">3279</a></td> <td valign="top">High Mobility Group (HMG) proteins</td> <td valign="top"><i>HMGB1</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3279">high mobility group box 1</a></td> <td valign="top">Endogenous ligand for Toll-like receptors 2 and 4, and RAGE- inhibitor tools 3-AESA and methotrexare curated</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3280">3280</a></td> <td valign="top">NF-kappa B TF proteins</td> <td valign="top"><i>RELA</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3280">RELA proto-oncogene, NF-kB subunit</a></td> <td valign="top">Key to regulating the interferon response to SARS-CoV-2 infection- 2 inhibitor toll compounds curated</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3281">3281</a></td> <td valign="top">NF-kappa B TF proteins</td> <td valign="top"><i>NFKB1</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3281">nuclear factor kappa B subunit 1</a></td> <td valign="top">dimerises with RELA to form most abundant NF-kB TF, promotes expression of genes that drive the immune response and acute phase responses to infection and tissue trauma</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3282">3282</a></td> <td valign="top">NF-kappa B TF proteins</td> <td valign="top"><i>NFKB2</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3282">nuclear factor kappa B subunit 2</a></td> <td valign="top">Transcriptional activator or repressor of genes involved in inflammation and the immune response</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3283">3283</a></td> <td valign="top">NF-kappa B TF proteins</td> <td valign="top"><i>REL</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3283">REL proto-oncogene, NF-kB subunit</a></td> <td valign="top">Involved in apoptosis, inflammation and the immune response- can be oncogenic</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3284">3284</a></td> <td valign="top">NF-kappa B TF proteins</td> <td valign="top"><i>RELB</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3284">RELB proto-oncogene, NF-kB subunit</a></td> <td valign="top">RelB-NFκB/p50 and RelB-NFκB/p52 heterodimers are transcriptional activators</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3285">3285</a></td> <td valign="top">Synuclein proteins</td> <td valign="top"><i>SNCA</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3285">synuclein alpha</a></td> <td valign="top">Two anti-SNCA mAbs that block toxic synuclein alpha oligomer/fibril formation have been curated</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3286">3286</a></td> <td valign="top">Synuclein proteins</td> <td valign="top"><i>SNCB</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3286">synuclein beta</a></td> <td valign="top">non-amyloid component in Alzheimer’s disease plaques</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3287">3287</a></td> <td valign="top">Synuclein proteins</td> <td valign="top"><i>SNCG</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3287">synuclein gamma</a></td> <td valign="top">Third member of this small protein family</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3288">3288</a></td> <td valign="top">N6-methyladenosine readers</td> <td valign="top"><i>YTHDC1</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3288">YTH N6-methyladenosine RNA binding protein C1</a></td> <td valign="top">target for the development of cancer therapeutics- selective inhibitor curated</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3289">3289</a></td> <td valign="top">M28: Aminopeptidase Y</td> <td valign="top"><i>QPCTL</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3289">glutaminyl-peptide cyclotransferase like</a></td> <td valign="top">Small molecule gQC inhibitors offer an approach to promote tumour-specific immunity- 4 inhibitors curated</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3290">3290</a></td> <td valign="top">Hydrolases & Lipases</td> <td valign="top"><i>LYPLA1</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3290">lysophospholipase 1</a></td> <td valign="top">Synthetic and natural product tool inhibitors curated</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3291">3291</a></td> <td valign="top">Hydrolases & Lipases</td> <td valign="top"><i>LYPLA2</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3291">lysophospholipase 2</a></td> <td valign="top">Synthetic and natural product tool inhibitors curated</td> </tr> <tr> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3292">3292</a></td> <td valign="top">RAB subfamily</td> <td valign="top"><i>RAB32</i></td> <td valign="top"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3292">RAB32, member RAS oncogene family</a></td> <td valign="top">RAB32 S71R identified as a risk factor in familial Parkinson’s disease, in same pathway as LRRK2 activation</td> </tr> </tbody> </table> <p> </p> <h3>Antibacterial Curation</h3> <p>Our collaboration with Antibiotic DB (ADB; <a class="ms-outlook-linkify" href="http://www.antibioticdb.com/" target="_blank" rel="noopener">www.antibioticdb.com</a>) continues to allow us to extend the coverage of ligands with annotated antibacterial activity in GtoPdb and provide comprehensive chemistry and pharmacology for select antibacterials curated within ADB, via reciprocal links. This project is supported by the Global Antibiotic Research and Development Partnership (GARDP; <a class="ms-outlook-linkify" href="https://gardp.org/" target="_blank" rel="noopener">https://gardp.org/</a>).</p> <p>Currently we have <a href="https://www.guidetopharmacology.org/GRAC/LigandListForward?type=AntiBac&database=all"><b>562 ligands</b></a> tagged in GtoPdb as ‘antibacterial’ and <b>537 </b>of these have links to compounds at ADB. Since our last release we have added <b>25</b> new antibacterial ligands including:</p> <ul type="disc"> <li><b>6</b> drugs that are approved, or have been approved in the past, for clinical use in human</li> <li><b>13</b> compounds that progressed to clinical evaluation</li> </ul> <h3>Website Updates</h3> <ul> <li>Updated <a href="https://www.guidetopharmacology.org/download.jsp#data">data download files</a> <ul> <li>Updated version of our endogenous/natural ligand pairings and detailed endogenous/natural ligand pairings files. Please access from our <a href="https://www.guidetopharmacology.org/download.jsp">downloads page</a>.</li> </ul> </li> <li>ChEMBL <ul> <li>The <a href="https://www.guidetopharmacology.org/GRAC/pharmacologySearch.jsp">pharmacology search tool</a> and our <a href="https://www.guidetopharmacology.org/GRAC/ligandActivityDisplay.jsp">ligand activity charts</a> now use the latest version of ChEMBL (version 34) – updated from ChEMBL 32.</li> </ul> </li> </ul> </div> <div class="post-data"> Posted in <a href="https://blog.guidetopharmacology.org/category/chemical-curation/" rel="category tag">Chemical curation</a>, <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/technical/" rel="category tag">Technical</a> </div> </div> <div id="post-4621" class="post-4621 post type-post status-publish format-standard hentry category-chemical-curation category-database-updates category-technical"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2024/03/27/database-release-2024-1/" rel="bookmark">Database Release 2024.1</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2024/03/27/database-release-2024-1/" title="10:26 am" rel="bookmark"><span class="timestamp">March 27, 2024</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2024/03/27/database-release-2024-1/#comments">2 Comments</a> </span> </div> <div class="post-entry"> <p>A new release, version 2024.1, has been made of the IUPHAR/BPS Guide to Pharmacology database. Released on 26th March 2024 this is the first release of the year. The following blog post gives details of the key content updates and website changes. GtoPdb now contains:</p> <ul> <li><strong>3,067</strong> human targets, <strong>1,732 </strong>of which have curated quantitative ligand interactions.</li> <li><strong>12,590</strong> ligands, <strong>9,204 </strong>of which have curated quantitative target interactions.</li> <li><strong>1,981 </strong>approved drugs, <strong>1,128</strong> with curated quantitative interactions.</li> <li>Clinical use summaries for over <strong>3,704</strong> ligands of which <strong>1,971 </strong>are approved drugs.</li> <li>A total of <strong>20,789 </strong>curated binding constants</li> <li>Data curated from over <strong>45,000</strong> references</li> </ul> <h3>Curation Update</h3> <h4>Targets</h4> <p>11 new protein targets have been added to the GtoPdb since our last update. Ten of these are enzymes, with SIGLEC15 being the only new non-enzyme protein. PPP1CA, PPP2CA and ZDHHC3 were added as part of our natural products project. The remainder were added when new ligands for the targets were identified from literature searches</p> <table border="1" cellspacing="0" cellpadding="0"> <tbody> <tr style="color: blue" bgcolor="lightgrey"> <td valign="top" width="73"><strong>TID</strong></td> <td valign="top" width="124"><strong>Family</strong></td> <td valign="top" width="74"><strong>Gene</strong></td> <td valign="top" width="113"><strong>Name</strong></td> <td valign="top" width="314"><strong>Comment</strong></td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3263">3263</a></td> <td valign="top" width="124">Protein phosphatase catalytic subunits</td> <td valign="top" width="74"><i>PPP2CA</i></td> <td valign="top" width="113"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3263">protein phosphatase 2 catalytic subunit alpha</a></td> <td valign="top" width="314">Molecular target of natural marine toxins (okadaic acid, microcystin-LR, calyculin A)</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3264">3264</a></td> <td valign="top" width="124">Protein phosphatase catalytic subunits</td> <td valign="top" width="74"><i>PPP1CA</i></td> <td valign="top" width="113"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3264">protein phosphatase 1 catalytic subunit alpha</a></td> <td valign="top" width="314">Molecular target of natural marine toxins (okadaic acid,</p> <p>microcystin-LR, calyculin A)</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3265">3265</a></td> <td valign="top" width="124">SIGLECs (conserved)</td> <td valign="top" width="74"><i>SIGLEC15</i></td> <td valign="top" width="113"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3265">sialic acid binding Ig like lectin 15</a></td> <td valign="top" width="314">Anti-SIGLEC15 mAb demonstrated experimental anti-tumour potential</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3266">3266</a></td> <td valign="top" width="124">Mono-ADP-ribosylating PARPs</td> <td valign="top" width="74"><i>TIPARP</i></td> <td valign="top" width="113"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3266">TCDD inducible poly(ADP-ribose) polymerase</a></td> <td valign="top" width="314">Inhibitors are proposed to promote immunomodulatory and antineoplastic actions (atamparib, (S)-XY-05)</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3267">3267</a></td> <td valign="top" width="124">Mono-ADP-ribosylating PARPs</td> <td valign="top" width="74"><i>PARP10</i></td> <td valign="top" width="113"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3267">poly(ADP-ribose) polymerase family member 10</a></td> <td valign="top" width="314">Dual PARP10/PARP15 inhibition might be beneficial in cancer treatment (see compound 8a [PMID: 35500474])</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3268">3268</a></td> <td valign="top" width="124">Mono-ADP-ribosylating PARPs</td> <td valign="top" width="74"><i>PARP11</i></td> <td valign="top" width="113"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3268">poly(ADP-ribose) polymerase family member 11</a></td> <td valign="top" width="314">The PARP11 inhibitor ITK7 is curated</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3269">3269</a></td> <td valign="top" width="124">Mono-ADP-ribosylating PARPs</td> <td valign="top" width="74"><i>PARP14</i></td> <td valign="top" width="113"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3269">poly(ADP-ribose) polymerase family member 14</a></td> <td valign="top" width="314">Involved in the immune response and lymphocyte physiology; highly expressed in aggressive B cell lymphoma. RBN012759 used to explore anti-tumour potential of PARP14 inhibition.</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3270">3270</a></td> <td valign="top" width="124">Mono-ADP-ribosylating PARPs</td> <td valign="top" width="74"><i>PARP15</i></td> <td valign="top" width="113"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3270">poly(ADP-ribose) polymerase family member 15</a></td> <td valign="top" width="314">Dual PARP10/PARP15 inhibition might be beneficial in cancer treatment (see compound 8a [PMID: 35500474])</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3271">3271</a></td> <td valign="top" width="124">2.3.1.- Acyltransferases</td> <td valign="top" width="74"><i>ZDHHC3</i></td> <td valign="top" width="113"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3272">zinc finger DHHC-type palmitoyltransferase 3</a></td> <td valign="top" width="314">benzosceptrin C promotes T cell-mediated anti-tumour effect <i>in vitro</i> and <i>in vivo; </i>proposed as an alternative to anti-PD-L1 or anti-PD-1 immunotherapies</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3272">3272</a></td> <td valign="top" width="124">S1: Chymotrypsin</td> <td valign="top" width="74"><i>CTRB1</i></td> <td valign="top" width="113">chymotrypsinogen B1</td> <td valign="top" width="314">Experimental inhibitor beta ph61 is curated</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3273">3273</a></td> <td valign="top" width="124">AAA ATPases</td> <td valign="top" width="74"><i>CLPP</i></td> <td valign="top" width="113"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3273">caseinolytic mitochondrial matrix peptidase proteolytic subunit</a></td> <td valign="top" width="314">Validated target for the development of anti-tumour drugs; activator compound 16z [PMID: 35609303] and PAM ONC201 curated</td> </tr> </tbody> </table> <h4>Ligands</h4> <p>Release of the newest proposed INN list (PL130) in February provided the opportunity to curate new nominally clinically-relevant entities. There were 414 INNs in this list. So far we have curated 27 kinase inhibitors from PL130, and where possible we have endeavoured to match the INNs to research codes in disclosed clinical pipelines, primary literature sources and clinical trials. We hope that this depth of curation provides additional insight and information for users of the GtoPdb. Occasionally the INNs match ligand structures that we have previously curated from other sources. Of note in PL130 was the inclusion of INNs for PROTAC type degrader molecules (zomiradomide, lirodegimod), and a kallikrein B1 gene editing agent (lonvoguran), both of which are relatively new classes of clinical interventions. We will continue to analyse this list to see if we can identify either new drug targets, or new pharmacological modalities for existing targets.</p> <p><b>Drug approvals</b></p> <p>Since the beginning of 2024 the FDA have approved 7 new drugs: as can be seen in the table below all but two of these are curated in the GtoPdb.</p> <table border="1" width="906" cellspacing="0" cellpadding="0"> <tbody> <tr style="color: blue" bgcolor="lightgrey"> <td valign="top" width="65"><strong>Ligand ID</strong></td> <td valign="top" width="100"><strong>INN</strong></td> <td valign="top" width="65"><strong>Indication</strong></td> </tr> <tr> <td align="left" valign="top">n/i</td> <td align="left" valign="top">berdazimer</td> <td align="left" valign="top">To treat molluscum contagiosum</td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10772">10772</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12188">12188</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10772">cefepime</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12188">enmetazobactam</a></td> <td align="left" valign="top">To treat complicated urinary tract infections</td> </tr> <tr> <td align="left" valign="top">n/i</td> <td align="left" valign="top">letibotulinumtoxinA-wlbg</td> <td align="left" valign="top">To temporarily improve the appearance of moderate-to-severe glabellar lines</td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9592">9592</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9592">tislelizumab-jsgr</a></td> <td align="left" valign="top">To treat unresectable or metastatic esophageal squamous cell carcinoma</td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12026">12026</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12026">resmetirom</a></td> <td align="left" valign="top">To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring</td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10070">10070</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10070">aprocitentan</a></td> <td align="left" valign="top">To treat hypertension</td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7490">7490</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7490">givinostat</a></td> <td align="left" valign="top">To treat Duchenne muscular dystrophy in individuals aged 6 years and older</td> </tr> </tbody> </table> <p><em>n/i (not included_ as the agent does not meet the current criteria for inclusion in the GtoPdb.</em></p> <h3>Antibacterial Curation</h3> <p>Our collaboration with Antibiotic DB (ADB; <a class="ms-outlook-linkify" href="http://www.antibioticdb.com/" target="_blank" rel="noopener">www.antibioticdb.com</a>) continues to allow us to extend the coverage of ligands with annotated antibacterial activity in GtoPdb and provide comprehensive chemistry and pharmacology for select antibacterials curated within ADB, via reciprocal links. This project is supported by the Global Antibiotic Research and Development Partnership (GARDP; <a class="ms-outlook-linkify" href="https://gardp.org/" target="_blank" rel="noopener">https://gardp.org/</a>).</p> <p>Currently we have <a href="https://www.guidetopharmacology.org/GRAC/LigandListForward?type=AntiBac&database=all"><b>537 ligands</b></a> tagged in GtoPdb as ‘antibacterial’ and <b>512 </b>of these have links to compounds at ADB. Since our last release we have added <b>30</b> new antibacterial ligands including:</p> <ul type="disc"> <li><b>6</b> drugs that are approved, or have been approved in the past, for clinical use in human</li> <li><b>18</b> compounds that progressed to clinical evaluation</li> </ul> <h3>Website Updates</h3> <ul> <li>Updated <a href="https://www.guidetopharmacology.org/GRAC/chemSearch.jsp#structureSearch">ligand substructure search</a> to fix an issue with searches returning no results when explicit hydrogen atoms are included in the query structure. <ul> <li>The search now opens a new tab for the results so that the original search tab with the query structure remains open and editable to support easier refinement by users of their query.</li> </ul> </li> <li>Updates to our web services <ul> <li>Antibacterial tag is now include as filter for ligands</li> <li>Interaction JSON extended to include target names, ligand names and selectivity</li> <li>Updated download files</li> </ul> </li> <li>Updated <a href="https://www.guidetopharmacology.org/download.jsp#data">data download files</a> <ul> <li>Approved drugs with their targets, including gene names, Entrez IDs and Ensembl IDs</li> <li>Interaction downloads split by target class</li> </ul> </li> <li>Website <ul> <li><a href="https://www.guidetopharmacology.org/databaseContent.jsp">Database content</a> move from about page to it’s own page</li> </ul> </li> </ul> </div> <div class="post-data"> Posted in <a href="https://blog.guidetopharmacology.org/category/chemical-curation/" rel="category tag">Chemical curation</a>, <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/technical/" rel="category tag">Technical</a> </div> </div> <div id="post-4612" class="post-4612 post type-post status-publish format-standard hentry category-concise-guide-to-pharmacology category-tutorials-and-guides"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2024/02/21/bjp-concise-guide-to-pharmacology-2023-24-out-now/" rel="bookmark">BJP Concise Guide to Pharmacology 2023/24 – out now!</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2024/02/21/bjp-concise-guide-to-pharmacology-2023-24-out-now/" title="9:24 am" rel="bookmark"><span class="timestamp">February 21, 2024</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2024/02/21/bjp-concise-guide-to-pharmacology-2023-24-out-now/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <h2>The essential guide for those working in the vital search for new drugs</h2> <h4>A FREE education and research resource</h4> <h4>What’s in it for you?</h4> <p>Published as a special issue in the British journal of Pharmacology every 2 years, <a href="https://bpspubs.onlinelibrary.wiley.com/toc/14765381/2023/180/S2">The Concise Guide to PHARMACOLOGY</a> provides brief overviews of the key properties of over 1,800 human drug targets and their pharmacology, and is a view of the data in the <a href="http://www.guidetopharmacology.org/">IUPHAR/BPS Guide to PHARMACOLOGY</a> that allows side by side comparison of members of families of drug targets.</p> <p>As a go to place for finding the best tools to use in the laboratory for any targets you are working on, and as an up to date list of the key reference material to read, <strong>there is no better resource for a pharmacologist.</strong></p> <h4>The Concise Guide to Pharmacology provides:</h4> <ul> <li>An evidence base, with over 4,650 references cited and listed</li> <li>Official internationally approved classification and nomenclature for human drug targets</li> <li>Links to chemical and omic databases, PubMed or Patents to obtain further information</li> <li>Pharmacological tools to identify a particular target in experimental investigations</li> <li>Links to the open access <a href="http://www.guidetopharmacology.org/">IUPHAR/BPS Guide to PHARMACOLOGY database.</a></li> </ul> <h4>Enjoy FREE access to:</h4> <ul> <li>Introduction and other protein targets</li> <li>G protein-coupled receptors</li> <li>Ion channels</li> <li>Nuclear hormone receptors</li> <li>Catalytic receptors</li> <li>Transporters</li> <li>Enzymes</li> </ul> <h4>International scale and scientific value</h4> <ul> <li>Made up of over 500 pages, where nearly 1,800 human drug targets are described</li> <li>Over 3,300 ligands are identified, including over 2,000 synthetic organic molecules and over 50 antibodies</li> <li>Over 5,600 interactions between ligands and targets are described quantitatively, allowing assessment of the potency/affinity of these interactions</li> <li>It provides an authoritative voice on nomenclature of these pharmacological targets through close links with NC-IUPHAR</li> <li>This edition was put together with the help of over 215 collaborators representing industry and academia from 22 countries<br /><br /></li> </ul> <h4>Not just for pharmacologists</h4> <p>The broad coverage includes 3 sections on ion channels, which will be of interest to <strong>physiologists. </strong>For many examples, molecular data are correlated with ion conductances at the cellular and channel level. Additionally, the large section on enzymes, with a major focus on kinases, peptidase and proteinases, will be relevant for <strong>biochemists</strong> and <strong>cell biologists</strong> wishing to identify whether selective tools for their enzyme of interest are available.</p> <h4><br />Teach pharmacology?</h4> <p>For those who teach pharmacology, the Concise Guide provides a handy starting point for researching specific pharmacological targets (receptors, ion channels, transporters, enzymes and other targets) which may be identified in lectures and practical classes. The further reading highlighted for these targets will allow greater depth of insight from authoritative sources.</p> <p>Use it as a teaching resource and make sure your students have free access:</p> <p><a href="http://www.guidetopharmacology.org/concise">www.guidetopharmacology.org/concise</a></p> <h4><br />How to make the most of the Concise Guide to PHARMACOLOGY 2023/2024</h4> <p>For those new to a research topic, the Concise Guide allows a ready comparison of individual pharmacological targets within a family.</p> <p><strong>Overview – </strong>Each family is introduced with an Overview, which includes the nomenclature status of the family and general data, for example on the endogenous ligands for the particular receptor family.</p> <p><strong>Table of Targets –</strong> Each table of targets includes clickable links to HUGO Gene Nomenclature Committee (HGNC) and UniProt, free online databases of the gene and protein information.</p> <p>Where available, the table identifies the pharmacology (the most selective tools available) of that individual molecular target, with agonists, antagonists, substrates, products, and labelled ligands listed.</p> <p><strong>Comments sections </strong>underneath the tables identify generic or species variation and any association of targets with inherited disorders, together with any limitations of the pharmacological tools.</p> <p><strong>Further reading </strong>focusses on published reviews of the target family, highlighting the most relevant and recent publications, allowing the reader to identify further relevant resources for increasing the depth and breadth of their understanding.</p> <p><em>This post has been copied and re-produced from the British Journal of Pharmacology website (<a href="https://bpspubs.onlinelibrary.wiley.com/journal/14765381/concise_guide_to_pharmacology.html">https://bpspubs.onlinelibrary.wiley.com/journal/14765381/concise_guide_to_pharmacology.html</a>) in order to publicise the Concise Guide to Pharmacology directly to followers of this blog and users of the IUPHAR/BPS Guide to Pharmacology.</em></p> </div> <div class="post-data"> Posted in <a href="https://blog.guidetopharmacology.org/category/concise-guide-to-pharmacology/" rel="category tag">Concise Guide to Pharmacology</a>, <a href="https://blog.guidetopharmacology.org/category/tutorials-and-guides/" rel="category tag">Tutorials and Guides</a> </div> </div> <div id="post-4604" class="post-4604 post type-post status-publish format-standard hentry category-hot-topics category-uncategorized"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2023/12/13/gtopdb-is-a-global-core-biodata-resource/" rel="bookmark">GtoPdb is a Global Core Biodata Resource</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2023/12/13/gtopdb-is-a-global-core-biodata-resource/" title="4:25 pm" rel="bookmark"><span class="timestamp">December 13, 2023</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2023/12/13/gtopdb-is-a-global-core-biodata-resource/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>The <a href="https://www.guidetopharmacology.org">IUPHAR/BPS Guide to Pharmacology</a> is delighted to be named as one of 15 new Global Core Biodata Resources (GCBRs) by the <a href="https://globalbiodata.org/">Global Biodata Coalition (GBC).</a></p> <p>The GBC announced the outcome of its 2023 selection round for GCBRs on 11th December 2023 – you can read about the announcement <a href="https://globalbiodata.org/global-biodata-coalition-announces-outcome-of-2023-global-core-biodata-resource-selection-process/">here</a>.</p> <p>GtoPdb is proud to meet the stringent eligibility criteria that were part of the selection process. This covered scientific focus, size and reach of the user communities, quality of service, governance and impact on global research. </p> <p>The inclusion of the 15 new resources brings the total number of GCBrs to 52. The full list of GCBRs can be viewed <a href="https://globalbiodata.org/what-we-do/global-core-biodata-resources/list-of-current-global-core-biodata-resources/">here.</a></p> <blockquote> <p>The GBC defines biodata resources as any biological, life science, or biomedical database that archives research data generated by scientists, or functions as a knowledgebase by adding value to scientific data by aggregation, processing, and expert curation. Global Core Biodata Resources are biodata resources that are of fundamental importance to the wider biological and life sciences community and the long term preservation of biological data. They:</p> <ul> <li>provide free and open access to their data,</li> <li>are used extensively both in terms of the number and distribution of their users,</li> <li>are mature and comprehensive,</li> <li>are are considered authoritative in their field,</li> <li>are of high scientific quality, and</li> <li>provide a professional standard of service delivery.</li> </ul> <p>Through its GCBR designation, the GBC seeks to draw the attention of life science funders to the most critical of the global set of biodata resources and to better understand the challenges and needs for biodata resource long-term sustainability. The GCBRs are deposition databases and knowledgebases of fundamental importance to the global life sciences and biomedical research communities, providing open access and long-term preservation of key biological data. Sustained, long-term support for these databases is paramount, as their discontinuation would have a highly detrimental impact on the global research endeavour.</p> </blockquote> <p> </p> </div> <div class="post-data"> Posted in <a href="https://blog.guidetopharmacology.org/category/hot-topics/" rel="category tag">Hot Topics</a>, <a href="https://blog.guidetopharmacology.org/category/uncategorized/" rel="category tag">Uncategorized</a> </div> </div> <div id="post-4586" class="post-4586 post type-post status-publish format-standard hentry category-chemical-curation category-database-updates category-technical"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2023/11/29/database-release-2023-3/" rel="bookmark">Database Release 2023.3</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2023/11/29/database-release-2023-3/" title="12:25 pm" rel="bookmark"><span class="timestamp">November 29, 2023</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2023/11/29/database-release-2023-3/#comments">1 Comment</a> </span> </div> <div class="post-entry"> <p>The latest release of the IUPHAR/BPS Guide to Pharmacology database was made on 29th November 2023. This database release is version 2023.3, and is the third release this year. The following blog post gives details of the key content updates and website changes. GtoPdb now contains:</p> <ul> <li><strong>3,056</strong> human targets, <strong>1,715</strong> of which have curated quantitative ligand interactions.</li> <li><strong>12,344</strong> ligands, <strong>9,072 </strong>of which have curated quantitative target interactions.</li> <li><strong>1,956 </strong>approved drugs, <strong>1,117</strong> with curated quantitative interactions.</li> <li>Clinical use summaries for over <strong>3,596</strong> ligands of which <strong>1,947 </strong>are approved drugs.</li> <li>A total of <strong>20,338</strong> curated binding constants</li> <li>Data curated from just over <strong>44,000</strong> references</li> </ul> <h3>NAR Publication and Database Report</h3> <p>In October 2023 our latest NAR Database Issue update was published:</p> <p>Harding SD, Armstrong JF, Faccenda E, Southan C, Alexander SPH, Davenport AP, Spedding M, Davies JA. (2023) <b>The IUPHAR/BPS Guide to PHARMACOLOGY in 2024</b>. <i>Nucl. Acids Res.</i> 2023 Oct 28:gkad944. Online ahead of print. doi: <a href="https://doi.org/10.1093/nar/gkad944" target="_blank" rel="noopener">10.1093/nar/gkad944</a>. [<a href="https://academic.oup.com/nar/advance-article/doi/10.1093/nar/gkad944/7332061" target="_blank" rel="noopener">Full text</a>]. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37897341/" target="_blank" rel="noopener">37897341</a>.</p> <p>In this update we report on recent developments to the resource and describe expansion in content over the six database releases made during the last two years. The database update section of this paper focuses on two areas relating to important global health challenges. The first, SARS-CoV-2 COVID-19, remains a major concern and we describe our efforts to expand the database to include a new family of coronavirus proteins. The second area is antimicrobial resistance, for which we have extended our coverage of antibacterials in partnership with AntibioticDB, a collaboration that has continued through support from GARDP.</p> <p>In November, our latest Database Report became available, covering in more detail the work we have undertaken in terms of curation and development, alongside usage statistics in the last six months <a href="https://dev.guidetopharmacology.org/pdfs/GtoPdb_Database_Report_Nov_2023.pdf">GtoPdb_Database_Report_Nov_2023.pdf</a>. Our report is accessible via our Zenodo repository: <a href="https://doi.org/10.5281/zenodo.10078018">https://doi.org/10.5281/zenodo.10078018</a></p> <h3>Curation Update</h3> <h4>Targets</h4> <p>New targets since Release Version 2023.2: We have curated a range of new targets and we highlight novel ligands that modulate their functions, and any therapeutic potential associated with pharmacological target manipulation.</p> <table border="1" cellspacing="0" cellpadding="0"> <tbody> <tr style="color: blue" bgcolor="lightgrey"> <td valign="top" width="73"><strong>TID</strong></td> <td valign="top" width="124"><strong>Family</strong></td> <td valign="top" width="74"><strong>Gene</strong></td> <td valign="top" width="113"><strong>Name</strong></td> <td valign="top" width="314"><strong>Comment</strong></td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3248">3248</a></td> <td>Lipid transfer/lipopolysaccharide binding proteins</td> <td valign="top" width="74">CETP</td> <td valign="top" width="113"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3248">cholesteryl ester transfer protein</a></td> <td valign="top" width="333">A range of inhibitors with interaction data (e.g. anacetrapib, evacetrapib, dalcetrapib, obicetrapib): clinical potential for atherosclerotic cardiovascular disease & other dyslipidemias</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3249">3249</a></td> <td valign="top" width="126">Carnitine palmitoyltransferases</td> <td valign="top" width="74">CPT1A</td> <td valign="top" width="114"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3249">carnitine palmitoyltransferase 1A</a></td> <td valign="top" width="333">2 inhibitors with interaction data (teglicar, etomoxir); oncology potential</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3250">3250</a></td> <td valign="top" width="126">Carnitine palmitoyltransferases</td> <td valign="top" width="74">CPT1B</td> <td valign="top" width="114"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3250">carnitine palmitoyltransferase 1B</a></td> <td valign="top" width="333">1 inhibitor interaction (teglicar);; oncology potential</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3251">3251</a></td> <td valign="top" width="126">Carnitine palmitoyltransferases</td> <td valign="top" width="74">CPT1C</td> <td valign="top" width="114"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3251">carnitine palmitoyltransferase 1C</a></td> <td valign="top" width="312">No ligands identified</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3252">3252</a></td> <td valign="top" width="126">Carnitine palmitoyltransferases</td> <td valign="top" width="74">CPT2</td> <td valign="top" width="114"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3252">carnitine palmitoyltransferase 2</a></td> <td valign="top" width="333">2 inhibitors with interaction data (teglicar, compound 16 [PMID: 17585909]); oncology potential</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3253">3253</a></td> <td valign="top" width="124">Hydrolases & Lipases</td> <td valign="top" width="74">PNPLA2</td> <td valign="top" width="115"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3253">patatin like phospholipase domain containing 2</a></td> <td valign="top" width="343">Potential of lipase inhibitors to contribute to antiviral effects for RNA viruses, plus one inhibitor with interaction data for atglistatin. Also curated new inhibitors for other lipases (LIPE compound 41 [PMID: 15026062], MAGL & FAAH CAY10499.</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3254">3254</a></td> <td valign="top" width="124">E3 ubiquitin ligase components</td> <td valign="top" width="74">ZBTB25</td> <td valign="top" width="115"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3254">zinc finger and BTB domain containing 25</a></td> <td valign="top" width="333">CoV Mpro ubiquitination and degradation (= ?antiviral activity)</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3255">3255</a></td> <td valign="top" width="126">Protein tyrosine phosphatases non-receptor type (PTPN)</td> <td valign="top" width="74">PTPN2</td> <td valign="top" width="115"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3255">protein tyrosine phosphatase, non-receptor type 2</a></td> <td valign="top" width="333">dual PTPN1/2 inhib compound 182 [PMID: 37500611], oncology</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3256">3256</a></td> <td valign="top" width="124">Diacylglycerol kinases</td> <td valign="top" width="74">DGKA</td> <td valign="top" width="113"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3256">diacylglycerol kinase alpha</a></td> <td valign="top" width="343">dual inhibitor BMS-502 promotes immune stimulation (T cells); potential upregulation of anti-tumour immune response</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3257">3257</a></td> <td valign="top" width="124">Diacylglycerol kinases</td> <td valign="top" width="74">DGKZ</td> <td valign="top" width="113"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3257">diacylglycerol kinase zeta</a></td> <td valign="top" width="343">dual inhibitor BMS-502 promotes immune stimulation (T cells); potential upregulation of anti-tumour immune response</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3258">3258</a></td> <td valign="top" width="124">Hydrolases & Lipases</td> <td valign="top" width="74">NEU2</td> <td valign="top" width="113"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3258">neuraminidase 2</a></td> <td valign="top" width="333">regulation of cellular glycans repertoire. 2 novel inhibitors/experimental tools: compound 22 [PMID: 30457869] & compound 13c [PMID: 30457869]</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3259">3259</a></td> <td valign="top" width="125">3.6.4.12 RecQ helicases family</td> <td valign="top" width="74">WRN</td> <td valign="top" width="113"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3259">WRN RecQ like helicase</a></td> <td valign="top" width="343">Novel inhibitors curated with quantitative interaction data, including one (HRO761) in clinical development for oncology potential</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3260">3260</a></td> <td valign="top" width="125">3.6.4.12 RecQ helicases family</td> <td valign="top" width="74">BLM</td> <td valign="top" width="113"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3260">BLM RecQ like helicase</a></td> <td valign="top" width="336">Novel inhibitors curated with quantitative interaction data, including one allosteric inhibitor (compound 2 [PMID: 33647232])</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3261">3261</a></td> <td valign="top" width="124">Coronavirus (CoV) proteins</td> <td valign="top" width="74">ORF1ab</td> <td valign="top" width="113"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3261">CoV nsp13 (helicase)</a></td> <td valign="top" width="338">Novel inhibitors curated; antiviral potential- more details below</td> </tr> <tr> <td valign="top" width="64"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3262">3262</a></td> <td valign="top" width="124">E3 ubiquitin ligase components</td> <td valign="top" width="74">KLHDC2</td> <td valign="top" width="113"><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3262">kelch domain containing 2</a></td> <td valign="top" width="341">A substrate-recognition component of an E3 ligase complex that’s involved in the C-end degron protein homeostasis pathway; a tractable target for PROTAC design and development. A <span style="font-size: 12.0pt">KLHDC2-based</span> kinase degrading PROTAC (<a href="https://dev.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13031" target="_blank" rel="noopener noreferrer">KYH1872</a>) has been curated, which demonstrates the utility of exploiting <span style="font-size: 12.0pt">KLHDC2 for targeted protein degradation in drug design.</span></td> </tr> </tbody> </table> <h4>Ligands</h4> <p>Since our last update in August 2023, the FDA have approved 20 new drugs (58 in total so far for 2023, so ahead of the 52 for all of 2022). Only 3 of these did not meet the criteria to be included in GtoPdb</p> <table style="height: 2632px" border="1" width="906" cellspacing="0" cellpadding="0"> <tbody> <tr style="color: blue" bgcolor="lightgrey"> <td colspan="7"><strong>20 newly approved drugs, 17 added to the GtoPdb</strong></td> </tr> <tr style="color: blue" bgcolor="lightgrey"> <td valign="top" width="65"><strong>Ligand ID</strong></td> <td valign="top" width="100"><strong>INN</strong></td> <td valign="top" width="124"><strong>Trade name</strong></td> <td valign="top" width="73"><strong>Type</strong></td> <td valign="top" width="20"><strong>FDA Approval date</strong></td> <td valign="top" width="65"><strong>Indication</strong></td> <td valign="top" width="94"><strong>Other Approval date</strong></td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12240">12240</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12240">talquetamab-tgvs</a></td> <td align="left" valign="top">Talvey</td> <td align="left" valign="top">monoclonal antibody</td> <td align="left" valign="top">09/08/2023</td> <td align="left" valign="top">To treat adults with relapsed or refractory multiple myeloma who have received at least four prior therapies</td> <td align="left" valign="top">n/a</td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12289">12889</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12889">elranatamab-bcmm</a></td> <td align="left" valign="top">Elrexfio</td> <td align="left" valign="top">monoclonal antibody</td> <td align="left" valign="top">14/08/2023</td> <td align="left" valign="top">To treat adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy</td> <td align="left" valign="top">n/a</td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8276">8276</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8276">palovarotene</a></td> <td align="left" valign="top">Sohonos</td> <td align="left" valign="top">small molecule</td> <td align="left" valign="top">16/08/2023</td> <td align="left" valign="top">To reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressiva</td> <td align="left" valign="top">n/a</td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12900">12900</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12900">pozelimab-bbfg</a></td> <td align="left" valign="top">Veopoz</td> <td align="left" valign="top">monoclonal antibody</td> <td align="left" valign="top">18/08/2023</td> <td align="left" valign="top">To treat patients 1 year old and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease</td> <td align="left" valign="top">n/a</td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10679">10679</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10679">motixafortide</a></td> <td align="left" valign="top">Aphexda</td> <td align="left" valign="top">peptide</td> <td align="left" valign="top">08/09/2023</td> <td align="left" valign="top">To use with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma</td> <td align="left" valign="top">n/a</td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7791">7791</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7791">momelotinib</a></td> <td align="left" valign="top">Ojjaara</td> <td align="left" valign="top">small molecule</td> <td align="left" valign="top">15/09/2023</td> <td align="left" valign="top">To treat intermediate or high-risk myelofibrosis in adults with anemia</td> <td align="left" valign="top">n/a</td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12930">12930</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12930">gepirone</a></td> <td align="left" valign="top">Exxua</td> <td align="left" valign="top">small molecule</td> <td align="left" valign="top">22/09/2023</td> <td align="left" valign="top">To treat major depressive disorder</td> <td align="left" valign="top">n/a</td> </tr> <tr> <td align="left" valign="top">n/a</td> <td align="left" valign="top">cipaglucosidase alfa-atga</td> <td align="left" valign="top">Pombiliti</td> <td align="left" valign="top">peptide</td> <td align="left" valign="top">28/09/2023</td> <td align="left" valign="top">To treat late-onset Pompe disease</td> <td align="left" valign="top">20/03/2023</td> </tr> <tr> <td align="left" valign="top">n/a</td> <td align="left" valign="top">nedosiran</td> <td align="left" valign="top">Rivfloza</td> <td align="left" valign="top">nucleotide</td> <td align="left" valign="top">29/09/2023</td> <td align="left" valign="top">To lower urinary oxalate levels in patients 9 years and older with primary hyperoxaluria type 1 and relatively preserved kidney function</td> <td align="left" valign="top">n/a</td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9331">9331</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9331">etrasimod</a></td> <td align="left" valign="top">Velsipity</td> <td align="left" valign="top">small molecule</td> <td align="left" valign="top">12/10/2023</td> <td align="left" valign="top">To treat moderately to severely active ulcerative colitis in adults</td> <td align="left" valign="top">n/a</td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10404">10404</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10404">zilucoplan</a></td> <td align="left" valign="top">Zilbrysq</td> <td align="left" valign="top">peptide</td> <td align="left" valign="top">17/10/2023</td> <td align="left" valign="top">To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive</td> <td align="left" valign="top">n/a</td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9247">9247</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9247">vamorolone</a></td> <td align="left" valign="top">Agamree</td> <td align="left" valign="top">small molecule</td> <td align="left" valign="top">26/10/2023</td> <td align="left" valign="top">To treat Duchenne muscular dystrophy</td> <td align="left" valign="top">n/a</td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9846">9846</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9846">mirikizumab-mrkz</a></td> <td align="left" valign="top">Omvoh</td> <td align="left" valign="top">monoclonal antibody</td> <td align="left" valign="top">26/10/2023</td> <td align="left" valign="top">To treat ulcerative colitis</td> <td align="left" valign="top">26/05/2023</td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12989">12989</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12989">toripalimab-tpzi</a></td> <td align="left" valign="top">Loqtorzi</td> <td align="left" valign="top">monoclonal antibody</td> <td align="left" valign="top">30/10/2023</td> <td align="left" valign="top">To treat advanced nasopharyngeal carcinoma</td> <td align="left" valign="top">n/a</td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9428">9428</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9428">fruquintinib</a></td> <td align="left" valign="top">Fruzaqla</td> <td align="left" valign="top">small molecule</td> <td align="left" valign="top">09/11/2023</td> <td align="left" valign="top">To treat metastatic colorectal cancer.</td> <td align="left" valign="top">n/a</td> </tr> <tr> <td align="left" valign="top">n/a</td> <td align="left" valign="top">ADAMTS13, recombinant-krhn</td> <td align="left" valign="top">Adzynma</td> <td align="left" valign="top">peptide</td> <td align="left" valign="top">09/11/2023</td> <td align="left" valign="top">To treat congenital thrombotic thrombocytopenic purpura</td> <td align="left" valign="top">n/a</td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10316">10316</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10316">repotrectinib</a></td> <td align="left" valign="top">Augtyro</td> <td align="left" valign="top">small molecule</td> <td align="left" valign="top">15/11/2023</td> <td align="left" valign="top">To treat locally advanced or metastatic ROS1-positive non-small cell lung cancer</td> <td align="left" valign="top">n/a</td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13030">13030</a>; <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4214">4214</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13030">taurolidine</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4214">heparin</a></td> <td align="left" valign="top">Defencath</td> <td align="left" valign="top">mixture</td> <td align="left" valign="top">15/11/2023</td> <td align="left" valign="top">To reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter</td> <td align="left" valign="top">n/a</td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7709">7709</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7709">capivasertib</a></td> <td align="left" valign="top">Truqap</td> <td align="left" valign="top">small molecule</td> <td align="left" valign="top">16/11/2023</td> <td align="left" valign="top">To treat HR+ve, HER2-ve adv breast cancer with AKT pathway activating mutations</td> <td align="left" valign="top">n/a</td> </tr> <tr> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7746">7746</a></td> <td align="left" valign="top"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7746">nirogacestat</a></td> <td align="left" valign="top">Ogsiveo</td> <td align="left" valign="top">small molecule</td> <td align="left" valign="top">27/11/2023</td> <td align="left" valign="top">To treat progressing desmoid tumours</td> <td align="left" valign="top">n/a</td> </tr> </tbody> </table> <h4>SARS-CoV-2 & COVID-19</h4> <p>We have been keeping up to date with the progress of SARS-CoV-2 antiviral development by the <a href="https://postera.ai/moonshot/" target="_blank" rel="noopener noreferrer">COVID Moonshot</a> open science project. In collaboration with the non-profit Drugs for Neglected Diseases initiative a clinical lead, DNDi-6510, has been selected, although its chemical structure has not yet been disclosed. We have however included a selection of Moonshot-discovered Mpro inhibitors as examples of their endeavours, and more details are available in the 2023 publication <a href="https://pubmed.ncbi.nlm.nih.gov/37943932/" target="_blank" rel="noopener noreferrer">PMID: 37943932</a></p> <p>The Moonshot Mpro inhibitors in GtoPdb are:</p> <p><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13003" target="_blank" rel="noopener noreferrer">MAT-POS-e194df51-1</a></p> <p><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12227" target="_blank" rel="noopener noreferrer">PET-UNK-29afea89-2</a></p> <p><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12226" target="_blank" rel="noopener noreferrer">MAT-POS-b3e365b9-1</a></p> <p><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11764" target="_blank" rel="noopener noreferrer">MAT-POS-932d1078-3</a></p> <p><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11174" target="_blank" rel="noopener noreferrer">DAV-CRI-14a23e73-1</a></p> <p>On the theme of SARS-CoV-2 antiviral development, we have included some new ligands that are reported as inhibitors of the CoV helicase (nsp13). Since the helicase is a crucial component of the CoV replication machinery, its inhibition is predicted to offer antiviral potential. Nsp13 is also reported to reduce the host interferon response, so limiting this effect would also likely contribute to COVID-19 therapeutic efficacy. To enhance nsp13’s inclusion we generated a new target entry (<a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3261" target="_blank" rel="noopener noreferrer">nsp13</a>), to permit curation of quantitative ligand-target interaction data in the format used throughout other sections of the GtoPdb.</p> <p>Nsp13 modulators curated are:</p> <p><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10881" target="_blank" rel="noopener noreferrer">compound 16 [PMID: 31955138]</a></p> <p><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13022" target="_blank" rel="noopener noreferrer">compound 4b [Ramsey <i>et al</i>., 2023]</a></p> <p><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13028" target="_blank" rel="noopener noreferrer">compound 1b [PMID: 37562607]</a></p> <h3></h3> <h3>Antibacterial Curation</h3> <p>Our collaboration with Antibiotic DB (ADB; <a class="ms-outlook-linkify" href="http://www.antibioticdb.com/" target="_blank" rel="noopener">www.antibioticdb.com</a>) continues to allow us to extend the coverage of ligands with annotated antibacterial activity in GtoPdb and provide comprehensive chemistry and pharmacology for select antibacterials curated within ADB, via reciprocal links. This project is supported by the Global Antibiotic Research and Development Partnership (GARDP; <a class="ms-outlook-linkify" href="https://gardp.org/" target="_blank" rel="noopener">https://gardp.org/</a>).</p> <p>Currently we have <a href="https://www.guidetopharmacology.org/GRAC/LigandListForward?type=AntiBac&database=all"><b>507 ligands</b></a> tagged in GtoPdb as ‘antibacterial’ and <b>488 </b>of these have links to compounds at ADB. Since our last release we have added <b>35</b> new antibacterial ligands including:</p> <ul type="disc"> <li><b>19</b> drugs that are approved, or have been approved in the past, for clinical use in human</li> <li><b>2</b> drugs that are approved for use in veterinary practice</li> <li><b>2</b> that are WHO EML listed medicines</li> <li><b>11</b> compounds that are in clinical development</li> </ul> <p> </p> </div> <div class="post-data"> Posted in <a href="https://blog.guidetopharmacology.org/category/chemical-curation/" rel="category tag">Chemical curation</a>, <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/technical/" rel="category tag">Technical</a> </div> </div> <div id="post-4569" class="post-4569 post type-post status-publish format-standard hentry category-chemical-curation category-database-updates category-technical"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2023/08/07/database-release-2023-2/" rel="bookmark">Database Release 2023.2</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2023/08/07/database-release-2023-2/" title="4:12 pm" rel="bookmark"><span class="timestamp">August 7, 2023</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2023/08/07/database-release-2023-2/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>The latest release of the IUPHAR/BPS Guide to Pharmacology database was made on 7th August 2023. This database release is version 2023.2, and is the second release this year. The following blog post gives details of the key content updates and website changes. GtoPdb now contains:</p> <ul> <li><strong>3,039</strong> human targets, <strong>1,695</strong> of which have curated quantitative ligand interactions.</li> <li><strong>12,163</strong> ligands, <strong>8,959 </strong>of which have curated quantitative target interactions.</li> <li><strong>1,918</strong> approved drugs, <strong>1,107</strong> with curated quantitative interactions.</li> <li>Clinical use summaries for over <strong>3,494</strong> ligands of which <strong>1,910 </strong>are approved drugs.</li> <li>A total of <strong>20,139</strong> curated binding constants</li> <li>Data curated from just under <strong>44,000</strong> references</li> </ul> <h3>Curation Update</h3> <p>Since our last release in April we have added 14 new protein targets with clinical relevance, that have been identified from primary literature. They all have associated ligands which are also new additions. The majority of these new targets are being investigated for applications in different cancers as you can see in the table below.</p> <table border="1" cellspacing="0" cellpadding="0"> <tbody> <tr style="color: blue" bgcolor="lightgrey"> <td valign="top" width="73"><b>Target ID</b></td> <td valign="top" width="266"><b>Name</b></td> <td valign="top" width="368"><b>Therapeutic area</b></td> </tr> <tr> <td valign="top" width="73">3230</td> <td valign="top" width="266">DNA polymerase theta</td> <td valign="top" width="368">oncology</td> </tr> <tr> <td valign="top" width="73">3231</td> <td valign="top" width="266">DNA polymerase beta</td> <td valign="top" width="368">oncology</td> </tr> <tr> <td valign="top" width="73">3232</td> <td valign="top" width="266">BCL3 transcription coactivator</td> <td valign="top" width="368">oncology</td> </tr> <tr> <td valign="top" width="73">3233</td> <td valign="top" width="266">F-box protein 3 (E3 ligase component)</td> <td valign="top" width="368">inflammation</td> </tr> <tr> <td valign="top" width="73">3234</td> <td valign="top" width="266">Cbl proto-oncogene B</td> <td valign="top" width="368">oncology</td> </tr> <tr> <td valign="top" width="73">3235</td> <td valign="top" width="266">S-phase kinase associated protein 2 (E3 ligase component)</td> <td valign="top" width="368">oncology</td> </tr> <tr> <td valign="top" width="73">3236</td> <td valign="top" width="266">ketohexokinase</td> <td valign="top" width="368">metabolic disease</td> </tr> <tr> <td valign="top" width="73">3237</td> <td valign="top" width="266">axin 2</td> <td valign="top" width="368">oncology</td> </tr> <tr> <td valign="top" width="73">3238</td> <td valign="top" width="266">phospholipid scramblase 1</td> <td valign="top" width="368">viral infection</td> </tr> <tr> <td valign="top" width="73">3239</td> <td valign="top" width="266">glutathione peroxidase 4</td> <td valign="top" width="368">oncology</td> </tr> <tr> <td valign="top" width="73">3240</td> <td valign="top" width="266">TEA domain transcription factor 1</td> <td valign="top" width="368">oncology</td> </tr> <tr> <td valign="top" width="73">3241</td> <td valign="top" width="266">TEA domain transcription factor 2</td> <td valign="top" width="368">oncology</td> </tr> <tr> <td valign="top" width="73">3242</td> <td valign="top" width="266">TEA domain transcription factor 3</td> <td valign="top" width="368">oncology</td> </tr> <tr> <td valign="top" width="73">3243</td> <td valign="top" width="266">TEA domain transcription factor 4</td> <td valign="top" width="368">oncology</td> </tr> <tr> <td valign="top" width="73">3244</td> <td valign="top" width="266">DDB1 and CUL4 associated factor 1 (DCAF1)</td> <td valign="top" width="368">novel E3 ligase for targeted protein degradation applications (e.g. PROTAC development)</td> </tr> </tbody> </table> <p>A range of new ligands have been added. In addition to new information contributed by our target family subcommittees, additional sources for new ligands include primary med chem literature, patents, company pipeline analysis, INN lists, structure disclosures from scientific meetings and scanning of clinical trials for novel disease-associated agents.</p> <p>Our PROTACs, molecular glues and other degraders ligand family (<a id="LPlnk683656" href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1030)has" target="_blank" rel="noopener noreferrer">https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1030)</a> has been expanded to over 90 experimental and investigational compounds, which in total target over 45 mainly human proteins, but we have two PROTACS that target the coronavirus 3CL-protease (Mpro).</p> <p>Since our last update we have annotated 22 newly approved drugs – 15/22 are fully curated in the Guide. The other 7 don’t meet our selection criteria (e.g. target is non-human or is non-protein, imaging reagent, non-specific MMOA).</p> <table style="height: 2632px" border="1" width="906" cellspacing="0" cellpadding="0"> <tbody> <tr style="color: blue" bgcolor="lightgrey"> <td colspan="7"><strong>22 newly approved drugs, 15 added to the GtoPdb</strong></td> </tr> <tr style="color: blue" bgcolor="lightgrey"> <td valign="top" width="65"><strong>Ligand ID</strong></td> <td valign="top" width="100"><strong>INN</strong></td> <td valign="top" width="124"><strong>Trade name</strong></td> <td valign="top" width="73"><strong>Type</strong></td> <td valign="top" width="20"><strong>FDA Approval date</strong></td> <td valign="top" width="65"><strong>Indication</strong></td> <td valign="top" width="94"><strong>Other Approval date</strong></td> </tr> <tr> <td valign="top" width="64">n/a</td> <td valign="top" width="142">tofersen</td> <td valign="top" width="75">Qalsody</td> <td valign="top" width="80">nucleotide</td> <td valign="top" width="91">25/04/2023</td> <td valign="top" width="164">To treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation</td> <td valign="top" width="91">n/a</td> </tr> <tr> <td valign="top" width="64">12653</td> <td valign="top" width="142"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12653">keverprazan</a></td> <td valign="top" width="75"></td> <td valign="top" width="80">sm</td> <td valign="top" width="91">n/a</td> <td valign="top" width="164">To treat reflux oesophagitis and duodenal ulcer</td> <td valign="top" width="91">15/02/2023 (China)</td> </tr> <tr> <td valign="top" width="64">n/a</td> <td valign="top" width="142">pegunigalsidase alfa-iwxj</td> <td valign="top" width="75">Elfabrio</td> <td valign="top" width="80">pep</td> <td valign="top" width="91">09/05/2023</td> <td valign="top" width="164">To treat confirmed Fabry disease</td> <td valign="top" width="91">04/05/2023 (EMA)</td> </tr> <tr> <td valign="top" width="64">10422</td> <td valign="top" width="142"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10422">fezolinetant</a></td> <td valign="top" width="75">Veozah</td> <td valign="top" width="80">sm</td> <td valign="top" width="91">13/05/2023</td> <td valign="top" width="164">To treat moderate to severe hot flashes caused by menopause</td> <td valign="top" width="91">n/a</td> </tr> <tr> <td valign="top" width="64">n/a</td> <td valign="top" width="142">perfluorhexyloctane</td> <td valign="top" width="75">Miebo</td> <td valign="top" width="80">inert sm</td> <td valign="top" width="91">18/05/2023</td> <td valign="top" width="164">To treat signs and symptoms of dry eye disease</td> <td valign="top" width="91">n/a</td> </tr> <tr> <td valign="top" width="64">11442</td> <td valign="top" width="142"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11442">epcoritamab-bysp</a></td> <td valign="top" width="75">Epkinly</td> <td valign="top" width="80">mAb</td> <td valign="top" width="91">19/05/2023</td> <td valign="top" width="164">To treat R/R DLBCL and HGBL</td> <td valign="top" width="91">n/a</td> </tr> <tr> <td valign="top" width="64">n/a: 12693</td> <td valign="top" width="142">sulbactam; <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12693">durlobactam</a></td> <td valign="top" width="75">Xacduro</td> <td valign="top" width="80">sm</td> <td valign="top" width="91">23/05/2023</td> <td valign="top" width="164">To treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of <i>Acinetobacter baumannii-calcoaceticus complex</i></td> <td valign="top" width="91">n/a</td> </tr> <tr> <td valign="top" width="64">11503; 8804</td> <td valign="top" width="142"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11503">nirmatrelvir</a>; <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8804">ritonavir</a></td> <td valign="top" width="75">Paxlovid</td> <td valign="top" width="80">sm</td> <td valign="top" width="91">25/05/2023</td> <td valign="top" width="164">To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19</td> <td valign="top" width="91">2021 (UK), 2022 (EMA)</td> </tr> <tr> <td valign="top" width="64">n/a</td> <td valign="top" width="142">flotufolastat F 18</td> <td valign="top" width="75">Posluma</td> <td valign="top" width="80">sm</td> <td valign="top" width="91">25/05/2023</td> <td valign="top" width="164">To use with positron emission tomography imaging in certain patients with prostate cancer</td> <td valign="top" width="91">n/a</td> </tr> <tr> <td valign="top" width="64">8312</td> <td valign="top" width="142"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=83123">sotagliflozin</a></td> <td valign="top" width="75">Inpefa</td> <td valign="top" width="80">sm</td> <td valign="top" width="91">26/05/2023</td> <td valign="top" width="164">To treat heart failure</td> <td valign="top" width="91">26/04/2019 (EMA; T1DM)</td> </tr> <tr> <td valign="top" width="64">12757</td> <td valign="top" width="142"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12757">glofitamab-gxbm</a></td> <td valign="top" width="75">Columvi</td> <td valign="top" width="80">mAb</td> <td valign="top" width="91">15/06/2023</td> <td valign="top" width="164">To treat DLBCL or LBCL)</td> <td valign="top" width="91">n/a</td> </tr> <tr> <td valign="top" width="64">9559</td> <td valign="top" width="142"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9559">ritlecitinib</a></td> <td valign="top" width="75">Litfulo</td> <td valign="top" width="80">sm</td> <td valign="top" width="91">24/06/2023</td> <td valign="top" width="164">To treat severely patchy hair loss (alopecia areata)</td> <td valign="top" width="91">n/a</td> </tr> <tr> <td valign="top" width="64">9801</td> <td valign="top" width="142"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9801">rozanolixizumab-noli</a></td> <td valign="top" width="75">Rystiggo</td> <td valign="top" width="80">mAb</td> <td valign="top" width="91">27/06/2023</td> <td valign="top" width="164">To treat antibody positive generalized myasthenia gravis</td> <td valign="top" width="91">n/a</td> </tr> <tr> <td valign="top" width="64">12013</td> <td valign="top" width="142"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12013">somatrogon-ghla</a></td> <td valign="top" width="75">Ngenla</td> <td valign="top" width="80">pep</td> <td valign="top" width="91">27/06/2023</td> <td valign="top" width="164">To treat growth failure due to inadequate secretion of endogenous growth hormone</td> <td valign="top" width="91">14/02/2022 (EMA)</td> </tr> <tr> <td valign="top" width="64">n/a</td> <td valign="top" width="142">nirsevimab-alip</td> <td valign="top" width="75">Beyfortus</td> <td valign="top" width="80">mAb</td> <td valign="top" width="91">17/07/2023</td> <td valign="top" width="164">To prevent respiratory syncytial virus (RSV) lower respiratory tract disease in infants</td> <td valign="top" width="91">31/10/2022 (EMA)</td> </tr> <tr> <td valign="top" width="64">9846</td> <td valign="top" width="142"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9846">mirikizumab</a></td> <td valign="top" width="75">Omvoh</td> <td valign="top" width="80">mAb</td> <td valign="top" width="91">n/a</td> <td valign="top" width="164">Induction and maintenance therapy for ulcerative colitis</td> <td valign="top" width="91">27/03/2023 (Japan)</td> </tr> <tr> <td valign="top" width="64">11182</td> <td valign="top" width="142"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11182">concizumab</a></td> <td valign="top" width="75">Alhemo</td> <td valign="top" width="80">mAb</td> <td valign="top" width="91">n/a</td> <td valign="top" width="164">To treat hemophilia B</td> <td valign="top" width="91">2023 (Canada)</td> </tr> <tr> <td valign="top" width="64">5658</td> <td valign="top" width="142"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5658">quizartinib</a></td> <td valign="top" width="75">Vanflyta</td> <td valign="top" width="80">sm</td> <td valign="top" width="91">20/07/2023</td> <td valign="top" width="164">To use as part of a treatment regimen for newly diagnosed acute myeloid leukemia that meets certain criteria (ie FLT3-ITD +ve)</td> <td valign="top" width="91">2019 (Japan)</td> </tr> <tr> <td valign="top" width="64">n/a</td> <td valign="top" width="142">cantharidin</td> <td valign="top" width="75">Ycanth</td> <td valign="top" width="80">sm</td> <td valign="top" width="91">21/07/2023</td> <td valign="top" width="164">To treat molluscum contagiosum</td> <td valign="top" width="91">n/a</td> </tr> <tr> <td valign="top" width="64">n/a</td> <td valign="top" width="142">lotilaner</td> <td valign="top" width="75">Xdemvy</td> <td valign="top" width="80">sm</td> <td valign="top" width="91">25/07/2023</td> <td valign="top" width="164">To treat Demodex blepharitis</td> <td valign="top" width="91">n/a</td> </tr> <tr> <td valign="top" width="64">12858</td> <td valign="top" width="142"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12858">zuranolone</a></td> <td valign="top" width="75">Zurzuvae</td> <td valign="top" width="80">sm</td> <td valign="top" width="91">04/08/2023</td> <td valign="top" width="164">To treat postpartum depression</td> <td valign="top" width="91">n/a</td> </tr> <tr> <td valign="top" width="64">12857</td> <td valign="top" width="142"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12857">avacincaptad pegol</a></td> <td valign="top" width="75">Izervay</td> <td valign="top" width="80">nucleotide</td> <td valign="top" width="91">05/08/2023</td> <td valign="top" width="164">To treat geographic atrophy (secondary to AMD)</td> <td valign="top" width="91">n/a</td> </tr> </tbody> </table> <h3>Antibacterial Curation</h3> <p><span style="font-weight: 400">We are pleased to report that the Global Antibiotic Research and Development Partnership (GARDP; <a href="https://gardp.org/">https://gardp.org/</a>) has extended their funding of our collaboration with Antibiotic DB (ADB; <a href="https://www.antibioticdb.com/">www.antibioticdb.com</a>) for a further 2 years. Through this interaction, GtoPdb provides chemistry and pharmacology for a curated set of antibacterial compounds with links to ADB.</span></p> <p><span style="font-weight: 400">Currently we have </span><b>471 ligands</b><span style="font-weight: 400"> tagged in GtoPdb as ‘antibacterial’ and </span><b>455 </b><span style="font-weight: 400">of these have links to compounds at ADB. The antibacterials in the GtoPdb include approved drugs, WHO essential Medicines-listed medicines and a number of investigational and experimental compounds.</span></p> <p> </p> <p> </p> </div> <div class="post-data"> Posted in <a href="https://blog.guidetopharmacology.org/category/chemical-curation/" rel="category tag">Chemical curation</a>, <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/technical/" rel="category tag">Technical</a> </div> </div> <div id="post-4551" class="post-4551 post type-post status-publish format-standard hentry category-chemical-curation category-database-updates category-technical"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2023/04/26/database-release-2023-1/" rel="bookmark">Database Release 2023.1</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2023/04/26/database-release-2023-1/" title="10:35 am" rel="bookmark"><span class="timestamp">April 26, 2023</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2023/04/26/database-release-2023-1/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>The latest release of the IUPHAR/BPS Guide to Pharmacology database was made on 26th April 2023. This database release is version 2023.1, and is the first release this year. The following blog post gives details of the key content updates and website changes. GtoPdb now contains:</p> <ul> <li><strong>3,023</strong> human targets, <strong>1,662</strong> of which have curated quantitative ligand interactions.</li> <li><strong>11,944</strong> ligands, <strong>8,814 </strong>of which have curated quantitative target interactions.</li> <li><strong>1,872</strong> approved drugs, <strong>1,098</strong> with curated quantitative interactions.</li> <li>Clinical use summaries for over <strong>3,385</strong> ligands of which <strong>1,866 </strong>are approved drugs.</li> <li>A total of <strong>19,890</strong> curated binding constants</li> <li>Data curated from over <strong>43,543</strong> references</li> </ul> <h3>Curation Update</h3> <p>Updates have been made to many target family summary pages in preparation for generating the 2023-24 issue of the Concise Guide to PHARMACOLOGY (due for publication at the end of the year). More significant modifications have been made to the summary pages for the <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=72">GABAA receptors</a> (in Ion channels) and <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=51">Orexin receptors</a> (in GPCRs). A major overhaul of the <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=117">Taste 2 GPCRs</a> (Bitter taste receptors) has been completed, with newly annotated details for ligands that interact with these receptors. We thank all of our contributors who have given so freely of their time to make these updates possible.</p> <p>As a regular review of the INN lists from the WHO, we added 31 new kinase inhibitors to the Guide (see table 1), that were included in the Jan 2023 list of proposed INNs (List 128). The chemical structures allowed us to connect around half of these (16/31) INNs to clinical leads (some with declared name>structure), and others to patents from which we could obtain otherwise unpublished target information and interaction data. Five of the structures matched ligands that were already in the Guide. In total we have found interaction data for 27/31 of these inhibitors. For a few, we were unable to track down very little additional information.</p> <table style="height: 505px" border="1" width="928" cellspacing="0" cellpadding="0"> <tbody> <tr style="color: blue" bgcolor="lightgrey"> <td colspan="9"><strong>31 new kinase inhibitors added to the GtoPdb</strong></td> </tr> <tr style="color: blue" bgcolor="lightgrey"> <td valign="top" width="65"><strong>Ligand ID</strong></td> <td valign="top" width="100"><strong>INN</strong></td> <td valign="top" width="124"><strong>Name/code</strong></td> <td valign="top" width="73"><strong>Target</strong></td> <td valign="top" width="20"></td> <td valign="top" width="65"><strong>Ligand ID</strong></td> <td valign="top" width="94"><strong>INN</strong></td> <td valign="top" width="115"><strong>Name/code</strong></td> <td valign="top" width="89"><strong>Target</strong></td> </tr> <tr> <td valign="top" width="65">9131</td> <td valign="top" width="100">plixorafenib</td> <td valign="top" width="124">PLX8394</td> <td valign="top" width="73">BRAF</td> <td valign="top" width="20"></td> <td valign="top" width="57">12738</td> <td valign="top" width="100">ficonalkib</td> <td valign="top" width="124">n/a</td> <td valign="top" width="73">ALK</td> </tr> <tr> <td valign="top" width="57">10094</td> <td valign="top" width="100">sofnobrutinib</td> <td valign="top" width="124">n/a</td> <td valign="top" width="73">BTK</td> <td valign="top" width="20"></td> <td valign="top" width="57">12379</td> <td valign="top" width="94">flizasertib</td> <td valign="top" width="115">n/a</td> <td valign="top" width="89">RIPK1</td> </tr> <tr> <td valign="top" width="57">11746</td> <td valign="top" width="100">monzosertib</td> <td valign="top" width="124">AS0141</td> <td valign="top" width="73">CDC7</td> <td valign="top" width="20"></td> <td valign="top" width="57">12380</td> <td valign="top" width="94">mifanertinib</td> <td valign="top" width="115">n/a</td> <td valign="top" width="89">EGFR</td> </tr> <tr> <td valign="top" width="57">12155</td> <td valign="top" width="100">zasocitinib</td> <td valign="top" width="124">NDI-034858</td> <td valign="top" width="73">TYK2</td> <td valign="top" width="20"></td> <td valign="top" width="57">12381</td> <td valign="top" width="94">resencatinib</td> <td valign="top" width="115">n/a</td> <td valign="top" width="89">RET</td> </tr> <tr> <td valign="top" width="57">12319</td> <td valign="top" width="100">lartesertib</td> <td valign="top" width="124">M4076</td> <td valign="top" width="73">ATM</td> <td valign="top" width="20"></td> <td valign="top" width="57">12382</td> <td valign="top" width="94">risovalisib</td> <td valign="top" width="115">CYH33</td> <td valign="top" width="89">PI3Kα</td> </tr> <tr> <td valign="top" width="57">12357</td> <td valign="top" width="100">elenestinib</td> <td valign="top" width="124">BLU-263</td> <td valign="top" width="73">KIT</td> <td valign="top" width="20"></td> <td valign="top" width="57">12383</td> <td valign="top" width="94">risvodetinib</td> <td valign="top" width="115">IkT-148009?</td> <td valign="top" width="89">Abelson-family tyrosine kinases</td> </tr> <tr> <td valign="top" width="57">12368</td> <td valign="top" width="100">boditrectinib</td> <td valign="top" width="124">AUM601/HL5101</td> <td valign="top" width="73">pan-NTRK</td> <td valign="top" width="20"></td> <td valign="top" width="57">12384</td> <td valign="top" width="94">rovadicitinib</td> <td valign="top" width="115">n/a</td> <td valign="top" width="89">JAK</td> </tr> <tr> <td valign="top" width="57">12369</td> <td valign="top" width="100">ifebemtinib</td> <td valign="top" width="124">BI-853520/IN10018</td> <td valign="top" width="73">FAK</td> <td valign="top" width="20"></td> <td valign="top" width="57">12385</td> <td valign="top" width="94">tinodasertib</td> <td valign="top" width="115">AUM001/ETC206</td> <td valign="top" width="89">MKNK1/2</td> </tr> <tr> <td valign="top" width="57">12370</td> <td valign="top" width="100">lirafugratinib</td> <td valign="top" width="124">RLY-4008</td> <td valign="top" width="73">FGFR</td> <td valign="top" width="20"></td> <td valign="top" width="57">12386</td> <td valign="top" width="94">zelasudil</td> <td valign="top" width="115">n/a</td> <td valign="top" width="89">ROCK</td> </tr> <tr> <td valign="top" width="57">12371</td> <td valign="top" width="100">milrebrutinib</td> <td valign="top" width="124">AS-1763</td> <td valign="top" width="73">BTK</td> <td valign="top" width="20"></td> <td valign="top" width="57">12387</td> <td valign="top" width="94">zongertinib</td> <td valign="top" width="115">BI 1810631?</td> <td valign="top" width="89">ERBB2</td> </tr> <tr> <td valign="top" width="57">12372</td> <td valign="top" width="100">oditrasertib</td> <td valign="top" width="124">n/a</td> <td valign="top" width="73">RIPK1</td> <td valign="top" width="20"></td> <td valign="top" width="57">12388</td> <td valign="top" width="94">zotizalkib</td> <td valign="top" width="115">TPX0131</td> <td valign="top" width="89">ALK</td> </tr> <tr> <td valign="top" width="57">12373</td> <td valign="top" width="100">narmafotinib</td> <td valign="top" width="124">AMP945</td> <td valign="top" width="73">FAK</td> <td valign="top" width="20"></td> <td valign="top" width="57">12389</td> <td valign="top" width="94">zurletrectinib</td> <td valign="top" width="115">n/a</td> <td valign="top" width="89">NTRK</td> </tr> <tr> <td valign="top" width="57">12374</td> <td valign="top" width="100">pumecitinib</td> <td valign="top" width="124">PG-011?</td> <td valign="top" width="73">JAK</td> <td valign="top" width="20"></td> <td valign="top" width="57">12390</td> <td valign="top" width="94">nimucitinib</td> <td valign="top" width="115">n/a</td> <td valign="top" width="89">JAKs</td> </tr> <tr> <td valign="top" width="57">12375</td> <td valign="top" width="100">adrixetinib</td> <td valign="top" width="124">n/a</td> <td valign="top" width="73">AXL, MER, CSF1R</td> <td valign="top" width="20"></td> <td valign="top" width="57">12391</td> <td valign="top" width="94">vabametkib</td> <td valign="top" width="115">n/a</td> <td valign="top" width="89">MET</td> </tr> <tr> <td valign="top" width="57">12376</td> <td valign="top" width="100">darizmetinib</td> <td valign="top" width="124">HRX-0215?</td> <td valign="top" width="73">MKK4</td> <td valign="top" width="20"></td> <td valign="top" width="57">12392</td> <td valign="top" width="94">zidesamtinib</td> <td valign="top" width="115">NVL-520</td> <td valign="top" width="89">ROS1</td> </tr> <tr> <td valign="top" width="57">12377</td> <td valign="top" width="100">emzeltrectinib</td> <td valign="top" width="124">n/a</td> <td valign="top" width="73">NTRK</td> <td valign="top" width="20"></td> <td valign="top" width="57"></td> <td valign="top" width="94"></td> <td valign="top" width="115"></td> <td valign="top" width="89"></td> </tr> </tbody> </table> <p> </p> <p class="x_MsoNormal">A new set of antivirals for SARS-CoV-2 have been curated, based on patent extractions by our collaborator Chris Southan:</p> <p class="x_MsoNormal"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12588">example I-1 [WO2023283831]</a> (12588), <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12589">TBK845</a> (12589), <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12590">example 18 [WO2022013684]</a> (12590), <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12591">GDI-036</a> (12591), <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12592">example 45 [WO2022229458]</a> (12592) and <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12593">compound 6 [WO2022133588]</a> (12593) are Mpro inhibitors, and <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12596">PLpro inhibitor 7</a> (12596) inhibits the other crucial coronavirus protease PLpro. New to this list of antivirals are two PROTAC class protein degraders, both of which target the Mpro for proteosomal degradation; these are <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12594">CoV Mpro CRBN PROTAC 9 [US11530195]</a> (21594) and <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12595">CoV Mpro VHL PROTAC 9 [US11518759]</a> (12595).</p> <p class="x_MsoNormal">Keeping up with drug approvals for 2023, there have been 14 new drugs approved by the FDA since the beginning of the year. The table below provides the ligand IDs for the 11/14 that are curated in the Guide.</p> <table style="height: 505px" border="1" width="940" cellspacing="0" cellpadding="0"> <tbody> <tr style="color: blue" bgcolor="lightgrey"> <td colspan="7"><strong>14 new drugs approved by FDA in 2023. 11 added to the GtoPdb have ID in first column</strong></td> </tr> <tr style="color: blue" bgcolor="lightgrey"> <td width="75"><strong>Ligand ID</strong></td> <td><b>INN</b></td> <td><b>Trade name</b></td> <td><b>Type</b></td> <td><b>FDA Approval date</b></td> <td><b>Indication</b></td> <td><b>EMA approval date</b></td> </tr> <tr> <td>12202</td> <td>lecanemab</td> <td>Leqembi</td> <td>mAb</td> <td>06/01/2023</td> <td>To treat Alzheimer’s disease</td> <td>n/a</td> </tr> <tr> <td>12335</td> <td>bexagliflozin</td> <td>Brenzavvy</td> <td>sm</td> <td>20/01/2023</td> <td>To improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise</td> <td>n/a</td> </tr> <tr> <td>11628</td> <td>pirtobrutinib</td> <td>Jaypirca</td> <td>sm</td> <td>27/01/2023</td> <td>To treat mantle cell lymphoma</td> <td>n/a</td> </tr> <tr> <td>12339</td> <td>elacestrant</td> <td>Orserdu</td> <td>sm</td> <td>27/01/2023</td> <td>To treat advanced/metastatic ER-positive, HER2-negative, ESR1 mutated breast cancer</td> <td>n/a</td> </tr> <tr> <td>8455</td> <td>daprodustat</td> <td>Jesduvroq</td> <td>sm</td> <td>01/02/2023</td> <td>To treat anemia caused by chronic kidney disease for adults on dialysis for at least four months</td> <td>n/a</td> </tr> <tr> <td>n/a</td> <td>velmanase alfa-tycv</td> <td>Lamzede</td> <td>pep</td> <td>16/02/2023</td> <td>To treat non-central nervous system manifestations of alpha-mannosidosis</td> <td>23/03/2018</td> </tr> <tr> <td>8448</td> <td>sparsentan</td> <td>Filspari</td> <td>sm</td> <td>17/02/2023</td> <td>To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression</td> <td>n/a</td> </tr> <tr> <td>n/a</td> <td>efanesoctocog alfa</td> <td>Altuviiio</td> <td>Fc fusion peptide</td> <td>23/02/2023</td> <td>Routine prophylaxis and on-demand treatment to control bleeding episodes, as well as perioperative management (surgery) for adults and children with hemophilia A</td> <td>n/a</td> </tr> <tr> <td>7573</td> <td>omaveloxolone</td> <td>Skyclarys</td> <td>sm</td> <td>28/02/2023</td> <td>To treat Friedreich’s ataxia in adults and adolescents aged 16 years and older</td> <td>n/a</td> </tr> <tr> <td>11513</td> <td>zavegepant</td> <td>Zavzpret</td> <td>sm</td> <td>10/03/2023</td> <td>To treat migraine with or without aura in adults</td> <td>n/a</td> </tr> <tr> <td>12482</td> <td>trofinetide</td> <td>Daybue</td> <td>pep</td> <td>13/03/2023</td> <td>To treat Rett syndrome</td> <td>n/a</td> </tr> <tr> <td>11583</td> <td>retifanlimab</td> <td>Zynyz</td> <td>mAb</td> <td>22/03/2023</td> <td>To treat metastatic or recurrent locally advanced Merkel cell carcinoma</td> <td>n/a</td> </tr> <tr> <td>n/a</td> <td>rezafungin</td> <td>Rezzayo</td> <td>sm</td> <td>22/03/2023</td> <td>To treat candidemia and invasive candidiasis</td> <td>n/a</td> </tr> <tr> <td>9424</td> <td>leniolisib</td> <td>Joenja</td> <td>sm</td> <td>24/03/2023</td> <td>To treat activated phosphoinositide 3-kinase delta syndrome (APDS)</td> <td>n/a</td> </tr> </tbody> </table> <h3>Antibacterial Curation</h3> <p><span style="font-weight: 400">We are pleased to report that the Global Antibiotic Research and Development Partnership (GARDP; <a href="https://gardp.org/">https://gardp.org/</a>) has extended their funding of our collaboration with Antibiotic DB (ADB; <a href="https://www.antibioticdb.com/">www.antibioticdb.com</a>) for a further 2 years. Through this interaction, GtoPdb provides chemistry and pharmacology for a curated set of antibacterial compounds with links to ADB.</span></p> <p><span style="font-weight: 400">Currently we have </span><b>425 ligands</b><span style="font-weight: 400"> tagged in GtoPdb as ‘antibacterial’ and </span><b>413 </b><span style="font-weight: 400">of these have links to compounds at ADB. The antibacterials in the GtoPdb include approved drugs, WHO essential Medicines-listed medicines and a number of investigational and experimental compounds.</span></p> <h3>Web-Application & Database Update</h3> <p>We have updated the version of ChEMBL used on the website. This is now at ChEMBL version 32. On the Guide to Pharmacology website we use data from ChEMBL to supplement both our <a href="https://www.guidetopharmacology.org/GRAC/pharmacologySearch.jsp">pharmacology search</a> and ligand activity charts.</p> <p>We have updated our PubChem CID outlinks – updating ~380 links some of which had been to deprecated CIDs.</p> <p>We have also done a check and update of our Ensembl out-links, updating deprecated ID/links in a number of cases.</p> <p> </p> </div> <div class="post-data"> Posted in <a href="https://blog.guidetopharmacology.org/category/chemical-curation/" rel="category tag">Chemical curation</a>, <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/technical/" rel="category tag">Technical</a> </div> </div> <div id="post-4560" class="post-4560 post type-post status-publish format-standard hentry category-guide-to-immunopharmacology category-uncategorized"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2023/04/25/new-cymdeithas-ddysgedig-cymru-learned-society-of-wales-fellows/" rel="bookmark">New Cymdeithas Ddysgedig Cymru / Learned Society of Wales Fellows</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2023/04/25/new-cymdeithas-ddysgedig-cymru-learned-society-of-wales-fellows/" title="11:39 am" rel="bookmark"><span class="timestamp">April 25, 2023</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2023/04/25/new-cymdeithas-ddysgedig-cymru-learned-society-of-wales-fellows/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>We wish to offer our congratulations to <a href="https://discovery-brain-sciences.ed.ac.uk/our-staff/research-groups/jamie-davies">Professor Jamie Davies</a>, Professor of Experimental Anatomy, University of Edinburgh, who has been elected to the <a href="https://www.learnedsociety.wales/">Cymdeithas Ddysgedig Cymru/Learned Society of Wales</a>. The society’s new Fellows include academics from across Welsh and UK universities, writers, researchers and leaders from the world of higher education, as well as law, medicine and the media</p> <p>Jamie has led the <a href="http://www.guidetopharmacology.org">IUPHAR/BPS Guide to PHARMACOLOGY</a> database since 2014, having taken over from Professor Tony Harmar, and has been instrumental in the launch of <a href="http://www.guidetoimmunopharmacology.org">IUPHAR Guide to IMMUNOPHARMACOLOGY</a> and <a href="http://www.guidetomalariapharmacology.org">IUPHAR/MMV Guide to Malaria PHARMACOLOGY</a>. Professor Davies said, “I am delighted to be elected, and hope to play my small part in helping to promote the sciences in the land of my birth.”</p> <p>Also elected to the society is <a href="https://www.immunology.cam.ac.uk/Networkdirectory/ceb27%40cam.ac.uk">Professor Clare Bryant</a>, Professor of Innate Immunity, Cambridge University. Professor Bryant specialises in the field of innate immunity, which is one of the first lines of defence against antigens, harmful materials, entering the body. This has led to work developing medicines for treating allergies and Alzheimer’s disease. She was also instrumental in supporting the establishment of the IUPHAR Guide to IMMUNOPHARMACOLOGY.</p> <p>Both Jamie and Clare are 2 of 5 new Fellows elected under the medicine and medical sciences speciality, and you can read more about them here: <a href="https://www.learnedsociety.wales/introducing-our-new-fellows-2023-stemm-1-category" rel="nofollow">https://www.learnedsociety.wales/introducing-our-new-fellows-2023-stemm-1-category</a></p> <p>Well done Jamie and Clare!</p> </div> <div class="post-data"> Posted in <a href="https://blog.guidetopharmacology.org/category/guide-to-immunopharmacology/" rel="category tag">Guide to Immunopharmacology</a>, <a href="https://blog.guidetopharmacology.org/category/uncategorized/" rel="category tag">Uncategorized</a> </div> </div> <div id="post-4524" class="post-4524 post type-post status-publish format-standard hentry category-chemical-curation category-technical category-tutorials-and-guides"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2022/12/19/exploiting-the-guide-to-pharmacology-substance-sid-tags-in-pubchem/" rel="bookmark">Exploiting the Guide to Pharmacology substance (SID) tags in PubChem</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2022/12/19/exploiting-the-guide-to-pharmacology-substance-sid-tags-in-pubchem/" title="5:11 pm" rel="bookmark"><span class="timestamp">December 19, 2022</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2022/12/19/exploiting-the-guide-to-pharmacology-substance-sid-tags-in-pubchem/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>This post on SID tagging has been reproduced, with permission, from Dr. Chris Southan’s <a href="https://cdsouthan.blogspot.com/2022/11/guide-to-pharmacology-selectable.html">original post</a> in his blog – <a href="https://cdsouthan.blogspot.com/">Bio <-> Chem</a>. </p> <p>It is intended to be user-orientated, those interested in the technicalities are welcome to contact the Guide to Pharmacology <a href="https://www.guidetopharmacology.org/revealEmail.jsp">curation team</a>. The links and counts in this post we taken on 19th Dec 2022 and reflect data from the 2022.4 GtoPdb release. </p> <p>Looking at the tags we have introduced will make this clearer. For starters, as many may know, as of release <a href="https://blog.guidetopharmacology.org/2022/12/13/database-release-2022-4/">2022.4</a> GtoPdb has <a href="https://www.ncbi.nlm.nih.gov/pcsubstance?term=%22IUPHAR/BPS%20Guide%20to%20PHARMACOLOGY%22%5BSourceName%5D&cmd=DetailsSearch">11603</a> PubChem substance (SID) records. Looking at <a href="https://pubchem.ncbi.nlm.nih.gov/substance/472319339">SID472319339</a> we can find the following comments.</p> <p><img src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhDFLhawlKjqrDzDkvvjQF-U6BXB8GA_aZ49wKI98jCWF3LfjZimgxDHoic00fLnjuY0ckmAlvKlqFAqHyI387UAmbUie6bTsaSHk3M0wImV2ouIPPbgs-ISQrO0LxTPs4lgUKYFlqvjyBl8lO-Jrzxe7SrlhZrcgIv4hZK_meGFym7KKgAH5K8utHB/w640-h220/Tags_01.JPG" /></p> <p>This includes the explicit tags </p> <p><b>gtopdb_approved – Substance is an approved drug in GtoPdb</b>.</p> <p><b>gtopdb_antibacterial – Substance is tagged as an antibacterial in GtoPdb</b>.</p> <p>So we can employ an interface selection for the <b>gtopdb_approved</b> tag to get <a href="https://www.ncbi.nlm.nih.gov/pcsubstance?term=%22IUPHAR/BPS%20Guide%20to%20PHARMACOLOGY%22%5BAll%20Fields%5D%20AND%20gtopdb_approved%5Bcomment%5D&cmd=DetailsSearch">1813</a> “approved” (you don’t usually need the [comment] as a field restrict but useful for more complex queries).</p> <p><a href="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/screenshot-from-2022-12-19-16-55-11.png"><img data-attachment-id="4542" data-permalink="https://blog.guidetopharmacology.org/2022/12/19/exploiting-the-guide-to-pharmacology-substance-sid-tags-in-pubchem/screenshot-from-2022-12-19-16-55-11/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/screenshot-from-2022-12-19-16-55-11.png" data-orig-size="1404,711" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="Screenshot from 2022-12-19 16-55-11" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/screenshot-from-2022-12-19-16-55-11.png?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/screenshot-from-2022-12-19-16-55-11.png?w=605" class="alignnone size-large wp-image-4542" src="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/screenshot-from-2022-12-19-16-55-11.png?w=605" alt="" width="605" height="306" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/screenshot-from-2022-12-19-16-55-11.png?w=605 605w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/screenshot-from-2022-12-19-16-55-11.png?w=1210 1210w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/screenshot-from-2022-12-19-16-55-11.png?w=150 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/screenshot-from-2022-12-19-16-55-11.png?w=300 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/screenshot-from-2022-12-19-16-55-11.png?w=768 768w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/screenshot-from-2022-12-19-16-55-11.png?w=1024 1024w" sizes="(max-width: 605px) 100vw, 605px" /></a></p> <p>Similarly we can select as per below for the <a href="https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22IUPHAR%2FBPS+Guide+to+PHARMACOLOGY%22%5BAll+Fields%5D+AND+gtopdb_antibacterial+%5Bcomment%5D">365</a> antibacterial </p> <p><a href="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd2.png"><img data-attachment-id="4537" data-permalink="https://blog.guidetopharmacology.org/2022/12/19/exploiting-the-guide-to-pharmacology-substance-sid-tags-in-pubchem/cd2/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd2.png" data-orig-size="1436,688" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="cd2" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd2.png?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd2.png?w=605" class="alignnone size-large wp-image-4537" src="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd2.png?w=605" alt="" width="605" height="290" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd2.png?w=605 605w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd2.png?w=1210 1210w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd2.png?w=150 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd2.png?w=300 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd2.png?w=768 768w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd2.png?w=1024 1024w" sizes="(max-width: 605px) 100vw, 605px" /></a></p> <p>We can then make the requisite intersect via the “Advanced” option on the query interface as below:</p> <p><a href="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd3.png"><img data-attachment-id="4540" data-permalink="https://blog.guidetopharmacology.org/2022/12/19/exploiting-the-guide-to-pharmacology-substance-sid-tags-in-pubchem/cd3/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd3.png" data-orig-size="1088,180" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="cd3" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd3.png?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd3.png?w=605" class="alignnone size-large wp-image-4540" src="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd3.png?w=605" alt="" width="605" height="100" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd3.png?w=605 605w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd3.png?w=150 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd3.png?w=300 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd3.png?w=768 768w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd3.png?w=1024 1024w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd3.png 1088w" sizes="(max-width: 605px) 100vw, 605px" /></a></p> <p>The intersection search is thus (“IUPHAR/BPS Guide to PHARMACOLOGY”[All Fields] AND gtopdb_antibacterial[comment]) AND (“IUPHAR/BPS Guide to PHARMACOLOGY”[All Fields] AND gtopdb_approved[comment]) with the result of <a href="https://www.ncbi.nlm.nih.gov/pcsubstance?term=%28%22IUPHAR/BPS%20Guide%20to%20PHARMACOLOGY%22%5BAll%20Fields%5D%20AND%20gtopdb_antibacterial%5Bcomment%5D%29%20AND%20%28%22IUPHAR/BPS%20Guide%20to%20PHARMACOLOGY%22%5BAll%20Fields%5D%20AND%20gtopdb_approved%5Bcomment%5D%29&cmd=DetailsSearch">146</a></p> <p>We have introduced an additional three selects. The first is </p> <p><b>gtopdb_immuno – Substance is curated in IUPHAR Guide to Immunopharmacology (GtoImmuPdb)</b> </p> <p>with <a href="https://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22IUPHAR%2FBPS+Guide+to+PHARMACOLOGY%22+gtopdb_immuno+%5Bcomment%5D">1384</a> SIDs as per below:</p> <p><a href="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd4.png"><img data-attachment-id="4541" data-permalink="https://blog.guidetopharmacology.org/2022/12/19/exploiting-the-guide-to-pharmacology-substance-sid-tags-in-pubchem/cd4/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd4.png" data-orig-size="1386,661" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="cd4" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd4.png?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd4.png?w=605" loading="lazy" class="alignnone size-large wp-image-4541" src="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd4.png?w=605" alt="" width="605" height="289" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd4.png?w=605 605w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd4.png?w=1210 1210w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd4.png?w=150 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd4.png?w=300 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd4.png?w=768 768w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd4.png?w=1024 1024w" sizes="(max-width: 605px) 100vw, 605px" /></a></p> <p>Cutting the story short we can easily spot the difference between the small-molecule entries that will be subsumed into Compound (CIDs) and the “Structure not Available” entries (two above) that, as large macromolecules, cannot form CIDs and will thus remain SID-only entries</p> <p>These are selectable via our fourth tag <b> </b></p> <p><b>gtopdb_antibody – GtoPdb identifies this substance as an Antibody </b></p> <p>With which we can select the <a href="https://www.ncbi.nlm.nih.gov/pcsubstance?term=gtopdb_antibody%5Bcomment%5D%20AND%20%22IUPHAR/BPS%20Guide%20to%20PHARMACOLOGY%22%5BSourceName%5D&cmd=DetailsSearch">335</a> antibody entries below :</p> <p><a href="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd5.png"><img data-attachment-id="4539" data-permalink="https://blog.guidetopharmacology.org/2022/12/19/exploiting-the-guide-to-pharmacology-substance-sid-tags-in-pubchem/cd5/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd5.png" data-orig-size="1445,681" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="cd5" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd5.png?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd5.png?w=605" loading="lazy" class="alignnone size-large wp-image-4539" src="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd5.png?w=605" alt="" width="605" height="285" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd5.png?w=605 605w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd5.png?w=1210 1210w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd5.png?w=150 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd5.png?w=300 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd5.png?w=768 768w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd5.png?w=1024 1024w" sizes="(max-width: 605px) 100vw, 605px" /></a></p> <p>As performed above the intersect below gives the <a href="https://www.ncbi.nlm.nih.gov/pcsubstance?term=%28gtopdb_antibody%5Bcomment%5D%20AND%20%22IUPHAR/BPS%20Guide%20to%20PHARMACOLOGY%22%5BSourceName%5D%29%20AND%20%28%22IUPHAR/BPS%20Guide%20to%20PHARMACOLOGY%22%5BAll%20Fields%5D%20AND%20gtopdb_approved%5Bcomment%5D%29&cmd=DetailsSearch">127</a> approved antibodies:</p> <p><a href="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd6.png"><img data-attachment-id="4545" data-permalink="https://blog.guidetopharmacology.org/2022/12/19/exploiting-the-guide-to-pharmacology-substance-sid-tags-in-pubchem/cd6/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd6.png" data-orig-size="1023,193" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="cd6" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd6.png?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd6.png?w=605" loading="lazy" class="alignnone size-large wp-image-4545" src="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd6.png?w=605" alt="" width="605" height="114" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd6.png?w=605 605w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd6.png?w=150 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd6.png?w=300 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd6.png?w=768 768w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/12/cd6.png 1023w" sizes="(max-width: 605px) 100vw, 605px" /></a></p> <p>Last but not least our fifth tag is </p> <p><b>gtopdb_malaria – Substance is curated in IUPHAR/MMV Guide to Malaria Pharmacology (GtoMPdb)</b></p> <p>Which brings back <a href="https://www.ncbi.nlm.nih.gov/pcsubstance?term=gtopdb_malaria%5Bcomment%5D%20AND%20%22IUPHAR/BPS%20Guide%20to%20PHARMACOLOGY%22%5BSourceName%5D&cmd=DetailsSearch">13</a><a href="https://www.ncbi.nlm.nih.gov/pcsubstance?term=gtopdb_malaria%5Bcomment%5D%20AND%20%22IUPHAR/BPS%20Guide%20to%20PHARMACOLOGY%22%5BSourceName%5D&cmd=DetailsSearch">5</a> </p> <p><img src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjnw5iU5xS1EQKEEpGVnEQj5cHYhgTMUnrUrBYafETNVGSlpy1gYrZiE_gPUqeuZdiTQufTxWT-lm7vzYChsbtiooXZYP4GA4vNE9zepqlr4k86j6R482r8WzZXxBDzhA5CGbaP5i0bG3SLnz8arTfKmzOUx8SROIf8LDTs1SVRn8YIfWNPJCqhIMpR/s961/Tags_08.JPG" /></p> <p> </p> <p><strong>Combining with Venny</strong></p> <p>Either by combining queries or (much easier) using the query history under the advanced tag we can make any sequence of Boolean selects (i.e. AND, OR, NOT) from combinations of our five tags for “approved” “immuno” “antibiotic” “antibody” or “antimalarial”. Below we can see another way of slicing and dicing via <a href="https://bioinfogp.cnb.csic.es/tools/venny/index2.0.2.html">Venny</a>. The example result shown below compares three of the tag lists we have already looked at. </p> <p><img src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjOxbRam1Mc2htfvdHfe7YacD8qGwv-W-1GpOA-eNmW5j5Z5zeQiTrGZ_W26qg4Fw0a2tj4ggGD7yGbixTGdo2OK0XBYECYSepc23kvka3Qgt-CU4uPDJSPavm6ds-s9bW_2a7e26luZhUGc9akh2B4P0BgoKagGFB2Nn8omLGrl7hBWAQUHgktXgPm/s1014/Tags_12.JPG" /></p> <div class="separator">One of the useful things with Venny is pull down any intersection lists. Below is the result of pasting the 70 SIDs from the 3-way intersect back into PubChem (the interface can take fairly large lists). </div> <div> </div> <div><img src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiiyLIa_9rNYV92NOHG3ENnIH-bOWCEUjw6_PPLzgAI87viLf9ES5ZC1xmKijdj0SDdKOnu5uJIQI1dF5NhPp42ZoIP_IZQIeq_GWZ_aP1y_R_PfN--iQYjhRqQdtzNEBYRLi9vUzbzGmv-A-LIrh-BgtuVMZSa7I6PHYaaZp586mjcY23knux2kO5G/s655/Tags_13.JPG" /></div> <div> <p>Another advantage of these GtoPdb specific retrievals is to be able to pivot across to small molecule CIDs. The steps to do this are shown below, highlighted in yellow.</p> <p><img src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi3SAHdlQq5p4mK6T13rIKtRwUBxESsBt8y1BFZDZqEL7yWZtkf-rVpiHqZidsWT_Yd6WuGUX0RV0q_xb2-3QagCkRgJsO8Cgs_WZsEcJfrveUpb3c_lGgK7N8R5oFFWOYSXP5KYlKm4_N30WBzc7BvYMI-MMXaEMZAj6fnEaolvC_UMfIPZaPqQUO9/s1181/Tags_09.JPG" /></p> </div> <p>The result below, transformed into a PubChem compound query, now retrieves all CIDs that include GtoPdb approved SIDs</p> <p><img src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhtg4rbafSUrduW3Z39ujoudKwcX438ASl7mMHoz7K3cxcMwLfKquVjAwYmbB3H_B3x0dUX8Q6Jf12cTp1rqDD2A0j9XdWZYjQnYc0-c_gK0UwKq4__iRlNNssrt5JtV0MybZv_JDrclz_m2k26Fzcc-dlDnsanL7SXgJXebV_SO3DLxxUsxjTUTU3S/s886/Tags_10.JPG" /></p> <p>Thus GtoPdb contains 1586 approved drug CIDs. Note that not all these are strictly “small molecules as we can see from the Mw ranking below where the top-ten are above 5000 Mw</p> <p><img src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgMO_POTeLCzKT3AbToEbOJj2k4FxulB0ksw8L_dkdutmv7UnH4lq0-juKzqfqFbr_n4PjHjcQzHNO0PvORgm7BUABeRZR3xajTjRA3Pn-8zizDmFnX5Sqpfosgp5qYe2Jp2g1PESl4pjZCLPLB1EHHVpyIucIloeLK_5ccdCnyxwjREZ2yU-QM0txm/s856/Tags_11.JPG" /></p> </div> <div class="post-data"> Posted in <a href="https://blog.guidetopharmacology.org/category/chemical-curation/" rel="category tag">Chemical curation</a>, <a href="https://blog.guidetopharmacology.org/category/technical/" rel="category tag">Technical</a>, <a href="https://blog.guidetopharmacology.org/category/tutorials-and-guides/" rel="category tag">Tutorials and Guides</a> </div> </div> <div id="post-4521" class="post-4521 post type-post status-publish format-standard hentry category-database-updates category-technical tag-coronavirus"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2022/12/13/database-release-2022-4/" rel="bookmark">Database Release 2022.4</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2022/12/13/database-release-2022-4/" title="4:55 pm" rel="bookmark"><span class="timestamp">December 13, 2022</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2022/12/13/database-release-2022-4/#comments">1 Comment</a> </span> </div> <div class="post-entry"> <p>The latest release of the IUPHAR/BPS Guide to Pharmacology database was made on 13th December 2022. This database release is version 2022.4, and is the fourth release this year. GtoPdb now contains:</p> <ul> <li><strong>3,013 </strong> human targets, <strong>1,633</strong> of which have curated quantitative ligand interactions.</li> <li><strong>11,596</strong> ligands, <strong>8,557 </strong>of which have curated quantitative target interactions.</li> <li><strong>1,813</strong> approved drugs, <strong>1,071</strong> with curated quantitative interactions.</li> <li>Clinical use summaries for over <strong>3,267</strong> ligands of which <strong>1,806 </strong>are approved drugs.</li> </ul> <div> <h3>Website Updates</h3> <p>Our PostgreSQL version has been update to 12.13.</p> </div> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/coronavirus/" rel="tag">coronavirus</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/technical/" rel="category tag">Technical</a> </div> </div> <div id="post-4517" class="post-4517 post type-post status-publish format-standard hentry category-hot-topics tag-aging tag-covid-19"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2022/12/07/hot-topics-fxr-inhibition-may-protect-from-sars-cov-2-infection-by-reducing-ace2/" rel="bookmark">Hot Topics: FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2022/12/07/hot-topics-fxr-inhibition-may-protect-from-sars-cov-2-infection-by-reducing-ace2/" title="10:01 am" rel="bookmark"><span class="timestamp">December 7, 2022</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2022/12/07/hot-topics-fxr-inhibition-may-protect-from-sars-cov-2-infection-by-reducing-ace2/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <h4 class="heading-title">FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2</h4> <p>This manuscript (1) reports on extensive and compelling experimental evidence and translational data from retrospective review of clinical registries, which show that pharmacological inhibition of the farnesoid X receptor (FXR) could be a novel intervention for the prevention or treatment of COVID-19. The in vitro and in vivo studies show that FXR antagonism reduces ACE2 expression, which subsequently reduces SARS-CoV-2 infection in the lung, liver and gastrointestinal tract.</p> <ol class="wp-block-list"> <li> <p>Brevini T, Maes M, Webb GJ, John BV, Fuchs CD, Buescher G, Wang L, Griffiths C, Brown ML, Scott WE 3rd, Pereyra-Gerber P, Gelson WTH, Brown S, Dillon S, Muraro D, Sharp J, Neary M, Box H, Tatham L, Stewart J, Curley P, Pertinez H, Forrest S, Mlcochova P, Varankar SS, Darvish-Damavandi M, Mulcahy VL, Kuc RE, Williams TL, Heslop JA, Rossetti D, Tysoe OC, Galanakis V, Vila-Gonzalez M, Crozier TWM, Bargehr J, Sinha S, Upponi SS, Fear C, Swift L, Saeb-Parsy K, Davies SE, Wester A, Hagström H, Melum E, Clements D, Humphreys P, Herriott J, Kijak E, Cox H, Bramwell C, Valentijn A, Illingworth CJR; UK-PBC research consortium, Dahman B, Bastaich DR, Ferreira RD, Marjot T, Barnes E, Moon AM, Barritt AS 4th, Gupta RK, Baker S, Davenport AP, Corbett G, Gorgoulis VG, Buczacki SJA, Lee JH, Matheson NJ, Trauner M, Fisher AJ, Gibbs P, Butler AJ, Watson CJE, Mells GF, Dougan G, Owen A, Lohse AW, Vallier L, Sampaziotis F. <a href="https://www.nature.com/articles/s41586-022-05594-0">FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2</a>. Nature. 2022 Dec 5. doi: <a href="https://www.nature.com/articles/s41586-022-05594-0">10.1038/s41586-022-05594-0</a>. Epub ahead of print. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/36470304/">36470304</a>.</p> </li> </ol> <p>Comments by the <strong>Guide to Pharmacology Curation Team, </strong>University of Edinburgh</p> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/aging/" rel="tag">aging</a>, <a href="https://blog.guidetopharmacology.org/tag/covid-19/" rel="tag">COVID-19</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/hot-topics/" rel="category tag">Hot Topics</a> </div> </div> <div id="post-4505" class="post-4505 post type-post status-publish format-standard hentry category-database-updates category-technical tag-coronavirus"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2022/10/13/database-release-2022-3/" rel="bookmark">Database Release 2022.3</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2022/10/13/database-release-2022-3/" title="11:45 am" rel="bookmark"><span class="timestamp">October 13, 2022</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2022/10/13/database-release-2022-3/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>The latest release of the IUPHAR/BPS Guide to Pharmacology database was made on 13th October 2022. This database release is version 2022.3, and is the third release this year. The following blog post gives details of the key content updates and website changes. GtoPdb now contains:</p> <ul> <li><strong>3,007</strong> human targets, <strong>1,627</strong> of which have curated quantitative ligand interactions.</li> <li><strong>11,532</strong> ligands, <strong>8,517 </strong>of which have curated quantitative target interactions.</li> <li><strong>1,782</strong> approved drugs, <strong>1,057</strong> with curated quantitative interactions.</li> <li>Clinical use summaries for over <strong>3,227</strong> ligands of which <strong>1,774 </strong>are approved drugs.</li> </ul> <div> <h3>New ligands</h3> <p>For this release we can announce the inclusion of new ligand entries for chemical structures that have been revealed during recent ‘first disclosure’ sessions at scientific conferences. For those structures that meet our inclusion criteria, we have curated details of any clinical studies, or intended therapeutic use for these new entries, and included quantitative interaction data where we have been able to find it, as well as any source references.</p> <table style="height:505px;" border="1" width="928" cellspacing="0" cellpadding="0"> <tbody> <tr> <td style="text-align:left;" colspan="3" valign="top"><b>ACS, Chicago Aug 2022</b></td> </tr> <tr> <td valign="top" width="100px"><b>Name</b></td> <td valign="top" width="50px"><b>Ligand ID</b></td> <td valign="top" width="200px"><b>MMOA</b></td> </tr> <tr> <td valign="top">evixapodlin/GS-4224</td> <td valign="top">11684</td> <td valign="top">oral small molecule PD-L1 inhib</td> </tr> <tr> <td valign="top">compound 17</td> <td valign="top">12152</td> <td valign="top">oral MRGPRX2 antagonist</td> </tr> <tr> <td valign="top">FLX475</td> <td valign="top">12153</td> <td valign="top">oral CCR4 antagonist</td> </tr> <tr> <td valign="top">mitiperstat/AZD4831</td> <td valign="top">12154</td> <td valign="top">MPO inhibitor</td> </tr> <tr> <td valign="top">NDI-034858</td> <td valign="top">12155</td> <td valign="top">TYK2-selective kinase inhibitor</td> </tr> <tr> <td valign="top">onfasprodil</td> <td valign="top">12156</td> <td valign="top">NR2B (GluN2B; GRIN2B)-selective negative allosteric modulator</td> </tr> <tr> <td valign="top">GLPG3970</td> <td valign="top">12157</td> <td valign="top">SIK2/3 inhibitor</td> </tr> <tr> <td valign="top">PF-07258669</td> <td valign="top">12158</td> <td valign="top">MC4R antagonist</td> </tr> <tr> <td style="text-align:left;" colspan="3" valign="top"></td> </tr> <tr> <td style="text-align:left;" colspan="3" valign="top"><b>EFMC-ISMC, Nice Sep 2022</b></td> </tr> <tr> <td valign="top">vicasinabin/RG7774</td> <td valign="top">11890</td> <td valign="top">oral CB2R agonist</td> </tr> <tr> <td valign="top">compound 22 [WO2019141694A1]</td> <td valign="top">12181</td> <td valign="top">inhaled PI4KB inhibitor</td> </tr> </tbody> </table> <h3><b>New COVID-19 drug targets </b></h3> <p>2 new targets have been added, including interactions with small molecule modulators:</p> <p>A host enzyme: <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3207">phosphodiesterase 12 (PDE12)</a>; Two tool compounds have been added, compound 1 [PMID: 26055709] and compound 3 [PMID: 26055709], and we are awaiting disclosure of two lead compound structures that were reported in a bioRxiv preprint in Sept 2022 <a href="https://www.biorxiv.org/content/10.1101/2022.09.23.509178v1.full" target="_blank" rel="noopener noreferrer">https://www.biorxiv.org/content/10.1101/2022.09.23.509178v1.full</a></p> <p>A coronavirus protein: <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3206">Non-structural protein 15 (aka endoribonuclease NendoU)</a>. Two allosteric inhibitors have been reported, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12200">FUZS-5</a> (Ligand ID 12200) and <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12199">LIZA-7</a> (Ligand ID 12199). The docking positions of these compounds within nsp15 have been determined by X-ray crystallography <a href="https://www.biorxiv.org/content/10.1101/2022.09.26.509485v1" target="_blank" rel="noopener noreferrer">https://www.biorxiv.org/content/10.1101/2022.09.26.509485v1</a>. We have included <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8696">tipiracil</a> (8696) in the inhibitors table as it has also demonstrated some activity against SARS-CoV-2 nsp15.</p> <h3>Antibacterial Ligands</h3> <p>As part of our continuing collaboration with <a href="https://antibioticdb.com/">AntibioticDB</a> and <a href="https://gardp.org/">GARDP</a> we now have <a href="https://www.guidetopharmacology.org/GRAC/LigandListForward?type=AntiBac&database=all">351 curated antibacterial ligands</a> in the Guide to PHARMACOLOGY.</p> <h3>Website Updates</h3> <p>Our <a href="https://www.guidetopharmacology.org/GRAC/chemSearch.jsp#structureSearch">chemical structure search</a> now uses the <a href="https://cdk.github.io/">Chemistry Development Kit (CDK)</a> to power the similarity search. The Chemistry Development Kit (CDK) is a collection of free and open-source modular Java libraries for processing chemical information.</p> </div> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/coronavirus/" rel="tag">coronavirus</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/technical/" rel="category tag">Technical</a> </div> </div> <div id="post-4491" class="post-4491 post type-post status-publish format-standard hentry category-database-updates category-technical tag-coronavirus"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2022/06/09/database-release-2022-2/" rel="bookmark">Database Release 2022.2</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2022/06/09/database-release-2022-2/" title="12:01 pm" rel="bookmark"><span class="timestamp">June 9, 2022</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2022/06/09/database-release-2022-2/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>A new database release (version 2022.2) of the IUPHAR/BPS Guide to Pharmacology was made on 9th June 2022. This blog post gives details of the key content updates and website changes. GtoPdb now contains:</p> <ul> <li><strong>3,002</strong> human targets, <strong>1,611</strong> of which have curated quantitative ligand interactions.</li> <li><strong>11,348</strong> ligands, <strong>8,396 </strong>of which have curated quantitative target interactions.</li> <li><strong>1,756</strong> approved drugs, <strong>1,052</strong> with curated quantitative interactions.</li> <li>Clinical use summaries for over <strong>3,146</strong> ligands of which <strong>1,752 </strong>are approved drugs.</li> </ul> <div> <h3><b>New targets and their interactions with newly curated ligands</b></h3> <p><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3200">Selectin E</a> (OID 3200) and a selective antagonist <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11995">uproleselan</a> (LID 11995): Selectin E is a vascular adhesion molecule present on the endothelial cell surface that is involved in leukocyte migration and in cancer cell trafficking (especially metastasis). Uproleselan-mediated antagonism of selectin E binding is being investigated for anti-cancer potential and has been repositioned for anti-inflammatory action in patients with severe COVID-19 pneumonia (predicted to reduce leukocyte recruitment to the inflamed lungs).</p> <p><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3199">Palmitoyl-protein thioesterase 1</a> (OID 3199) and the inhibitor <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11991">ezurpimtrostat</a> (LID 11991): Ezurpimtrostat (GNS561) is a small molecule inhibitor of palmitoyl-protein thioesterase 1 (PPT1). It induces lysosomal dysregulation which leads to inhibition of late-stage autophagy and cell death. Antitumour and antiviral activities have been demonstrated <em>in vitro</em> and <em>in vivo</em>. Anti-SARS-CoV-2 activity is being investigated in Phase 2 clinical trial <a href="https://clinicaltrials.gov/ct2/show/NCT04637828">NCT04637828</a>.</p> <p><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3198">CoV Non-structural protein 14</a> (nsp14 OID 3198) has been added as a separate entry in the Coronavirus (CoV) proteins family to allow effective curation of nsp14 inhibitors. The methyltransferase (MTase) activity of nsp14 is required for capping of the viral RNA transcript. Inhibition of this activity should disrupt viral replication. Two experimental inhibitors have been curated, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11981">TO507</a> (LID 11981) and <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11971">compound 25</a> [PMID: 35439007] (LID 11971).</p> <h3>New ligands</h3> <p>We have added those ligands from the DrugHunter ‘Molecules of the month’ sets for April and May that were absent from our curated ligands. Of the total April/May combined set of 18 compounds, we had already included 5 through our own curation efforts, and added 11 as new entries. We did not add branaplam (a RNA-targeted splicing modulator for spinal muscular atrophy and/or Huntington’s disease) as it doesn’t act via a defined protein target, and we didn’t add the HIV-1 protease inhibitor ‘compound 14’ as we currently don’t include HIV proteins as ligand/drug targets.</p> <h3>SARS-CoV-2/COVID-19 related ligands for coronavirus page- new and updates to existing entries</h3> <p>We reviewed the compounds in current COVID-19 clinical trials (from clinicaltrials.gov) to identify agents (particularly small molecule compounds) that either didn’t exist in the GtoPdb or which needed updated curation wrt clinical potential as antivirals or treatments for symptomatic COVID-19. The results include:</p> <ul> <li><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11984">acebilustat</a> (CTX-4430)</li> <li><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11986">AMY-101</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3951">ambrisentan</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7034">apabetalone</a> (RVX 208)</li> <li><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11987">BIO101</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11971">compound 25</a> [PMID: 35439007]</li> <li><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11988">danicopan</a> (ACH-4471)</li> <li><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10056">dapansutrile</a> (OLT1177)</li> <li><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11991">ezurpimtrostat</a> (GNS561)</li> <li><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11985">isuzinaxib</a> (APX-115)</li> <li><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11981">TO507</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11995">uproleselan</a> (GMI-1271)</li> <li><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11679">zapnometinib</a> (ATR-002)</li> </ul> <div> <h3>New FDA drug approvals</h3> <p>In May, the FDA approved 3 drugs that are ‘first-in-class’ therapeutics. In date order of approval these are:</p> <ul> <li><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11549">Vonoprazan</a> (LID 11549) is the first potassium competitive acid blocker (PCAB) class drug to be FDA approved. Its interaction with the gastric proton pump (H+,K+-ATPase) is reversible, so it offers advantages over the existing irreversible proton pump inhibitors (PPIs). <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12008">Tegoprazan</a> and <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12007">revaprazan</a> are two additional PCABs that are authorised for clinical use in South Korea.</li> <li><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9686">Tapinarof</a> is the first aryl hydrocarbon receptor (AhR) agonist to enter clinical use. It is indicated for the treatment of psoriasis, and provides a number of advantages compared to standard corticosteroid treatments, particularly in respect of side-effects and long-term use.</li> <li><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11429">Tirzepatide</a> is the first in its class of dual acting glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonists (‘twincretin’). The FDA approved it for T2DM management. Recently published Phase 3 results from the SURMOUNT-1 study (<a href="https://clinicaltrials.gov/ct2/show/NCT04184622">NCT04184622</a>) demonstrate that this dual agonist approach also produces significant and sustained weight reduction in obese patients [PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/35658024/">35658024</a>].</li> </ul> </div> </div> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/coronavirus/" rel="tag">coronavirus</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/technical/" rel="category tag">Technical</a> </div> </div> <div id="post-4486" class="post-4486 post type-post status-publish format-standard hentry category-database-updates category-events category-guide-to-immunopharmacology category-guide-to-malaria-pharmacology"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2022/05/31/prof-jamie-davies-rse-fellow/" rel="bookmark">Prof. Jamie Davies – RSE Fellow</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2022/05/31/prof-jamie-davies-rse-fellow/" title="10:41 am" rel="bookmark"><span class="timestamp">May 31, 2022</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2022/05/31/prof-jamie-davies-rse-fellow/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>Congratulations to <a href="https://www.ed.ac.uk/discovery-brain-sciences/our-staff/research-groups/jamie-davies">Professor Jamie Davies</a>, Professor of Experimental Anatomy, University of Edinburgh, who has been elected to a Fellowship by <a href="https://rse.org.uk/">The Royal Society of Edinburgh</a>, Scotland’s National Academy.</p> <p>Fellowships are awarded to individuals in academia, business and public service who are judged to be eminently distinguished in their subject.</p> <p>Jamie has led the <a href="http://www.guidetopharmacology.org">IUPHAR/BPS Guide to PHARMACOLOGY</a> database since 2014, having taken over from Professor Tony Harmar (also a Fellow of the Society), and has been instrumental in the launch of <a href="https://www.guidetoimmunopharmacology.org/immuno/index.jsp">IUPHAR Guide to IMMUNOPHARMACOLOGY</a> and <a href="https://www.guidetomalariapharmacology.org/malaria/index.jsp">IUPHAR/MMV Guide to Malaria PHARMACOLOGY</a>.</p> <p> </p> </div> <div class="post-data"> Posted in <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/events/" rel="category tag">Events</a>, <a href="https://blog.guidetopharmacology.org/category/guide-to-immunopharmacology/" rel="category tag">Guide to Immunopharmacology</a>, <a href="https://blog.guidetopharmacology.org/category/guide-to-malaria-pharmacology/" rel="category tag">Guide to Malaria Pharmacology</a> </div> </div> <div id="post-4448" class="post-4448 post type-post status-publish format-standard hentry category-hot-topics tag-aging tag-covid-19"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2022/04/13/hot-topics-a-new-study-shows-that-human-ageing-is-absolutely-precise-when-disease-is-eliminated-and-accompanied-by-a-disintegration-of-metabolic-efficiency/" rel="bookmark">Hot Topics: A new study shows that human ageing is absolutely precise, when disease is eliminated, and accompanied by a disintegration of metabolic efficiency</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2022/04/13/hot-topics-a-new-study-shows-that-human-ageing-is-absolutely-precise-when-disease-is-eliminated-and-accompanied-by-a-disintegration-of-metabolic-efficiency/" title="4:29 pm" rel="bookmark"><span class="timestamp">April 13, 2022</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2022/04/13/hot-topics-a-new-study-shows-that-human-ageing-is-absolutely-precise-when-disease-is-eliminated-and-accompanied-by-a-disintegration-of-metabolic-efficiency/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p><strong>Human ageing is just disintegration, but absolutely precise, linked to loss of VO<sub>2 </sub>max, which is why COVID is age-related</strong>.</p> <p>A new study (1) shows that the decline in human performance with age at 5000 m, an athletic event requiring high VO<sub>2</sub> max (oxygen use), is remarkably precise, and unavoidable, and related to entropy, even at an individual level. Women and men show an identical age-related decline, up to ~100 years old. The precision of the decline shows the limitations for therapy of aging. Mortality incidence for COVID19 shows a similar relationship. The authors propose that initial VO<sub>2</sub> max has a critical role in COVID sensitivity because of the direct relationship of disease severity with oxygen use, and the parallel decline in aging: mitochondria are targeted by viruses. The highest human recorded VO<sub>2</sub> max is 96, but is only 13 in nursing home residents, where metabolic capacity is massively reduced.</p> <p>Humans, with a long active life, may therefore have already optimised ageing and metabolism (2) compared to short-lived animals which are used in studies of anti-ageing drugs. </p> <p>As the results involve the very best age-related performances of humanity (by definition healthy), and there is absolute mathematical precision in the decline, there is no room for improvement, so drugs to slow ageing (apart from offsetting specific ageing-related diseases) may well remain a mirage. The results of the study are compatible with decline due to entropy, just a general disintegration, with different diseases developing by chance, heredity or the environment in a disintegrating body.</p> <p>Funding could be better spent on ensuring a humane and dignified exit at the end of life when metabolism breaks down completely. Nevertheless, exercise (such as 5000M parkruns) has been previously shown to extend active life by ~7 years (3).</p> <ol class="wp-block-list"><li>Spedding M, Marvaud R, Marck A, Delarochelambert Q, Toussaint JF. Aging, VO2 max, entropy, and COVID-19. Indian J Pharmacol 2022;54:58-62. <a href="https://www.ijp-online.com/text.asp?2022/54/1/58/339909">https://www.ijp-online.com/text.asp?2022/54/1/58/339909</a>. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35343209/">35343209</a>.</li><li>Bozek K, Wei Y, Yan Z, Liu X, Xiong J, Sugimoto M, Tomita M, Pääbo S, Pieszek R, Sherwood CC, Hof PR, Ely JJ, Steinhauser D, Willmitzer L, Bangsbo J, Hansson O, Call J, Giavalisco P, Khaitovich P. Exceptional evolutionary divergence of human muscle and brain metabolomes parallels human cognitive and physical uniqueness. PLoS Biol. 2014 May 27;12(5):e1001871. doi: 10.1371/journal.pbio.1001871. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/24866127/">24866127</a>.</li><li>Garatachea N, Pareja-Galeano H, Sanchis-Gomar F, Santos-Lozano A, Fiuza-Luces C, Morán M, Emanuele E, Joyner MJ, Lucia A. Exercise attenuates the major hallmarks of aging. Rejuvenation Res. 2015 Feb;18(1):57-89. doi: 10.1089/rej.2014.1623. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/25431878/">25431878</a>.</li></ol> <p>Comments by the <strong>Guide to Pharmacology Curation Team, </strong>University of Edinburgh</p> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/aging/" rel="tag">aging</a>, <a href="https://blog.guidetopharmacology.org/tag/covid-19/" rel="tag">COVID-19</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/hot-topics/" rel="category tag">Hot Topics</a> </div> </div> <div id="post-4444" class="post-4444 post type-post status-publish format-standard hentry category-hot-topics tag-hot-topic tag-sars-cov-2"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2022/04/12/hot-topics-endothelin-1-pathway-a-new-therapeutic-target-for-covid-19/" rel="bookmark">Hot Topics: Endothelin-1 pathway, a new therapeutic target for COVID-19</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2022/04/12/hot-topics-endothelin-1-pathway-a-new-therapeutic-target-for-covid-19/" title="2:02 pm" rel="bookmark"><span class="timestamp">April 12, 2022</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2022/04/12/hot-topics-endothelin-1-pathway-a-new-therapeutic-target-for-covid-19/#comments">1 Comment</a> </span> </div> <div class="post-entry"> <p>SARS-CoV-2 gains entry into the body mainly via the lungs. After entering the blood, the virus rapidly multiplies to infect nearby cells. Endothelial cells line every blood vessel and have a surface area similar to a tennis court. These cells are especially vulnerable to virus infection as they express the the virus entry receptor, ACE2. Endothelial cells are also a source of endothelin-1 (ET-1), which is released in response to injury to cause long lasting vasoconstriction, reducing oxygen supply to vital organs. In the lungs, this can cause breathing difficulty, which in severe cases requires patients to be given oxygen and put on a ventilator.</p> <p>The study compared ET-1 in the plasma of patients infected with COVID-19 who were hospitalised during the first wave of the pandemic, including those placed on ventilators (1). Significantly higher levels of ET-1 were measured in these patients, compared with infected individuals with mild or no symptoms. The release of multiple copies of the virus following infection is known to damage endothelial cells and the results show stored ET-1 is also released into the bloodstream.</p> <p>Currently, medicines that block the detrimental actions of ET-1 are used to treat rare forms of lung disease that share some of the clinical features of COVID-19 infection. The results provide evidence to support testing these medicines in clinical trials to see if they would benefit the most severely affected patients. The virus continues to evolve and in addition to vaccines and bespoke antivirals, that may be susceptible to the development of resistance, it is important to develop alternative ways to block the harmful actions of the virus. By targeting the damaging actions of SARS-CoV-2 on the host cells, medicines are likely to remain effective irrespective of evolving mutations in the virus.</p> <ol class="wp-block-list"><li>Abraham GR, Kuc RE, Althage M, Greasley PJ, Ambery P, Maguire JJ, Wilkinson IB, Hoole SP, Cheriyan J, Davenport AP. Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19. J Mol Cell Cardiol. 2022 Mar 23:S0022-2828(22)00051-7. <a href="https://www.sciencedirect.com/science/article/pii/S0022282822000517?via%3Dihub">doi: 10.1016/j.yjmcc.2022.03.007</a>. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35339512/">35339512</a>. </li></ol> <p>Comments by the <strong>Guide to Pharmacology Curation Team, </strong>University of Edinburgh</p> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/hot-topic/" rel="tag">hot topic</a>, <a href="https://blog.guidetopharmacology.org/tag/sars-cov-2/" rel="tag">SARS-CoV-2</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/hot-topics/" rel="category tag">Hot Topics</a> </div> </div> <div id="post-4403" class="post-4403 post type-post status-publish format-standard hentry category-database-updates category-technical tag-coronavirus"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2022/03/31/database-release-2022-1/" rel="bookmark">Database Release 2022.1</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2022/03/31/database-release-2022-1/" title="2:03 pm" rel="bookmark"><span class="timestamp">March 31, 2022</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2022/03/31/database-release-2022-1/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>We are pleased to announce that the first IUPHAR/BPS Guide to Pharmacology of 2022 was made on 31st March 2022. database. This release is version 2022.1 and this blog post gives details of the key content updates and website changes. GtoPdb now contains:</p> <ul> <li><strong>3,000</strong> human targets, <strong>1,607</strong> of which with curated quantitative ligand interactions.</li> <li><strong>11,270</strong> ligands, <strong>8,349 </strong>of which have curated quantitative target interactions.</li> <li><strong>1,734</strong> approved drugs, <strong>1,044</strong> with curated quantitative interactions.</li> <li>Clinical use summaries for over <strong>3,093</strong> ligands of which <strong>1,730 </strong>are approved drugs.</li> </ul> <div> <div class="block-editor-block-list__layout is-root-container"> <h3>Coronavirus</h3> <p>The Guide to Pharmacology <a href="https://www.guidetopharmacology.org/coronavirus.jsp" target="_blank" rel="noreferrer noopener">coronavirus information page</a> continues to be updated on a regular basis to capture the latest pharmacological strategies under investigation to mitigate against COVID-19.</p> <p>Notable additions and updates for this period include:</p> <p><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7792">Baricitinib</a> – In March 2022, data reported from the largest of the baricitinib studies (part of the University of Oxford-led RECOVERY trial) indicated that it provided clinical benefit in hospitalised COVID-19 patients, including in those already receiving other standard care immunomodulatory treatments (<i>e.g.</i><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2768">dexamethasone</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6881">tocilizumab</a>) or the antiviral drug <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10715">remdesivir</a>. This made baricitinib the 4th effective COVID-19 therapy to be identified by the RECOVERY trial.</p> <p><a id="N-0385"></a><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11956">N-0385</a> – A serine protease inhibitor, that was originally reported as a <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2418">matriptase</a> inhibitor. More recently revealed to inhibit SARS-CoV-2 infection via inhibition of <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2421">TMPRSS2</a> (the host protease hijacked by the coronavirus to cleave spike and facilitate entry into host cells), thus functioning as an ‘entry inhibitor’. The Nature article (<a href="https://www.nature.com/articles/s41586-022-04661-w">DOI: 10.1038/s41586-022-04661-w</a>) proposes prophylactic and therapeutic potential, as well as pan-coronavirus efficacy that is independent of virus strain. May have applications in combination with antivirals with other MMOAs e.g. Mpro (<a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11503">nirmatrelvir</a>) or RdRp (e.g. <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&ligandId=10737">molnupiravir</a><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10715">, remdesivir</a>) inhibitors.</p> <h3>Curation Updates</h3> <p>2021.4 update we have added <strong>131 new ligands</strong>. We have also made updates to ~38 existing ligand comments and ~28 clinical use comments. An additional 10 existing ligand have now been tagged as approved drugs, bringing the total approved drugs in GtoPdb to 1,730.</p> <p>All new ligands have been manually curated with chemical or peptide structures, links to external resources, general comments, notes on clinical development where appropriate, target interaction data and patent pointers where available. Two particular sets are from recent collaborative blogposts. The first consisted of six <a href="https://cdsouthan.blogspot.com/2022/03/drug-hunter-compounds-from-feb-2022.html">DrugHunter compounds from Feb 2022</a>. The second set of six was the popular <a href="https://cdsouthan.blogspot.com/2022/03/acs-first-disclosures-2022.html">ACS First Disclosures </a>from their March spring meeting (see BLU945 below). For most of these fresh drug discovery ligands (some of which are patent-only and not yet published) we will be the first source to provide name-to-structure matches both in our own database and in PubChem (including PubChem < > PubMed links).</p> <p>A few new interesting ligands are:</p> </div> <ul> <li><b><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11954">YCT529</a></b> – Oral retinoic acid receptor alpha (RAR-α) antagonist, that is being investigated as a non-hormonal male contraceptive. Its development and function were presented at the spring meeting of the American Chemical Society (ACS) in March 2022 (but not as a First Disclosure). Antagonising RAR-α disrupts spermatogenesis. YCT529 is formulated as a sodium salt. It exerts the expected <i>in vivo</i> effect on sperm development. The RAR-α-selective antagonists BMS-189532, BMS-189614 and and <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=summary&ligandId=11955">BMS-189532</a> have been reported previously (PMID: 24040487, PMID: 32671394).</li> <li><b><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11948">BLU945</a></b> – A fourth generation non-covalent, and orally available EGFR inhibitor, that was designed to inhibit the EGFR pathway and provide anti-tumour activity in NSCLC with EGFR resistance mutations (EGFR with triple mutations) that block sensitivity to the 3rd generation EGFR inhibitor <a href="https://.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7719">osimertinib.</a></li> <li><strong><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11941">compound 17b</a></strong> [<a href="https://pubmed.ncbi.nlm.nih.gov/35286086/">PMID: 35286086</a>] – A <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11941">gefitinib</a>–<a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1016">tamoxifen</a> hybrid molecule, that was developed to combat triple-negative breast cancer. It simultaneously targets both estrogen receptor and epidermal growth factor receptor (EGFR) pathways to block cancer cell growth.</li> </ul> <h4>New Targets</h4> <p>Whilst no new targets have been added to the database for this release we want to draw attention to the set of novel protein targets for drugs that were approved by the FDA (US), EMA (EU) and/or PMDA (Japan) in 2021. 14 targets of the 2021 approved drugs set are novel, and 9 of these 14 are indicated for rare diseases*. Links to our pages for these targets and drugs (where available) are provided in the table below :</p> <table style="height:712px;" width="1048"> <tbody> <tr> <td width="285"><strong>Target</strong></td> <td width="186"><strong>Approved drug</strong></td> <td width="177"><strong>Drug class</strong></td> <td width="306"><strong>Indication</strong></td> </tr> <tr> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8716">Angiopoietin-related protein 3 (ANGPTL3)</a></td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8717">evinacumab</a>*</td> <td>mAb</td> <td>Homozygous familial hypercholesterolaemia</td> </tr> <tr> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5083">Thymic stromal lymphopoietin (TSLP)</a></td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8933">tezepelumab</a></td> <td>mAb</td> <td>Severe asthma</td> </tr> <tr> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5873">Interleukin-17F (IL17F)</a></td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9411">bimekizumab</a></td> <td>mAb</td> <td>Psoriasis</td> </tr> <tr> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4980">Interleukin-13 (IL13)</a></td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8001">tralokinumab</a></td> <td>mAb</td> <td>Atopic dermatitis</td> </tr> <tr> <td><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2985">Neonatal Fc receptor (FCGRT)</a></td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9777">efgartigimod alfa</a>*</td> <td>mAb</td> <td>Myasthenia gravis</td> </tr> <tr> <td><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3114">SARS-CoV-2 Spike protein</a></td> <td width="186"><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11332">regdanvimab</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11333">sotrovimab</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11327">casirivimab</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11328">imdevimab</a></td> <td>mAb</td> <td>COVID-19</td> </tr> <tr> <td><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=853&objId=3192#3192">Tissue factor (TF)</a></td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11719">tisotumab vedotin</a></td> <td>mAb-ADC</td> <td>Cervical cancer</td> </tr> <tr> <td><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=852&objId=3196#3196">Transferrin receptor protein 1 (TFRC)</a></td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11772">pabinafusp alfa</a>*</td> <td>Fusion protein</td> <td>Hunter syndrome</td> </tr> <tr> <td>Molybdenum cofactor biosynthesis protein 1 (MOCS1)</td> <td>fosdenopterin*</td> <td>Synthetic substrate</td> <td>Molybdenum cofactor deficiency type A</td> </tr> <tr> <td><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1748">Natriuretic peptide receptor 2 (NPR2) a.k.a. Guanylyl cyclase-B</a></td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9068">vosoritide</a>*</td> <td>Peptide</td> <td>Achondroplasia</td> </tr> <tr> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&ligandId=9414">Complement C3 (C3)</a></td> <td>pegcetacoplan*</td> <td>Peptide</td> <td>Paroxysmal nocturnal hemoglobinuria</td> </tr> <tr> <td>CMV serine/threonine protein kinase UL97 (UL97)</td> <td>maribavir*</td> <td>Small-molecule (inhibitor)</td> <td>Post-transplant CMV infection/disease</td> </tr> <tr> <td><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2824">GTPase KRas (KRAS)</a></td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10678">sotorasib</a>*</td> <td>Small-molecule (inhibitor)</td> <td>Non-small-cell lung cancer</td> </tr> <tr> <td><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1043&objId=3148#3148">Hypoxia-inducible factor 2 alpha (HIF2α)</a></td> <td><a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11251">belzutifan</a>*</td> <td>Small-molecule (inhibitor)</td> <td>von Hippel–Lindau disease</td> </tr> </tbody> </table> <h3>Website Updates</h3> <ul> <li>Our download files now have an comment line added at the top which indicated the database version number and release date. This line is preceded by a double-hash ‘##’. We ask user to take note of this as it may have an impact on any existing downstream processing that users conduct.</li> <li>Our <a href="https://dev.guidetopharmacology.org/DATA/targets_and_families.csv">targets and families download file</a> has been update to contain Ensembl Gene IDs.</li> </ul> <h3>Guide to Malaria Pharmacology (GtoMPdb)</h3> <p>These are the recent advancements made in the GtoMPdb for this database release:</p> <p>The <a href="http://guidetomalariapharmacology.org/GRAC/FamilyDisplayForward?familyId=970">Antimalarial targets family</a> and the <a href="http://guidetomalariapharmacology.org/GRAC/FamilyDisplayForward?familyId=999">Antimalarial ligands family</a> have been updated, giving a total of 40 <em>P. falciparum</em> (3D7) targets and 134 ligands tagged as antimalarial in the database. Work has continued on the process of adding subfamilies to the <a href="http://guidetomalariapharmacology.org/GRAC/FamilyDisplayForward?familyId=970">Antimalarial targets family</a>.</p> </div> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/coronavirus/" rel="tag">coronavirus</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/technical/" rel="category tag">Technical</a> </div> </div> <div id="post-4386" class="post-4386 post type-post status-publish format-standard hentry category-hot-topics tag-ace2 tag-sars-cov-2"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2022/02/06/sars-cov-2-and-the-truncated-ace-2-variant/" rel="bookmark">Hot Topics: SARS-CoV-2 and the truncated ACE-2 variant</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2022/02/06/sars-cov-2-and-the-truncated-ace-2-variant/" title="5:10 pm" rel="bookmark"><span class="timestamp">February 6, 2022</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2022/02/06/sars-cov-2-and-the-truncated-ace-2-variant/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>ACE2 (Guide to Pharmacology <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1614">Target id: 1614</a>) normally functions as an enzyme metabolising peptides that regulate the cardiovascular system. As is well known though, it has recently gained additional scientific fame by also acting as a receptor for SARS-CoV-2. This study [1] compared the distribution in human tissue of ACE2 versus deltaACE2, a recently discovered truncated isoform that has lost the spike binding sites for SARS-CoV-2, and is predicted to confer reduced susceptibility to viral infection. ACE2 was highly expressed in human lung, kidney, heart, liver and vasculature. However, deltaACE2 was the predominant protein alternative initiation variant in lung airway and liver bile duct epithelia, which may be a contributing factor to variation in response to the virus. A diagrammatic relationships of the full length and dACE is shown below. </p> <p></p> <figure class="wp-block-image size-large"><a href="https://blog.guidetopharmacology.org/wp-content/uploads/2022/02/image.png"><img data-attachment-id="4392" data-permalink="https://blog.guidetopharmacology.org/image/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2022/02/image.png" data-orig-size="397,499" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="image" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2022/02/image.png?w=239" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2022/02/image.png?w=397" loading="lazy" width="397" height="499" src="https://blog.guidetopharmacology.org/wp-content/uploads/2022/02/image.png?w=397" alt="" class="wp-image-4392" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2022/02/image.png 397w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/02/image.png?w=119 119w, https://blog.guidetopharmacology.org/wp-content/uploads/2022/02/image.png?w=239 239w" sizes="(max-width: 397px) 100vw, 397px" /></a></figure> <p>The discovery of this novel short dACE2 variant in two independent reports may have important implications in COVID-19 research. It is enzymatically inactive, and the absence of the spike binding domains of the full-length ACE2 suggests dACE2 does not bind SARS-CoV-2 spike protein. It is still unclear what the precise effects of such an alternative form are in both normal physiology and in relation to SARS-CoV-2 infection and Long COVID, but the ratio of dACE2 versus the full-length protein may be a contributing factor in the wide inter-individual variation in response to COVID-19</p> <ol class="wp-block-list" type="1"><li>Williams TL, Strachan G, Macrae RGC, Kuc RE, Nyimanu D, Paterson AL, Sinha S, Maguire JJ, and Davenport AP. Differential expression in humans of the viral entry receptor ACE2 compared with the short deltaACE2 isoform lacking SARS-CoV-2 binding sites. <em>Sci Rep.</em> <strong>11</strong>:24336. (2021). [PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/34934117/"> 34934117</a>]</li></ol> <p>Contributed by <strong>Christopher Southan</strong>, <a href="https://orcid.org/0000-0001-9580-0446"> ORCID 0000-0001-9580-0446</a>, Data Science, Medicines Discovery Catapult and Honorary Fellow, University of Edinburgh</p> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/ace2/" rel="tag">ACE2</a>, <a href="https://blog.guidetopharmacology.org/tag/sars-cov-2/" rel="tag">SARS-CoV-2</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/hot-topics/" rel="category tag">Hot Topics</a> </div> </div> <div id="post-4363" class="post-4363 post type-post status-publish format-standard hentry category-database-updates category-guide-to-malaria-pharmacology"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2021/12/14/database-release-2021-4/" rel="bookmark">Database Release 2021.4</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2021/12/14/database-release-2021-4/" title="11:01 am" rel="bookmark"><span class="timestamp">December 14, 2021</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2021/12/14/database-release-2021-4/#comments">1 Comment</a> </span> </div> <div class="post-entry"> <p>The 2021.4 release of the IUPHAR Guide to Pharmacology was made on 14th December 2021. This blog post gives details of the key content updates and website change The 2021.4 release contains:</p>     <ul> <li><strong>3,000</strong> human targets with curated quantitative ligand interactions.</li> <li><strong>11,139</strong> ligands, <strong>8,240 </strong>of which have curated quantitative target interactions.</li> <li><strong>1,717</strong> approved drugs, <strong>1,033</strong> with curated quantitative interactions.</li> <li>Clinical use summaries for over <strong>3,052</strong> ligands of which <strong>1,713 </strong>are approved drugs.</li> </ul>   <div> <div class="block-editor-block-list__layout is-root-container"> <h3 id="block-7d846edf-2781-4642-991d-4041ef937373" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: Heading">Coronavirus</h3> <p id="block-a8bfc870-a808-4a35-94d3-f7f9d43c2faa" class="block-editor-rich-text__editable block-editor-block-list__block wp-block is-hovered rich-text" role="group" aria-multiline="true" aria-label="Paragraph block">The Guide to Pharmacology <a href="https://www.guidetopharmacology.org/coronavirus.jsp" target="_blank" rel="noreferrer noopener">coronavirus information page</a> continues to be updated on a regular basis to capture the latest pharmacological strategies under investigation to mitigate against COVID-19.</p> <p role="group" aria-multiline="true" aria-label="Paragraph block">Updates have most notably been made to the comments for <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10737">molnupiravir (EIDD-2801, MK-4482)</a>. This followed its MHRA approval on 4th Nov 2021 as a treatment or recently diagnosed SARS-CoV-2 infection in non-hospitalised individuals who have at least one risk factor for developing severe illness.</p> <p role="group" aria-multiline="true" aria-label="Paragraph block">Also add to the ligand list is <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11503">PF-07321332</a>, an oral SARS-CoV-2 3CL protease (Mpro) inhibitor, and clinical lead compound from Pfizer. It was progressed to clinical trial to determine safety and efficacy as a treatment for COVID-19. Phase 1 (<a href="https://clinicaltrials.gov/ct2/show/NCT04756531" target="_blank" rel="noopener">NCT04756531</a>) results were published in Science, in early November 2021 DOI: <a href="https://doi.org/10.1126/science.abl4784" target="_blank" rel="noopener">10.1126/science.abl4784</a>. A few days after the Phase 1 results were published, Pfizer announced that interim analysis from their Phase 3 EPIC-HR study (<a href="https://clinicaltrials.gov/ct2/show/NCT04960202" target="_blank" rel="noopener">NCT04960202</a>), indicated that PF-07321332 (in combination with ritonavir, as a formulation with the trade name Paxlovid) reduced the risk of hospitalisation or death by almost 90% in patients who were at high risk of progressing to severe illness, and who were treated within 3 days of symptom onset <a href="https://bit.ly/3wxA5of" target="_blank" rel="noopener">https://bit.ly/3wxA5of</a>.</p> <p role="group" aria-multiline="true" aria-label="Paragraph block">OAS1 (<a href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8086" target="_blank" rel="noopener">HGNC:8086</a>; UniProt: <a href="https://www.uniprot.org/uniprot/P00973" target="_blank" rel="noopener">P00973</a><a>), an interferon-induced gene that is part of the innate antiviral defence system within host cells, has been added to the target table.</a></p> <h3 id="block-53a21c12-ad3e-47fe-b289-e491a29262b2" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: Heading">Curation Updates</h3> <p class="moz-quote-pre">Since our <a href="https://blog.guidetopharmacology.org/2021/09/02/database-release-2021-3/">2021.3 update</a> we have added over ~110 new ligands. These have all been manually curated with chemical or peptide structures, links to external resources, general comments, notes on clinical development where appropriate, and target interaction data where this is available.</p> <p class="moz-quote-pre">We have also made updates to ~46 existing ligand comments and ~52 clinical use comments. An additional 18 existing ligand have now been tagged as approved drugs, bringing the total approved drugs in GtoPdb to 1,716.</p> <h4>New Targets</h4> <p>5 new targets have been added to the database since the last release. These include <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=751&objId=3194#3194"><b>HtrA serine peptidase 1,</b></a><span style="font-weight:400;"> the target of <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11759">galegenimab</a> (Ph 2 geographic atrophy); </span><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=784&objId=3193#3193"><b>heat shock protein family A (Hsp70) member 5</b></a>, a <span style="font-weight:400;">potential therapeutic target for viral infections (incl. SARS-CoV-2), chemoresistant cancers and inflammation; </span><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=853&objId=3192#3192"><b>coagulation factor III, tissue factor</b></a><span style="font-weight:400;">, the target of <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11719">tisotumab vedotin</a> (approved, oncology);</span><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1069&objId=3195#3195"><b>clusterin</b></a><span style="font-weight:400;">: the target of <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11763">sotevtamab</a> (Ph 2 immunomodulator, antineoplastic); and </span><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=852&objId=3196#3196"><b>transferrin receptor (CD71)</b></a>,<span style="font-weight:400;"> which is exploited to improve site-specific drug delivery, including drug delivery across the blood-brain barrier e.g. <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11772">pabinafusp alfa</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11773">lepunafusp alfa</a> that deliver enzymes that are deficient in lysosomal storage disorders (both approved in Japan).</span></p> <h3 id="block-a7e13e77-527b-4530-92b4-1568e3413aa2" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: Heading">Website Updates</h3> <ul id="block-ebf0b7b3-d169-4924-9ac2-3cef9a6be6c3" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: List"> <li>The Guide to PHARMACOLOGY home-page has been revised, giving priority to the ways users can access the data. The site search and links to advanced search tools are more prominent. New panels link to ligand activity graphs, GtoImmuPdb, GtoMPdb, and current key resources. Page elements are more condensed to the top of the page and the site banner has been updated. </li> </ul> <div data-shortcode="caption" id="attachment_4371" style="width: 615px" class="wp-caption aligncenter"><a href="https://blog.guidetopharmacology.org/wp-content/uploads/2021/09/newhomepage.png"><img aria-describedby="caption-attachment-4371" data-attachment-id="4371" data-permalink="https://blog.guidetopharmacology.org/2021/09/02/database-release-2021-3/newhomepage/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/09/newhomepage.png" data-orig-size="975,1053" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="GtoPdb home page" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/09/newhomepage.png?w=278" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/09/newhomepage.png?w=605" loading="lazy" class="wp-image-4371 size-large" src="https://blog.guidetopharmacology.org/wp-content/uploads/2021/09/newhomepage.png?w=605" alt="new GtoPdb home page" width="605" height="653" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2021/09/newhomepage.png?w=605 605w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/09/newhomepage.png?w=139 139w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/09/newhomepage.png?w=278 278w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/09/newhomepage.png?w=768 768w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/09/newhomepage.png 975w" sizes="(max-width: 605px) 100vw, 605px" /></a><p id="caption-attachment-4371" class="wp-caption-text">Screenshot of the new GtoPdb home page. The site search is now more prominent, alongside the more advance search tools.</p></div> <ul id="block-ebf0b7b3-d169-4924-9ac2-3cef9a6be6c3" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: List"> <li>New <a href="https://www.guidetopharmacology.org/DATA/detailed_endogenous_ligands.csv">detailed endogenous ligand download file</a> – this includes quantitative interaction data for endogenous pairings, along with the export of relevant comment fields.</li> </ul> <h3 id="block-d52fb3be-7e9f-42c0-8df5-4fb9d25b9402" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: Heading">Guide to Malaria Pharmacology (GtoMPdb)</h3> <p id="block-9b2743cd-3ca0-48c2-ac34-82960f513b21" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Paragraph block">These are the recent advancements made in the GtoMPdb for this database release:</p> <ul id="block-01daa642-92bb-4e11-9090-8a4f8cd27e6a" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: List"> <li>The <a href="http://guidetomalariapharmacology.org/GRAC/FamilyDisplayForward?familyId=970">Antimalarial targets family</a> and the <a href="http://guidetomalariapharmacology.org/GRAC/FamilyDisplayForward?familyId=999">Antimalarial ligands family</a> have been updated, giving a total of 40 <em>P. falciparum</em> (3D7) targets and 125 ligands tagged as antimalarial in the database.</li> <li>Work has continued on the process of adding subfamilies to the <a href="http://guidetomalariapharmacology.org/GRAC/FamilyDisplayForward?familyId=970">Antimalarial targets family</a>.</li> </ul> </div> </div> </div> <div class="post-data"> Posted in <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/guide-to-malaria-pharmacology/" rel="category tag">Guide to Malaria Pharmacology</a> </div> </div> <div id="post-4344" class="post-4344 post type-post status-publish format-standard hentry category-uncategorized tag-award tag-hidden-ref"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2021/10/11/hidden-ref-award-to-guide-to-pharmacology/" rel="bookmark">Hidden REF award to Guide to Pharmacology</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2021/10/11/hidden-ref-award-to-guide-to-pharmacology/" title="4:34 pm" rel="bookmark"><span class="timestamp">October 11, 2021</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2021/10/11/hidden-ref-award-to-guide-to-pharmacology/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p class="x_MsoNormal">It is with great pleasure that we can announce that the IUPHAR/BPS Guide to PHARMACOLOGY has been given a hidden REF award in the category ‘applications of research’.</p> <p><a href="https://blog.guidetopharmacology.org/wp-content/uploads/2021/10/hidrefcert2021-e1633704894697.jpg"><img data-attachment-id="4346" data-permalink="https://blog.guidetopharmacology.org/2021/10/11/hidden-ref-award-to-guide-to-pharmacology/hidrefcert2021/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/10/hidrefcert2021-e1633704894697.jpg" data-orig-size="2073,1490" data-comments-opened="1" data-image-meta="{"aperture":"2.4","credit":"","camera":"iPad","caption":"","created_timestamp":"1633607758","copyright":"","focal_length":"4.28","iso":"125","shutter_speed":"0.066666666666667","title":"","orientation":"1"}" data-image-title="hidden ref certificate" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/10/hidrefcert2021-e1633704894697.jpg?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/10/hidrefcert2021-e1633704894697.jpg?w=605" loading="lazy" class="size-medium wp-image-4346 aligncenter" src="https://blog.guidetopharmacology.org/wp-content/uploads/2021/10/hidrefcert2021-e1633704894697.jpg?w=300" alt="Guide to Pharmacology hidden REF certificate" width="300" height="216" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2021/10/hidrefcert2021-e1633704894697.jpg?w=300 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/10/hidrefcert2021-e1633704894697.jpg?w=600 600w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/10/hidrefcert2021-e1633704894697.jpg?w=150 150w" sizes="(max-width: 300px) 100vw, 300px" /></a></p> <p>The hidden Ref (<a href="https://hidden-ref.org">https://hidden-ref.org</a>) is a national ‘competition’, supported by publishers, learned societies etc. (<a href="https://hidden-ref.org/supporters/">https://hidden-ref.org/supporters/</a>) , designed to celebrate and recognise the range of important research achievements that may not fit neatly into a REF submission.</p> <p><strong>“The ways in which the research impact is judged overlooks many of the people who are vital to the success of research. It’s only by recognising everyone who is vital to the conduct of research that we will create an environment in which to advance it.”</strong></p> <p class="x_MsoNormal">We are of course very grateful to receive this award, and our thanks go to the hidden REF committees.</p> <p class="x_MsoNormal">Being recognised in this way is a testament to the hard work of the entire Guide to PHARMACOLOGY team, both past and present, who’s vision and dedication has provided the research community with such an invaluable resource.</p> <p>The award ceremony is available to view and you can watch the specific announcement of the GtoPdb award in the following video (starts ~10 mins in):</p> <p><div class="jetpack-video-wrapper"><span class="embed-youtube" style="text-align:center; display: block;"><iframe class="youtube-player" width="560" height="315" src="https://www.youtube.com/embed/btjRNG0NANg?version=3&rel=1&showsearch=0&showinfo=1&iv_load_policy=1&fs=1&hl=en&autohide=2&start=584&wmode=transparent" allowfullscreen="true" style="border:0;" sandbox="allow-scripts allow-same-origin allow-popups allow-presentation allow-popups-to-escape-sandbox"></iframe></span></div></p> <p>More information on the hidden REF is provide in this video:</p> <p><div class="jetpack-video-wrapper"><span class="embed-youtube" style="text-align:center; display: block;"><iframe class="youtube-player" width="560" height="315" src="https://www.youtube.com/embed/lpC3A3Vgrfs?version=3&rel=1&showsearch=0&showinfo=1&iv_load_policy=1&fs=1&hl=en&autohide=2&wmode=transparent" allowfullscreen="true" style="border:0;" sandbox="allow-scripts allow-same-origin allow-popups allow-presentation allow-popups-to-escape-sandbox"></iframe></span></div></p> <div id="info" class="style-scope ytd-video-primary-info-renderer"></div> <p> </p> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/award/" rel="tag">award</a>, <a href="https://blog.guidetopharmacology.org/tag/hidden-ref/" rel="tag">hidden REF</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/uncategorized/" rel="category tag">Uncategorized</a> </div> </div> <div id="post-4322" class="post-4322 post type-post status-publish format-standard hentry category-database-updates category-technical tag-coronavirus tag-immunopharmacology tag-malaria"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2021/09/02/database-release-2021-3/" rel="bookmark">Database Release 2021.3</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2021/09/02/database-release-2021-3/" title="3:09 pm" rel="bookmark"><span class="timestamp">September 2, 2021</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2021/09/02/database-release-2021-3/#comments">1 Comment</a> </span> </div> <div class="post-entry"> <div class="wp-block-group"><div class="wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow"> <div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-1 wp-block-columns-is-layout-flex"> <div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow" style="flex-basis:100%;"> <p>The new release of the IUPHAR Guide to Pharmacology was made on 2nd September 2021 – this is version 2021.3. This blog post gives details of the key content updates and website changes.</p> <p>The 2021.3 release contains:</p> <ul class="wp-block-list"> <li><strong>1,596</strong> human targets with curated quantitative ligand interactions.</li> <li><strong>11,025</strong> ligands, <strong>8,161</strong> of which have curated quantitative target interactions.</li> <li><strong>1,688</strong> approved drugs, <strong>1,018</strong> with curated quantitative interactions.</li> <li>Clinical use summaries for over <strong>3,005</strong> ligands of which <strong>1,684 </strong>are approved drugs.</li> </ul> <div> <div class="block-editor-block-list__layout is-root-container"> <h3 id="block-7d846edf-2781-4642-991d-4041ef937373" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: Heading">Coronavirus</h3> <p id="block-a8bfc870-a808-4a35-94d3-f7f9d43c2faa" class="block-editor-rich-text__editable block-editor-block-list__block wp-block is-hovered rich-text" role="group" aria-multiline="true" aria-label="Paragraph block">The Guide to Pharmacology <a href="https://www.guidetopharmacology.org/coronavirus.jsp" target="_blank" rel="noreferrer noopener">coronavirus information page</a> continues to be updated on a regular basis to capture the latest pharmacological strategies under investigation to mitigate against COVID-19. </p> <p role="group" aria-multiline="true" aria-label="Paragraph block">Most recently we have added the <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11602">DX600</a> experimental peptide, which has been shown to prevent pseudotyped SARS-CoV-2 from entering heart cells (<a href="https://www.nature.com/articles/s42003-021-02453-y">Williams et al., Commun. Biol, 2021</a>). Also added are two monoclonal antibody cocktails. The first, AZD7442, is a combination of <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11329">cilgavimab</a> and <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11330">tixagevimab</a>, which reach phase 3 clinical evalutaion, and is proposed to have therapeutic potential in treating individuals who respond poorly to vaccination. The second, Ronapreve, is a combination of <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11327">imdevimab</a> and <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11328">casirivimab</a>, aimed at blocking SARS-CoV-2 entry into cells it was approved by the UK’s MHRA in August 2021 having previous been approved by both the FDA and Japanese Ministry of Health.</p> <h3 id="block-53a21c12-ad3e-47fe-b289-e491a29262b2" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: Heading">Curation Updates</h3> <p class="moz-quote-pre">Since our <a href="https://blog.guidetopharmacology.org/2021/06/25/database-release-2021-2/">2021.2 update</a> we have added over ~120 new ligands. These have all been manually curated with chemical or peptide structures, links to external resources, general comments, notes on clinical development where appropriate, and target interaction data where this is available.</p> <p class="moz-quote-pre">We have also made updates to over 170 existing ligand comments and 102 bioactivity comments. An additional 8 existing ligand have now been tagged as approved drugs, bringing the total approved drugs in GtoPdb to 1,688.</p> <h3 id="block-a7e13e77-527b-4530-92b4-1568e3413aa2" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: Heading">Website Updates</h3> <ul id="block-ebf0b7b3-d169-4924-9ac2-3cef9a6be6c3" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: List"> <li>We have extended the database to be able to curate and display HELM notation for peptides. Currently this has been added to over 60 peptides, with more planned in future releases.</li> <li>New, antibacterial ligand category, <a href="https://www.guidetopharmacology.org/GRAC/LigandListForward?type=AntiBac&database=all">https://www.guidetopharmacology.org/GRAC/LigandListForward?type=AntiBac&database=all</a></li> </ul> <h3 id="block-d52fb3be-7e9f-42c0-8df5-4fb9d25b9402" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: Heading">Guide to Malaria Pharmacology (GtoMPdb)</h3> <p id="block-9b2743cd-3ca0-48c2-ac34-82960f513b21" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Paragraph block">These are the recent advancements made in the GtoMPdb for this database release:</p> <ul id="block-01daa642-92bb-4e11-9090-8a4f8cd27e6a" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: List"> <li>The <a href="http://guidetomalariapharmacology.org/GRAC/FamilyDisplayForward?familyId=970">Antimalarial targets family</a> and the <a href="http://guidetomalariapharmacology.org/GRAC/FamilyDisplayForward?familyId=999">Antimalarial ligands family</a> have been updated, giving a total of 39 <em>P. falciparum</em> (3D7) targets and 114 ligands tagged as antimalarial in the database.</li> <li>The <em>Plasmodium</em> target <a href="https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=3191">Plasmodium falciparum histone acetyltransferase GCN5</a> was added during this release.</li> <li>Work has continued on the process of adding subfamilies to the <a href="http://guidetomalariapharmacology.org/GRAC/FamilyDisplayForward?familyId=970">Antimalarial targets family</a>.</li> </ul> <div class="block-editor-block-list__layout is-root-container"> <p role="group" aria-multiline="true" aria-label="Paragraph block"> </p> </div> </div> </div> </div> </div> </div></div> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/coronavirus/" rel="tag">coronavirus</a>, <a href="https://blog.guidetopharmacology.org/tag/immunopharmacology/" rel="tag">immunopharmacology</a>, <a href="https://blog.guidetopharmacology.org/tag/malaria/" rel="tag">malaria</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/technical/" rel="category tag">Technical</a> </div> </div> <div id="post-4300" class="post-4300 post type-post status-publish format-standard hentry category-hot-topics tag-hot-topic tag-kinase-inhibitors tag-pharmacology"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2021/08/06/hot-topics-trends-in-kinase-drug-discovery-twenty-years-of-successfully-targeting-the-kinome/" rel="bookmark">Hot Topics: Trends in kinase drug discovery: twenty years of successfully targeting the kinome</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2021/08/06/hot-topics-trends-in-kinase-drug-discovery-twenty-years-of-successfully-targeting-the-kinome/" title="10:21 am" rel="bookmark"><span class="timestamp">August 6, 2021</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2021/08/06/hot-topics-trends-in-kinase-drug-discovery-twenty-years-of-successfully-targeting-the-kinome/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>The FDA approval of imatinib in 2001 was a breakthrough in molecularly targeted cancer therapy and heralded the emergence of kinase inhibitors as a key drug class in the oncology area and beyond. Continued advances in the molecular understanding of cancer, multiple approaches to drug design, and the increasing number of resolved kinase structures (1) have facilitated the development of kinase inhibitors with improved potency, selectivity, and efficacy.</p> <p>Two new analyses published in <em>Nature Reviews Drug Discovery</em> present the historical development of kinase inhibitors as well as the current outlook on kinase drug discovery. Cohen et al. (1) present a detailed study on FDA-approved small molecular weight kinase inhibitors titled <em>Kinase drug discovery 20 years after imatinib: progress and future directions</em>. The analysis encompasses the pivotal events in kinase inhibitor development and remarkable progress made over the past 20 years in improving the potency and specificity of small molecule kinase inhibitors (SMKIs) and the kinase pathways targeted in drug discovery. Importantly, the development of drug resistance to kinase inhibitors and how these challenges are being met in the future of kinase drug discovery are discussed.</p> <p>The new analysis <em>Trends in kinase drug discovery: targets, indications and inhibitor design</em> published this month by Attwood et al. (2) analyses the landscape of approved and investigational therapies targeting kinases and trends within it, including the most popular targets of kinase inhibitors and their expanding range of indications. Furthermore, strategies for kinase inhibitor design, including the development of allosteric and covalent inhibitors, bifunctional inhibitors, and chemical degraders are discussed. Since the approval of fasudil in 1995, the number of approved kinase inhibitors worldwide as increased to 98 drugs, of which 71 are SMKIs and 10 monoclonal antibodies approved by the FDA. Remarkably, the number of FDA-approved SMKIs has more than doubled in the past five years and they constitute ~15% of all novel drug approvals by the FDA. While oncology is still the predominant area for their application, there have been important approvals for indications such as rheumatoid arthritis, and one-third of the SMKIs in clinical development address disorders beyond oncology. Nearly 600 investigational kinase-targeting agents that were registered in ClinicalTrials.gov were included this analysis, consisting of 475 novel SMKIs and 124 biological agents. Information on clinical trials of SMKIs reveals that ~110 novel kinases are currently being explored as targets, which together with the ~45 targets of approved kinase inhibitors represent only ~30% of the human kinome (4), indicating that there are still substantial unexplored opportunities for this drug class.</p> <p>In summary, although there have been substantial advances in kinase drug discovery, there are still many challenges and opportunities in this field. The potential for developing novel types of kinase inhibitors is large and it is expected that this will continue to be a major area of growth in the next 20 years.</p> <p><strong>Comments by Misty Attwood and <a href="https://www.guidetopharmacology.org/GRAC/ContributorDisplayForward?contributorId=311">Helgi Schiöth</a>, </strong>University of Uppsala, Uppsala, Sweden. Helgi Schiöth is Chair for NC-IUPHAR Subcommitees for <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=38">Melanocortin receptors</a> and <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=57">Prolactin-releasing peptide receptor</a>. Twitter: <a href="https://twitter.com/FunctPharm">@FunctPharm</a></p> <p></p> <ol class="wp-block-list" type="1"><li>Structural Genomics Consortium (SGC): <a href="https://www.thesgc.org/">https://www.thesgc.org/</a>.</li><li>Cohen, P., Cross, D. & Jänne, P.A. Kinase drug discovery 20 years after imatinib: progress and future directions. <em>Nat Rev Drug Discov</em> <strong>20, </strong>551–569 (2021). [PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/34002056/" target="_blank" rel="noreferrer noopener"> 34002056</a>]</li><li>Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., Schiöth, H. B. Trends in kinase drug discovery: targets, indications and inhibitor design. <em>Nat Rev Drug Discov</em>. In press (2021). [PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34354255/" target="_blank" rel="noreferrer noopener">34354255</a>]</li><li>IUPHAR Guide to Pharmacology: <a href="https://www.guidetopharmacology.org">https://www.guidetopharmacology.org</a>.</li></ol> <p></p> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/hot-topic/" rel="tag">hot topic</a>, <a href="https://blog.guidetopharmacology.org/tag/kinase-inhibitors/" rel="tag">kinase inhibitors</a>, <a href="https://blog.guidetopharmacology.org/tag/pharmacology/" rel="tag">pharmacology</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/hot-topics/" rel="category tag">Hot Topics</a> </div> </div> <div id="post-4292" class="post-4292 post type-post status-publish format-standard hentry category-database-updates category-technical tag-coronavirus tag-immunopharmacology tag-malaria"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2021/06/25/database-release-2021-2/" rel="bookmark">Database Release 2021.2</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2021/06/25/database-release-2021-2/" title="1:44 pm" rel="bookmark"><span class="timestamp">June 25, 2021</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2021/06/25/database-release-2021-2/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <div class="wp-block-group"><div class="wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow"> <div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-2 wp-block-columns-is-layout-flex"> <div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow" style="flex-basis:100%;"> <p>The new release of the IUPHAR Guide to Pharmacology was made on 25th June 2021 – this is version 2020.2. This blog post gives details of the key content updates and website changes.</p> <p>The 2021.2 release contains:</p> <ul class="wp-block-list"> <li><strong>1,588</strong> human targets with curated quantitative ligand interactions.</li> <li><strong>10,894</strong> ligands, <strong>8,066</strong> of which have curated quantitative target interactions.</li> <li><strong>1,664</strong> approved drugs, <strong>1,006</strong> with curated quantitative interactions.</li> <li>Clinical use summaries for over <strong>2,934</strong> ligands of which <strong>1,660 </strong>are approved drugs.</li> </ul> <div> <div class="block-editor-block-list__layout is-root-container"> <h3 id="block-53a21c12-ad3e-47fe-b289-e491a29262b2" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: Heading">Curation Updates</h3> <p class="moz-quote-pre">Since our <a href="https://blog.guidetopharmacology.org/2021/03/18/database-release-2021-1/">2021.2 update</a> we have added over 70 new ligands. These have all been manually curated with chemical or peptide structures, links to external resources, general comments, notes on clinical development where appropriate, and target interaction data where this is available. We have also made update to over 40 existing ligand comments and clinical use summaries. Bioactivity comments have been updated on 10 ligands and 16 existing ligand have now been tagged as approved drugs.</p> <h3 id="block-a7e13e77-527b-4530-92b4-1568e3413aa2" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: Heading">Website Updates</h3> <ul id="block-ebf0b7b3-d169-4924-9ac2-3cef9a6be6c3" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: List"> <li>New homepage (beta version) is available. This is a minor re-working of our homepage to prioritise the database search tools and access to ligand activity charts, immunopharmacology and malaria pharmacology. </li> <li>Added links from solute-carrier targets to the RESOLUTE – Solute Carrier Knowledgebase</li> </ul> <h3 id="block-d52fb3be-7e9f-42c0-8df5-4fb9d25b9402" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: Heading">Guide to Malaria Pharmacology (GtoMPdb)</h3> <p id="block-9b2743cd-3ca0-48c2-ac34-82960f513b21" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Paragraph block">These are the recent advancements made in the GtoMPdb for this database release:</p> <ul id="block-01daa642-92bb-4e11-9090-8a4f8cd27e6a" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: List"> <li>The <a href="http://guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=970">Antimalarial targets family</a> and the <a href="http://guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=999">Antimalarial ligands family</a> have been updated, giving a total of 38 <em>P. falciparum</em> (3D7) targets and 110 ligands tagged as antimalarial in the database.</li> <li>The <em>Plasmodium</em> target <a href="https://.www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=3184">Plasmodium falciparum subtilisin-like protease 1</a> was added during this release.</li> <li>Work has continued on the process of adding subfamilies to the <a href="http://guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=970">Antimalarial targets family</a>, with the ‘Plasmepsin family (peptidases)” subfamily now renamed as “<a href="https://.www.guidetomalariapharmacology.org/GRAC/FamilyDisplayForward?familyId=1063">Peptidases and proteinases (Plasmodium spp.)</a>” and expanded to include four <em>Plasmodium </em>targets.</li> </ul> <div class="block-editor-block-list__layout is-root-container"> <h3 id="block-7d846edf-2781-4642-991d-4041ef937373" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: Heading">Coronavirus</h3> <p id="block-a8bfc870-a808-4a35-94d3-f7f9d43c2faa" class="block-editor-rich-text__editable block-editor-block-list__block wp-block is-hovered rich-text" role="group" aria-multiline="true" aria-label="Paragraph block"><em>The Guide to Pharmacology <a href="https://www.guidetopharmacology.org/coronavirus.jsp" target="_blank" rel="noreferrer noopener">coronavirus information page</a> continues to be updated on a regular basis to capture the latest pharmacological strategies under investigation to mitigate against COVID-19.</em></p> </div> </div> </div> </div> </div> </div></div> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/coronavirus/" rel="tag">coronavirus</a>, <a href="https://blog.guidetopharmacology.org/tag/immunopharmacology/" rel="tag">immunopharmacology</a>, <a href="https://blog.guidetopharmacology.org/tag/malaria/" rel="tag">malaria</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/technical/" rel="category tag">Technical</a> </div> </div> <div id="post-4247" class="post-4247 post type-post status-publish format-standard hentry category-database-updates category-technical tag-coronavirus tag-immunopharmacology tag-malaria"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2021/03/18/database-release-2021-1/" rel="bookmark">Database Release 2021.1</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2021/03/18/database-release-2021-1/" title="4:46 pm" rel="bookmark"><span class="timestamp">March 18, 2021</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2021/03/18/database-release-2021-1/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <div class="wp-block-group"><div class="wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow"> <div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-3 wp-block-columns-is-layout-flex"> <div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow" style="flex-basis:100%;"> <p>Here are the details for the first release in 2021 of the Guide to PHARMACOLOGY database, version 2021.1. This is the last release before we move forward with the process of preparing the next edition of the Concise Guide to Pharmacology (2021/22). As such, the release contains many updates specifically with the CGTP in mind.</p> <p>The 2021.1 release contains:</p> <ul class="wp-block-list"><li><strong>1,580</strong> human targets with curated quantitative ligand interactions.</li><li><strong>10,821</strong> ligands, <strong>8,016</strong> of which have curated quantitative target interactions.</li><li><strong>1,643</strong> approved drugs, <strong>995</strong> with curated quantitative interactions.</li><li>Clinical use summaries for over <strong>2,899</strong> ligands of which <strong>1,639</strong> are approved drugs.</li></ul> <div> <div class="block-editor-block-list__layout is-root-container"> <h3 id="block-7d846edf-2781-4642-991d-4041ef937373" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: Heading">Coronavirus</h3> <p id="block-a8bfc870-a808-4a35-94d3-f7f9d43c2faa" class="block-editor-rich-text__editable block-editor-block-list__block wp-block is-hovered rich-text" role="group" aria-multiline="true" aria-label="Paragraph block"><em>The Guide to Pharmacology <a href="https://www.guidetopharmacology.org/coronavirus.jsp" target="_blank" rel="noreferrer noopener">coronavirus information page</a> continues to be updated on a regular basis to capture the latest pharmacological strategies under investigation to mitigate against COVID-19.</em></p> </div> <p role="group" aria-multiline="true" aria-label="Paragraph block">The peptide <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4942">GM-CSF</a> has been added to the targets lists as this has been indicated as a principal marker of sever COVID-19 immunopathology. Ligands added in include <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11470">ensovibep (MP0420)</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11421">emovododstat</a> & <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11395">MK-7110</a>. Updates made to comments for <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7999">sarliumab</a> and <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6881">tocilizumab</a>.</p> <div class="block-editor-block-list__layout is-root-container"> <h3 id="block-53a21c12-ad3e-47fe-b289-e491a29262b2" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: Heading">Curation Updates</h3> <p>There have been some fairly significant updates in this release as a precursor to preparing the 2021/22 edition of the Concise Guide to Pharmacology.</p> <p class="moz-quote-pre">A new family of enzymes, <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=845">Peptidyl-prolyl cis/trans isomerases (PPIases)</a>, has been added. This includes some of the best understood PPIases, in particular those that are therapeutic targets (current or under investigation). We have added several pharmacological modulators that can be used to investigate their biological roles, as well as relevant clinical candidate compounds.</p> <p class="moz-quote-pre">Ten of our ligands have been updated to reflect their approval by the FDA in the first quarter of 2021: <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10010">vericiguat</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11386">cabotegravir</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11388">voclosporin</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8293">tepotinib</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8916">umbralisib</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8717">evinacumab-dgnb</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9626">trilaciclib</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11444">casimersen</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11450">serdexmethylphenidate</a> and <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6058">tivozanib</a>.</p> <p class="moz-quote-pre">Since our <a href="https://blog.guidetopharmacology.org/2020/11/12/database-release-2020-5/" target="_blank" rel="noopener">2020.5 update</a> we have added 220 new ligands. These have all been manually curated with chemical or peptide structures, links to external resources, general comments, notes on clinical development where appropriate, and target interaction data where this is available.</p> <p class="moz-quote-pre">Many of our target family summary pages have been reviewed by our expert committees, and revised in preparation for generating the next edition of the Concise Guide to PHARMACOLOGY (2021/22 ed).</p> <h3 id="block-a7e13e77-527b-4530-92b4-1568e3413aa2" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: Heading">Website Updates</h3> <ul id="block-ebf0b7b3-d169-4924-9ac2-3cef9a6be6c3" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: List"> <li>New ligand ID mapping file is available from downalods. This mapps GtoPdb ligand IDs to other database identifiers (inc. PubChem CID/SID, ChEMBL, ChEBI, UniProt, DrugBank and DrugCentral)</li> <li>Also a new download file that provide all GtoPdb ligands, with structures, as a SDF (structure-data file).</li> <li>Links from ligand summary pages to Reactome reactions and drug entities</li> <li>Minor fixes to family tree-hierarchy display to hide expand/collapse buttons if there are no nodes to expand.</li> <li>Update to RCSB PDB ligand links (updated URL)</li> <li>New home page (beta version) is accessible here <a href="https://www.guidetopharmacology.org/index_beta.jsp" rel="nofollow">https://www.guidetopharmacology.org/index_beta.jsp</a></li> </ul> <h3 id="block-d52fb3be-7e9f-42c0-8df5-4fb9d25b9402" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: Heading">Guide to Malaria Pharmacology (GtoMPdb)</h3> <p id="block-9b2743cd-3ca0-48c2-ac34-82960f513b21" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Paragraph block">These are the recent advancements made in the GtoMPdb for this database release:</p> <ul id="block-01daa642-92bb-4e11-9090-8a4f8cd27e6a" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: List"> <li>The <a href="http://guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=970">Antimalarial targets family</a> and the <a href="http://guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=999">Antimalarial ligands family</a> have been updated, giving a total of 37 <em>P. falciparum</em> (3D7) targets and 105 ligands tagged as antimalarial in the database.</li> <li>The <em>Plasmodium</em> targets added during this release are: <ul id="block-01daa642-92bb-4e11-9090-8a4f8cd27e6a" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: List"> <li><a href="https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=3166">Plasmodium falciparum tryptophan–tRNA ligase</a></li> <li><a href="https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=3168">Plasmodium falciparum isoleucine–tRNA ligase</a></li> <li><a href="https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=3173">Plasmodium falciparum bifunctional farnesyl/geranylgeranyl diphosphate synthase</a></li> <li><a href="https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=3174">Plasmodium falciparum acetyl-CoA synthetase</a></li> </ul> </li> <li>We have begun the process of adding subfamilies to the <a href="http://guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=970">Antimalarial targets family</a> (see <strong>Figure 1</strong>).</li> </ul> <p><img data-attachment-id="4264" data-permalink="https://blog.guidetopharmacology.org/screenshot-2021-02-25-at-18-39-57/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/03/screenshot-2021-02-25-at-18.39.57.png" data-orig-size="1158,890" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="screenshot-2021-02-25-at-18.39.57" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/03/screenshot-2021-02-25-at-18.39.57.png?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/03/screenshot-2021-02-25-at-18.39.57.png?w=605" loading="lazy" class="alignnone size-full wp-image-4264" src="https://blog.guidetopharmacology.org/wp-content/uploads/2021/03/screenshot-2021-02-25-at-18.39.57.png" alt="screenshot-2021-02-25-at-18.39.57" width="1158" height="890" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2021/03/screenshot-2021-02-25-at-18.39.57.png 1158w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/03/screenshot-2021-02-25-at-18.39.57.png?w=150&h=115 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/03/screenshot-2021-02-25-at-18.39.57.png?w=300&h=231 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/03/screenshot-2021-02-25-at-18.39.57.png?w=768&h=590 768w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/03/screenshot-2021-02-25-at-18.39.57.png?w=1024&h=787 1024w" sizes="(max-width: 1158px) 100vw, 1158px"><strong>Figure 1</strong>. The Antimalarial targets family page illustrating the new subfamily classification (highlighted in magenta).</p> </div> </div> </div> </div> </div></div> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/coronavirus/" rel="tag">coronavirus</a>, <a href="https://blog.guidetopharmacology.org/tag/immunopharmacology/" rel="tag">immunopharmacology</a>, <a href="https://blog.guidetopharmacology.org/tag/malaria/" rel="tag">malaria</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/technical/" rel="category tag">Technical</a> </div> </div> <div id="post-4222" class="post-4222 post type-post status-publish format-standard hentry category-uncategorized tag-coronavirus tag-pre-release-ligands"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2021/02/01/gtopdb-pre-release-ligands-2021-1/" rel="bookmark">GtoPdb pre-release ligands (2021.1)</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2021/02/01/gtopdb-pre-release-ligands-2021-1/" title="5:09 pm" rel="bookmark"><span class="timestamp">February 1, 2021</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2021/02/01/gtopdb-pre-release-ligands-2021-1/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>These are some of the ligands under curation (pre-release) in the Guide to Pharmacology. We expect them to be available on the website at the next database release (2021.1).</p> <p><strong><span style="text-decoration:underline;">Ligand ID: 11395</span></strong><br />Names: <strong>MK-7110</strong><br />Comment: MK-7110 (originally OncoImmune’s CD24Fc) is a synthetic protein that fuses the nonpolymorphic regions of CD24 (which is an agonist of Siglec-10) to the Fc region of human IgG1 [PubMed ID:19264983]. It.is being investigated as a modulator of the innate immune system, originally as an intervention to ameliorate graft-versus-host disease in leukemia patients receiving stem cell transplants, or autoimmune diseases. The peptide’s sequence was extracted from OncoImmune’s patent US20130231464A1 the first 30 amino acids are the CD24 region and the remainder belong to the IgG1 Fc domain.<br />Coronavirus relevance: A clinical stage synthetic fusion protein and CD24 mimetic, that enhances CD24/SIGLEC10 suppression of DAMP-triggered activation of the immune response and associated tissue damage. Repositioned to combat COVID-19 inflammation (currently Phase 3).</p> <p><strong><span style="text-decoration:underline;">Ligand ID: 11421</span></strong><br />Names: <strong>emvododstat</strong><br />Comment: Emvododstat (PTC299) is an orally bioavailable inhibitor of dihydroorotate dehydrogenase (DHODH) that was developed by PTC Therapeutics for anti-cancer potential. It inhibits de novo pyrimidine nucleotide (UMP) biosynthesis and exhibits broad activity against leukemia <em>in vitro</em> and <em>in vivo</em>.<br />Coronavirus relevance: Emvododstat inhibits replication of SARS-CoV-2 in vitro (EC<sub>50</sub> 2.0-31.6 nM) and other RNA viruses. It blocks production of inflammatory cytokines in infected cell cultures.</p> <div class="wp-block-image"> <figure class="alignleft size-large"><img data-attachment-id="4233" data-permalink="https://blog.guidetopharmacology.org/11421/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/02/11421.gif" data-orig-size="309,180" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="11421" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/02/11421.gif?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/02/11421.gif?w=309" loading="lazy" width="309" height="180" class="wp-image-4233 aligncenter" src="https://blog.guidetopharmacology.org/wp-content/uploads/2021/02/11421.gif?w=309" alt="" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2021/02/11421.gif 309w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/02/11421.gif?w=150 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/02/11421.gif?w=300 300w" sizes="(max-width: 309px) 100vw, 309px" /> <figcaption>2D structure of emvododstat</figcaption> </figure> </div> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p><strong><span style="text-decoration:underline;">Ligand ID: 11470</span></strong><br />Names: <strong>ensovibep (MP0420)</strong><br />Comment: MP0420 is a DARPin that binds to the SARS-CoV-2 spike glycoprotein, and offers virus neutralising potential. It is being progressed to clinical trial by Molecular Partners and Novartis. DARPins are protein-based therapeutics, with the high selectivity and affinity of antibodies, but are around 10% of the size. They are easier to manufacture than whole antibodies, and may be suitable for subcutaneous administration rather than infusion. Molecular Partners have developed two multi-valent DARPins that are designed to engage multiple sites of the SARS-CoV-2 spike glycoprotein. Novartis and Molecular Partners are working together on both MP0420 and MP0423 for COVID-19.</p> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/coronavirus/" rel="tag">coronavirus</a>, <a href="https://blog.guidetopharmacology.org/tag/pre-release-ligands/" rel="tag">pre-release ligands</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/uncategorized/" rel="category tag">Uncategorized</a> </div> </div> <div id="post-4182" class="post-4182 post type-post status-publish format-standard has-post-thumbnail hentry category-hot-topics"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2021/01/22/hot-topics-gene-symbol-usage-and-the-need-to-do-better/" rel="bookmark">Hot Topics: Gene Symbol usage and the need to do better</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2021/01/22/hot-topics-gene-symbol-usage-and-the-need-to-do-better/" title="1:03 pm" rel="bookmark"><span class="timestamp">January 22, 2021</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2021/01/22/hot-topics-gene-symbol-usage-and-the-need-to-do-better/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <a href="https://blog.guidetopharmacology.org/2021/01/22/hot-topics-gene-symbol-usage-and-the-need-to-do-better/" title="Hot Topics: Gene Symbol usage and the need to do better" > <img width="311" height="255" src="https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-e1613731556638.jpg?w=311" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-e1613731556638.jpg 311w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-e1613731556638.jpg?w=150 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-e1613731556638.jpg?w=300 300w" sizes="(max-width: 311px) 100vw, 311px" data-attachment-id="4204" data-permalink="https://blog.guidetopharmacology.org/2021/01/22/hot-topics-gene-symbol-usage-and-the-need-to-do-better/capture-18/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-e1613731556638.jpg" data-orig-size="311,255" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="Capture" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-e1613731556638.jpg?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-e1613731556638.jpg?w=311" /> </a> <p>The GtoPdb team need no convincing about the importance of eliminating equivocality in gene and gene product names, as they are used in the pharmacology, chemical biology and drug discovery literature. Crucially, this also applies to their inclusion in curated database bioactivity records such as GtoPdb. We were thus particularly pleased to see “<strong>Standardizing gene product nomenclature</strong>” that appeared recently in PNAS [1]. This included not only an honourable mention of the Nomenclature Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR) but also the citation of our most recent Concise Guide Introduction [2]. </p> <p>The collaboration between NC-IUPHAR and HGNC for standardising the nomenclature of pharmacological targets goes back well over a decade. This has been (and continues to be) an iterative process whereby NC (after extensive consultation) recommends naming schema for certain target classes that are different to those approved by HGNC. This is typically done on the basis of well established publication usage in the pharmacological community. In many cases these older protein family names predate completion of the human genome. This can be illustrated for the case of the <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=80">Voltage-gated calcium channels </a> as shown in the GtoPdb family page below.</p> <p><img data-attachment-id="4204" data-permalink="https://blog.guidetopharmacology.org/2021/01/22/hot-topics-gene-symbol-usage-and-the-need-to-do-better/capture-18/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-e1613731556638.jpg" data-orig-size="311,255" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="Capture" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-e1613731556638.jpg?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-e1613731556638.jpg?w=311" class="wp-image-4204" style="width:900px;" src="https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture.jpg" alt=""></p> <p>As we can see in the page for <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=528&familyId=80&familyType=IC">Cav1.1</a> curation adds a full set of synonyms including CACNA1S and “calcium voltage-gated channel subunit alpha1 S” as approved <a href="https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1397">HGNC Symbol and name</a>, respectively. Below we can see the reciprocal cross-pointing between HGNC and GtoPdb/NC-IUPHAR. </p> <p><img data-attachment-id="4216" data-permalink="https://blog.guidetopharmacology.org/2021/01/22/hot-topics-gene-symbol-usage-and-the-need-to-do-better/capture-19/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-1.jpg" data-orig-size="955,115" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"cdsoutharn","camera":"","caption":"","created_timestamp":"1612177436","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="Capture" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-1.jpg?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-1.jpg?w=605" loading="lazy" width="900" height="108" class="wp-image-4216" style="width:900px;" src="https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-1.jpg" alt="" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-1.jpg?w=900&h=108 900w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-1.jpg?w=150&h=18 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-1.jpg?w=300&h=36 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-1.jpg?w=768&h=92 768w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-1.jpg 955w" sizes="(max-width: 900px) 100vw, 900px"><img data-attachment-id="4217" data-permalink="https://blog.guidetopharmacology.org/2021/01/22/hot-topics-gene-symbol-usage-and-the-need-to-do-better/capture-20/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-2.jpg" data-orig-size="949,117" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"cdsoutharn","camera":"","caption":"","created_timestamp":"1612177718","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="Capture" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-2.jpg?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-2.jpg?w=605" loading="lazy" width="900" height="111" class="wp-image-4217" style="width:900px;" src="https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-2.jpg" alt="" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-2.jpg?w=900&h=111 900w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-2.jpg?w=150&h=18 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-2.jpg?w=300&h=37 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-2.jpg?w=768&h=95 768w, https://blog.guidetopharmacology.org/wp-content/uploads/2021/01/capture-2.jpg 949w" sizes="(max-width: 900px) 100vw, 900px"></p> <p>We have commented some time ago on ambiguity issues arising from the necessity of curatorial resolution for authors’ descriptions of key entities to standardized identifiers, including mapping between ligands and target protein names [3]. We consequently hope both papers will contribute to greater use of both HGNC and NC-IUPHAR nomenclature in the pharmacology literature. </p> <p><strong>Comments by <a href="https://www.guidetopharmacology.org/GRAC/ContributorDisplayForward?contributorId=707">Chris Southan</a>, Fellow of the University of Edinburgh, Owner of TW2Informatics, Chair of NC-IUPHAR Subcommitees for Proteases and Drug Targets and Chemistry (DRUTACS).</strong></p> <p>[1] Kenji Fujiyoshi, Elspeth A. Bruford, Pawel Mroz, Cynthe L. Sims, Timothy J. O’Leary, Anthony W. I. Lo, Neng Chen, Nimesh R. Patel, Keyur Pravinchandra Patel, Barbara Seliger, Mingyang Song, Federico A. Monzon, Alexis B. Carter, Margaret L. Gulley, Susan M. Mockus, Thuy L. Phung, Harriet Feilotter, Heather E. Williams, and Shuji Ogino (2021) <strong>Opinion: Standardizing gene product nomenclature-a call to action</strong>, <em>Proc Natl Acad Sci U S A</em> Jan 19;118(3) doi: 10.1073/pnas.2025207118, <a href="https://pubmed.ncbi.nlm.nih.gov/33408252/">PMID: 33408252</a>. </p> <p>[2] Stephen P H Alexander, Eamonn Kelly, Alistair Mathie, John A Peters, Emma L Veale, Jane F Armstrong, Elena Faccenda, Simon D Harding, Adam J Pawson, Joanna L Sharman, Christopher Southan, O Peter Buneman, John A Cidlowski, Arthur Christopoulos, Anthony P Davenport, Doriano Fabbro , Michael Spedding, Jörg Striessnig , Jamie A Davies, CGTP Collaborators (2019) <strong>The Concise Guide to Pharmacology 2019/20: Introduction and Other Protein Targets</strong>, <em>Br J Pharmacol</em>. Dec; 176 (Suppl 1): S1–S20, <a href="//pubmed.ncbi.nlm.nih.gov/31710719/">PMID: 31710719</a>.</p> <p>[3] Christopher Southan 1, Joanna L Sharman 1, Elena Faccenda 1, Adam J Pawson 1, Simon D Harding 1, Jamie A Davies 1 (2018) <strong> Challenges of Connecting Chemistry to Pharmacology: Perspectives from Curating the IUPHAR/BPS Guide to PHARMACOLOGY</strong> <em>ACS Omega</em>, Jul 31;3(7):8408-8420, <a href="https://pubmed.ncbi.nlm.nih.gov/30087946/">PMID: 30087946</a>.</p> </div> <div class="post-data"> Posted in <a href="https://blog.guidetopharmacology.org/category/hot-topics/" rel="category tag">Hot Topics</a> </div> </div> <div id="post-4174" class="post-4174 post type-post status-publish format-standard hentry category-events tag-antibiotics tag-bps tag-covid tag-covid-19 tag-malaria tag-pharmacology-2020"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2020/12/16/gtopdb-at-pharmacology-2020/" rel="bookmark">GtoPdb at Pharmacology 2020</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2020/12/16/gtopdb-at-pharmacology-2020/" title="9:37 am" rel="bookmark"><span class="timestamp">December 16, 2020</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2020/12/16/gtopdb-at-pharmacology-2020/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>The <a href="https://www.bps.ac.uk/news-events/events/2020/pharmacology-2020" target="_blank" rel="noreferrer noopener">BPS Pharmacology 2020 Meeting</a> is being held virtually this year, but this hasn’t diminished Guide to Pharmacology presence.</p> <p>On Monday 14th, Dr. Simon Harding presented our poster on ‘Expansion for anti-malarial, antibiotics and COVID-19’. <a rel="noreferrer noopener" href="https://pharmacology2020.ipostersessions.com/default.aspx?s=18-ED-AA-EE-9E-DF-96-77-AB-2B-6C-18-DF-11-FF-59" target="_blank">Click to view poster</a>.</p> <p>On Tuesday 15th, Dr. Chris Southan gave on oral presentation on Curating SARS-CoV-2 viral targets for the IUPHAR/BPS Guide to Pharmacology’. The session is currently available ‘on-demand’ at <a href="https://live.bethereglobal.com/s/pharmacology-2020/15082">this link</a>. These are available to register attendees for one month.</p> <p>Chris also presented a poster on ‘SARS-CoV-2/COVID-19 pharmacological roadmap: strategy for curating and updating drug targets in the Guide to Pharmacology Coronavirus Information page’. <a href="https://pharmacology2020.ipostersessions.com/default.aspx?s=C4-76-B7-36-51-0B-BD-31-7B-F1-9B-58-23-CE-F5-FD" target="_blank" rel="noreferrer noopener">Click to view poster</a>.</p> <p>Follow this link to view the <a rel="noreferrer noopener" href="http://www.guidetopharmacology.org/coronavirus.jsp" target="_blank">GtoPdb Coronavirus Information Page.</a></p> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/antibiotics/" rel="tag">antibiotics</a>, <a href="https://blog.guidetopharmacology.org/tag/bps/" rel="tag">bps</a>, <a href="https://blog.guidetopharmacology.org/tag/covid/" rel="tag">covid</a>, <a href="https://blog.guidetopharmacology.org/tag/covid-19/" rel="tag">COVID-19</a>, <a href="https://blog.guidetopharmacology.org/tag/malaria/" rel="tag">malaria</a>, <a href="https://blog.guidetopharmacology.org/tag/pharmacology-2020/" rel="tag">pharmacology 2020</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/events/" rel="category tag">Events</a> </div> </div> <div id="post-4154" class="post-4154 post type-post status-publish format-standard hentry category-database-updates category-technical tag-coronavirus tag-immunopharmacology tag-malaria"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2020/11/12/database-release-2020-5/" rel="bookmark">Database Release 2020.5</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2020/11/12/database-release-2020-5/" title="10:57 am" rel="bookmark"><span class="timestamp">November 12, 2020</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2020/11/12/database-release-2020-5/#comments">1 Comment</a> </span> </div> <div class="post-entry"> <div class="wp-block-group"> <div class="wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow"> <div class="wp-block-columns is-layout-flex wp-container-core-columns-is-layout-4 wp-block-columns-is-layout-flex"> <div class="wp-block-column is-layout-flow wp-block-column-is-layout-flow" style="flex-basis:100%;"> <p>We are pleased to announce the latest release of the Guide to PHARMACOLOGY database, version 2020.5. This is the last planned release for 2020.</p> <p>The 2020.5 release contains:</p> <ul> <li><strong>1,567</strong> human targets with curated quantitative ligand interactions.</li> <li><strong>10,659</strong> ligands, <strong>7,884</strong> of which have curated quantitative target interactions.</li> <li><strong>1,614</strong> approved drugs, <strong>974</strong> with curated quantitative interactions.</li> <li>Clinical use summaries for over <strong>2,800</strong> ligands.</li> </ul> <div> <div class="block-editor-block-list__layout is-root-container"> <h3 id="block-7d846edf-2781-4642-991d-4041ef937373" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: Heading">Coronavirus</h3> <p id="block-a8bfc870-a808-4a35-94d3-f7f9d43c2faa" class="block-editor-rich-text__editable block-editor-block-list__block wp-block is-hovered rich-text" role="group" aria-multiline="true" aria-label="Paragraph block">The Guide to Pharmacology <a href="https://www.guidetopharmacology.org/coronavirus.jsp" target="_blank" rel="noreferrer noopener">coronavirus information page</a> continues to be updated on a regular basis to capture the latest pharmacological strategies under investigation to mitigate against COVID-19.</p> <p class="moz-quote-pre">We have curated some of the entities from the WHO list of COVID-related therapeutics that was released at the end of October: <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11320">alunacedase alfa</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11308">eclitasertib</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11307">enpatoran</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10737">molnupiravir</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11304">nezulcitinib</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11305">subasumstat</a>.</p> <h3 id="block-53a21c12-ad3e-47fe-b289-e491a29262b2" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: Heading">Curation Updates</h3> <p class="moz-quote-pre">There have been updates to the S1P and LPA receptor families, the bradykinin receptors family, and the S1P turnover enzymes. The <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=138">P-type ATPases</a> have been expanded and reorganised.</p> <p class="moz-quote-pre">A new family of transporters has been added, <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1048">SLC66 Lysosomal amino acid transporters</a>, and <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3165">cyclic GMP-AMP synthase (cGAS)</a> has been added as a new immunopharmacology target.</p> <h3 id="block-a7e13e77-527b-4530-92b4-1568e3413aa2" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: Heading">Website Updates</h3> <ul id="block-ebf0b7b3-d169-4924-9ac2-3cef9a6be6c3" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: List"> <li>We have started taking step to identify and and fix high-priority accessibility problems</li> <li>Links to <a href="https://www.antibioticdb.com/" target="_blank" rel="noreferrer noopener">AntibioticDB</a> now cover over 280 ligands.</li> </ul> <h3 id="block-d52fb3be-7e9f-42c0-8df5-4fb9d25b9402" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: Heading">Guide to Malaria Pharmacology (GtoMPdb)</h3> <p id="block-9b2743cd-3ca0-48c2-ac34-82960f513b21" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Paragraph block">These are the recent advancements made in the GtoMPdb for this database release:</p> <ul id="block-01daa642-92bb-4e11-9090-8a4f8cd27e6a" class="block-editor-rich-text__editable block-editor-block-list__block wp-block rich-text" role="group" aria-multiline="true" aria-label="Block: List"> <li>The <a href="http://guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=970">Antimalarial targets family</a> and the <a href="http://guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=999">Antimalarial ligands family</a> have been updated, giving a total of 33 <em>P. falciparum</em> (3D7) targets and 100 ligands tagged as antimalarial in the database.</li> </ul> <div class="block-list-appender wp-block"> </div> </div> </div> </div> </div> </div> </div> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/coronavirus/" rel="tag">coronavirus</a>, <a href="https://blog.guidetopharmacology.org/tag/immunopharmacology/" rel="tag">immunopharmacology</a>, <a href="https://blog.guidetopharmacology.org/tag/malaria/" rel="tag">malaria</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/technical/" rel="category tag">Technical</a> </div> </div> <div id="post-4116" class="post-4116 post type-post status-publish format-standard hentry category-database-updates tag-2020-4 tag-database-release tag-oncology-targets tag-who-essential-medicines"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2020/09/24/database-release-2020-4/" rel="bookmark">Database Release 2020.4</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2020/09/24/database-release-2020-4/" title="11:44 am" rel="bookmark"><span class="timestamp">September 24, 2020</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2020/09/24/database-release-2020-4/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>The latest release of the Guide to PHARMACOLOGY database, version 2020.4, has now been made. </p> <h3 class="wp-block-heading">Coronavirus</h3> <p>The Guide to Pharmacology <a rel="noreferrer noopener" href="https://www.guidetopharmacology.org/coronavirus.jsp" target="_blank">coronavirus information page</a> continues to be updated on a regular basis to capture the latest pharmacological strategies under investigation to mitigate against COVID-19. </p> <p>GtoPdb curates <a rel="noreferrer noopener" href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1034" target="_blank">Coronavirus (CoV) proteins</a> under viral protein targets in our hierarchy. This family contains 15 CoV proteins. Updates in this release to the CoV 3C-like (main) protease include outlinks to CHEMBL (CHEMBL3927) and UniProt (P0C6U8); the addition of 4 further <a rel="noreferrer noopener" href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3111&familyId=1034&familyType=OTHER#PDBStructures" target="_blank">3D structures</a> (3VB3, 2GX4, 6LZE and 6XHL) and and additional 19 <a rel="noreferrer noopener" href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3111&familyId=1034&familyType=OTHER#Inhibitors" target="_blank">curated ligand interactions</a>.</p> <h3 class="wp-block-heading">Curation Updates</h3> <p>We’ve added some new targets proteins along with associated pharmacological ligands. These include the following five, that are all oncology targets:</p> <ul class="wp-block-list"><li><a rel="noreferrer noopener" href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3136" target="_blank">MDM2 proto-oncogene</a></li><li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1041#3134" target="_blank" rel="noreferrer noopener">Ser/Thr protein phosphatase PPM1D</a></li><li><a rel="noreferrer noopener" href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3133" target="_blank">cytidine deaminase/CDA</a></li><li><a rel="noreferrer noopener" href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3145" target="_blank">porcupine O-acyltransferase</a></li><li><a rel="noreferrer noopener" href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1043#3148" target="_blank">HIF-2α</a> (EPAS1) </li></ul> <p>Also added is <a rel="noreferrer noopener" href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3135" target="_blank">C-type lectin receptor CLEC4C</a>, an anti-inflammatory target, and <a rel="noreferrer noopener" href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3144" target="_blank">N-acetyltransferase 8 like</a> (ANAT), a target for the treatment of Canavan disease which is a rare aspartoacylase deficiency-mediated neurodegenerative condition.<br><br>The list of <a href="https://www.guidetopharmacology.org/GRAC/LigandListForward?type=WHO-essential&database=all">WHO essential medicines</a> has been expanded with the inclusion of many antibiotics and antivirals.</p> <p>Overall this release sees updates made to targets across 35 targets families. These are listed below with links to family page in the database: </p> <p><strong>GPCRs</strong><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=3">Adenosine receptors</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=10">Bradykinin receptors</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=12">Calcium-sensing receptor</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=5">Complement peptide receptors</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=20">Dopamine receptors</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=31">Gonadotrophin-releasing hormone receptors</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=48">Hydroxycarboxylic acid receptors</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=35">Leukotriene receptors</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=38">Melanocortin receptors</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=39">Melatonin receptors</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=41">Motilin receptor</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=44">Neuropeptide S receptor</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=47">Neurotensin receptors</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=57">Prolactin-releasing peptide receptor</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=54">QRFP receptor</a></p> <p><strong>Ion-Channels</strong><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=73">Glycine receptors</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=77">P2X receptors</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=81">Voltage-gated potassium channels</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=124">Voltage-gated proton channel</a></p> <p><strong>Catalytic Receptors</strong><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=939">Nitric oxide (NO)-sensitive (soluble) guanylyl cyclase</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=662">Transmembrane guanylyl cyclases</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=334">Tumour necrosis factor (TNF) receptor family</a></p> <p><strong>Enzymes</strong><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=273">N-Acylethanolamine turnover</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=944">2-Acylglycerol ester turnover</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=777">Sphingosine 1-phosphate lyase</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=778">Sphingosine 1-phosphate phosphatase</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=776">Sphingosine 1-phosphate turnover</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=787">Sphingosine kinase</a></p> <p><strong>Transporters</strong><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=179">Neutral amino acid transporter subfamily</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=186">SLC14 family of facilitative urea transporters</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=215">SLC28 family</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=216">SLC29 family</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=337">SLC51 family of steroid-derived molecule transporters</a><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=180">SLC8 family of sodium/calcium exchangers</a></p> <p><strong>Other Proteins</strong><br><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=894">R7 family of RGS proteins</a></p> <h3 class="wp-block-heading">Website Updates</h3> <ul class="wp-block-list"><li>We updated our <a rel="noreferrer noopener" href="https://www.guidetopharmacology.org/GuidetoPHARMACOLOGY_Tutorial.pdf" target="_blank">website tutorial</a>, which now includes details on the advanced search and ligand activity graphs</li><li>New download files are available from the immunological process and cell type target associations pages</li><li>A new GPCR targets download files is available on each of the <a rel="noreferrer noopener" href="https://www.guidetopharmacology.org/GRAC/GPCRListForward?class=A" target="_blank">GPCR list page</a> (example here for Class A)</li><li>Bug fixes for web services</li><li>Links to <a rel="noreferrer noopener" href="https://www.antibioticdb.com/" target="_blank">AntibioticDB</a> now cover over 230 ligands.</li></ul> <h3 class="wp-block-heading">Guide to Malaria Pharmacology (GtoMPdb)</h3> <p>These are the recent advancements made in the GtoMPdb for this database release:</p> <ul class="wp-block-list"><li>The <a href="http://guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=970">Antimalarial targets family</a> and the <a href="http://guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=999">Antimalarial ligands family</a> have been updated, giving a total of 33 <em>P. falciparum</em> (3D7) targets and 90 ligands tagged as antimalarial in the database.</li><li>We have added a new species page for <a href="https://www.guidetomalariapharmacology.org/GRAC/MalariaTargetSpeciesDisplayForward?speciesId=126" target="_blank" rel="noreferrer noopener"><i>P. knowlesi</i></a>.</li></ul> <p></p> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/2020-4/" rel="tag">2020.4</a>, <a href="https://blog.guidetopharmacology.org/tag/database-release/" rel="tag">database release</a>, <a href="https://blog.guidetopharmacology.org/tag/oncology-targets/" rel="tag">oncology targets</a>, <a href="https://blog.guidetopharmacology.org/tag/who-essential-medicines/" rel="tag">WHO essential medicines</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a> </div> </div> <div id="post-4104" class="post-4104 post type-post status-publish format-standard hentry category-hot-topics tag-drug-targets tag-hot-topic tag-pharmacology"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2020/09/02/hot-topics-soluble-ligands-as-drug-targets/" rel="bookmark">Hot Topics: Soluble ligands as drug targets</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2020/09/02/hot-topics-soluble-ligands-as-drug-targets/" title="8:35 am" rel="bookmark"><span class="timestamp">September 2, 2020</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2020/09/02/hot-topics-soluble-ligands-as-drug-targets/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>Historically, the main classes of drug targets have been receptors, enzymes, ion channels and transporters which are primarily targeted by small molecules. However, advances in molecular biology, genomics, and pharmacology have facilitated the development of different therapeutic modalities which in turn have broadened the types of drug targets. In particular, soluble ligands have growing interest as targets and now constitute 10% of novel targets in clinical trials and are currently the third-largest target class of therapeutic agents targeting human protein products, after enzymes and receptors [1].</p> <p>A new analysis of ligand-targeting [2], illustrates the different classes of ligand-targeting drugs and targets as well as analysing the success of the different technology platforms. This emerging class of drug targets is very dynamic with 291 agents that target 99 unique ligands reaching clinical development from 1992 to 2020. In the last five years, the number of ligand-targeting agents which are FDA-approved has doubled to 34, while the number of clinically validated ligand targets has doubled to 22. Therapeutic antibodies are the most common class of both approved and investigative ligand-targeting agents, followed by decoy receptors. Several technology platforms are successfully being developed, enhancing the opportunities of drug development using antibody fragments, single-domain antibodies, aptamers, spiegelmers, engineered protein scaffolds, gene therapy, therapeutic vaccines and oligonucleotides. There is an increase in the number of agents that target more than one ligand, as well as the number of unique combinations of ligands. Advances in engineering technology and the ability to effectively and safely target more than one ligand has combined with increased knowledge of disease pathways to effectively utilize bispecific antibodies and decoy receptors, amongst others, to selectively disrupt multiple biological pathways by blocking two (or more) related or unrelated ligands. Cytokines and growth factors are the predominant types of targeted ligands (70%), which is consistent with the three major disease groups being treated by both approved and investigational agents: inflammation and autoimmune diseases, cancer, and ophthalmological diseases.</p> <p>Several factors contribute to the increasing importance of soluble ligands as drug targets, including the growing understanding of the role of the immune system in many diseases in conjunction with the tractability of cytokines as therapeutic agents, and the relative accessibility of ligands in comparison to their receptors to therapeutic agents. Given the increasing body of evidence that inflammation is involved in many diseases beyond typical inflammation disorders and the position of ligand-targeting drugs at the forefront of anti-inflammatory therapies, there will be continued interest in this class of agents. Furthermore, there is vast territory to explore in the ligand target landscape, as there are almost 600 endogenous human peptides according to IUPHAR/BPS Guide to PHARMACOLOGY (<a href="https://www.guidetopharmacology.org">https://www.guidetopharmacology.org</a>) with approximately 150 of these identified as having specifically curated immunopharmacological data associated with them (IUPHAR Guide to IMMUNOPHARMACOLOGY: <a href="https://www.guidetoimmunopharmacology.org/immuno/">https://www.guidetoimmunopharmacology.org/immuno/</a>).</p> <p>In conclusion, ligands as a type of drug target now merit consideration as a distinct and expanding group of targets for a range of therapeutic modalities that can exert their effects through single targets or selected combinations.</p> <p><strong>Comments by Misty Attwood and <a href="https://www.guidetopharmacology.org/GRAC/ContributorDisplayForward?contributorId=311">Helgi Schiöth</a>, </strong>University of Uppsala, Uppsala, Sweden. Helgi Schiöth is Chair for NC-IUPHAR Subcommitees for <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=38">Melanocortin receptors</a> and <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=57">Prolactin-releasing peptide receptor</a>. Twitter: <a href="https://twitter.com/FunctPharm">@FunctPharm</a></p> <ol> <li>Attwood, M. M., Rask- Andersen, M. & Schiöth, H. B. Orphan drugs and their impact on pharmaceutical development. <em>Trends Pharmacol. Sci.</em> 39, 525–535 (2018). [<span class="citation-part">PMID: </span><span class="identifier pubmed"> <a href="https://pubmed.ncbi.nlm.nih.gov/29779531/">29779531</a></span>]</li> <li>Attwood, M.M., Jonsson, J., Rask-Andersen, M & Schiöth, H. B. Soluble ligands as drug targets. <em>Nature Reviews Drug Discovery.</em> <span class="ahead-of-print"> Online ahead of print</span> (2020 Sep 2.). [PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32873970/">32873970</a>]</li> </ol> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/drug-targets/" rel="tag">Drug targets</a>, <a href="https://blog.guidetopharmacology.org/tag/hot-topic/" rel="tag">hot topic</a>, <a href="https://blog.guidetopharmacology.org/tag/pharmacology/" rel="tag">pharmacology</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/hot-topics/" rel="category tag">Hot Topics</a> </div> </div> <div id="post-4097" class="post-4097 post type-post status-publish format-standard hentry category-database-updates tag-pre-release-ligands"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2020/08/03/gtopdb-pre-release-ligands-2020-4/" rel="bookmark">GtoPdb pre-release ligands (2020.4)</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2020/08/03/gtopdb-pre-release-ligands-2020-4/" title="12:06 pm" rel="bookmark"><span class="timestamp">August 3, 2020</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2020/08/03/gtopdb-pre-release-ligands-2020-4/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>These are some of the ligands under curation (pre-release) in the Guide to Pharmacology. We expect them to be available on the website at the next database release (2020.4).<strong><a name="10745"></a></strong></p> <p><strong><a name="11132"></a><span style="text-decoration:underline;">Ligand ID: 11132</span></strong></p> <p>Name: <strong>otilimab</strong></p><p>Comment: Otilimab (MOR103, GSK3196165) is a clinical stage fully human IgG1λ antibody that targets the granulocyte-macrophage colony-stimulating factor (GM-CSF; <i>CSF2</i>). It is being investigated as a therapeutic for inflammatory diseases. MOR103 was developed using MorphoSys’ HuCAL® technology, and has been fully out-licensed otilimab to GSK. MOR103 is claimed as MOR-04357 in patent WO2006122797A2 (by BLAST peptide sequence matching).</p> <hr /><p><strong><a name="11139"></a><span style="text-decoration:underline;">Ligand ID: 11139</span></strong></p> <p>Name: <strong>favipiravir</strong></p><p><img data-attachment-id="4102" data-permalink="https://blog.guidetopharmacology.org/2020/08/03/gtopdb-pre-release-ligands-2020-4/attachment/11139/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/08/11139.gif" data-orig-size="142,107" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="11139" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/08/11139.gif?w=142" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/08/11139.gif?w=142" loading="lazy" class="alignnone size-full wp-image-4102" src="https://blog.guidetopharmacology.org/wp-content/uploads/2020/08/11139.gif" alt="11139" width="142" height="107" /></p><p>Comment: Favipiravir (T-705) is an orally delivered, guanine (purine) analogue antiviral drug (<i>cf.</i> <a href="https://dev.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10715">remdesivir</a> which is administered <i>i.v.</i>). It targets viral RNA-dependent RNA polymerase (RdRP) of RNA viruses and since the catalytic domain of RdRP is well conserved across species, has a broad-spectrum of activity; although Furuta <i>et al</i>. (2002) reported that actvity was weak against non-influenza virus RNA viruses [<a title="4. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y et al.. (2002) Antimicrob. Agents Chemother. 46 (4): 977-81">4</a>]. Favipiravir was originally identified through a chemical library screen against influenza virus RdRP [<a title="3. Furuta Y, Komeno T, Nakamura T. (2017) Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci. 93 (7): 449-463">3</a>]. Chemically, it is a prodrug. In human cells it undergoes phosphoribosylation and phosphorylation to its active form, favipiravir-ribofuranosyl-5′-triphosphate (F-RTP). F-RTP is bound by the RdRP, but it blocks enzyme activity and so terminates chain elongation [<a title="5. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. (2005) Antimicrob. Agents Chemother. 49 (3): 981-6; 6. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Le QM, Ozawa M, Furuta Y, Kawaoka Y. (2010) Proc. Natl. Acad. Sci. U.S.A. 107 (2): 882-7">5-6</a>].</p><p>IUPAC Name: 5-fluoro-2-oxo-1H-pyrazine-3-carboxamide</p><figure class="wp-block-image is-resized"></figure> <hr /> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/pre-release-ligands/" rel="tag">pre-release ligands</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a> </div> </div> <div id="post-4092" class="post-4092 post type-post status-publish format-standard hentry category-hot-topics tag-hot-topic tag-pharmacology"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2020/07/08/hot-topics-tmem163-regulates-atp-gated-p2x-receptor-and-behaviour/" rel="bookmark">Hot Topics: TMEM163 regulates ATP-gated P2X receptor and behaviour</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2020/07/08/hot-topics-tmem163-regulates-atp-gated-p2x-receptor-and-behaviour/" title="6:53 am" rel="bookmark"><span class="timestamp">July 8, 2020</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2020/07/08/hot-topics-tmem163-regulates-atp-gated-p2x-receptor-and-behaviour/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>It is now clear that ligand-gated ion channels (LGICs) are not “stand alone” functional units, but form complexes with other components, including scaffolding proteins, regulatory proteins and enzymes. Besides their important physiological roles, these modulating proteins are also potential targets for drug discovery. <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=77">P2X receptors</a> are LGICs for which ATP is the endogenous agonist. Seven P2X subunits have been identified and they form trimers to produce at least twelve different receptor subtypes. Here, the authors combined a genome-wide open reading frame (ORF) collection with high-throughput functional screening, to search for P2X receptor modulators.</p> <p>They first created a HEK-293 cell line that stably expressed human <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=479&familyId=77&familyType=IC">P2X2</a> plus <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=480&familyId=77&familyType=IC">P2X3</a> receptors, then one-by-one, co-expressed each of 17,284 non-redundant ORFs, which represents 90% of the known human protein-coding genes. They then compared the rise in intracellular [Ca<sup>2+</sup>] induced by the P2X3 agonist <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4093">α,β-meATP</a>, using a composite score of four measurements; 1) baseline, 2) peak and 3) steady-state [Ca<sup>2+</sup>], along with 4) time-course of the decay of the peak. The highest scoring ORFs were then co-expressed with P2X3 receptors in <em>Xenopus laevis</em> oocytes and their effects on ATP-induced ion currents determined. This process led to <a href="https://www.uniprot.org/uniprot/Q8TC26">TMEM163</a> being identified as a modulator of P2X3 receptors.</p> <p>TMEM163 comprises 289 amino acids, with a molecular weight of 31 kDa and predicted secondary structure of six transmembrane-spanning domains with intracellular NH<sub>2</sub>– and COOH-termini. When expressed on its own, TMEM163 had no ATP-dependent activity and when co-expressed, had no effect on the activity of AMPA, kainate, muscarinic or P2X2 receptors, nor on endogenous P2Y receptors in HEK-293 cells. It did, however, potentiate ATP-evoked currents mediated by <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=478&familyId=77&familyType=IC">P2X1</a> and <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=481&familyId=77&familyType=IC">P2X4</a> receptors and conversely, inhibited currents carried by <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=484&familyId=77&familyType=IC">P2X7</a> receptors. Thus TMEM163 appears to selectively modulate P2X receptor activity, but in a subtype-specific manner.</p> <p>More detailed analysis of its actions showed that TMEM163 potentiated P2X3 receptors by shifting the ATP concentration-response curve (CRC) to the left, with a five-fold decrease in the EC<sub>50</sub> and slowing the time-course of current decay. Surprisingly, it also substantially reduced the surface expression of P2X3 receptors. In contrast, the inhibitory effects on P2X7 receptors were associated with a decrease in both the potency of ATP and surface expression of the receptor.</p> <p>Next, the expression and effects of native TM163 was investigated in mice. <em>In situ</em> hybridisation and an anti-TM163 antibody showed TMEM163 to be present in primary cultures of mouse cerebellar neurones. Infection with a TMEM163 shRNA reduced protein expression by almost half and the peak amplitude of ATP-induced ion currents by a third. The effect on P2X3 receptor protein levels was not reported, however. To study its role <em>in vivo</em>, TMEM163 was knocked-out using CRISPR/Cas9 and pain-associated behaviour induced by ATP injection into the hind-paw studied. There was no difference in paw lifting between wild-type and knock-out mice, but freezing behaviour was reduced by about 50%. Notably, and in contrast to the data obtained using recombinant TMEM163, the total amount of P2X3 protein in dorsal root ganglion was unchanged. The ATP CRC was, however, shifted about five-fold to the right by TMEM163 knock-out, consistent with the leftwards shift seen using the recombinant proteins.</p> <p>By showing that that TMEM163 selectively modulates P2X receptor activity and in a subtype-specific manner, this study greatly improves our understanding of how native P2X receptors function. As such, TMEM163 is potentially a new target for drug discovery.</p> <p><strong>Comments by <a href="https://www.guidetopharmacology.org/GRAC/ContributorDisplayForward?contributorId=297">Charles Kennedy</a></strong>, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK. Chair for NC-IUPHAR Subcommitee for <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=77">P2X receptors</a>.</p> <ol> <li>Salm EJ, Dunn PJ, Shan L, Yamasaki M, Malewicz NM, Miyazaki T, Park J, Sumioka A, Hamer RRL, He WW, Morimoto-Tomita M, LaMotte RH, Tomita S. (2020). TMEM163 regulates ATP-gated P2X receptor and behaviour. Cell Rep, 31: 107704. PMID: <span class="identifier pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32492420/">32492420</a>.</span></li> </ol> <p> </p> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/hot-topic/" rel="tag">hot topic</a>, <a href="https://blog.guidetopharmacology.org/tag/pharmacology/" rel="tag">pharmacology</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/hot-topics/" rel="category tag">Hot Topics</a> </div> </div> <div id="post-4067" class="post-4067 post type-post status-publish format-standard hentry category-technical category-tutorials-and-guides tag-essential-medicines tag-guide tag-tutorial tag-who"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2020/06/26/accessing-who-essential-medicines-in-gtopdb/" rel="bookmark">Accessing WHO Essential Medicines in GtoPdb</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2020/06/26/accessing-who-essential-medicines-in-gtopdb/" title="12:34 pm" rel="bookmark"><span class="timestamp">June 26, 2020</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2020/06/26/accessing-who-essential-medicines-in-gtopdb/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>The Guide to Pharmacology (GtoPdb) currently contains data on over 10,000 different ligands which are categorised into an number of different groups or classifications. The <a href="https://www.guidetopharmacology.org/GRAC/LigandListForward?type=WHO-essential&database=all" target="_blank" rel="noopener">ligand list page</a> (<a href="https://www.guidetopharmacology.org/GRAC/LigandListForward?type=WHO-essential&database=all" target="_blank" rel="noopener">https://www.guidetopharmacology.org/GRAC/LigandListForward?type=WHO-essential&database=all</a>) provides a directory of all the ligands described in the database, divided into subsets according to chemical category.</p> <p>We have recently added a WHO Essential Medicine subset, which contains ligands in GtoPdb that are also in the latest WHO Model List of Essential Medicines (21st list, 2019) (<a href="https://www.who.int/medicines/publications/essentialmedicines/en/" target="_blank" rel="noopener">https://www.who.int/medicines/publications/essentialmedicines/en/</a>). This totals 224 ligands in our 2020.3 release.</p> <p>Selecting the WHO tab from the ligand list page shows this subset (Figure 1). Users can also download this set of ligands (as csv file) by clicking on the link in the top-right.</p> <p><div data-shortcode="caption" id="attachment_4064" style="width: 748px" class="wp-caption alignnone"><img aria-describedby="caption-attachment-4064" data-attachment-id="4064" data-permalink="https://blog.guidetopharmacology.org/2020/06/19/database-release-2020-3/who_list/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/who_list.png" data-orig-size="1432,568" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="who_list" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/who_list.png?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/who_list.png?w=605" loading="lazy" class=" wp-image-4064 alignnone" style="color:var(--color-text);font-size:1rem;" src="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/who_list.png" alt="who_list" width="738" height="293" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/who_list.png?w=738&h=293 738w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/who_list.png?w=150&h=59 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/who_list.png?w=300&h=119 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/who_list.png?w=768&h=305 768w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/who_list.png?w=1024&h=406 1024w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/who_list.png 1432w" sizes="(max-width: 738px) 100vw, 738px" /><p id="caption-attachment-4064" class="wp-caption-text"><br />Figure 1. GtoPdb ligand list page showing WHO subset. <a href="https://www.guidetopharmacology.org/GRAC/LigandListForward?type=WHO-essential&database=all" rel="nofollow">https://www.guidetopharmacology.org/GRAC/LigandListForward?type=WHO-essential&database=all</a></p></div></p> <p><strong>Accessing WHO tagged GtoPdb compound in PubChem</strong></p> <p>GtoPdb regularly uploads its set of co<span style="color:var(--color-text);font-size:1rem;">mpounds to PubChem, which provides all GtoPdb ligands with PubChem Substance Identifiers (SIDs), which are in turn mapped (by PubChem) to PubChem Compound Identifiers (CIDs). As part of our PubChem upload process we have developed our curatorial tagging within the depositor comment sections in the substance records (SIDs). This means users are able to make domain-specific queries, to be executed from both the PubChem Substance (SID) and PubChem Compound (CID) interfaces, by using an advanced search of ‘comments’ fields.</span></p> <p>We have now added a WHO tag to the comments fields in our PubChem upload (see example for cholorquine, Figure 2). <img data-attachment-id="4081" data-permalink="https://blog.guidetopharmacology.org/2020/06/26/accessing-who-essential-medicines-in-gtopdb/chloroquine2/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/chloroquine2.png" data-orig-size="941,642" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="chloroquine2" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/chloroquine2.png?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/chloroquine2.png?w=605" loading="lazy" class=" wp-image-4081 aligncenter" src="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/chloroquine2.png" alt="chloroquine2" width="576" height="393" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/chloroquine2.png?w=576&h=393 576w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/chloroquine2.png?w=150&h=102 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/chloroquine2.png?w=300&h=205 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/chloroquine2.png?w=768&h=524 768w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/chloroquine2.png 941w" sizes="(max-width: 576px) 100vw, 576px" /></p> <p>Figure 2. Depositor comment for Chloroquine (PubChem Substance ID 178102177) showing GtoPdb curatorial tagging to mark substance as included in WHO Essential Medicines List. <a href="https://pubchem.ncbi.nlm.nih.gov/substance/178102177#section=Depositor-Comments" rel="nofollow">https://pubchem.ncbi.nlm.nih.gov/substance/178102177#section=Depositor-Comments</a></p> <p>Therefore it is now possible, through the query below to easily access the WHO Essential Medicines in GtoPdb through PubChem.</p> <p><strong><em><a href="https://www.ncbi.nlm.nih.gov/pcsubstance?term=(%22iuphar%2Fbps%20guide%20to%20pharmacology%22%5BSourceName%5D)%20AND%20%22gtopdb%20who%22%5BComment%5D" target="_blank" rel="noopener">https://www.ncbi.nlm.nih.gov/pcsubstance?term=(%22iuphar%2Fbps%20guide%20to%20pharmacology%22%5BSourceName%5D)%20AND%20%22gtopdb%20who%22%5BComment%5D</a></em></strong></p> <p><div data-shortcode="caption" id="attachment_4082" style="width: 1192px" class="wp-caption aligncenter"><img aria-describedby="caption-attachment-4082" data-attachment-id="4082" data-permalink="https://blog.guidetopharmacology.org/2020/06/26/accessing-who-essential-medicines-in-gtopdb/pubchem_gtopdb_who/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/pubchem_gtopdb_who.png" data-orig-size="1182,915" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="pubchem_gtopdb_who" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/pubchem_gtopdb_who.png?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/pubchem_gtopdb_who.png?w=605" loading="lazy" class=" size-full wp-image-4082 aligncenter" src="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/pubchem_gtopdb_who.png" alt="pubchem_gtopdb_who" width="1182" height="915" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/pubchem_gtopdb_who.png 1182w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/pubchem_gtopdb_who.png?w=150&h=116 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/pubchem_gtopdb_who.png?w=300&h=232 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/pubchem_gtopdb_who.png?w=768&h=595 768w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/pubchem_gtopdb_who.png?w=1024&h=793 1024w" sizes="(max-width: 1182px) 100vw, 1182px" /><p id="caption-attachment-4082" class="wp-caption-text"><br />Figure 3. Search result in PubChem for IUPHAR/BPS Guide to PHARMACOLOGY substances that include ‘gtopdb_who’ in the comments. <a href="https://www.ncbi.nlm.nih.gov/pcsubstance/?term=(%22iuphar%2Fbps+guide+to+pharmacology%22%5BSourceName%5D)+AND+%22gtopdb+who%22%5BComment%5D" rel="nofollow">https://www.ncbi.nlm.nih.gov/pcsubstance/?term=(%22iuphar%2Fbps+guide+to+pharmacology%22%5BSourceName%5D)+AND+%22gtopdb+who%22%5BComment%5D</a></p></div></p> <p> </p> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/essential-medicines/" rel="tag">essential medicines</a>, <a href="https://blog.guidetopharmacology.org/tag/guide/" rel="tag">guide</a>, <a href="https://blog.guidetopharmacology.org/tag/tutorial/" rel="tag">tutorial</a>, <a href="https://blog.guidetopharmacology.org/tag/who/" rel="tag">WHO</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/technical/" rel="category tag">Technical</a>, <a href="https://blog.guidetopharmacology.org/category/tutorials-and-guides/" rel="category tag">Tutorials and Guides</a> </div> </div> <div id="post-4048" class="post-4048 post type-post status-publish format-standard hentry category-database-updates category-technical tag-antibiotic tag-coronavirus"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2020/06/19/database-release-2020-3/" rel="bookmark">Database Release 2020.3</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2020/06/19/database-release-2020-3/" title="3:03 pm" rel="bookmark"><span class="timestamp">June 19, 2020</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2020/06/19/database-release-2020-3/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>The latest release of the Guide to PHARMACOLOGY database, version 2020.3, has now been made. A large focus of our curation over the last couple of month since our <a href="_wp_link_placeholder">2020.2 release</a> We are pleased to have been able to make an expeditious database release (version 2020.2), following on from our last update in March 2020 in order to make public new curation specifically related to SARS-CoV-2.</p> <h2>Coronavirus</h2> <p>The Guide to Pharmacology <a href="https://www.guidetopharmacology.org/coronavirus.jsp" target="_blank" rel="noopener">coronavirus information page</a> continues to be updated on a regular basis to capture the latest pharmacological strategies under investigation to mitigate against COVID-19.</p> <p>Recently published in BJP is our review that “<em>sets out to identify opportunities for drug discovery in the treatment of COVID‐19 and in so doing, provide a rational roadmap whereby pharmacology and pharmacologists can mitigate against the global pandemic</em>“:</p> <p>Alexander SPH, Armstrong J, Davenport AP, Davies JA, Faccenda E, Harding SD, Levi-Schaffer F, Maguire JJ, Pawson AJ, Southan C, Spedding MJ. (2020). <b>A rational roadmap for SARS‐CoV‐2/COVID‐19 pharmacotherapeutic research and development. IUPHAR Review 29</b> <a href="https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bph.15094" target="_blank" rel="noopener"><i>Br J Pharmacol.</i> doi: 10.1111/bph.15094. </a> [PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/32358833/" target="_blank" rel="noopener">32358833</a>]</p> <h2>Content Updates</h2> <p><strong>Main target families with updated in this release:</strong></p> <p>GPCRs</p> <ul> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=14">Chemokine receptors</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=19">Corticotropin-releasing factor receptors</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=20">Dopamine receptors</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=23">Formylpeptide receptors</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=29">Glucagon receptor family</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=33">Histamine receptors</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=135">Lysophospholipid (S1P) receptors</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=50">Opioid receptors</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=59">Proteinase-activated receptors</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=65">Urotensin receptor</a></li> </ul> <p>Ion Channels</p> <ul> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=119">Aquaporins</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=129">CFTR</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=72">GABA<sub>A</sub> receptors</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=82">Voltage-gated sodium channels</a></li> </ul> <p>NHRs</p> <ul> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=86">Peroxisome proliferator-activated receptors</a></li> </ul> <p>Enzymes, Catalytic Receptors</p> <ul> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=285">Akt (Protein kinase B, PKB) family</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=507">Beta-adrenergic receptor kinases (âARKs)</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=738">M10: Matrix metallopeptidase</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=273"><i>N</i>-Acylethanolamine turnover;</a> in particular <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1398" target="_blank" rel="noopener"><i>N</i>-Acylphosphatidylethanolamine-phospholipase D</a> has had 4 inhibitor compounds added</li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=897">RAS subfamily</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=316">Toll-like receptor family</a></li> </ul> <p><strong>New drug target<br /> </strong></p> <p><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3128" target="_blank" rel="noopener">Acyl-CoA synthetase short chain family member 2</a> (ACSS2) is an emerging oncology drug target that plays a role in epithelial-mesenchymal transition (EMT) and cancer cell metastasis. Two ACSS2 inhibitor probe compounds have been curated.</p> <p><strong>AntibioticDB</strong></p> <p>As part of a collaboration with <a href="https://www.antibioticdb.com/" target="_blank" rel="noopener">AntibioticDB</a> (<a href="https://www.antibioticdb.com/" rel="nofollow">https://www.antibioticdb.com/</a>), we have now begun to identify and tag sets of antibiotic ligands in GtoPdb. Where we have identified mappings between these and compounds in the AntibioticDB repository, we’ve put in place direct links. The newly curated set includes approved and investigational antibiotics and pre-clinical leads, as well as compounds whose development has been discontinued.</p> <p><div data-shortcode="caption" id="attachment_4062" style="width: 1062px" class="wp-caption alignnone"><img aria-describedby="caption-attachment-4062" data-attachment-id="4062" data-permalink="https://blog.guidetopharmacology.org/2020/06/19/database-release-2020-3/teixobactin/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/teixobactin.png" data-orig-size="1052,1021" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="teixobactin" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/teixobactin.png?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/teixobactin.png?w=605" loading="lazy" class="alignnone size-full wp-image-4062" src="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/teixobactin.png" alt="teixobactin" width="1052" height="1021" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/teixobactin.png 1052w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/teixobactin.png?w=150&h=146 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/teixobactin.png?w=300&h=291 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/teixobactin.png?w=768&h=745 768w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/teixobactin.png?w=1024&h=994 1024w" sizes="(max-width: 1052px) 100vw, 1052px" /><p id="caption-attachment-4062" class="wp-caption-text">Teixobactin ligand summary page (<a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10972" rel="nofollow">https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10972</a>). At the bottom, a new specialist database link now existing to the mapped entry in AntibioticDB.</p></div></p> <h2>Website Updates</h2> <h4>Ligand Summary Pages</h4> <p>The layout of the ligand summary pages has been changed to hopefully provide more of the key information on a ligand at the top of these pages. In the example below we show how this looks for <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5535" target="_blank" rel="noopener">chloroquine</a>.</p> <h4><img data-attachment-id="4063" data-permalink="https://blog.guidetopharmacology.org/2020/06/19/database-release-2020-3/chloroquine/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/chloroquine.png" data-orig-size="1049,479" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="chloroquine" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/chloroquine.png?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/chloroquine.png?w=605" loading="lazy" class="alignnone size-full wp-image-4063" style="color:var(--color-text);font-size:1rem;font-weight:400;" src="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/chloroquine.png" alt="chloroquine" width="1049" height="479" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/chloroquine.png 1049w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/chloroquine.png?w=150&h=68 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/chloroquine.png?w=300&h=137 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/chloroquine.png?w=768&h=351 768w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/chloroquine.png?w=1024&h=468 1024w" sizes="(max-width: 1049px) 100vw, 1049px" /></h4> <p>The main information box now contains:</p> <ul> <li>Synonyms</li> <li>Icons to indicate key ligand classifications</li> <li>Drug approval indication</li> <li>GtoPdb curator comments</li> <li>Link to ligand activity graphs</li> </ul> <p>In addition, the 2D ligand structure is display beside this information in a expandable/retractable section where users can also view physico-chemical properties and SMILES/InChI/InChI Keys.</p> <p>Previously the top part of the ligand summary pages contained too much white space, repetitions of the ligand name and emphasised the ligand ID, physico-chemical properties and to some extent buried comments, SMILES/InChI keys and useful links (such as to the ligand activity graphs).</p> <p>The reorganisation of the page now emphasises key information. GtoPdb curator comments in particular contain a valuable description of the ligand and provide explanations as to why they have been curated in GtoPdb.</p> <p><strong>WHO essential medicines</strong></p> <p>Any ligands included in the World Health Organization (WHO) Model List of Essential Medicines (21st list, 2019) are now tagged in GtoPdb. This means users can easily view these ligands on our ligand list page:</p> <p><a href="https://www.guidetopharmacology.org/GRAC/LigandListForward?type=WHO-essential&database=all" target="_blank" rel="noopener">https://www.guidetopharmacology.org/GRAC/LigandListForward?type=WHO-essential&database=all</a></p> <p>It is also possible, as it is for all ligand lists, to download this set from this page by clicking the download link in the top-right of the table (see below).</p> <p><img data-attachment-id="4064" data-permalink="https://blog.guidetopharmacology.org/2020/06/19/database-release-2020-3/who_list/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/who_list.png" data-orig-size="1432,568" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="who_list" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/who_list.png?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/who_list.png?w=605" loading="lazy" class="alignnone size-full wp-image-4064" src="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/who_list.png" alt="who_list" width="1432" height="568" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/who_list.png 1432w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/who_list.png?w=150&h=59 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/who_list.png?w=300&h=119 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/who_list.png?w=768&h=305 768w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/who_list.png?w=1024&h=406 1024w" sizes="(max-width: 1432px) 100vw, 1432px" /></p> <h2>Other Updates</h2> <h4>ChEMBL 27</h4> <p>Both the ligand activity graphs and pharmacology search tools have now been updated to access the latest ChEMBL release (ChEMBL 27).</p> <p><strong>Links to DrugCentral 2020</strong></p> <p>We have added links to the DrugCentral 2020 Online Drug Compendium. DrugCentral provides information on active ingredients chemical entities, pharmaceutical products, drug mode of action, indications, pharmacologic action. It monitors FDA, EMA, and PMDA for new drug approval on regular basis to ensure currency of the resource. Limited information on discontinued and drugs approved outside US is also available however regulatory approval information can’t be verified. The database is developed and maintained by Oleg Ursu and Tudor Oprea and the web application is developed by Jayme Holmes.</p> <p>We have so far mapped 1433 ligands in GtoPdb to entries in DrugCentral.</p> <p> </p> <p> </p> <p> </p> <p> </p> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/antibiotic/" rel="tag">antibiotic</a>, <a href="https://blog.guidetopharmacology.org/tag/coronavirus/" rel="tag">coronavirus</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/technical/" rel="category tag">Technical</a> </div> </div> <div id="post-3972" class="post-3972 post type-post status-publish format-standard hentry category-hot-topics tag-gpcrs"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2020/05/17/hot-topics-a-gpcr-triple-for-peptides/" rel="bookmark">Hot Topics: A trio of GPCR peptide publications</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2020/05/17/hot-topics-a-gpcr-triple-for-peptides/" title="6:07 am" rel="bookmark"><span class="timestamp">May 17, 2020</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2020/05/17/hot-topics-a-gpcr-triple-for-peptides/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>This post covers three recent publications with a common theme and whose authors are collaborators with GtoPdb, thus making them as a trio particularly suitable for combined review. These are; <em>Discovery of Human Signaling Systems: Pairing Peptides to G Protein-Coupled Receptors </em>[1], <em>Novel approaches leading towards peptide GPCR de-orphanisation </em>[2] , and <em>Advances in therapeutic peptides targeting G protein-coupled receptors </em>[3]. As expected, these are all clearly written, contain valuable detail and each includes its own introduction. Therefore this piece does not need to go over these works <em>per se</em> but simply point out their coverage, domain of application, along with brief explanations of entity linking and/or external look-up options.</p> <p>For context, it should be pointed out that historical success in de-orphanising GPCRs (i.e. reproducibly pairing them with physiologically-relevant endogenous ligands) has been difficult and slow. This remains so, despite decades of intense effort from not only all major pharmaceutical companies but also academic groups utilising various flavours of de-orphanistaion screening approaches and technologies. This was pursued in parallel with cloning (and patenting) the complete repertoire of human GPCRs as they slowly came into view. Initially done via mining millions of expressed sequence tag (EST) transcripts in the mid 90’s, this later shifted focus to genomic DNA surfacing between appropriately 1998 and 2000. The modest progress even after the completion of the draft human genome can be discerned from the table below compiled in 2000 [4].</p> <p><img data-attachment-id="3981" data-permalink="https://blog.guidetopharmacology.org/2020/05/17/hot-topics-a-gpcr-triple-for-peptides/capture-10/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture.jpg" data-orig-size="509,389" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"cdsoutharn","camera":"","caption":"","created_timestamp":"1589754517","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="Capture" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture.jpg?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture.jpg?w=509" loading="lazy" class=" size-full wp-image-3981 aligncenter" src="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture.jpg" alt="Capture" width="509" height="389" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture.jpg 509w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture.jpg?w=150&h=115 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture.jpg?w=300&h=229 300w" sizes="(max-width: 509px) 100vw, 509px" /></p> <p>Progress ~ 2000- 2018 is outlined both in Concise Guide 2019/20 : G Protein-Coupled Receptors (<a href="https://www.ncbi.nlm.nih.gov/pubmed/31710717">PMID: 31710717</a>) [5] and in the Guide to Pharmacology <a href="https://www.guidetopharmacology.org/latestPairings.jsp">latest parings list </a>.</p> <p>As the first of this trio of papers, Foster et al. [1] have significantly advanced the de-orphanisation field in 2019 by integrating computational and experimental approaches for peptide-GPCR pairings. They began with comparative sequence and structural analyses to gain biological insights into the human peptide-receptor signalling landscape. They were then able to leverage these features to mine candidate peptide ligands from the entire human genome, arranged for these to be synthesised and then tested for activity in a broad range of pairing assays that included known ligands as positive controls. The impressive scope of results is indicated in their Fig 7 (below).</p> <p><img data-attachment-id="3991" data-permalink="https://blog.guidetopharmacology.org/2020/05/17/hot-topics-a-gpcr-triple-for-peptides/capture-12/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-2.jpg" data-orig-size="827,846" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"cdsoutharn","camera":"","caption":"","created_timestamp":"1589843470","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="Capture" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-2.jpg?w=293" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-2.jpg?w=605" loading="lazy" class="alignnone size-full wp-image-3991" src="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-2.jpg" alt="Capture" width="827" height="846" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-2.jpg 827w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-2.jpg?w=147&h=150 147w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-2.jpg?w=293&h=300 293w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-2.jpg?w=768&h=786 768w" sizes="(max-width: 827px) 100vw, 827px" /></p> <p>In summary, the 53 peptides with validated receptor-dependent responses first reported in this paper, has expanded the known human peptidergic signaling network from 348 to 407 interactions. It is also important to note that they were unable to reproduce no less than six reported parings in the literature from 2004 to 2016 (i.e. those de-orphanisations could not be verified).</p> <p>In collaboration with the Copenhagen crew, this paper was curated by the GtoPdb team according to their target mapping stringency and potency thresholds. Consequently, 11 new peptides have been annotated with the quantitative ligand binding data reported for the newly de-orphanised receptors. These are shown below with their PubChem <a href="https://www.ncbi.nlm.nih.gov/pcsubstance?LinkName=pubmed_pcsubstance&from_uid=31675498">Substance Links</a> (SIDs) for which <a href="https://www.ncbi.nlm.nih.gov/pcsubstance?term=%22IUPHAR%2FBPS%20Guide%20to%20PHARMACOLOGY%22%5BSourceName%5D%20AND%20hasnohold%5Bfilt%5D">GtoPdb</a> (so far) has becomes the only source of these compound structures (CIDs) from <a href="https://pubchem.ncbi.nlm.nih.gov/source/">over 730</a> submitters.</p> <p><img data-attachment-id="3986" data-permalink="https://blog.guidetopharmacology.org/2020/05/17/hot-topics-a-gpcr-triple-for-peptides/capture-11/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-1.jpg" data-orig-size="786,663" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"cdsoutharn","camera":"","caption":"","created_timestamp":"1589831262","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="Capture" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-1.jpg?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-1.jpg?w=605" loading="lazy" class="alignnone size-full wp-image-3986" src="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-1.jpg" alt="Capture" width="786" height="663" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-1.jpg 786w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-1.jpg?w=150&h=127 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-1.jpg?w=300&h=253 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-1.jpg?w=768&h=648 768w" sizes="(max-width: 786px) 100vw, 786px" />In <a href="https://pubchem.ncbi.nlm.nih.gov/">PubChem</a> these can be accessed by scrolling down to “Related information” on the lower right hand facet of <a href="https://www.ncbi.nlm.nih.gov/pubmed/31675498">PMID: 31675498</a> and clicking on “PubChem Substance”. Each entry has a pointer back to GtoPdb from the SID and the nomenclature of the peptides matches that used in the paper. However, users wanting to select these entries from within GtoPdb can go to <a href="https://www.guidetopharmacology.org/GRAC/chemSearch.jsp">Ligand Search Tools</a> > Search for data by literature reference > Enter PubMed Id: 31675498 > Select field to search: PubMed ID. This brings back 16 entries since it includes the 11 ligands above plus the five receptors for which binding data was curated (n.b. these instructions apply to the old PubMed interface, so some of this may change for the new interface). While the version of the article in <em>Cell</em> journal itself has no entity outlinks (except for references) the PubMed Central version has automatically linked the PDB IDs. All the GPCR protein/gene names should retrieve in GtoPdb or of course <a href="https://gpcrdb.org/">GPCRdb</a></p> <p>The second article in the trio is a review by Hauser et al [2]. This covers some of the same ground as above but includes an assessment of contemporary methodologies of de‐orphanisation. The informative Figure 1, summarising extensive data mining, is shown below.</p> <p><img data-attachment-id="3997" data-permalink="https://blog.guidetopharmacology.org/2020/05/17/hot-topics-a-gpcr-triple-for-peptides/capture-13/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-3.jpg" data-orig-size="974,752" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"cdsoutharn","camera":"","caption":"","created_timestamp":"1589899997","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="Capture" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-3.jpg?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-3.jpg?w=605" loading="lazy" class="alignnone size-full wp-image-3997" src="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-3.jpg" alt="Capture" width="974" height="752" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-3.jpg 974w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-3.jpg?w=150&h=116 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-3.jpg?w=300&h=232 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-3.jpg?w=768&h=593 768w" sizes="(max-width: 974px) 100vw, 974px" /></p> <p>In addition to indicating the ligand status of the GPCRs the circles extend to clinical relevance, disease therapeutic potential, publication density and tool compounds from <a href="https://www.ebi.ac.uk/chembl/">ChEMBL</a>. Note that while ChEMBL links to compounds with a wide range of potentcies GtoPdb has a more stringent annotation of smaller number of probe candidates including very recent publications (e.g. these 11 ligands above are not in ChEMBL26).</p> <p>One of the advantages of publishing in BJP is the provision of author-specified out-links to GtoPdb ligands and targets (see <a href="https://pubmed.ncbi.nlm.nih.gov/30087946/">PMID 30087946</a>). These have been duly added to the PDF for all GPCRs mentioned in the text as well as any ligands that were already in GtoPdb before this review. Examples for five links are shown below.</p> <p><img data-attachment-id="4008" data-permalink="https://blog.guidetopharmacology.org/2020/05/17/hot-topics-a-gpcr-triple-for-peptides/capture-15/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-5.jpg" data-orig-size="568,99" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"cdsoutharn","camera":"","caption":"","created_timestamp":"1589996762","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="Capture" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-5.jpg?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-5.jpg?w=568" loading="lazy" class=" wp-image-4008 aligncenter" src="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-5.jpg" alt="Capture" width="671" height="117" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-5.jpg 568w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-5.jpg?w=150&h=26 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-5.jpg?w=300&h=52 300w" sizes="(max-width: 671px) 100vw, 671px" /></p> <p>Clicking on “<a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=87">GPR15</a>” above thus takes us the full annotation for that receptor, including the agonist ligand records shown below.</p> <p><img data-attachment-id="4009" data-permalink="https://blog.guidetopharmacology.org/2020/05/17/hot-topics-a-gpcr-triple-for-peptides/capture-16/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-6.jpg" data-orig-size="934,282" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"cdsoutharn","camera":"","caption":"","created_timestamp":"1589996995","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="Capture" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-6.jpg?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-6.jpg?w=605" loading="lazy" class="alignnone size-full wp-image-4009" src="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-6.jpg" alt="Capture" width="934" height="282" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-6.jpg 934w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-6.jpg?w=150&h=45 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-6.jpg?w=300&h=91 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-6.jpg?w=768&h=232 768w" sizes="(max-width: 934px) 100vw, 934px" /></p> <p>Thus <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10568">GPR15L (71-81)</a> corresponds to <a href="https://pubchem.ncbi.nlm.nih.gov/substance/404859015">SID 404859015</a>. The format of Table 1 unfortunately precluded the addition of the live-links for the new ligands.</p> <p>The last of this trio is an in-depth review by Davenport et. al. [3] that encompasses translation aspects of peptides that modulate GPCRs into clinically effective drugs. This may even eventually extent to analogues of the peptides from the first two papers perhaps even related to new de-orphanisations. As detailed in this review therapeutic peptides have recently been undergoing a development technology renaissance via half- life extension, stapling and resistance to proteolysis. These measures improve pharmacokinetics and oral bioavailability that have hitherto been much less favourable for peptidic structures in comparison to conventional small-molecule drug candidates. An overview of these peptide approvals and advanced candidates is taken from their Figure 1.</p> <p><img data-attachment-id="4014" data-permalink="https://blog.guidetopharmacology.org/2020/05/17/hot-topics-a-gpcr-triple-for-peptides/capture-17/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-7.jpg" data-orig-size="1004,706" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"cdsoutharn","camera":"","caption":"","created_timestamp":"1590064573","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="Capture" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-7.jpg?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-7.jpg?w=605" loading="lazy" class="alignnone size-full wp-image-4014" src="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-7.jpg" alt="Capture" width="1004" height="706" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-7.jpg 1004w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-7.jpg?w=150&h=105 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-7.jpg?w=300&h=211 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/capture-7.jpg?w=768&h=540 768w" sizes="(max-width: 1004px) 100vw, 1004px" /></p> <p>This comprehensive review goes on to describe in detail 26 synthetic peptides approved for clinical use (20 agonists and 6 competitive antagonists) targeting eight class A receptor families. It also includes a useful structural perspectives not only on peptide binding sites but also addresses the frequently overlooked aspects associated with unnatural amino acids and chemical modifications.</p> <p>It seems somewhat anachronistic that the <em>Nat Rev Drug Discov</em> PDFs are entity link-free zones (although this <a href="https://www.go-fair.org/fair-principles/">FAIR</a>-gap has been pointed out to them). Notwithstanding, the GPCR names should retrieve cleanly from GtoPdb and GPCRdb. Most of the peptide names in the review should also retrieve their ligand entries from GtoPdb but these will eventually be cross-checked both for the resolution of equivocalities and addition of new development candidates with referenced binding data.</p> <p>Constituting a well-referenced overview of the field, these three papers also represent “good news” for peptides and their analogues. Notwithstanding, this <a href="https://www.slideshare.net/cdsouthan/peptide-tribulations-234339858">slide set</a> outlines some of the challenges for curating peptides and searching them in databases.</p> <p style="text-align:center;">**********************************</p> <p>Comments by <strong>Chris Southan</strong>, Fellow of the University Edinburgh, Owner of TW2Informatics , Chair of NC-IUPHAR Subcommitees for Proteases and Drug Targets and Chemistry (DRUTACS), ORCID 0000-0001-9580-0446. As declaration of interest (but not conflict!) Chris was pleased to be a co-supervisor for Alex Hauser’s PhD work on <a href="https://dra.ku.dk/activities/2019/phd-defences/alexander_hauser/">Computational Receptor Biology</a></p> <p>[1] <strong>Discovery of Human Signaling Systems: Pairing Peptides to G Protein-Coupled Receptors</strong>. Foster SR, Hauser AS, Vedel L, Strachan RT, Huang XP, Gavin AC, Shah SD, Nayak AP, Haugaard-Kedström LM, Penn RB, Roth BL, Bräuner-Osborne H, Gloriam DE. <em>Cell.</em> <strong>2019</strong> Oct 31;179(4):895-908.e21. doi: 10.1016/j.cell.2019.10.010. <a href="https://www.ncbi.nlm.nih.gov/pubmed/31675498">PMID: 31675498.</a></p> <p>[2] <strong>Novel approaches leading towards peptide GPCR de-orphanisation</strong>. Hauser AS, Gloriam DE, Bräuner-Osborne H, Foster SR. <em>Br J Pharmacol</em>. <strong>2020</strong> Mar;177(5):961-968. doi: 10.1111/bph.14950. Epub 2020 Feb 3. <a href="https://www.ncbi.nlm.nih.gov/pubmed/31863461">PMID: 31863461.</a></p> <p>[3] <strong>Advances in therapeutic peptides targeting G protein-coupled receptors</strong>. Anthony P. Davenport AP, Scully CCG , de Graaf C, Brown, AJH, Maguire JJ. <em>Nat Rev Drug Discov</em> (<strong>2020</strong>). <a href="https://www.nature.com/articles/s41573-020-0062-z#citeas">https://doi.org/10.1038/s41573-020-0062-z.</a></p> <p>[4] <strong>The impact of genomics on drug discovery</strong>. Beeley LJ, Duckworth DM, Southan C. <em>Prog Med Chem</em>. <strong>2000</strong>;37:1-43. <a href="https://www.ncbi.nlm.nih.gov/pubmed/10845246">PMID: 10845246. </a></p> <p>[5] <strong>The Concise Guide to PHARMACOLOGY 2019/20 : G Protein-Coupled Receptors. </strong>Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators. <em>Br J Pharmacol</em>. <strong>2019</strong> Dec;176 Suppl 1:S21-S141. doi: 10.1111/bph.14748. <a href="https://www.ncbi.nlm.nih.gov/pubmed/31710717">PMID: 31710717.</a></p> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/gpcrs/" rel="tag">GPCRs</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/hot-topics/" rel="category tag">Hot Topics</a> </div> </div> <div id="post-3961" class="post-3961 post type-post status-publish format-standard hentry category-database-updates tag-pre-release-ligands"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2020/05/04/gtopdb-pre-release-ligands-2020-3/" rel="bookmark">GtoPdb pre-release ligands (2020.3)</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2020/05/04/gtopdb-pre-release-ligands-2020-3/" title="8:54 am" rel="bookmark"><span class="timestamp">May 4, 2020</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2020/05/04/gtopdb-pre-release-ligands-2020-3/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>These are some of the ligands under curation (pre-release) in the Guide to Pharmacology. We expect them to be available on the website at the next database release (2020.3).<strong><a name="10745"></a></strong></p> <p><strong><a name="10891"></a><span style="text-decoration:underline;">Ligand ID: 10891</span></strong></p> <p>Name: <strong>aviptadil</strong></p><p><img data-attachment-id="4043" data-permalink="https://blog.guidetopharmacology.org/2020/05/04/gtopdb-pre-release-ligands-2020-3/attachment/10891/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/10891.gif" data-orig-size="1014,794" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="10891" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/10891.gif?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/10891.gif?w=605" loading="lazy" class="alignnone size-full wp-image-4043" src="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/10891.gif" alt="10891" width="1014" height="794" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/10891.gif 1014w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/10891.gif?w=150&h=117 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/10891.gif?w=300&h=235 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/05/10891.gif?w=768&h=601 768w" sizes="(max-width: 1014px) 100vw, 1014px" /></p> <p>Comment: Aviptadil is a vasoactive intestinal peptide analogue, VPAC1 receptor agonist.<br />The HELM annotation for aviptadil is PEPTIDE1{H.S.D.A.V.F.T.D.N.Y.T.R.L.R.K.Q.M.A.V.K.K.Y.L.N.S.I.L.N}$$$$.</p><hr /><p><strong><span style="text-decoration:underline;">Ligand ID: 10745</span></strong></p><p>Name: <strong>MDL-28170</strong></p> <figure class="wp-block-image size-large"><img data-attachment-id="4045" data-permalink="https://blog.guidetopharmacology.org/10745/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/10745.gif" data-orig-size="326,103" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="10745" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/10745.gif?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/10745.gif?w=326" loading="lazy" width="326" height="103" class="wp-image-4045" src="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/10745.gif?w=326" alt="" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/10745.gif 326w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/10745.gif?w=150 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/06/10745.gif?w=300 300w" sizes="(max-width: 326px) 100vw, 326px" /></figure> <p>IUPAC: benzyl N-[(2S)-3-methyl-1-oxo-1-[[(2S)-1-oxo-3-phenylpropan-2-yl]amino]butan-2-yl]carbamate</p> <p>Comment: PRD_002214 is a peptide-like inhibitor of the main protease (M<sup>PRO</sup>) of SARS-CoV-2. The structure was obtained from the RCSB Protein Data Bank entry <a href="https://www.rcsb.org/structure/6LU7" target="_blank" rel="noopener">6LU7</a> which shows the ligand in complex with the protease. The article describing the work has not yet been published (March 12, 2020), but the inhibitor (also referred to as N3) has been deployed in other M<sup>PRO</sup> crystallisation studies (<a href="https://pubmed.ncbi.nlm.nih.gov/16128623" target="_blank" rel="noopener">Yang et al. (2005)</a>).</p><hr /> <p><span style="text-decoration:underline;"><strong><a name="10752"></a>Ligand ID: 10752</strong></span></p> <p>Name: <strong>leronlimab</strong></p> <p>Comment: Leronlimab (PRO140) is a humanized anti-CCR5 (C-C motif chemokine receptor 5) monoclonal antibody [<a title="5. Jiao X, Nawab O, Patel T, Kossenkov AV, Halama N, Jaeger D, Pestell RG. (2019) Cancer Res. 79 (19): 4801-4807; 6. Miao M, De Clercq E, Li G. (2020) Expert Opin Drug Metab Toxicol. 16 (1): 11-30">5-6</a>]. It was originally developed by CytoDyn as a novel strategy to manage CCR5-tropic HIV infection.COVID-19: Leronlimab has been administered to a number of patients with severe COVID-19, to determine its potential to reduce cytokine storm caused by this disease.</p><hr /> <p><strong><a name="11026"></a>Ligand ID: 11026</strong></p> <p>Name: <strong>meplazumab</strong></p> <p>Comment: Meplazumab is a humanized IgG2 monoclonal antibody that targets CD147 (basigin). It is being developed by Jiangsu Pacific Meinuoke Bio Pharmaceutical.<br /><br /><b>COVID-19</b><br />SARS-CoV-2 may utilise CD147 as an additional entry receptor to infect host cells [<a title="2. Wang K, Chen W, Zhou Y-S, Lian JQ, Zhang Z, Du P, Gong L, Zhang Y, Cui H-Y, Geng J-J et al.. (2020) bioRxiv.org.">2</a>]. Meplazumab can block this interaction between CD147 and SARS-CoV-2 spike protein. </p> <hr class="wp-block-separator" /><hr class="wp-block-separator" /> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/pre-release-ligands/" rel="tag">pre-release ligands</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a> </div> </div> <div id="post-3954" class="post-3954 post type-post status-publish format-standard hentry category-database-updates category-technical"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2020/04/20/database-release-2020-2/" rel="bookmark">Database Release 2020.2</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2020/04/20/database-release-2020-2/" title="4:11 pm" rel="bookmark"><span class="timestamp">April 20, 2020</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2020/04/20/database-release-2020-2/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>We are pleased to have been able to make an expeditious database release (version 2020.2), following on from our last update in March 2020 in order to make public new curation specifically related to SARS-CoV-2.</p> <h2>Content Updates</h2> <ul> <li style="margin-bottom:2px;">GtoPdb now includes a new <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1034">SARS-Cov-2 protein</a> family which includes 13 members and is included under ‘anti-infective targets’ in our hierarchy</li> <li style="margin-bottom:2px;">The new targets in the SARS-CoV-2 protein family have been mapped to UniProt accessions were possible. Because so little is yet understood about SARS-CoV-2 at the molecular level, much of what is curated for these proteins has been predicted and/or extrapolated from what is known about SARS-CoV and MERS-CoV. We will of course update the pages as and when new data are published.</li> <li style="margin-bottom:2px;">Several new compounds, relevant to SARS-CoV-2 have now been added, including <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10716" target="_blank" rel="noopener">PRD_002214</a> and <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10720" target="_blank" rel="noopener">compound 13b</a> (virus main protease inhibitors), <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10732" target="_blank" rel="noopener">otamixaban</a> and <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10733" target="_blank" rel="noopener">I-432</a> (potential TMPRSS2 inhibitors), and <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10735" target="_blank" rel="noopener">β-D-N4-hydroxycytidine </a>(a broad spectrum antiviral compound).</li> </ul> <p>The Guide to Pharmacology <a href="https://www.guidetopharmacology.org/coronavirus.jsp" target="_blank" rel="noopener">coronavirus information page</a> continues to be updated on a regular basis to capture the latest pharmacological strategies under investigation to mitigate against COVID-19.</p> <p> </p> <p> </p> </div> <div class="post-data"> Posted in <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/technical/" rel="category tag">Technical</a> </div> </div> <div id="post-3929" class="post-3929 post type-post status-publish format-standard hentry category-database-updates tag-pre-release-ligands"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2020/03/13/gtopdb-pre-release-ligands/" rel="bookmark">GtoPdb pre-release ligands (2020.2)</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2020/03/13/gtopdb-pre-release-ligands/" title="11:42 am" rel="bookmark"><span class="timestamp">March 13, 2020</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2020/03/13/gtopdb-pre-release-ligands/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>These are some of the ligands under curation (pre-release) in the Guide to Pharmacology. We expect them to be available on the website at the next database release (2020.2 – no earlier than April 2020).</p> <ul> <li><a name="10716"></a> Ligand ID: 10716 <ul> <li>Name: <strong>PRD_002214</strong></li> <li><img data-attachment-id="3930" data-permalink="https://blog.guidetopharmacology.org/2020/03/13/gtopdb-pre-release-ligands/attachment/10716/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/10716.gif" data-orig-size="488,266" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="10716" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/10716.gif?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/10716.gif?w=488" loading="lazy" class="alignnone wp-image-3930" src="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/10716.gif" alt="10716" width="312" height="169" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/10716.gif?w=310&h=169 310w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/10716.gif?w=150&h=82 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/10716.gif?w=300&h=164 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/10716.gif 488w" sizes="(max-width: 312px) 100vw, 312px" /></li> <li>IUPAC: benzyl (2Z,4S)-4-[(2S)-4-methyl-2-[(2S)-3-methyl-2-[(2S)-2-[(5-methyl-1,2-oxazol-3-yl)formamido]propanamido]butanamido]pentanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate</li> <li>RCSB PDB: <a href="http://www.rcsb.org/bird/PRD_002214" target="_blank" rel="noopener">PRD_002214</a></li> <li>Comment: PRD_002214 is a peptide-like inhibitor of the main protease (M<sup>PRO</sup>) of SARS-CoV-2. The structure was obtained from the RCSB Protein Data Bank entry <a href="https://www.rcsb.org/structure/6LU7" target="_blank" rel="noopener">6LU7</a> which shows the ligand in complex with the protease. The article describing the work has not yet been published (March 12, 2020), but the inhibitor (also referred to as N3) has been deployed in other M<sup>PRO</sup> crystallisation studies (<a href="https://pubmed.ncbi.nlm.nih.gov/16128623" target="_blank" rel="noopener">Yang et al. (2005)</a>)</li> </ul> </li> </ul> <hr /> <ul> <li><a name="10720"></a>Ligand ID: 10720 <ul> <li>Name: <strong>compound 13b</strong></li> <li><img class="" src="https://www.guidetopharmacology.org/CHEMSTRUCT/iuphar/10720.gif" alt="Click here for structure editor" width="284" height="173" /></li> <li>IUPAC: Tert-butyl (1-((S)-1-(((S)-4-(benzylamino)-3,4-dioxo-1-((S)-2-oxopyrrolidin-3-yl)-butan-2-yl)ami-no)-3-cyclopropyl-1-oxopropan-2-yl)-2-oxo-1,2-dihydropyridin-3-yl)carbamate</li> <li>Comment: Compound 13b is an inhibitor of SARS-CoV-2 main protease (M<sup>pro</sup>) [<a title="3. Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R. (2020) Science.">3</a>]. It is a derivative of the prevoiusly reported α-ketoamide inhibitor <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10705">compound 11r [PMID: 32045235]</a>[<a title="1. Zhang L, Lin D, Kusov Y, Nian Y, Ma Q, Wang J, von Brunn A, Leyssen P, Lanko K, Neyts J et al.. (2020) J. Med. Chem.">1</a>]. Compound 13b has an enhanced plasma half-life compared to 11r, plus it exhibits substantial lung tropism and has shown suitability for inhalation-mediated administration.</li> </ul> </li> </ul> <hr /> <ul> <li><a name="10732"></a>Ligand ID: 10732 <ul> <li style="list-style-type:none;"> <ul> <li>Name: <strong>otamixaban</strong></li> <li><img src="https://www.guidetopharmacology.org/CHEMSTRUCT/iuphar/10732.gif" alt="Click here for structure editor" /></li> <li>IUPAC: methyl (2R,3R)-2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-1-ium-4-yl)benzoyl]amino]butanoate</li> <li>Comment: Otamixaban (FXV673) is an anticoagulant that was originally reported by Aventis Pharmaceuticals (Sanofi). It is a potent and selective direct inhibitor of coagulation factor Xa that is delivered intravenously. The INN record stipulates the (2R,3R) configuration. Virtual docking studies suggest that otamixaban may bind to the serine protease <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2421" target="_blank" rel="noopener">TMPRSS2</a>, which is linked to host cell entry by a number of viruses, in particular influenza viruses and respiratory viruses such as SARS-CoV-2. Inhibition of TMPRSS2 is being examined for antiviral activity. The TMPRSS2 inhibitory potential and/or antiviral activity of otamixaban have not yet been determined.</li> </ul> </li> </ul> </li> </ul> <hr /> <ul> <li><a name="10733"></a>Ligand ID: 10733 <ul> <li>Name: <strong>I-432</strong></li> <li><img src="https://www.guidetopharmacology.org/CHEMSTRUCT/iuphar/10733.gif" alt="Click here for structure editor" /></li> <li>IUPAC: 3-[(2R)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-[3-(4,6-dichlorocyclohexa-1,5-dien-1-yl)benzenesulfonamido]-3-oxopropyl]benzene-1-carboximidamide</li> <li>Comment: I-432 is an inhibitor of the serine protease <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2421" target="_blank" rel="noopener">TMPRSS2</a>. TMPRSS2, present in human airway cells, is involved in processes that support infection by a number of viruses, thus inhibitors of this protease are being investigated for anti-viral potential</li> </ul> </li> </ul> <hr /> <ul> <li><a name="10735"></a>Ligand ID: 10735 <ul> <li>Name: <strong>β-D-N<sup>4</sup>-hydroxycytidine</strong></li> <li style="list-style-type:none;"><img id="ligand_structure_display" class=" alignnone" src="https://www.guidetopharmacology.org/CHEMSTRUCT/iuphar/10735.gif" alt="Click here for structure editor" /></li> <li>IUPAC: 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-(hydroxyamino)pyrimidin-2-one</li> <li>Comment: Preliminary evidence from a <a href="https://www.biorxiv.org/content/10.1101/2020.03.19.997890v1">BioRxiv preprint</a> indicate that the ribonucleoside analog β-D-N<sup>4</sup>-hydroxycytidine (NHC, EIDD-1931) has broad spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs. The potency of NHC/EIDD-2801 against multiple coronaviruses, its therapeutic efficacy, and oral bioavailability in vivo, all highlight its potential utility as an effective antiviral against SARS-CoV-2 and other future zoonotic coronaviruses.</li> </ul> </li> </ul> <hr /> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/pre-release-ligands/" rel="tag">pre-release ligands</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a> </div> </div> <div id="post-3896" class="post-3896 post type-post status-publish format-standard has-post-thumbnail hentry category-database-updates category-technical tag-coronavirus"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2020/03/12/database-release-2020-1/" rel="bookmark">Database Release 2020.1</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2020/03/12/database-release-2020-1/" title="1:33 pm" rel="bookmark"><span class="timestamp">March 12, 2020</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2020/03/12/database-release-2020-1/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <a href="https://blog.guidetopharmacology.org/2020/03/12/database-release-2020-1/" title="Database Release 2020.1" > <img width="605" height="270" src="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/ligsumlink.png?w=605" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/ligsumlink.png?w=605 605w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/ligsumlink.png?w=150 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/ligsumlink.png?w=300 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/ligsumlink.png?w=768 768w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/ligsumlink.png 954w" sizes="(max-width: 605px) 100vw, 605px" data-attachment-id="3909" data-permalink="https://blog.guidetopharmacology.org/2020/03/12/database-release-2020-1/ligsumlink/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/ligsumlink.png" data-orig-size="954,425" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="ligSumLink" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/ligsumlink.png?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/ligsumlink.png?w=605" /> </a> <p>We are pleased to announce our first database release of 2020 – version 2020.1.</p> <h2>Coronavirus (Covid-19)</h2> <p>We have added a new <a href="https://www.guidetopharmacology.org/coronavirus.jsp" target="_blank" rel="noopener">coronavirus page</a> to the Guide to Pharmacology which aims to consolidate key pharmacological information and resources related to coronavirus. We have gathered information from various sources, with an aim to cover as many of the pharmacological strategies being considered as we could find. Links are provided to the key ligands and target pages in GtoPdb (where data is available). The page also provides other useful links and resource. We will aim to keep this page updated in this fast changing situation.</p> <h2>Tools</h2> <p>GtoPdb contains a couple of useful tools for searching and visualising pharamcology data – that combine data from ChEMBL with GtoPdb data. In this release we’ve update our site to make accessing the visualisation charts easier</p> <p><strong>Ligand Activity Charts</strong></p> <p>This tool provides charts with box plots summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Separate charts are created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.</p> <p>Previously, access to the charts was only found on a ligand’s summary page, under the biological activity tab. We’ve now moved that link so it appears more prominently on these pages.<img data-attachment-id="3909" data-permalink="https://blog.guidetopharmacology.org/2020/03/12/database-release-2020-1/ligsumlink/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/ligsumlink.png" data-orig-size="954,425" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="ligSumLink" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/ligsumlink.png?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/ligsumlink.png?w=605" loading="lazy" class=" size-full wp-image-3909 aligncenter" style="color:var(--color-text);" src="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/ligsumlink.png" alt="ligSumLink" width="954" height="425" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/ligsumlink.png 954w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/ligsumlink.png?w=150&h=67 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/ligsumlink.png?w=300&h=134 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/ligsumlink.png?w=768&h=342 768w" sizes="(max-width: 954px) 100vw, 954px"></p> <p>We have also added a new icon on the ligand list pages which indicated whether there are activity charts available for the ligand. Click the icon takes the users straight to the charts.</p> <p><div data-shortcode="caption" id="attachment_3910" style="width: 1179px" class="wp-caption aligncenter"><img aria-describedby="caption-attachment-3910" data-attachment-id="3910" data-permalink="https://blog.guidetopharmacology.org/2020/03/12/database-release-2020-1/iconimage/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/iconimage-e1583923909111.png" data-orig-size="1169,285" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="iconImage" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/iconimage-e1583923909111.png?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/iconimage-e1583923909111.png?w=605" loading="lazy" class="aligncenter size-full wp-image-3910" src="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/iconimage-e1583923909111.png" alt="iconImage" width="1169" height="285" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/iconimage-e1583923909111.png 1169w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/iconimage-e1583923909111.png?w=150&h=37 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/iconimage-e1583923909111.png?w=300&h=73 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/iconimage-e1583923909111.png?w=768&h=187 768w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/iconimage-e1583923909111.png?w=1024&h=250 1024w" sizes="(max-width: 1169px) 100vw, 1169px"><p id="caption-attachment-3910" class="wp-caption-text">New ‘bar-chart’ icon added to ligand list to indicate availability of activity charts</p></div></p> <h2>Publications</h2> <p>We have published a review of the Guide to Immunopharmacology in Immunology at the start of the year. The review provides a deeper context for how the resource can support research into the development of drugs targeted at modulating immune, inflammatory or infectious components of disease.</p> <p>Harding, S. D., Faccenda, E., Southan, C., Pawson, A. J., Maffia, P., Alexander, S., Davenport, A. P., Fabbro, D., Levi-Schaffer, F., Spedding, M., & Davies, J. A. (2020). <strong>The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology</strong>. <i>Immunology</i>, 10.1111/imm.13175. Advance online publication. <a href="https://doi.org/10.1111/imm.13175" target="_blank" rel="noopener">https://doi.org/10.1111/imm.13175</a></p> <h2>Content Updates</h2> <p>GPCRs:</p> <ul> <li><a href="http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=2" target="_blank" rel="noopener">Acetylcholine receptors (muscarinic)</a></li> <li><a href="http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=7" target="_blank" rel="noopener">Apelin receptor</a></li> <li><a href="http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=11" target="_blank" rel="noopener">Calcitonin receptor</a></li> <li><a href="http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=12" target="_blank" rel="noopener">Calcium-sensing receptor</a></li> <li><a href="http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=13" target="_blank" rel="noopener">Cannabinoid receptors</a></li> <li><a href="http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=14" target="_blank" rel="noopener">Chemokoine receptors</a></li> <li><a href="http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=24" target="_blank" rel="noopener">Free fatty acid receptors</a></li> <li><a href="http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=29" target="_blank" rel="noopener">Glucagon receptor family</a></li> <li><em><a href="http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=87" target="_blank" rel="noopener">GPR15</a></em></li> <li><em><a href="http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=114" target="_blank" rel="noopener">GPR68</a></em></li> <li><a href="http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=35" target="_blank" rel="noopener">Leukotriene receptors</a></li> <li><a href="http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=34" target="_blank" rel="noopener">Melatonin receptor</a></li> <li><a href="http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=50" target="_blank" rel="noopener">Opioid receptors</a></li> </ul> <p>Ion Channels:</p> <ul> <li><a href="http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=68" target="_blank" rel="noopener">5-HT3 receptors</a></li> <li><a href="http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=76" target="_blank" rel="noopener">Nicotinic acetylcholine receptors</a></li> <li><a href="http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=69" target="_blank" rel="noopener">Calcium- and sodium-activated potassium channels</a></li> <li><a href="http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=78" target="_blank" rel="noopener">Transient Receptor Potential channels</a></li> </ul> <p>NHRs:</p> <ul> <li><a href="http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=96" target="_blank" rel="noopener">3A. Estrogen receptors</a></li> <li><a href="http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=88" target="_blank" rel="noopener">1F. Retinoic acid-related orphans</a></li> <li><a href="http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=89" target="_blank" rel="noopener">1H. Liver X receptor-like receptors</a></li> </ul> <p>Enzymes and Other Protein Targets:</p> <ul> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=255" target="_blank" rel="noopener">Carboxylases</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797" target="_blank" rel="noopener">epidermal growth factor receptor</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=994" target="_blank" rel="noopener">2.7.1.40 Pyruvate kinases </a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1399" target="_blank" rel="noopener">Monoacylglycerol lipase</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=773" target="_blank" rel="noopener">Sphingomyelin phosphodiesterase</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=260" target="_blank" rel="noopener">Phosphodiesterases, 3′,5′-cyclic nucleotide</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=262" target="_blank" rel="noopener">CYP2 family</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=883" target="_blank" rel="noopener">Poly ADP-ribose polymerases</a></li> <li><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1722" target="_blank" rel="noopener">Thrombopoietin receptor</a></li> </ul> <p>Guide to Malaria Pharmacology Updates:</p> <ul> <li style="margin-bottom:2px;">3 P. falciparum (3D7) targets have been added to the Antimalarial targets family: <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3105" target="_blank" rel="noopener">PfCLK3</a>, <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3106" target="_blank" rel="noopener">PfPMV</a> and <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3107" target="_blank" rel="noopener">PfNCR1</a></li> <li>The Antimalarial ligands family now contains a total of <a href="https://www.guidetomalariapharmacology.org/GRAC/LigandListForward?type=AntiMal&database=all" target="_blank" rel="noopener">80 ligands</a> tagged as antimalarial in the database</li> </ul> <h2>Other Updates</h2> <h4>Updated display of ligand clinical trial data</h4> <p>The ligand summary pages have been updated to improve the display of clinical trials information. Key clinical trials involving the ligand are now displayed in a separate table, under the clinical data tab. The table includes link out the clinical trial plus trial title, type, source, curator comments and references.</p> <p><img data-attachment-id="3899" data-permalink="https://blog.guidetopharmacology.org/2020/03/12/database-release-2020-1/clinical_trial_snapshot/" data-orig-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/clinical_trial_snapshot.png" data-orig-size="948,418" data-comments-opened="1" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="clinical_trial_snapshot" data-image-description="" data-image-caption="" data-medium-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/clinical_trial_snapshot.png?w=300" data-large-file="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/clinical_trial_snapshot.png?w=605" loading="lazy" class=" wp-image-3899 aligncenter" src="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/clinical_trial_snapshot.png" alt="clinical_trial_snapshot" width="589" height="260" srcset="https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/clinical_trial_snapshot.png?w=589&h=260 589w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/clinical_trial_snapshot.png?w=150&h=66 150w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/clinical_trial_snapshot.png?w=300&h=132 300w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/clinical_trial_snapshot.png?w=768&h=339 768w, https://blog.guidetopharmacology.org/wp-content/uploads/2020/03/clinical_trial_snapshot.png 948w" sizes="(max-width: 589px) 100vw, 589px"></p> <p><strong>Approved drug with primary targets download</strong></p> <p>A new download file of all approved drugs and their primary targets has been added to the <a href="https://www.guidetopharmacology.org/download.jsp#data" target="_blank" rel="noopener">download</a> page.</p> <h4>New out-links</h4> <ul> <li style="margin-bottom:2px;"><a href="https://www.midwestern.edu/departments/marinepharmacology.xml" target="_blank" rel="noopener">Marine pharmacology</a> – Marine Pharmacology (Midwestern University): a website aimed at those with an interest in the preclinical and clinical pharmacology of marine compounds and the pharmaceutical potential of the enormous biodiversity of organisms present in the world’s oceans</li> <li><a href="https://pharos.nih.gov/" target="_blank" rel="noopener">Pharos</a> – Pharos is the user interface to the Knowledge Management Center (KMC) for the Illuminating the Druggable Genome (IDG) program</li> </ul> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/coronavirus/" rel="tag">coronavirus</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/database-updates/" rel="category tag">Database updates</a>, <a href="https://blog.guidetopharmacology.org/category/technical/" rel="category tag">Technical</a> </div> </div> <div id="post-3891" class="post-3891 post type-post status-publish format-standard hentry category-hot-topics tag-gpcrs tag-hot-topic tag-pharmacology tag-protein-structure tag-structure"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2020/03/09/hot-topics-virtual-screening-on-the-crystal-structure-of-the-g-protein-coupled-melatonin-mt1-receptor-reveals-several-new-chemical-scaffolds-with-biological-activity/" rel="bookmark">Hot Topics: Virtual screening on the crystal structure of the G protein-coupled melatonin MT1 receptor reveals several new chemical scaffolds with biological activity</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2020/03/09/hot-topics-virtual-screening-on-the-crystal-structure-of-the-g-protein-coupled-melatonin-mt1-receptor-reveals-several-new-chemical-scaffolds-with-biological-activity/" title="8:39 am" rel="bookmark"><span class="timestamp">March 9, 2020</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2020/03/09/hot-topics-virtual-screening-on-the-crystal-structure-of-the-g-protein-coupled-melatonin-mt1-receptor-reveals-several-new-chemical-scaffolds-with-biological-activity/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>Melatonin targets two high-affinity receptors, <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=287&familyId=39&familyType=GPCR" target="_blank" rel="noopener">MT<sub>1</sub></a> and <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=288&familyId=39&familyType=GPCR" target="_blank" rel="noopener">MT<sub>2</sub></a>, that belong to the G protein-coupled receptor (GPCR) superfamily (1,2). Drugs acting on melatonin receptors are subscribed for circadian disorders (jet lag, shift work, etc.), insomnia and major depression (3). All marketed drugs are non-selective agonists targeting both receptor types so far. Despite large chemical synthesis campaigns over the last 20 years, the pharmacology of melatonin receptors remains poorly explored with few inverse agonistic and signaling pathway-biased compounds and few selective compounds, in particular for the MT<sub>1</sub> type (2,4). This lack of pharmacological tools goes along with a rather poor diversity in terms of chemical scaffolds currently available (5). Put into this context, a virtual screening looked like a very promising approach to increase the diversity of chemical scaffolds for melatonin receptors, especially now that the crystal structure of the MT<sub>1</sub> receptor has been solved (6). The outcome of the virtual screening study performed by Stein <em>et al.</em> (7) met these high expectations. Overall, 15 new chemical scaffolds were identified from the primary docking of over 150 million virtual molecules (7). Some of the primary hits had pEC<sub>50</sub> values around 1nM, which is remarkable. In terms of functional properties, primary hits and derivatives showed agonistic and inverse agonistic properties with or without selectivity for MT<sub>1</sub> and MT<sub>2</sub>. Two MT<sub>1</sub> selective inverse agonists were further validated in vivo regarding their effects on circadian rhythm parameters in mice under free-running conditions, as well as using an experimental re-entrainment protocol corresponding to an ‘east-bound’ jet lag paradigm.</p> <p>This study is not only of great value for the melatonin receptor field but will also encourage virtual screening approaches on other GPCRs for which high-resolution structures are available. Compared to other GPCR structures, the MT<sub>1</sub> template structure has several limitations as it was in the inactive form despite the presence of the 2‐phenylmelatonin agonist, and it was heavily modified with 9 point mutations and several truncations to facilitate expression and stability (7,8). However, a favorable feature of MT<sub>1</sub> for virtual docking might be its ligand binding pocket which is rather small and hydrophobic with only two key residues important for high-affinity binding. This limits the number of poses to be screened by virtual docking. Moreover, although the screening was designed to identify MT<sub>1</sub> selective compounds, positive hits included also MT<sub>2</sub> selective and non-selective compounds suggesting that virtual screening is currently unable to predict type selective compounds. This might also depend on the quality of the receptor structure and the degree of divergence between receptor types.</p> <p>In conclusion, this article is a nice example of successful virtual screening on GPCRs, one of the desired benefits of crystal structures, that will accelerate the drug development process towards compounds with improved efficacy and target-selectivity.</p> <p>This study investigated two MT<sub>1</sub>-selective inverse agonists, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10666" target="_blank" rel="noopener">UCSF7447</a> and <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10665" target="_blank" rel="noopener">UCSF3384</a>, and a selective MT<sub>2</sub> agonist, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10667" target="_blank" rel="noopener">UCSF4226</a>, for their affinities.</p> <p><strong>Comments by Ralf Jockers</strong>, Institut Cochin, CNRS, INSERM, Université de Paris, Paris, France, Chair for NC-IUPHAR Subcommitee for <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=39" target="_blank" rel="noopener">Melatonin receptors</a>.</p> <ol> <li>Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. <em>Pharmacol Rev</em>. 2010;62(3):343-380.</li> <li>Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G, Cecon E, Zlotos DP. Update on Melatonin Receptors. IUPHAR Review. <em>Br J Pharmacol</em>. 2016;173(18):2702-2725</li> <li>Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. <em>Annu Rev Pharmacol Toxicol</em>. 2016;56:361-383.</li> <li>Cecon E, Oishi A, Jockers R. Melatonin receptors: molecular pharmacology and signalling in the context of system bias. <em>Br J Pharmacol</em>. 2017;175:3263–3280.</li> <li>Zlotos DP, Jockers R, Cecon E, Rivara S, Witt-Enderby PA. MT1 and MT2 Melatonin Receptors: Ligands, Models, Oligomers, and Therapeutic Potential. <em>J Med Chem</em>. 2014;57(8):3161-3185.</li> <li>Stauch B, Johansson LC, McCorvy JD, Patel N, Han GW, Huang XP, Gati C, Batyuk A, Slocum ST, Ishchenko A, Brehm W, White TA, Michaelian N, Madsen C, Zhu L, Grant TD, Grandner JM, Shiriaeva A, Olsen RHJ, Tribo AR, Yous S, Stevens RC, Weierstall U, Katritch V, Roth BL, Liu W, Cherezov V. Structural basis of ligand recognition at the human MT1 melatonin receptor. <em>Nature</em>. 2019;569(7755):284-288.</li> <li>Stein RM, Kang HJ, McCorvy JD, Glatfelter GC, Jones AJ, Che T, Slocum S, Huang XP, Savych O, Moroz YS, Stauch B, Johansson LC, Cherezov V, Kenakin T, Irwin JJ, Shoichet BK, Roth BL, Dubocovich ML. Virtual discovery of melatonin receptor ligands to modulate circadian rhythms. <em>Nature</em>. 2020. [PMID: <a href="https://www.ncbi.nlm.nih.gov/pubmed/32040955">32040955</a>]</li> <li>Cecon E, Liu L, Jockers R. Melatonin receptor structures shed new light on melatonin research. <em>J Pineal Res</em>. 2019:e12606.</li> </ol> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/gpcrs/" rel="tag">GPCRs</a>, <a href="https://blog.guidetopharmacology.org/tag/hot-topic/" rel="tag">hot topic</a>, <a href="https://blog.guidetopharmacology.org/tag/pharmacology/" rel="tag">pharmacology</a>, <a href="https://blog.guidetopharmacology.org/tag/protein-structure/" rel="tag">protein structure</a>, <a href="https://blog.guidetopharmacology.org/tag/structure/" rel="tag">structure</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/hot-topics/" rel="category tag">Hot Topics</a> </div> </div> <div id="post-3885" class="post-3885 post type-post status-publish format-standard hentry category-hot-topics tag-calcium-channel tag-hot-topic tag-pharmacology tag-vgics tag-voltage-gated"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2020/02/12/hot-topics-cardiac-ca2-channel-regulation-in-the-fight-or-flight-response-the-monomeric-small-g-protein-as-another-piece-in-the-puzzle/" rel="bookmark">Hot Topics: Cardiac Ca2+ Channel Regulation in the Fight-or-Flight Response: the monomeric small G-protein as another piece in the puzzle</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2020/02/12/hot-topics-cardiac-ca2-channel-regulation-in-the-fight-or-flight-response-the-monomeric-small-g-protein-as-another-piece-in-the-puzzle/" title="8:44 am" rel="bookmark"><span class="timestamp">February 12, 2020</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2020/02/12/hot-topics-cardiac-ca2-channel-regulation-in-the-fight-or-flight-response-the-monomeric-small-g-protein-as-another-piece-in-the-puzzle/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>Thirty eight years after the discovery that injection of the catalytic subunits of cyclic AMP-dependent protein kinase A (PKA) into isolated pig ventricular cardiac myocytes (1) increases the amplitude of L-type Ca<sup>2+</sup> current (today known to be formed by <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=529&familyId=80&familyType=IC">Ca<sub>v</sub>1.2</a> channels, (2)), we are now getting close to understand the responsible molecular mechanism. Initial research that has focused on direct regulatory mechanisms, such as the activation by the α-subunit of the stimulatory heterotrimeric G-protein Gs (3), and direct phosphorylation of the pore-forming α1- or accessory β2-subunit of the <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=529&familyId=80&familyType=IC">Ca<sub>v</sub>1.2</a> channel has not provided a conclusive answer. β-adrenergic modulation was not (α1 Ser-1928, (4)) or only partially (α1 Ser-1700/Thr-1704, (5)) prevented in mutant mice lacking predicted phosphorylation sites in α1 or β2 subunits (6). This was further supported by an elegant transgenic approach showing that expression of channel complexes with all PKA consensus sites mutated to alanine in the <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=529&familyId=80&familyType=IC">Ca<sub>v</sub>1.2</a> α1 and the β2 subunits (7) has no effects on β-adrenergic modulation.</p> <p>Assuming that other proteins may be involved in this regulatory pathway, Liu et al. (7) used a biotinylation-based proteomic proximity assay to identify proteins in the <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=529&familyId=80&familyType=IC">Ca<sub>v</sub>1.2</a> neighborhood regulated by isoproterenol treatment in cardiomyocytes. This led to the discovery of the small Ras-like G protein Rad as a potential candidate. It belongs to the family of the Rad, Rem, Rem2 and Gem/Kir (RGK) Ras-like GTP-binding proteins, which were shown earlier to inhibit high-voltage-activated Ca<sup>2+</sup> channels by binding to their β-subunits. Indeed, Rad appears to be the long-sought missing piece in the puzzle: in HEK293T Rad-mediated inhibition of cardiac <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=529&familyId=80&familyType=IC">Ca<sub>v</sub>1.2</a> channels was relieved by PKA phosphorylation. Modulation was prevented either by the simultaneous mutation of the known cardiac PKA phosphorylation sites of Rad to alanine or by inhibiting the interaction of Rad with the β-subunit.</p> <p>This mechanism may be universal and may also explain the PKA modulation of other types of β-subunit associated high-voltage activated Ca<sup>2+</sup> channels in Rad expressing cells. It also provides evidence that the mechanism of PKA modulation of <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=529&familyId=80&familyType=IC">Ca<sub>v</sub>1.2</a> Ca<sup>2+</sup> channels appears to differ in different cell types. Clearly, direct phosphorylation of Ser-1928 of the α1-subunit is not required for β-adrenergic regulation of Ca<sub>v</sub>1.2 in the heart (4,7). However, this residue is required for β-adrenergic stimulation of Ca<sup>2+</sup> channels in hippocampal neurons and for hyperglycaemia-induced stimulation of Ca<sup>2+</sup> currents in arterial smooth muscle cells (8,9).</p> <p>Despite compelling evidence for this novel mechanism, several questions remain: First, what is the role of Rad-dependent modulation of the cardiac L-type channel in intact cardiomyocytes, for example in cardiomyocytes expressing Rad with mutated PKA phosphorylation sites. Second, what is the relative importance of Rad versus modulation by direct phosphorylation of Ser-1700 (and Thr-1704), which has also been found to confer some of the PKA activation of L-type current in cardiomyocytes of Ser1700Ala mutant mice (5).</p> <p>Despite these open questions, we are now getting close to understand the molecular mechanisms underlying the fight-or-flight response.</p> <p><strong>Comments by Jörg Striessnig</strong>, University of Innsbruck, Chair for NC-IUPHAR Subcommitee for <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=80">Voltage-gated calcium channels</a>, Liaison for NC-IUPHAR subcommittees on <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=696&familyType=IC">Voltage-gated ion channels</a></p> <ol> <li>Osterrieder W, Brum G, Hescheler J, Trautwein W, Flockerzi V, Hofmann F. (1982) Injection of subunits of cyclic AMP-dependent protein kinase into cardiac myocytes modulates Ca2+ current. Nature 298, 576–8.</li> <li>Sinnegger-Brauns MJ, Hetzenauer A, Huber IG, Renström E, Wietzorrek G, Berjukov S, et al. (2004) Isoform-specific regulation of mood behavior and pancreatic β cell and cardiovascular function by L-type Ca<sup>2+</sup> J Clin Invest. 113: 1430–9.</li> <li>Yatani A, Codina J, Imoto Y, Reeves JP, Birnbaumer L, Brown AM. (1987) A G protein directly regulates mammalian cardiac calcium channels. Science 238, 1288–92.</li> <li>Lemke T, Welling A, Christel CJ, Blaich A, Bernhard D, Lenhardt P, et al. (2008) Unchanged beta-adrenergic stimulation of cardiac L-type calcium channels in Cav1.2 phosphorylation site S1928A mutant mice. J Biol Chem. 283, 34738–44.</li> <li>Fu Y, Westenbroek RE, Scheuer T, Catterall WA. (2014) Basal and beta-adrenergic regulation of the cardiac calcium channel Cav1.2 requires phosphorylation of serine 1700. Proc Natl Acad Sci U S A. 111, 16598–603.</li> <li>Brandmayr J, Poomvanicha M, Domes K, Ding J, Blaich A, Wegener JW, et al (2012) Deletion of the C-terminal phosphorylation sites in the cardiac beta-subunit does not affect the basic beta-adrenergic response of the heart and the Cav1.2 channel. J Biol Chem. 287, 22584–92.</li> <li>Liu G, Papa A, Katchman AN, Zakharov SI, Roybal D, Hennessey JA, et al. (2020) Mechanism of adrenergic CaV1.2 stimulation revealed by proximity proteomics. Nature 577, 695–700 [PMID: <a href="https://www.ncbi.nlm.nih.gov/pubmed/31969708">31969708</a>].</li> <li>Qian H, Patriarchi T, Price JL, Matt L, Lee B, Nieves-Cintrón M, et al. (2017) Phosphorylation of Ser1928 mediates the enhanced activity of the L-type Ca<sup>2+</sup> channel Cav1.2 by the β2-adrenergic receptor in neurons. Sci Signal. 10 (463), pii: eaaf9659</li> <li>Nystoriak MA, Nieves-Cintrón M, Patriarchi T, Buonarati OR, Prada MP, Morotti S, et al. (2017) Ser1928 phosphorylation by PKA stimulates the L-type Ca2+ channel Cav1.2 and vasoconstriction during acute hyperglycemia and diabetes. Sci Signal. 10(463), pii: eaaf9647</li> <li style="list-style-type:none;"></li> </ol> <p> </p> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/calcium-channel/" rel="tag">calcium channel</a>, <a href="https://blog.guidetopharmacology.org/tag/hot-topic/" rel="tag">hot topic</a>, <a href="https://blog.guidetopharmacology.org/tag/pharmacology/" rel="tag">pharmacology</a>, <a href="https://blog.guidetopharmacology.org/tag/vgics/" rel="tag">VGICs</a>, <a href="https://blog.guidetopharmacology.org/tag/voltage-gated/" rel="tag">voltage-gated</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/hot-topics/" rel="category tag">Hot Topics</a> </div> </div> <div id="post-3879" class="post-3879 post type-post status-publish format-standard hentry category-hot-topics tag-cannabinoids tag-cb1 tag-cb2 tag-receptor tag-structure"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2020/02/06/hot-topics-cannabinoid-receptor-stuctures/" rel="bookmark">Hot topics: Cannabinoid receptor stuctures</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2020/02/06/hot-topics-cannabinoid-receptor-stuctures/" title="10:19 am" rel="bookmark"><span class="timestamp">February 6, 2020</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2020/02/06/hot-topics-cannabinoid-receptor-stuctures/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>Two new reports cover further aspects of cannabinoid receptor binding as defined using cryo-EM. These expand on previous reports of the structure of the human <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=56"> CB<sub>1</sub> cannabinoid receptor</a> with the antagonists <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9231"> taranabant</a> and <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=summary&ligandId=9338"> AM6538</a> bound, and with the agonists <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10178"> MDMB-FUBINACA</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9612"> AM11542</a> and <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9613">AM841</a> bound. Previously reported also is the structure of the <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57&familyId=13&familyType=GPCR"> CB<sub>2</sub> cannabinoid receptor</a> with the antagonist <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10177"> AM10257</a> bound.</p> <p>In the first report (<a href="https://www.cell.com/cell/fulltext/S0092-8674(20)30054-4">1</a>), a non-selective, high potency agonist <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=733">WIN55212-2</a> was bound to a complex of the CB<sub>2</sub> cannabinoid receptor with G<sub>i</sub> to “complete the set” of agonist- and antagonist-bound versions of CB<sub>1</sub> and CB<sub>2</sub> receptors. The authors suggest marked similarities in the binding configuration of the agonist WIN55212-2 and the antagonist AM10257. Based on these structures, two novel ligands were generated; one predicted to be an agonist and the other an antagonist. The functional data supported these predictions, although both novel compounds were markedly less potent than their respective positive controls.</p> <p>In the second report (<a href="https://www.cell.com/cell/fulltext/S0092-8674(20)30055-6">2</a>), agonist-bound versions of both CB<sub>1</sub> and CB<sub>2</sub> cannabinoid receptors complexed with Gi were also described to ‘complete and expand the set’. AM12033 is a novel nitrilodimethylheptyl analogue of <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424"> THC</a> with high affinity at both receptors. Structures using this compound were compared to CB<sub>1</sub> receptors bound to the THC-like AM841. The authors suggest similar modes of interaction for agonists at the two receptors, supported by numerous examples of non-selective high potency agonists.</p> <p>Modelling of the second intracellular loop in both reports suggested a structural basis for the CB<sub>2</sub> receptor to couple poorly to Gs. Indeed, a single amino acid variation (L222 in CB<sub>1</sub> and P139 in CB<sub>2</sub> receptors) was highlighted in both studies and evidenced in the previous literature (<a href="https://www.ncbi.nlm.nih.gov/pubmed/23667597">https://www.ncbi.nlm.nih.gov/pubmed/23667597</a>).</p> <p><strong>Comments by Prof. Steve Alexander (<a href="https://twitter.com/mqzspa" target="_blank" rel="noopener">@mqzspa</a>),</strong> <strong>University of Nottingham, UK</strong></p> <p>(1) Xing C. <i>et al.</i> Cryo-EM Structure of the Human Cannabinoid Receptor CB2-G <sub>i</sub> Signaling Complex. <i>Cell</i> (2020) doi:<span class="identifier doi">10.1016/j.cell.2020.01.007 </span>[PMID:<a href="https://www.ncbi.nlm.nih.gov/pubmed/32004460" target="_blank" rel="noopener">32004460</a>]</p> <p>(2) Hua T. <i>et al. </i>Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-G<sub>i</sub> Complex Structures. <i>Cell</i> (2020) doi:10.1016/j.cell.2020.01.008 [PMID:<a href="https://www.ncbi.nlm.nih.gov/pubmed/32004463" target="_blank" rel="noopener">32004463</a>]</p> <p> </p> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/cannabinoids/" rel="tag">cannabinoids</a>, <a href="https://blog.guidetopharmacology.org/tag/cb1/" rel="tag">CB1</a>, <a href="https://blog.guidetopharmacology.org/tag/cb2/" rel="tag">CB2</a>, <a href="https://blog.guidetopharmacology.org/tag/receptor/" rel="tag">receptor</a>, <a href="https://blog.guidetopharmacology.org/tag/structure/" rel="tag">structure</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/hot-topics/" rel="category tag">Hot Topics</a> </div> </div> <div id="post-3870" class="post-3870 post type-post status-publish format-standard hentry category-hot-topics tag-ace2 tag-coronavirus tag-dendritic-cells tag-hcov-229e tag-immunopharmacology tag-pharmacology"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2020/02/03/hot-topics-a-brief-update-on-coronaviruses/" rel="bookmark">Hot Topics: A brief update on coronaviruses</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2020/02/03/hot-topics-a-brief-update-on-coronaviruses/" title="2:54 pm" rel="bookmark"><span class="timestamp">February 3, 2020</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2020/02/03/hot-topics-a-brief-update-on-coronaviruses/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>The new respiratory coronavirus from Wuhan in China is causing intense research activity in the world. Viruses are evidently associated with respiratory infections ranging in severity from the common cold to pneumonia and death. More than 200 viral types have been associated with the common cold, of which 50% of infections are rhinovirus, but also respiratory syncitial virus, influenza – and coronaviruses, particularly human coronavirus-229E (HCoV-229E), which is ‘relatively benign’. Monocytes are relatively resistant to HcoV-229E infection, but rapidly invades, replicates in, and kills dendritic cells within a few hours of infection (Mesel-Lemoine et al., 2012) [1]. Dendritic cells are the sentinel cells in the respiratory tract, and plasmacytoid dendritic cells are a crucial antiviral defence via interferon production. Thus, these viruses can impair control of viral dissemination and the formation of long-lasting immune memory. The cellular receptor for HcoV-229E is CD-13 (<a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1560" target="_blank" rel="noopener">aminopeptidase-N</a>).<br /> The cellular receptors for coronaviruses are critical for cell entry. Severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), and HCoV-NL63, bind to <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1614" target="_blank" rel="noopener">angiotensin converting enzyme2, ACE2</a>, on ciliated cells in the respiratory tract, the crystal structure is known (Song et al., 2018) [2]. The SARS-CoV spike (S) glycoprotein (with S1 and S2 sub-units) on the outer envelope binds to <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1614" target="_blank" rel="noopener">ACE2</a>, fusing viral and cellular membranes, triggering conformational transformations. Cleavage of the S1/S2 subunits by proteases is critical. Indeed, Simmons et al (2005) [3] showed that SARS-CoV infection involved receptor binding, conformational changes receptor binding and subsequent cathepsin L (and type II transmembrane serine proteases) proteolysis within endosomes – with inhibitors of cathepsin L preventing viral entry. SARS-CoV may lead to markedly elevated cytokine levels, leading to tissue damage, pneumonitis, and acute respiratory distress syndrome (ARDS). The spike proteins in SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) are crucial for host specificity and jumping between species, e.g. from bats to humans (Lu et al., 2015) [4], and also the recent cross-over to swine acute diarrhoea syndrome coronavirus (SADS-CoV) to pigs (Zhou et al., 2018) [5]. There is intense interest in the complicated ways whereby coronaviruses engage with their target receptors, are activated and replicate. The rapid evolution of coronaviruses is critical as humans have little or no pre-existing immunity SARS- or MERS-CoV.</p> <p>ACE2 has been identified as a potential receptor for the novel coronavirus that was identified as the cause of the respiratory disease outbreak in Wuhan in late 2019 (referred to as 2019 – nCoV by the WHO, or Wuhan coronavirus) [6,7 & 9]. 2019-nCoV is a betacoronavirus, and, in common with the SARS-CoV [8], the viral spike protein is postulated to engage ACE2 for viral entry [7]. The data presented by Letko and Munzter [7] is preliminary and has not been peer-reviewed, but a rapid pace of research is needed in the present circumstances. For example, in another recent, preliminary report, ACE2 receptor expression is highly expressed in type II alveolar cells (AT2) with much individual variation and the authors reported that the cells also expressed many genes involved in viral reproduction and transmission [10]. While these findings are preliminary, the rapid publications in bioRxiv and similar archives are crucial in what is now officially a global health emergency. This report is a hot topic in the <a href="https://www.guidetopharmacology.org" target="_blank" rel="noopener">IUPHAR/BPS Guide to PHARMACOLOGY</a> (<a href="https://www.guidetopharmacology.org" rel="nofollow">https://www.guidetopharmacology.org</a>), and further underlines the importance of immunopharmacology and the <a href="https://www.guidetoimmunopharmacology.org/immuno/index.jsp" target="_blank" rel="noopener">IUPHAR Guide to IMMUNOPHARMACOLOGY</a> (<a href="https://www.guidetoimmunopharmacology.org/immuno/index.jsp" rel="nofollow">https://www.guidetoimmunopharmacology.org/immuno/index.jsp</a>).</p> <p><strong>Comments by Prof. Michael Spedding, Spedding Reseach Solutions; Prof. Steve Alexander (<a href="https://twitter.com/mqzspa?lang=en" target="_blank" rel="noopener">@mqzspa</a>), University of Nottingham; Dr. Elena Faccenda, University of Edinburgh; and Prof. Francesca Levi-Schaffer, The Hebrew University of Jerusalem.</strong></p> <p><em>Note from bioRxiv: <span style="color:var(--color-text);">bioRxiv is receiving many new papers on coronavirus 2019-nCoV. A reminder: these are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.</span></em></p> <p> </p> <ol> <li>Mesel-Lemoine M, Millet J, Vidalain PO, Law H, Vabret A, Lorin V, Escriou N, Albert ML, Nal B, Tangy F. A human coronavirus responsible for the common cold massively kills dendritic cells but not monocytes. J Virol. 2012 Jul;86(14):7577-87. doi: 10.1128/JVI.00269-12. Epub 2012 May 2. PubMed PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/22553325" target="_blank" rel="noopener">22553325</a>; PubMed Central PMCID: PMC3416289.</li> <li>Song W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathog. 2018 Aug 13;14(8):e1007236. doi: 10.1371/journal.ppat.1007236. eCollection 2018 Aug. PubMed PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/30102747" target="_blank" rel="noopener">30102747</a>; PubMed Central PMCID: PMC6107290.</li> <li>Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81. Epub 2005 Aug 4. PubMed PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/16081529" target="_blank" rel="noopener">16081529</a>; PubMed Central PMCID: PMC1188015.</li> <li>Lu R, Wang Y, Wang W, Nie K, Zhao Y, Su J, Deng Y, Zhou W, Li Y, Wang H, Wang W, Ke C, Ma X, Wu G, Tan W. Complete Genome Sequence of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) from the First Imported MERS-CoV Case in China. Genome Announc. 2015 Aug 13;3(4). pii: e00818-15. doi: 10.1128/genomeA.00818-15. PubMed PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/26272560" target="_blank" rel="noopener">26272560</a>; PubMed Central PMCID: PMC4536671.</li> <li>Zhou L, Sun Y, Lan T, Wu R, Chen J, Wu Z, Xie Q, Zhang X, Ma J. Retrospective detection and phylogenetic analysis of swine acute diarrhoea syndrome coronavirus in pigs in southern China. Transbound Emerg Dis. 2019 Mar;66(2):687-695. doi: 10.1111/tbed.13008. Epub 2019 Jan 9. PubMed PMID: <a href="//pubmed.ncbi.nlm.nih.gov/30171801" target="_blank" rel="noopener">30171801</a>.</li> <li>Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020 Jan 24;12(2). pii: E135. doi: 10.3390/v12020135. PubMed PMID: <a href="//pubmed.ncbi.nlm.nih.gov/31991541" target="_blank" rel="noopener">31991541</a>.</li> <li>Letko M, Munster V. Functional assessment of cell entry and receptor usage for lineage B β coronaviruses, including 2019-nCoV. bioRxiv 2020.01.22.915660; doi: <a href="https://doi.org/10.1101/2020.01.22.915660" target="_blank" rel="noopener">10.1101/2020.01.22.915660</a></li> <li>Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005 Sep 16;309(5742):1864-8. PubMed PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/16166518" target="_blank" rel="noopener">16166518</a>.</li> <li>Peng Z, Shi Z-L. (2020) Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv 2020.01.22.914952; doi: <a href="https://www.biorxiv.org/content/10.1101/2020.01.22.914952v2" target="_blank" rel="noopener">10.1101/2020.01.22.914952 </a></li> <li>Yu Zhao, Zixian Zhao, Yujia Wang, Yueqing Zhou, Yu Ma, Wei Zuo.Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov bioRxiv 2020.01.26.919985 doi: <a href="https://doi.org/10.1101/2020.01.26.919985" target="_blank" rel="noopener">10.1101/2020.01.26.919985</a></li> </ol> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/ace2/" rel="tag">ACE2</a>, <a href="https://blog.guidetopharmacology.org/tag/coronavirus/" rel="tag">coronavirus</a>, <a href="https://blog.guidetopharmacology.org/tag/dendritic-cells/" rel="tag">dendritic cells</a>, <a href="https://blog.guidetopharmacology.org/tag/hcov-229e/" rel="tag">HcoV-229E</a>, <a href="https://blog.guidetopharmacology.org/tag/immunopharmacology/" rel="tag">immunopharmacology</a>, <a href="https://blog.guidetopharmacology.org/tag/pharmacology/" rel="tag">pharmacology</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/hot-topics/" rel="category tag">Hot Topics</a> </div> </div> <div id="post-3858" class="post-3858 post type-post status-publish format-standard hentry category-hot-topics tag-calcium-channel tag-hot-topic tag-pharmacology tag-protein-structure tag-vgics tag-voltage-gated"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2020/01/07/hot-topics-cryo-em-structure-of-a-selective-t-type-calcium-channel-blocker-bound-to-the-cav3-1-voltage-gated-calcium-channel/" rel="bookmark">Hot Topics: Cryo-EM structure of a selective T-type calcium channel blocker bound to the Cav3.1 voltage-gated calcium channel</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2020/01/07/hot-topics-cryo-em-structure-of-a-selective-t-type-calcium-channel-blocker-bound-to-the-cav3-1-voltage-gated-calcium-channel/" title="1:26 pm" rel="bookmark"><span class="timestamp">January 7, 2020</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2020/01/07/hot-topics-cryo-em-structure-of-a-selective-t-type-calcium-channel-blocker-bound-to-the-cav3-1-voltage-gated-calcium-channel/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>Nieng Yan’s group has now published the cryo-EM structure of the selective T-type Ca<sup>2+</sup> channel blocker <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7718">Z944</a> bound to the pore-forming α1-subunit of <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=535&familyId=80&familyType=IC">Cav3.1</a> T-type Ca<sup>2+</sup> channels (1). This nicely adds to recent publications reporting of the high-resolution structures of L-type Ca<sup>2+</sup> channel blockers (<a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2514">nifedipine</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2523">nimodipine</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6981">amlodipine</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2406">verapamil</a>, <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2298">diltiazem</a>) bound to the rabbit <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=528&familyId=80&familyType=IC">Cav1.1</a> skeletal muscle Ca<sup>2+</sup> channel (2) and to the model Ca<sup>2+</sup> channel CavAb (Ca<sup>2+</sup>-selectivity engineered into the bacterial homotetrameric Na<sup>+</sup>-channel NavAb; 3, 4).</p> <p>Together these three publications provide important insight into how small molecule channel blockers interact with their high affinity binding domains within Ca<sup>2+</sup> channels. They also reveal a remarkable similarity between the core structures (i.e. the voltage-sensors and the pore domains) between not only the closely related <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=528&familyId=80&familyType=IC">Cav1.1</a> and <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=535&familyId=80&familyType=IC">Cav3.1</a> channels but also their bacterial ancestor CavAb.</p> <p>Moreover, although some differences exist, the binding poses of L-type Ca<sup>2+</sup> channel blockers in the mammalian <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=528&familyId=80&familyType=IC">Cav1.1</a> and the bacterial CavAb channel are very similar. In both structures <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2406">verapamil</a> and <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2298">diltiazem</a> bind within the central cavity, compatible with their pore-blocking properties predicted in functional studies. In contrast, dihydropyridines like <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2523">nimodipine</a> and <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2514">nifedipine</a> bind within a fenestration created by adjacent transmembrane S6 helices (IIIS6 and IVS6). These fenestrations penetrate the sides of the central cavities in both voltage gated Na<sup>+</sup>– and Ca<sup>2+</sup> channels and connect them to the surrounding lipid bilayer of the plasma membrane (5). In accordance with functional studies, these dihydropyridines must therefore inhibit L-type channels by allosterically interfering with gating rather than pore block.</p> <p>These findings raise the important question about how <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7718">Z944</a> can selectively inhibit T-type Ca<sup>2+</sup> channels. This drug is currently in clinical development for the treatment of epilepsy and neuropathic pain. It appears that <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7718">Z944</a> bound to <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=535&familyId=80&familyType=IC">Cav3.1</a> combines the binding modes of both pore blockers and allosteric blockers. Its phenyl ring projects into the fenestration between repeats II and III (similar to <a href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2514">nifedipine</a> binding), whereas the other end of the molecule projects down through the central cavity to the intracellular mouth of the pore. A prominent interaction was found with lysine-1462, a residue unique for T-type channels. Its mutation to L-type residues reduced drug sensitivity in functional studies suggesting that it is one of the determinants for T-type selectivity.</p> <p>Taken together the accumulating structural insight into drug binding and modulation will greatly facilitate structure-guided drug discovery. This may lead to new oral subtype-selective blockers of voltage-gated Ca<sup>2+</sup> channels with therapeutic potential for the treatment of epilepsy (T-type), pain (T-type, N-type), tremor (T-type), primary aldosteronism (<a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=530&familyId=80&familyType=IC">Cav1.3</a> L-type), progression of Parkinsons disease (<a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=530&familyId=80&familyType=IC">Cav1.3</a>, R-type) or rare neurodevelopmental disorders (<a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=530&familyId=80&familyType=IC">Cav1.3</a> L-type) (6,7).</p> <p><strong>Comments by Jörg Striessnig</strong>, University of Innsbruck, Chair for NC-IUPHAR Subcommitee for <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=80">Voltage-gated calcium channels</a>, Liaison for NC-IUPHAR subcommittees on <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=696&familyType=IC">Voltage-gated ion channels</a></p> <ol> <li>Zhao, Y., Huang, G., Wu, Q., Wu, K., Li, R., Lei, J., Pan, X., and Yan, N. (2019). Cryo-EM structures of apo and antagonist-bound human Cav3.1. Nature. 576, 492–497 [PMID: <a href="https://www.ncbi.nlm.nih.gov/pubmed/31766050">31766050</a>].</li> <li>Zhao, Y., Huang, G., Wu, J., Wu, Q., Gao, S., Yan, Z., Lei, J., and Yan, N. (2019). Molecular Basis for Ligand Modulation of a Mammalian Voltage-Gated Ca<sup>2+</sup> Cell 177, 1495-1506 [PMID: <a href="https://www.ncbi.nlm.nih.gov/pubmed/31150622">31150622</a>].</li> <li>Tang, L., El-Din, T.M.G., Swanson, T.M., Pryde, D.C., Scheuer, T., Zheng, N., and Catterall, W.A. (2016). Structural basis for inhibition of a voltage-gated Ca<sup>2+</sup> channel by Ca<sup>2+</sup> antagonist drugs. Nature 537, 117–121 [PMID: <a href="https://www.ncbi.nlm.nih.gov/pubmed/https://www.ncbi.nlm.nih.gov/pubmed/27556947">27556947</a>].</li> <li>Tang, L., Gamal El-Din, T.M., Lenaeus, M.J., Zheng, N., and Catterall, W.A. (2019). Structural Basis for Diltiazem Block of a Voltage-Gated Ca<sup>2+</sup> Mol. Pharmacol. 96, 485–492 [PMID: <a href="https://www.ncbi.nlm.nih.gov/pubmed/31391290">31391290</a>].</li> <li>Payandeh, J., Scheuer, T., Zheng, N., Catterall, W.A., 2011. The crystal structure of a voltage-gated sodium channel. Nature 475, 353–358 [PMID: <a href="https://www.ncbi.nlm.nih.gov/pubmed/21743477">21743477</a>].</li> <li>Pinggera, A., and Striessnig, J. (2016). Cav 1.3 (CACNA1D) L-type Ca<sup>2+</sup> channel dysfunction in CNS disorders. J. Physiol. (Lond.) 594, 5839–5849.</li> <li>Benkert, J., Hess, S., Roy, S., Beccano-Kelly, D., Wiederspohn, N., Duda, J., Simons, C., Patil, K., Gaifullina, A., Mannal, N., et al. (2019). Cav2.3 channels contribute to dopaminergic neuron loss in a model of Parkinson’s disease. Nat. Commun. 10, 5094. doi:10.1038/s41467-019-12834-x</li> <li style="list-style-type:none;"></li> </ol> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/calcium-channel/" rel="tag">calcium channel</a>, <a href="https://blog.guidetopharmacology.org/tag/hot-topic/" rel="tag">hot topic</a>, <a href="https://blog.guidetopharmacology.org/tag/pharmacology/" rel="tag">pharmacology</a>, <a href="https://blog.guidetopharmacology.org/tag/protein-structure/" rel="tag">protein structure</a>, <a href="https://blog.guidetopharmacology.org/tag/vgics/" rel="tag">VGICs</a>, <a href="https://blog.guidetopharmacology.org/tag/voltage-gated/" rel="tag">voltage-gated</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/hot-topics/" rel="category tag">Hot Topics</a> </div> </div> <div id="post-3853" class="post-3853 post type-post status-publish format-standard hentry category-hot-topics tag-gpcrs tag-hot-topic tag-pharmacology tag-protein-structure"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2019/12/12/hot-topics-deciphering-the-crystal-structure-of-the-leukotriene-receptor-cyslt2-opens-up-for-improved-therapeutics/" rel="bookmark">Hot Topics: Deciphering the crystal structure of the leukotriene receptor CysLT2 opens up for improved therapeutics</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2019/12/12/hot-topics-deciphering-the-crystal-structure-of-the-leukotriene-receptor-cyslt2-opens-up-for-improved-therapeutics/" title="9:29 am" rel="bookmark"><span class="timestamp">December 12, 2019</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2019/12/12/hot-topics-deciphering-the-crystal-structure-of-the-leukotriene-receptor-cyslt2-opens-up-for-improved-therapeutics/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p>Leukotrienes are lipid mediators of inflammation, initially recognized for their role in asthma, but also having potent effects in for example cardiovascular and neurological diseases as well as in cancer. The initial pharmacological classification of <a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=35" target="_blank" rel="noopener">leukotriene receptors</a> based on antagonist selectivity in smooth muscle was shown to be valid at the gene and protein levels. Following the recent description of the <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=269&familyId=35&familyType=GPCR" target="_blank" rel="noopener">CysLT1 receptor</a> structure, Gusach <em>et al</em>. now describe the crystal structures of the <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=270&familyId=35&familyType=GPCR" target="_blank" rel="noopener">CysLT2 receptor</a> in complex with dual CysLT1/CysLT2 receptor antagonists (1). This is an important advancement, since it allows to reveal specific characteristics of the two CysLT receptors in terms of ligand recognition and subtype selectivity. In this context, differences in the intracellular helix 8 emerge as particular subtype determinants, which may affect G-protein regulation and β-arrestin binding. The study by Gusach <em>et al.</em> (1) further provides structural insights into the changes in ligand binding and downstream signaling by CysLT2R disease-related single nucleotide polymorphisms (SNP) associated with asthma and cancer. The deciphering of the crystal structures for the CysLT1 and CysLT2 receptors will open up for the design of CysLT receptor antagonists with improved affinity/efficacy or subtype selectivity profiles. The insights into the CysLT receptor genome-structure-function relations may facilitate the prediction of disease associations and potentially further expanding the therapeutic indications of CysLT receptor antagonists.</p> <p><strong>Comments by </strong><strong>Magnus Bäck, MD PhD, (</strong><a href="https://twitter.com/TransCardio" target="_blank" rel="noopener">@TransCardio</a><strong>), </strong>Karolinska Institutet and University Hospital, Stockholm, Sweden; Chairman NC-IUPHAR subcommittee on Leukotriene Receptors</p> <p>(1) Gusach, A., Luginina, A., Marin, E. <i>et al.</i> Structural basis of ligand selectivity and disease mutations in cysteinyl leukotriene receptors. <i>Nat Commun</i> <b>10, </b>5573 (2019) doi:10.1038/s41467-019-13348-2 [PMID:<a href="https://www.ncbi.nlm.nih.gov/pubmed/31811124" target="_blank" rel="noopener">31811124</a>]</p> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/gpcrs/" rel="tag">GPCRs</a>, <a href="https://blog.guidetopharmacology.org/tag/hot-topic/" rel="tag">hot topic</a>, <a href="https://blog.guidetopharmacology.org/tag/pharmacology/" rel="tag">pharmacology</a>, <a href="https://blog.guidetopharmacology.org/tag/protein-structure/" rel="tag">protein structure</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/hot-topics/" rel="category tag">Hot Topics</a> </div> </div> <div id="post-3848" class="post-3848 post type-post status-publish format-standard hentry category-hot-topics tag-gpcrs tag-hot-topic tag-protein-structure"> <h1 class="post-title"><a href="https://blog.guidetopharmacology.org/2019/11/28/hot-topics-new-crystal-structure-of-the-muscarinic-m5-receptor-completes-the-set/" rel="bookmark">Hot Topics: New crystal structure of the muscarinic M5 receptor completes the set</a></h1> <div class="post-meta"> <span class="meta-prep meta-prep-author posted">Posted on </span><a href="https://blog.guidetopharmacology.org/2019/11/28/hot-topics-new-crystal-structure-of-the-muscarinic-m5-receptor-completes-the-set/" title="10:32 am" rel="bookmark"><span class="timestamp">November 28, 2019</span></a><span class="byline"> by </span><span class="author vcard"><a class="url fn n" href="https://blog.guidetopharmacology.org/author/guidetopharmacology/" title="View all posts by guidetopharmacology">guidetopharmacology</a></span> <span class="comments-link"> <span class="mdash">—</span> <a href="https://blog.guidetopharmacology.org/2019/11/28/hot-topics-new-crystal-structure-of-the-muscarinic-m5-receptor-completes-the-set/#respond">Leave a comment</a> </span> </div> <div class="post-entry"> <p><a href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=2">Muscarinic receptors</a> consist of 5 G protein-coupled receptors which along with nicotinic ion channels mediate the effects of acetylcholine. Despite years of research on the role of muscarinic receptors in the brain and periphery the <a href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=17&familyId=2&familyType=GPCR">Muscarinic M5</a> receptor has stood out in contrast to M1 -M4 as one which we know little about. The M5 receptor has a unique and unusual distribution in the brain being enriched in mid brain dopamine neurons and in the cerebellum. A lack of selective chemical tools has hampered our ability to study the function of the receptor. Now Vuckovic et al. [1] have solved the X-ray crystal structure of the M5 receptor in complex with the non-selective antagonist tiotropium in the presence of a conformational stabilizing mutation. Since tiotropium was also used to solve the structure of several other muscarinic receptors a direct comparison can be made across the subtypes which will enable the design of selective tool compounds. Significant progress has been made in utilizing crystal structures to design selective orthosteric and allosteric ligands at this family of receptors. This final structure completes the set of muscarinic receptor structures solved and hopefully will pave the way to further understanding of the biology of M5 and its role in disorders such as drug addiction and depression.</p> <p><strong>Comments by Fiona H. Marshall, Discovery Research UK, MSD (<a href="https://twitter.com/aston_fm?lang=en" target="_blank" rel="noopener">@aston_fm</a>)</strong></p> <p>(1) Vuckovic Z et al. (2019). Crystal Structure of the M<sub>5</sub> Muscarinic Acetylcholine Receptor. <i>Proc Natl Acad Sci USA</i>, DOI: 10.1073/pnas.1914446116. [PMID: <a href="https://www.ncbi.nlm.nih.gov/pubmed/31772027" target="_blank" rel="noopener noreferrer">31772027</a>]</p> </div> <div class="post-data"> Tagged with: <a href="https://blog.guidetopharmacology.org/tag/gpcrs/" rel="tag">GPCRs</a>, <a href="https://blog.guidetopharmacology.org/tag/hot-topic/" rel="tag">hot topic</a>, <a href="https://blog.guidetopharmacology.org/tag/protein-structure/" rel="tag">protein structure</a><br /> Posted in <a href="https://blog.guidetopharmacology.org/category/hot-topics/" rel="category tag">Hot Topics</a> </div> </div> <div class="navigation"> <div class="previous"><a href="https://blog.guidetopharmacology.org/page/2/" >‹ Older posts</a></div> <div class="next"></div> </div> </div> <div id="widgets" class="grid col-300 fit"> <div id="top-posts-4" class="widget-wrapper widget_top-posts"><div class="widget-title">Top Posts & Pages</div><ul class='widgets-list-layout no-grav'> <li><a href="https://blog.guidetopharmacology.org/2025/04/01/database-release-2025-1/" title="Database Release 2025.1" class="bump-view" data-bump-view="tp"><img loading="lazy" width="40" height="40" src="https://secure.gravatar.com/blavatar/b0ee620758eba563c7003e3aeb0236b12bff8ba81d569b54bdd4ab6b9471a595?s=40" srcset="https://secure.gravatar.com/blavatar/b0ee620758eba563c7003e3aeb0236b12bff8ba81d569b54bdd4ab6b9471a595?s=40 1x" alt="Database Release 2025.1" data-pin-nopin="true" class="widgets-list-layout-blavatar" /></a><div class="widgets-list-layout-links"> <a href="https://blog.guidetopharmacology.org/2025/04/01/database-release-2025-1/" title="Database Release 2025.1" class="bump-view" data-bump-view="tp">Database Release 2025.1</a> </div> </li></ul> </div><div id="rss_links-3" class="widget-wrapper widget_rss_links"><div class="widget-title">Follow this Blog!</div><p class="size-small"><a class="feed-image-link" href="https://blog.guidetopharmacology.org/feed/" title="Subscribe to Posts"><img src="https://blog.guidetopharmacology.org/i/rss/orange-small.png" alt="RSS Feed" /></a> <a href="https://blog.guidetopharmacology.org/feed/" title="Subscribe to Posts">RSS - Posts</a></p> </div><div id="facebook-likebox-4" class="widget-wrapper widget_facebook_likebox"> <div id="fb-root"></div> <div class="fb-page" data-href="https://www.facebook.com/pages/Guide-to-PHARMACOLOGY/231393780304076" data-width="225" data-height="130" data-hide-cover="false" data-show-facepile="false" data-tabs="timeline" data-hide-cta="false" data-small-header="false"> <div class="fb-xfbml-parse-ignore"><blockquote cite="https://www.facebook.com/pages/Guide-to-PHARMACOLOGY/231393780304076"><a href="https://www.facebook.com/pages/Guide-to-PHARMACOLOGY/231393780304076"></a></blockquote></div> </div> </div> </div> </div> </div> <div id="footer" class="clearfix"> <div id="footer-wrapper"> <div class="grid col-940"> <div class="grid col-540"> </div> <div class="grid col-380 fit"> <ul class="social-icons"> <li class="twitter-icon"><a href="https://twitter.com/GuidetoPHARM"><img src="https://s2.wp.com/wp-content/themes/pub/responsive/icons/twitter-icon.png" width="24" height="24" alt="Twitter"></a></li><li class="facebook-icon"><a href="https://www.facebook.com/pages/Guide-to-PHARMACOLOGY/231393780304076"><img src="https://s2.wp.com/wp-content/themes/pub/responsive/icons/facebook-icon.png" width="24" height="24" alt="Facebook"></a></li><li class="linkedin-icon"><a href="https://uk.linkedin.com/company/guide-to-pharmacology"><img src="https://s2.wp.com/wp-content/themes/pub/responsive/icons/linkedin-icon.png" width="24" height="24" alt="LinkedIn"></a></li> </ul> </div> </div> <div class="grid col-300 copyright"> © 2025 <a href="https://blog.guidetopharmacology.org/" title="guidetopharmacology blog">guidetopharmacology blog</a> </div> <div class="grid col-300 scroll-top"><a href="#scroll-top" title="scroll to top">↑</a></div> <div class="grid col-300 fit powered"> <a href="https://wordpress.com/?ref=footer_blog" rel="nofollow">Blog at WordPress.com.</a> </div> </div> </div> <script type="text/javascript"> var infiniteScroll = {"settings":{"id":"content-blog","ajaxurl":"https:\/\/blog.guidetopharmacology.org\/?infinity=scrolling","type":"scroll","wrapper":true,"wrapper_class":"infinite-wrap","footer":"wrapper","click_handle":"1","text":"Older posts","totop":"Scroll back to top","currentday":"28.11.19","order":"DESC","scripts":[],"styles":[],"google_analytics":false,"offset":1,"history":{"host":"blog.guidetopharmacology.org","path":"\/page\/%d\/","use_trailing_slashes":true,"parameters":""},"query_args":{"error":"","m":"","p":0,"post_parent":"","subpost":"","subpost_id":"","attachment":"","attachment_id":0,"name":"","pagename":"","page_id":0,"second":"","minute":"","hour":"","day":0,"monthnum":0,"year":0,"w":0,"category_name":"","tag":"","cat":"","tag_id":"","author":"","author_name":"","feed":"","tb":"","paged":0,"meta_key":"","meta_value":"","preview":"","s":"","sentence":"","title":"","fields":"all","menu_order":"","embed":"","category__in":[],"category__not_in":[],"category__and":[],"post__in":[],"post__not_in":[],"post_name__in":[],"tag__in":[],"tag__not_in":[],"tag__and":[],"tag_slug__in":[],"tag_slug__and":[],"post_parent__in":[],"post_parent__not_in":[],"author__in":[],"author__not_in":[],"search_columns":[],"lazy_load_term_meta":false,"posts_per_page":50,"ignore_sticky_posts":false,"suppress_filters":false,"cache_results":true,"update_post_term_cache":true,"update_menu_item_cache":false,"update_post_meta_cache":true,"post_type":"","nopaging":false,"comments_per_page":"50","no_found_rows":false,"order":"DESC"},"query_before":"2025-04-11 13:41:42","last_post_date":"2019-11-28 10:32:43","body_class":"infinite-scroll neverending","loading_text":"Loading new page","stats":"blog=28218243&v=wpcom&tz=0&user_id=0&home=1&subd=guidetopharmacology&x_pagetype=infinite"}}; </script>  <script type="speculationrules"> {"prefetch":[{"source":"document","where":{"and":[{"href_matches":"\/*"},{"not":{"href_matches":["\/wp-*.php","\/wp-admin\/*","\/files\/*","\/wp-content\/*","\/wp-content\/plugins\/*","\/wp-content\/themes\/pub\/responsive\/*","\/*\\?(.+)"]}},{"not":{"selector_matches":"a[rel~=\"nofollow\"]"}},{"not":{"selector_matches":".no-prefetch, .no-prefetch a"}}]},"eagerness":"conservative"}]} </script> <script type="text/javascript" src="//0.gravatar.com/js/hovercards/hovercards.min.js?ver=2025157d8bf6c02970a26c6b0c26b0fcfc89796aa30f84307cffd8fd28d2bcca53dd7a" id="grofiles-cards-js"></script> <script type="text/javascript" id="wpgroho-js-extra"> /* <![CDATA[ */ var WPGroHo = {"my_hash":""}; /* ]]> */ </script> <script crossorigin='anonymous' type='text/javascript' src='https://s2.wp.com/wp-content/mu-plugins/gravatar-hovercards/wpgroho.js?m=1610363240i'></script> <script> // Initialize and attach hovercards to all gravatars ( function() { function init() { if ( typeof Gravatar === 'undefined' ) { return; } if ( typeof Gravatar.init !== 'function' ) { return; } Gravatar.profile_cb = function ( hash, id ) { WPGroHo.syncProfileData( hash, id ); }; Gravatar.my_hash = WPGroHo.my_hash; Gravatar.init( 'body', '#wp-admin-bar-my-account', { i18n: { 'Edit your profile →': 'Edit your profile →', 'View profile →': 'View profile →', 'Contact': 'Contact', 'Send money': 'Send money', 'Sorry, we are unable to load this Gravatar profile.': 'Sorry, we are unable to load this Gravatar profile.', 'Profile not found.': 'Profile not found.', 'Too Many Requests.': 'Too Many Requests.', 'Internal Server Error.': 'Internal Server Error.', }, } ); } if ( document.readyState !== 'loading' ) { init(); } else { document.addEventListener( 'DOMContentLoaded', init ); } } )(); </script> <div style="display:none"> </div> <div id="infinite-footer"> <div class="container"> <div class="blog-info"> <a id="infinity-blog-title" href="https://blog.guidetopharmacology.org/" rel="home"> guidetopharmacology blog </a> </div> <div class="blog-credits"> <a href="https://wordpress.com/?ref=footer_blog" rel="nofollow">Blog at WordPress.com.</a> </div> </div> </div> <script type="text/javascript"> ( function() { function init() { document.body.addEventListener( 'is.post-load', function() { if ( typeof __ATA.insertInlineAds === 'function' ) { __ATA.insertInlineAds(); } } ); } if ( document.readyState !== 'loading' ) { init(); } else { document.addEventListener( 'DOMContentLoaded', init ); } } )(); </script>  <script type="text/javascript"> ( function () { var setupPrivacy = function() { // Minimal Mozilla Cookie library // https://developer.mozilla.org/en-US/docs/Web/API/Document/cookie/Simple_document.cookie_framework var cookieLib = window.cookieLib = {getItem:function(e){return e&&decodeURIComponent(document.cookie.replace(new RegExp("(?:(?:^|.*;)\\s*"+encodeURIComponent(e).replace(/[\-\.\+\*]/g,"\\$&")+"\\s*\\=\\s*([^;]*).*$)|^.*$"),"$1"))||null},setItem:function(e,o,n,t,r,i){if(!e||/^(?:expires|max\-age|path|domain|secure)$/i.test(e))return!1;var c="";if(n)switch(n.constructor){case Number:c=n===1/0?"; expires=Fri, 31 Dec 9999 23:59:59 GMT":"; max-age="+n;break;case String:c="; expires="+n;break;case Date:c="; expires="+n.toUTCString()}return"rootDomain"!==r&&".rootDomain"!==r||(r=(".rootDomain"===r?".":"")+document.location.hostname.split(".").slice(-2).join(".")),document.cookie=encodeURIComponent(e)+"="+encodeURIComponent(o)+c+(r?"; domain="+r:"")+(t?"; path="+t:"")+(i?"; secure":""),!0}}; // Implement IAB USP API. window.__uspapi = function( command, version, callback ) { // Validate callback. if ( typeof callback !== 'function' ) { return; } // Validate the given command. if ( command !== 'getUSPData' || version !== 1 ) { callback( null, false ); return; } // Check for GPC. If set, override any stored cookie. if ( navigator.globalPrivacyControl ) { callback( { version: 1, uspString: '1YYN' }, true ); return; } // Check for cookie. var consent = cookieLib.getItem( 'usprivacy' ); // Invalid cookie. if ( null === consent ) { callback( null, false ); return; } // Everything checks out. Fire the provided callback with the consent data. callback( { version: 1, uspString: consent }, true ); }; // Initialization. document.addEventListener( 'DOMContentLoaded', function() { // Internal functions. var setDefaultOptInCookie = function() { var value = '1YNN'; var domain = '.wordpress.com' === location.hostname.slice( -14 ) ? '.rootDomain' : location.hostname; cookieLib.setItem( 'usprivacy', value, 365 * 24 * 60 * 60, '/', domain ); }; var setDefaultOptOutCookie = function() { var value = '1YYN'; var domain = '.wordpress.com' === location.hostname.slice( -14 ) ? '.rootDomain' : location.hostname; cookieLib.setItem( 'usprivacy', value, 24 * 60 * 60, '/', domain ); }; var setDefaultNotApplicableCookie = function() { var value = '1---'; var domain = '.wordpress.com' === location.hostname.slice( -14 ) ? '.rootDomain' : location.hostname; cookieLib.setItem( 'usprivacy', value, 24 * 60 * 60, '/', domain ); }; var setCcpaAppliesCookie = function( applies ) { var domain = '.wordpress.com' === location.hostname.slice( -14 ) ? '.rootDomain' : location.hostname; cookieLib.setItem( 'ccpa_applies', applies, 24 * 60 * 60, '/', domain ); } var maybeCallDoNotSellCallback = function() { if ( 'function' === typeof window.doNotSellCallback ) { return window.doNotSellCallback(); } return false; } // Look for usprivacy cookie first. var usprivacyCookie = cookieLib.getItem( 'usprivacy' ); // Found a usprivacy cookie. if ( null !== usprivacyCookie ) { // If the cookie indicates that CCPA does not apply, then bail. if ( '1---' === usprivacyCookie ) { return; } // CCPA applies, so call our callback to add Do Not Sell link to the page. maybeCallDoNotSellCallback(); // We're all done, no more processing needed. return; } // We don't have a usprivacy cookie, so check to see if we have a CCPA applies cookie. var ccpaCookie = cookieLib.getItem( 'ccpa_applies' ); // No CCPA applies cookie found, so we'll need to geolocate if this visitor is from California. // This needs to happen client side because we do not have region geo data in our $SERVER headers, // only country data -- therefore we can't vary cache on the region. if ( null === ccpaCookie ) { var request = new XMLHttpRequest(); request.open( 'GET', 'https://public-api.wordpress.com/geo/', true ); request.onreadystatechange = function () { if ( 4 === this.readyState ) { if ( 200 === this.status ) { // Got a geo response. Parse out the region data. var data = JSON.parse( this.response ); var region = data.region ? data.region.toLowerCase() : ''; var ccpa_applies = ['california', 'colorado', 'connecticut', 'delaware', 'indiana', 'iowa', 'montana', 'new jersey', 'oregon', 'tennessee', 'texas', 'utah', 'virginia'].indexOf( region ) > -1; // Set CCPA applies cookie. This keeps us from having to make a geo request too frequently. setCcpaAppliesCookie( ccpa_applies ); // Check if CCPA applies to set the proper usprivacy cookie. if ( ccpa_applies ) { if ( maybeCallDoNotSellCallback() ) { // Do Not Sell link added, so set default opt-in. setDefaultOptInCookie(); } else { // Failed showing Do Not Sell link as required, so default to opt-OUT just to be safe. setDefaultOptOutCookie(); } } else { // CCPA does not apply. setDefaultNotApplicableCookie(); } } else { // Could not geo, so let's assume for now that CCPA applies to be safe. setCcpaAppliesCookie( true ); if ( maybeCallDoNotSellCallback() ) { // Do Not Sell link added, so set default opt-in. setDefaultOptInCookie(); } else { // Failed showing Do Not Sell link as required, so default to opt-OUT just to be safe. setDefaultOptOutCookie(); } } } }; // Send the geo request. request.send(); } else { // We found a CCPA applies cookie. if ( ccpaCookie === 'true' ) { if ( maybeCallDoNotSellCallback() ) { // Do Not Sell link added, so set default opt-in. setDefaultOptInCookie(); } else { // Failed showing Do Not Sell link as required, so default to opt-OUT just to be safe. setDefaultOptOutCookie(); } } else { // CCPA does not apply. setDefaultNotApplicableCookie(); } } } ); }; // Kickoff initialization. if ( window.defQueue && defQueue.isLOHP && defQueue.isLOHP === 2020 ) { defQueue.items.push( setupPrivacy ); } else { setupPrivacy(); } } )(); </script>  <div class="widget widget_eu_cookie_law_widget"> <div class="hide-on-button ads-active" data-hide-timeout="30" data-consent-expiration="180" id="eu-cookie-law" style="display: none" > <form method="post"> <input type="submit" value="Close and accept" class="accept" /> Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use. <br /> To find out more, including how to control cookies, see here: <a href="https://automattic.com/cookies/" rel="nofollow"> Cookie Policy </a> </form> </div> </div> <div id="actionbar" dir="ltr" style="display: none;" class="actnbr-pub-responsive actnbr-has-follow actnbr-has-actions"> <ul> <li class="actnbr-btn actnbr-hidden"> <a class="actnbr-action actnbr-actn-follow " href=""> <svg class="gridicon" height="20" width="20" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20"><path clip-rule="evenodd" d="m4 4.5h12v6.5h1.5v-6.5-1.5h-1.5-12-1.5v1.5 10.5c0 1.1046.89543 2 2 2h7v-1.5h-7c-.27614 0-.5-.2239-.5-.5zm10.5 2h-9v1.5h9zm-5 3h-4v1.5h4zm3.5 1.5h-1v1h1zm-1-1.5h-1.5v1.5 1 1.5h1.5 1 1.5v-1.5-1-1.5h-1.5zm-2.5 2.5h-4v1.5h4zm6.5 1.25h1.5v2.25h2.25v1.5h-2.25v2.25h-1.5v-2.25h-2.25v-1.5h2.25z" fill-rule="evenodd"></path></svg> <span>Subscribe</span> </a> <a class="actnbr-action actnbr-actn-following no-display" href=""> <svg class="gridicon" height="20" width="20" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20"><path fill-rule="evenodd" clip-rule="evenodd" d="M16 4.5H4V15C4 15.2761 4.22386 15.5 4.5 15.5H11.5V17H4.5C3.39543 17 2.5 16.1046 2.5 15V4.5V3H4H16H17.5V4.5V12.5H16V4.5ZM5.5 6.5H14.5V8H5.5V6.5ZM5.5 9.5H9.5V11H5.5V9.5ZM12 11H13V12H12V11ZM10.5 9.5H12H13H14.5V11V12V13.5H13H12H10.5V12V11V9.5ZM5.5 12H9.5V13.5H5.5V12Z" fill="#008A20"></path><path class="following-icon-tick" d="M13.5 16L15.5 18L19 14.5" stroke="#008A20" stroke-width="1.5"></path></svg> <span>Subscribed</span> </a> <div class="actnbr-popover tip tip-top-left actnbr-notice" id="follow-bubble"> <div class="tip-arrow"></div> <div class="tip-inner actnbr-follow-bubble"> <ul> <li class="actnbr-sitename"> <a href="https://blog.guidetopharmacology.org"> <img loading='lazy' alt='' src='https://secure.gravatar.com/blavatar/b0ee620758eba563c7003e3aeb0236b12bff8ba81d569b54bdd4ab6b9471a595?s=50&d=https%3A%2F%2Fs2.wp.com%2Fi%2Flogo%2Fwpcom-gray-white.png' srcset='https://secure.gravatar.com/blavatar/b0ee620758eba563c7003e3aeb0236b12bff8ba81d569b54bdd4ab6b9471a595?s=50&d=https%3A%2F%2Fs2.wp.com%2Fi%2Flogo%2Fwpcom-gray-white.png 1x, https://secure.gravatar.com/blavatar/b0ee620758eba563c7003e3aeb0236b12bff8ba81d569b54bdd4ab6b9471a595?s=75&d=https%3A%2F%2Fs2.wp.com%2Fi%2Flogo%2Fwpcom-gray-white.png 1.5x, https://secure.gravatar.com/blavatar/b0ee620758eba563c7003e3aeb0236b12bff8ba81d569b54bdd4ab6b9471a595?s=100&d=https%3A%2F%2Fs2.wp.com%2Fi%2Flogo%2Fwpcom-gray-white.png 2x, https://secure.gravatar.com/blavatar/b0ee620758eba563c7003e3aeb0236b12bff8ba81d569b54bdd4ab6b9471a595?s=150&d=https%3A%2F%2Fs2.wp.com%2Fi%2Flogo%2Fwpcom-gray-white.png 3x, https://secure.gravatar.com/blavatar/b0ee620758eba563c7003e3aeb0236b12bff8ba81d569b54bdd4ab6b9471a595?s=200&d=https%3A%2F%2Fs2.wp.com%2Fi%2Flogo%2Fwpcom-gray-white.png 4x' class='avatar avatar-50' height='50' width='50' /> guidetopharmacology blog </a> </li> <div class="actnbr-message no-display"></div> <form method="post" action="https://subscribe.wordpress.com" accept-charset="utf-8" style="display: none;"> <div class="actnbr-follow-count">Join 40 other subscribers</div> <div> <input type="email" name="email" placeholder="Enter your email address" class="actnbr-email-field" aria-label="Enter your email address" /> </div> <input type="hidden" name="action" value="subscribe" /> <input type="hidden" name="blog_id" value="28218243" /> <input type="hidden" name="source" value="https://blog.guidetopharmacology.org/" /> <input type="hidden" name="sub-type" value="actionbar-follow" /> <input type="hidden" id="_wpnonce" name="_wpnonce" value="37141ef91c" /> <div class="actnbr-button-wrap"> <button type="submit" value="Sign me up"> Sign me up </button> </div> </form> <li class="actnbr-login-nudge"> <div> Already have a WordPress.com account? <a href="https://wordpress.com/log-in?redirect_to=https%3A%2F%2Fr-login.wordpress.com%2Fremote-login.php%3Faction%3Dlink%26back%3Dhttps%253A%252F%252Fblog.guidetopharmacology.org%252F2025%252F04%252F01%252Fdatabase-release-2025-1%252F">Log in now.</a> </div> </li> </ul> </div> </div> </li> <li class="actnbr-ellipsis actnbr-hidden"> <svg class="gridicon gridicons-ellipsis" height="24" width="24" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><g><path d="M7 12c0 1.104-.896 2-2 2s-2-.896-2-2 .896-2 2-2 2 .896 2 2zm12-2c-1.104 0-2 .896-2 2s.896 2 2 2 2-.896 2-2-.896-2-2-2zm-7 0c-1.104 0-2 .896-2 2s.896 2 2 2 2-.896 2-2-.896-2-2-2z"/></g></svg> <div class="actnbr-popover tip tip-top-left actnbr-more"> <div class="tip-arrow"></div> <div class="tip-inner"> <ul> <li class="actnbr-sitename"> <a href="https://blog.guidetopharmacology.org"> <img loading='lazy' alt='' src='https://secure.gravatar.com/blavatar/b0ee620758eba563c7003e3aeb0236b12bff8ba81d569b54bdd4ab6b9471a595?s=50&d=https%3A%2F%2Fs2.wp.com%2Fi%2Flogo%2Fwpcom-gray-white.png' srcset='https://secure.gravatar.com/blavatar/b0ee620758eba563c7003e3aeb0236b12bff8ba81d569b54bdd4ab6b9471a595?s=50&d=https%3A%2F%2Fs2.wp.com%2Fi%2Flogo%2Fwpcom-gray-white.png 1x, https://secure.gravatar.com/blavatar/b0ee620758eba563c7003e3aeb0236b12bff8ba81d569b54bdd4ab6b9471a595?s=75&d=https%3A%2F%2Fs2.wp.com%2Fi%2Flogo%2Fwpcom-gray-white.png 1.5x, https://secure.gravatar.com/blavatar/b0ee620758eba563c7003e3aeb0236b12bff8ba81d569b54bdd4ab6b9471a595?s=100&d=https%3A%2F%2Fs2.wp.com%2Fi%2Flogo%2Fwpcom-gray-white.png 2x, https://secure.gravatar.com/blavatar/b0ee620758eba563c7003e3aeb0236b12bff8ba81d569b54bdd4ab6b9471a595?s=150&d=https%3A%2F%2Fs2.wp.com%2Fi%2Flogo%2Fwpcom-gray-white.png 3x, https://secure.gravatar.com/blavatar/b0ee620758eba563c7003e3aeb0236b12bff8ba81d569b54bdd4ab6b9471a595?s=200&d=https%3A%2F%2Fs2.wp.com%2Fi%2Flogo%2Fwpcom-gray-white.png 4x' class='avatar avatar-50' height='50' width='50' /> guidetopharmacology blog </a> </li> <li class="actnbr-folded-follow"> <a class="actnbr-action actnbr-actn-follow " href=""> <svg class="gridicon" height="20" width="20" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20"><path clip-rule="evenodd" d="m4 4.5h12v6.5h1.5v-6.5-1.5h-1.5-12-1.5v1.5 10.5c0 1.1046.89543 2 2 2h7v-1.5h-7c-.27614 0-.5-.2239-.5-.5zm10.5 2h-9v1.5h9zm-5 3h-4v1.5h4zm3.5 1.5h-1v1h1zm-1-1.5h-1.5v1.5 1 1.5h1.5 1 1.5v-1.5-1-1.5h-1.5zm-2.5 2.5h-4v1.5h4zm6.5 1.25h1.5v2.25h2.25v1.5h-2.25v2.25h-1.5v-2.25h-2.25v-1.5h2.25z" fill-rule="evenodd"></path></svg> <span>Subscribe</span> </a> <a class="actnbr-action actnbr-actn-following no-display" href=""> <svg class="gridicon" height="20" width="20" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20"><path fill-rule="evenodd" clip-rule="evenodd" d="M16 4.5H4V15C4 15.2761 4.22386 15.5 4.5 15.5H11.5V17H4.5C3.39543 17 2.5 16.1046 2.5 15V4.5V3H4H16H17.5V4.5V12.5H16V4.5ZM5.5 6.5H14.5V8H5.5V6.5ZM5.5 9.5H9.5V11H5.5V9.5ZM12 11H13V12H12V11ZM10.5 9.5H12H13H14.5V11V12V13.5H13H12H10.5V12V11V9.5ZM5.5 12H9.5V13.5H5.5V12Z" fill="#008A20"></path><path class="following-icon-tick" d="M13.5 16L15.5 18L19 14.5" stroke="#008A20" stroke-width="1.5"></path></svg> <span>Subscribed</span> </a> </li> <li class="actnbr-signup"><a href="https://wordpress.com/start/">Sign up</a></li> <li class="actnbr-login"><a href="https://wordpress.com/log-in?redirect_to=https%3A%2F%2Fr-login.wordpress.com%2Fremote-login.php%3Faction%3Dlink%26back%3Dhttps%253A%252F%252Fblog.guidetopharmacology.org%252F2025%252F04%252F01%252Fdatabase-release-2025-1%252F">Log in</a></li> <li class="flb-report"> <a href="https://wordpress.com/abuse/?report_url=https://blog.guidetopharmacology.org" target="_blank" rel="noopener noreferrer"> Report this content </a> </li> <li class="actnbr-reader"> <a href="https://wordpress.com/reader/feeds/19302318"> View site in Reader </a> </li> <li class="actnbr-subs"> <a href="https://subscribe.wordpress.com/">Manage subscriptions</a> </li> <li class="actnbr-fold"><a href="">Collapse this bar</a></li> </ul> </div> </div> </li> </ul> </div> <script> window.addEventListener( "load", function( event ) { var link = document.createElement( "link" ); link.href = "https://s0.wp.com/wp-content/mu-plugins/actionbar/actionbar.css?v=20250116"; link.type = "text/css"; link.rel = "stylesheet"; document.head.appendChild( link ); var script = document.createElement( "script" ); script.src = "https://s0.wp.com/wp-content/mu-plugins/actionbar/actionbar.js?v=20250204"; script.defer = true; document.body.appendChild( script ); } ); </script> <div id="jp-carousel-loading-overlay"> <div id="jp-carousel-loading-wrapper"> <span id="jp-carousel-library-loading"> </span> </div> </div> <div class="jp-carousel-overlay" style="display: none;"> <div class="jp-carousel-container">  <div class="jp-carousel-wrap swiper-container jp-carousel-swiper-container jp-carousel-transitions" itemscope itemtype="https://schema.org/ImageGallery"> <div class="jp-carousel swiper-wrapper"></div> <div class="jp-swiper-button-prev swiper-button-prev"> <svg width="25" height="24" viewBox="0 0 25 24" fill="none" xmlns="http://www.w3.org/2000/svg"> <mask id="maskPrev" mask-type="alpha" maskUnits="userSpaceOnUse" x="8" y="6" width="9" height="12"> <path d="M16.2072 16.59L11.6496 12L16.2072 7.41L14.8041 6L8.8335 12L14.8041 18L16.2072 16.59Z" fill="white"/> </mask> <g mask="url(#maskPrev)"> <rect x="0.579102" width="23.8823" height="24" fill="#FFFFFF"/> </g> </svg> </div> <div class="jp-swiper-button-next swiper-button-next"> <svg width="25" height="24" viewBox="0 0 25 24" fill="none" xmlns="http://www.w3.org/2000/svg"> <mask id="maskNext" mask-type="alpha" maskUnits="userSpaceOnUse" x="8" y="6" width="8" height="12"> <path d="M8.59814 16.59L13.1557 12L8.59814 7.41L10.0012 6L15.9718 12L10.0012 18L8.59814 16.59Z" fill="white"/> </mask> <g mask="url(#maskNext)"> <rect x="0.34375" width="23.8822" height="24" fill="#FFFFFF"/> </g> </svg> </div> </div>  <div class="jp-carousel-close-hint"> <svg width="25" height="24" viewBox="0 0 25 24" fill="none" xmlns="http://www.w3.org/2000/svg"> <mask id="maskClose" mask-type="alpha" maskUnits="userSpaceOnUse" x="5" y="5" width="15" height="14"> <path d="M19.3166 6.41L17.9135 5L12.3509 10.59L6.78834 5L5.38525 6.41L10.9478 12L5.38525 17.59L6.78834 19L12.3509 13.41L17.9135 19L19.3166 17.59L13.754 12L19.3166 6.41Z" fill="white"/> </mask> <g mask="url(#maskClose)"> <rect x="0.409668" width="23.8823" height="24" fill="#FFFFFF"/> </g> </svg> </div>  <div class="jp-carousel-info"> <div class="jp-carousel-info-footer"> <div class="jp-carousel-pagination-container"> <div class="jp-swiper-pagination swiper-pagination"></div> <div class="jp-carousel-pagination"></div> </div> <div class="jp-carousel-photo-title-container"> <h2 class="jp-carousel-photo-caption"></h2> </div> <div class="jp-carousel-photo-icons-container"> <a href="#" class="jp-carousel-icon-btn jp-carousel-icon-info" aria-label="Toggle photo metadata visibility"> <span class="jp-carousel-icon"> <svg width="25" height="24" viewBox="0 0 25 24" fill="none" xmlns="http://www.w3.org/2000/svg"> <mask id="maskInfo" mask-type="alpha" maskUnits="userSpaceOnUse" x="2" y="2" width="21" height="20"> <path fill-rule="evenodd" clip-rule="evenodd" d="M12.7537 2C7.26076 2 2.80273 6.48 2.80273 12C2.80273 17.52 7.26076 22 12.7537 22C18.2466 22 22.7046 17.52 22.7046 12C22.7046 6.48 18.2466 2 12.7537 2ZM11.7586 7V9H13.7488V7H11.7586ZM11.7586 11V17H13.7488V11H11.7586ZM4.79292 12C4.79292 16.41 8.36531 20 12.7537 20C17.142 20 20.7144 16.41 20.7144 12C20.7144 7.59 17.142 4 12.7537 4C8.36531 4 4.79292 7.59 4.79292 12Z" fill="white"/> </mask> <g mask="url(#maskInfo)"> <rect x="0.8125" width="23.8823" height="24" fill="#FFFFFF"/> </g> </svg> </span> </a> <a href="#" class="jp-carousel-icon-btn jp-carousel-icon-comments" aria-label="Toggle photo comments visibility"> <span class="jp-carousel-icon"> <svg width="25" height="24" viewBox="0 0 25 24" fill="none" xmlns="http://www.w3.org/2000/svg"> <mask id="maskComments" mask-type="alpha" maskUnits="userSpaceOnUse" x="2" y="2" width="21" height="20"> <path fill-rule="evenodd" clip-rule="evenodd" d="M4.3271 2H20.2486C21.3432 2 22.2388 2.9 22.2388 4V16C22.2388 17.1 21.3432 18 20.2486 18H6.31729L2.33691 22V4C2.33691 2.9 3.2325 2 4.3271 2ZM6.31729 16H20.2486V4H4.3271V18L6.31729 16Z" fill="white"/> </mask> <g mask="url(#maskComments)"> <rect x="0.34668" width="23.8823" height="24" fill="#FFFFFF"/> </g> </svg> <span class="jp-carousel-has-comments-indicator" aria-label="This image has comments."></span> </span> </a> </div> </div> <div class="jp-carousel-info-extra"> <div class="jp-carousel-info-content-wrapper"> <div class="jp-carousel-photo-title-container"> <h2 class="jp-carousel-photo-title"></h2> </div> <div class="jp-carousel-comments-wrapper"> <div id="jp-carousel-comments-loading"> <span>Loading Comments...</span> </div> <div class="jp-carousel-comments"></div> <div id="jp-carousel-comment-form-container"> <span id="jp-carousel-comment-form-spinner"> </span> <div id="jp-carousel-comment-post-results"></div> <form id="jp-carousel-comment-form"> <label for="jp-carousel-comment-form-comment-field" class="screen-reader-text">Write a Comment...</label> <textarea name="comment" class="jp-carousel-comment-form-field jp-carousel-comment-form-textarea" id="jp-carousel-comment-form-comment-field" placeholder="Write a Comment..." ></textarea> <div id="jp-carousel-comment-form-submit-and-info-wrapper"> <div id="jp-carousel-comment-form-commenting-as"> <fieldset> <label for="jp-carousel-comment-form-email-field">Email (Required)</label> <input type="text" name="email" class="jp-carousel-comment-form-field jp-carousel-comment-form-text-field" id="jp-carousel-comment-form-email-field" /> </fieldset> <fieldset> <label for="jp-carousel-comment-form-author-field">Name (Required)</label> <input type="text" name="author" class="jp-carousel-comment-form-field jp-carousel-comment-form-text-field" id="jp-carousel-comment-form-author-field" /> </fieldset> <fieldset> <label for="jp-carousel-comment-form-url-field">Website</label> <input type="text" name="url" class="jp-carousel-comment-form-field jp-carousel-comment-form-text-field" id="jp-carousel-comment-form-url-field" /> </fieldset> </div> <input type="submit" name="submit" class="jp-carousel-comment-form-button" id="jp-carousel-comment-form-button-submit" value="Post Comment" /> </div> </form> </div> </div> <div class="jp-carousel-image-meta"> <div class="jp-carousel-title-and-caption"> <div class="jp-carousel-photo-info"> <h3 class="jp-carousel-caption" itemprop="caption description"></h3> </div> <div class="jp-carousel-photo-description"></div> </div> <ul class="jp-carousel-image-exif" style="display: none;"></ul> <a class="jp-carousel-image-download" href="#" target="_blank" style="display: none;"> <svg width="25" height="24" viewBox="0 0 25 24" fill="none" xmlns="http://www.w3.org/2000/svg"> <mask id="mask0" mask-type="alpha" maskUnits="userSpaceOnUse" x="3" y="3" width="19" height="18"> <path fill-rule="evenodd" clip-rule="evenodd" d="M5.84615 5V19H19.7775V12H21.7677V19C21.7677 20.1 20.8721 21 19.7775 21H5.84615C4.74159 21 3.85596 20.1 3.85596 19V5C3.85596 3.9 4.74159 3 5.84615 3H12.8118V5H5.84615ZM14.802 5V3H21.7677V10H19.7775V6.41L9.99569 16.24L8.59261 14.83L18.3744 5H14.802Z" fill="white"/> </mask> <g mask="url(#mask0)"> <rect x="0.870605" width="23.8823" height="24" fill="#FFFFFF"/> </g> </svg> <span class="jp-carousel-download-text"></span> </a> <div class="jp-carousel-image-map" style="display: none;"></div> </div> </div> </div> </div> </div> </div> <link crossorigin='anonymous' rel='stylesheet' id='all-css-0-2' href='https://s2.wp.com/_static/??-eJydkNEKwjAMRX/IGscGwwfxU6S2Yetsm9KkK/69AzcUfJG9JSfhhBuoSRmKglEgFJV8GVxkmFCSNo+1By4RAtnikcHoTIXRA1eXMKt7idbj0TAfYL9s29nAP74F1WQofIvX2W3GaCmDLkJBizjzueA1szNKRgyoRvRLCLCOBTJyoshuRjU7i8S/ZGfM6uyAwiCUVCJeKpbn+2nXcGn6rmtP/blppxcaDZgp&cssminify=yes' type='text/css' media='all' /> <style id='core-block-supports-inline-css'> .wp-container-core-columns-is-layout-1{flex-wrap:nowrap;}.wp-container-core-columns-is-layout-2{flex-wrap:nowrap;}.wp-container-core-columns-is-layout-3{flex-wrap:nowrap;}.wp-container-core-columns-is-layout-4{flex-wrap:nowrap;} </style> <link crossorigin='anonymous' rel='stylesheet' id='all-css-2-2' href='https://s1.wp.com/wp-content/mu-plugins/jetpack-plugin/sun/modules/tiled-gallery/tiled-gallery/tiled-gallery.css?m=1743811044i&cssminify=yes' type='text/css' media='all' /> <script type="text/javascript" src="https://s1.wp.com/wp-content/js/mobile-useragent-info.js?m=1609849039i&ver=20241018" id="mobile-useragent-info-js" defer="defer" data-wp-strategy="defer"></script> <script type="text/javascript" id="jetpack-facebook-embed-js-extra"> /* <![CDATA[ */ var jpfbembed = {"appid":"249643311490","locale":"en_US"}; /* ]]> */ </script> <script type="text/javascript" id="jetpack-carousel-js-extra"> /* <![CDATA[ */ var jetpackSwiperLibraryPath = {"url":"https:\/\/s2.wp.com\/wp-content\/mu-plugins\/jetpack-plugin\/sun\/_inc\/build\/carousel\/swiper-bundle.min.js"}; var jetpackCarouselStrings = {"widths":[370,700,1000,1200,1400,2000],"is_logged_in":"","lang":"en","ajaxurl":"https:\/\/blog.guidetopharmacology.org\/wp-admin\/admin-ajax.php","nonce":"edaaa7bb41","display_exif":"1","display_comments":"1","single_image_gallery":"1","single_image_gallery_media_file":"","background_color":"black","comment":"Comment","post_comment":"Post Comment","write_comment":"Write a Comment...","loading_comments":"Loading Comments...","image_label":"Open image in full-screen.","download_original":"View full size <span class=\"photo-size\">{0}<span class=\"photo-size-times\">\u00d7<\/span>{1}<\/span>","no_comment_text":"Please be sure to submit some text with your comment.","no_comment_email":"Please provide an email address to comment.","no_comment_author":"Please provide your name to comment.","comment_post_error":"Sorry, but there was an error posting your comment. Please try again later.","comment_approved":"Your comment was approved.","comment_unapproved":"Your comment is in moderation.","camera":"Camera","aperture":"Aperture","shutter_speed":"Shutter Speed","focal_length":"Focal Length","copyright":"Copyright","comment_registration":"0","require_name_email":"1","login_url":"https:\/\/guidetopharmacology.wordpress.com\/wp-login.php?redirect_to=https%3A%2F%2Fblog.guidetopharmacology.org%2F2022%2F12%2F19%2Fexploiting-the-guide-to-pharmacology-substance-sid-tags-in-pubchem%2F","blog_id":"28218243","meta_data":["camera","aperture","shutter_speed","focal_length","copyright"],"stats_query_args":"blog=28218243&v=wpcom&tz=0&user_id=0&home=1&subd=guidetopharmacology","is_public":"1"}; /* ]]> */ </script> <script crossorigin='anonymous' type='text/javascript' src='https://s1.wp.com/_static/??-eJydUUFuwzAM+9BcYVmL7jLsKYNjK5lSWTYiOUF/vwRr2qKHYeiRFElBFMzFhSyGYtBy7l3h2pMozHmMPqoL7FVRYVgob+ymZjfoC9zZUr2ZKPZoCliXaT4ROvYzGKbC3vCB/yNnQCs+nC4YtAp8kQRoK3EEko6EDJ2GMTNv+LxLJI+h9o1pWVxqCyNqyaI04XrMDa0xVEz/bdXkmV1CqU+c0PmA7dKBw9RifLqD4MdcFfkq24j7EhY51/j7vEhqMKHEPK6jkvncEW/yz/Txetw3h/e3w7EZfgBo0Mf8'></script> <script type="text/javascript" crossorigin='anonymous' src="https://s0.wp.com/wp-content/plugins/gutenberg-core/v20.0.4/build/hooks/index.min.js?m=1741299224i&ver=84e753e2b66eb7028d38" id="wp-hooks-js"></script> <script type="text/javascript" crossorigin='anonymous' src="https://s0.wp.com/wp-content/plugins/gutenberg-core/v20.0.4/build/i18n/index.min.js?m=1741299224i&ver=bd5a2533e717a1043151" id="wp-i18n-js"></script> <script type="text/javascript" id="wp-i18n-js-after"> /* <![CDATA[ */ wp.i18n.setLocaleData( { 'text direction\u0004ltr': [ 'ltr' ] } ); /* ]]> */ </script> <script crossorigin='anonymous' type='text/javascript' src='https://s2.wp.com/wp-content/mu-plugins/jetpack-mu-wpcom-plugin/sun/jetpack_vendor/automattic/jetpack-classic-theme-helper/dist/responsive-videos/responsive-videos.js?m=1737671034i'></script> <script type="text/javascript" crossorigin='anonymous' src="https://s0.wp.com/wp-content/mu-plugins/jetpack-plugin/sun/_inc/build/tiled-gallery/tiled-gallery/tiled-gallery.min.js?m=1685112397i&ver=14.6-a.2" id="tiled-gallery-js" defer="defer" data-wp-strategy="defer"></script> <script crossorigin='anonymous' type='text/javascript' src='https://s0.wp.com/wp-content/mu-plugins/carousel-wpcom/carousel-wpcom.js?m=1620989527i'></script> <script type="text/javascript"> (function () { var wpcom_reblog = { source: 'toolbar', toggle_reblog_box_flair: function (obj_id, post_id) { // Go to site selector. This will redirect to their blog if they only have one. const postEndpoint = `https://wordpress.com/post`; // Ideally we would use the permalink here, but fortunately this will be replaced with the // post permalink in the editor. const originalURL = `${ document.location.href }?page_id=${ post_id }`; const url = postEndpoint + '?url=' + encodeURIComponent( originalURL ) + '&is_post_share=true' + '&v=5'; const redirect = function () { if ( ! window.open( url, '_blank' ) ) { location.href = url; } }; if ( /Firefox/.test( navigator.userAgent ) ) { setTimeout( redirect, 0 ); } else { redirect(); } }, }; window.wpcom_reblog = wpcom_reblog; })(); </script> <script type="text/javascript"> (function() { var extend = function(out) { out = out || {}; for (var i = 1; i < arguments.length; i++) { if (!arguments[i]) continue; for (var key in arguments[i]) { if (arguments[i].hasOwnProperty(key)) out[key] = arguments[i][key]; } } return out; }; extend( window.infiniteScroll.settings.scripts, ["jetpack-mu-wpcom-settings","rlt-proxy","jquery-core","jquery-migrate","jquery","responsive-modernizr","cmp-script-stub","wpcom-actionbar-placeholder","grofiles-cards","wpgroho","mobile-useragent-info","wordads-client","eu-cookie-law-script","the-neverending-homepage","responsive-scripts","responsive-small-menu","jetpack-facebook-embed","jetpack-carousel","wp-polyfill","wp-hooks","wp-i18n","jetpack-responsive-videos","tiled-gallery","carousel-wpcom"] ); extend( window.infiniteScroll.settings.styles, ["wordads-global","eu-cookie-law-style","the-neverending-homepage","wp-block-library","jetpack-layout-grid","jetpack-ratings","mediaelement","wp-mediaelement","coblocks-frontend","wpcom-core-compat-playlist-styles","wpcom-bbpress2-staff-css","responsive-style","reblogging","geo-location-flair","h4-global","wp-emoji-styles","videopress-video-style","jetpack-sharing-buttons-style","classic-theme-styles","global-styles","jetpack_facebook_likebox","akismet-widget-style","jetpack-global-styles-frontend-style","jetpack-carousel-swiper-css","jetpack-carousel","jetpack-responsive-videos","jetpack-top-posts-widget","tiled-gallery","core-block-supports","core-block-supports-duotone"] ); })(); </script> <span id="infinite-aria" aria-live="polite"></span> <script src="//stats.wp.com/w.js?68" defer></script> <script type="text/javascript"> _tkq = window._tkq || []; _stq = window._stq || []; _tkq.push(['storeContext', {'blog_id':'28218243','blog_tz':'0','user_lang':'en','blog_lang':'en','user_id':'0'}]); _stq.push(['view', {'blog':'28218243','v':'wpcom','tz':'0','user_id':'0','home':'1','subd':'guidetopharmacology'}]); _stq.push(['extra', {'crypt':'UE5XaGUuOTlwaD85flAmcm1mcmZsaDhkV11YdWtpP0NsWnVkPS9sL0ViLndld3BsSjRjQ0FmMWk0bjhweV9IZytCcTR+dC89OVc4Jmh5SCV+OU1GMzFfblZqTT1wS1ElMzJreF1pQTIwWUxNajJjNHJMZVA2JXJJTC5GWls4fmlSWHgsXytRbFhqdHFYMX5SNjZpYWUueiZzbCthTENwTzFsMS8uYWcxVVpWK1R2fGNWfFZZeXxXPVU9Z0VvcnNVTHR5NDAwbERXVDB2c3g5WXNLOGJDUjVTSE12eFpfVTdLRzBZVjlUNjU2dlpFRyxkTkFzJTFoZ10scC41Ll9tMDFRLEJBTV1GY1NwOS5NQm82Uld8TiZFbVQ3TytBbU84U05vZ1NsOEI1JXZfajF4OVEwdDVDakpBZzVSTn53P0VXc1stZEUwXUJId1Y2WEN2Qn5CJWp3LElFOUh3a2NPQ3NbLE9DYmQtQi44N2JpOVtxVD9KJg=='}]); _stq.push([ 'clickTrackerInit', '28218243', '0' ]); </script> <noscript><img src="https://pixel.wp.com/b.gif?v=noscript" style="height:1px;width:1px;overflow:hidden;position:absolute;bottom:1px;" alt="" /></noscript> <script defer id="bilmur" data-customproperties="{"enq_jquery":"1","enq_wp-polyfill":"1","logged_in":"0","wptheme":"pub\/responsive","wptheme_is_block":"0"}" data-provider="wordpress.com" data-service="simple" data-site-tz="Etc/GMT-0" src="/wp-content/js/bilmur-3-4-combined.min.js?i=12&m=202515"></script><script> ( function() { function getMobileUserAgentInfo() { if ( typeof wpcom_mobile_user_agent_info === 'object' ) { wpcom_mobile_user_agent_info.init(); var mobileStatsQueryString = ''; if ( wpcom_mobile_user_agent_info.matchedPlatformName !== false ) { mobileStatsQueryString += '&x_' + 'mobile_platforms' + '=' + wpcom_mobile_user_agent_info.matchedPlatformName; } if ( wpcom_mobile_user_agent_info.matchedUserAgentName !== false ) { mobileStatsQueryString += '&x_' + 'mobile_devices' + '=' + wpcom_mobile_user_agent_info.matchedUserAgentName; } if ( wpcom_mobile_user_agent_info.isIPad() ) { mobileStatsQueryString += '&x_' + 'ipad_views' + '=' + 'views'; } if ( mobileStatsQueryString != '' ) { new Image().src = document.location.protocol + '//pixel.wp.com/g.gif?v=wpcom-no-pv' + mobileStatsQueryString + '&baba=' + Math.random(); } } } document.addEventListener( 'DOMContentLoaded', getMobileUserAgentInfo ); } )(); </script></body> </html>